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ABSTRACT 
Vaccinia virus (VACV) is considered the prototypical poxvirus and is a common therapeutic 
agent, especially in the fields of vector and oncolytic research. In this last case, understanding 
viral-host interactions is crucial for developing targeted anti-cancer treatments. One aspect of 
interest is the VACV infection phenotype, which is typified by alterations to cell structure, 
adoption of motility and manipulation of host transcription. These features are reminiscent of a 
host process – epithelial to mesenchymal transition (EMT). Given the parallels between EMT and 
VACV infection, we wanted to ascertain if classical pathways, which modulate mesenchymal 
transitions, are activated by VACV. Using various techniques, we found that VACV induces TGF-
β signalling at both the transcriptional and protein levels, promoting an EMT-like phenotype. Our 
results suggest that VACV utilises a transcription factor in this pathway, Smad4, for efficient cell-
to-cell spread, replication and induction of cell migration. As other microbes induce EMT to 
promote infection spread and pathogenesis, we theorised this was the case for VACV. However, 
unlike these other contexts, this process appears entirely independent of the canonical TGF-β 
receptor during VACV infection. Further investigation showed this feature to be unique to VACV 
as it did not occur in infection with related poxvirus, Ectromelia virus (ECTV). Phenotypic and 
transcriptomic characterisation revealed a potential role for vaccinia viral growth factor (VGF) in 
the activation of TGF-β signalling during infection. Whether this is via direct interaction, or 
actions of related cross-talk pathway, the epidermal growth factor receptor (EGFR) pathway, is yet 
to be determined. Given that the TGF-β and EGFR pathways are aberrantly regulated during 
tumour development, and VACV is a potent oncolytic agent, this research could provide us with 
information to hone oncolytic agents.  
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1.1 PERCEPTION OF VIRUSES 
1.1.1 “Virus” 
According to the Oxford Latin dictionary, the original meaning of the word virus is poison, slime 
or venom. From the etymology, it is easy to see why general perceptions of viruses remain 
negative today. Historically, viruses were discovered as a direct result of the diseases they cause. 
For example, the first virus to be identified, the tobacco mosaic virus, was named for the mottled, 
mosaic-like pattern it caused in leaves of infected tobacco plants. This finding was made by 
European botanists, Martinus Beijerinck, Dimitri Ivanovsky, Adolf Mayer and Erwin Baur. These 
scientists noted the presence of an infectious agent in tobacco leaves, which could pass through 
filters designed to stop bacteria, still cause disease, and yet could not do so in the absence of a 
living host [1]. Today we recognise these particles as viruses. 
Since their discovery in the late 1800s, viruses have been implicated in a number of devastating 
global disease outbreaks. For instance, one of the deadliest pandemics in history occurred in 1918, 
when the Spanish Flu influenza virus infected a staggering 1/3 of the global population, killing 
approximately 50 million people worldwide [2]. Another horrific and ancient disease, smallpox, 
caused by variola virus, killed an estimated 300-500 million people prior to its eradication in 1979 
[3]. Around the same time, the human immunodeficiency virus/ acquired immune deficiency 
syndrome (HIV/AIDS) epidemic took hold and has cost an approximate 36 million lives to date, 
according to the World Health Organisation (WHO, 2016).  
In recent years, the general public has been hit by an onslaught of viral outbreaks, including the 
SARS-Coronavirus (2003) (SARS-CoV), avian Influenza A (H5N1) (2007), swine Influenza A 
(H1N1) (2009), ebolavirus (2014), Zika virus (2015) and Dengue virus (2017) epidemics to name 
a few (WHO, 2018). Given this history, it is no surprise that viruses are typically considered 
harmful and dangerous infectious agents. 
However, many viruses are able to be manipulated to our benefit. These therapeutic viruses may 
change the reputation of their disease-causing fellows, just as probiotics and food-grade yeasts 
have enhanced the status of bacteria and fungi, leading to an altered global perception of viruses. 
 
1.1.2 The good guys – Vaccines, vectors and oncolytics 
Due to their small size and lack of complexity, viruses can be easily manipulated and repurposed 
to fill specific treatment niches. This methodology has led to the development of numerous virion-
based therapies, including those in the vaccine, vector-based and oncolytic virus fields. 
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Of the therapeutic viruses, the most widely used are those relating to vaccine technologies. 
Vaccines, in the form we recognise them today, have been used since the late 1700s, prior to the 
identification of the first viral agents [4]. They work by stimulating an immune response to a 
particular disease in order to confer protection from falling ill or passing disease on to other 
people. In many cases, they have proved to be highly effective. For example, introduction of the 
smallpox vaccine led to the first declaration of disease eradication. In fact, the incidence of 
numerous diseases where a commercial vaccine is available has dropped off dramatically (Figure 
1.1A). This includes poliomyelitis, measles, and chickenpox [5-8]. Furthermore, it is believed to 
be a top strategy for protection against other burdensome diseases caused by HIV, ebolavirus and 
hepatitis C virus (HCV).  
A more contemporary field of research is viral vector-based technologies. In this case, the virus 
acts as an envelope in which desired proteins or genes are packaged and transported to a tissue of 
interest. One potential use for these vectors is as vehicles for gene therapy. For example, cystic 
fibrosis is caused by a genetic mutation in chromosome 7 in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene. This defect results in major respiratory issues throughout a 
patient’s life. Researchers have developed viral vectors which carry wild-type copies of the CFTR 
gene, transport them to the lungs and insert them into the host genome; potentially alleviating 
disease phenotype when delivered effectively [9]. In recent years, the number of successful viral 
vector-based gene therapy clinical trials has been steadily increasing (Figure 1.1B). Viral-based 
delivery systems also outspan all the other gene delivery systems combined (Figure 1.1C). In fact, 
in the last year, the first viral-based gene therapy products, GlyberaR® and Strimvelis®, were 
licensed for patient use in Europe to treat a lipase deficiency and severe combined 
immunodeficiency, respectively [10].  
The most novel treatment viruses are those related to oncolysis. These oncolytic viruses destroy 
cancer cells through a biphasic approach; initially replicating within cancer cells to promote cell 
lysis, before recruiting immune cells to infected tumours to hasten their destruction (Figure 1.2). 
Both steps are essential for efficient clearance of cancer tissues. Oncolytic viruses have garnered a 
lot of interest due to their potent and effective nature, resulting in an ever-increasing number of 
related publications (Figure 1.1D). Generally, they are considered an improvement on current 
treatment options, due to their non-invasive, safe and cost-effective nature. Early last year, the first 
oncolytic agent to be approved by the FDA, Imlygic®, was released commercially for treatment of 
melanoma [11]. As the research in this thesis pertains most closely to oncolytic virus research, this 
section will be described in detail in future sections. 
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Figure 1.1 – Helpful viruses and their uses 
(A) Since the introduction of vaccines against viral pathogens, the incidence of these diseases has decreased 
dramatically. The dotted line in the graph refers to infection rates after vaccine introduction. In comparison, 
other diseases without a commercial vaccine available, such as HIV and ebolavirus, remain constant burdens, 
either decreasing in incidence at a slow rate, remaining stagnant, or increasing in prevalence over time. (B, C) 
Other than vaccines, viral gene therapy vectors also act as helpful tools, for re-writing detrimental genetic 
anomalies within a host genome. (B) The number of global gene therapy trials has increased dramatically in 
recent years (Data from the Journal of Gene Medicine). (C) A significant proportion of these use virus-based 
vectors for delivery. (Adapted from [12]). (D) Oncolytic virotherapy publications have also increased over the 
past 20 or so years, especially in comparison to their discovery period in the mid-1960s (Data obtained from 
PubMed, NIH, USA).  
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1.2 ONCOLYTIC VIRUSES 
1.2.1 The field of oncolytics 
Oncolytic agents are fairly novel in the scheme of cancer therapeutics. Their discovery and use 
have come after established treatments such as chemotherapy, radiotherapy or surgical resection of 
tumour tissues. By definition, an oncolytic agent is a virus that preferentially and/or selectively 
infects, replicates within and modulates lysis of cancer cells [13]. These oncolytic-based therapies 
are effective due to their dual anti-tumour effect (described in Figure 1.2). This bi-fold response 
results in longer lasting tumour immunity than traditional therapies.  
The effectivity of oncolytic viruses is determined by their ability to replicate more efficiently 
within tumour cells than healthy cells. Luckily, a number of viruses inherently possess this 
characteristic, enabled by features found within the tumour microenvironment. For instance, due 
to their continually replicating nature, tumour cells have plentiful resources available for 
replication for the virus to repurpose for its own reproduction [14, 15]. Apoptotic and cell cycle 
arrest pathways are also often defective or deregulated, which allows the virus to replicate without 
interference from the cell or infection-mediated cell death [16]. Finally, immune recruitment and 
local antiviral responses are poor within tumour sites, facilitating a longer period of unchecked 
viral replication within these malignancies [17]. 
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Figure 1.2 – Many features of the tumour microenvironment favour viral infection 
Upon the development of a tumour, cancer cells alter a number of features to survive and prosper. These include 
dysregulation of the cell cycle and growth arrest responses, to promote rampant proliferation, suppression of the 
immune response to continue replicating unhindered and undetected, as well as inhibition of programmed cell 
death to limit the host’s anti-tumour response. These characteristics, whilst benefiting the tumour, also make the 
environment ripe for increased viral replication. The virus can then aid in tumour death via direct lysis, 
attraction of immune cells and anti-tumour vaccination, or destruction of endothelial cells and the blood supply 
feeding the tumour.  
 
 
1.2.2 Common oncolytic viruses 
Numerous viruses fall into the oncolytic category as they are able to take advantage of features of 
the tumour microenvironment for their own replication. Research is now focused on improving the 
abilities of these viruses, enhancing their safety, specificity and efficacy as anti-cancer treatments. 
Common examples of oncolytic viruses include adenovirus (AdV), herpes simplex virus (HSV), 
measles virus, reovirus and vaccinia virus (VACV) [14]. 
Within oncolytic virus research, a significant proportion of clinical trials are devoted to AdV 
studies, as these viruses are small and their capsids can easily be modified to make viral entry very 
tissue specific in nature [18]. In fact, the first oncolytic to be approved was an oncolytic AdV, 
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Onyx-015, released in China for treatment of head and neck tumours [19]. Onyx-015 contains a 
mutation which only allows it to replicate in cells lacking p53. As p53 is a powerful tumour 
suppressor, it is lost only in tumour cells, meaning viral replication is restricted to these cells alone 
[20]. CG0070 is another AdV, like Onyx-15, in phase I and II trials for treating bladder cancer. It 
displays reasonable effectivity in high-risk cases, with 6 of 15 patients displaying an enduring 
absence of disease after 6 months [21]. However, this virus is specific to bladder tumour tissues 
with a defect in their retinoblastoma pathway. With its niche selectivity, it may not be ideal as a 
broad anti-cancer treatment. Another limitation of these tailored adenoviruses is they can be less 
potent than other oncolytic viruses, and so, at low doses, can promote tumour regrowth after viral 
clearance [22]. 
The second-most well-researched oncolytic virus is HSV-1. One example, Imlygic®, also known 
as T-Vec, is a recently approved HSV-1-mediated intratumoral melanoma treatment [23]. 
However, whilst relatively effective, groups are now suggesting there is no added benefit of 
Imlygic® treatment over others for treating advanced melanomas. It is also less cost-effective and 
is only recommended to be used when systemic immunotherapy options are not suitable 
(information obtained from the National Institute for Health Care and Excellence, UK) [24]. 
Another HSV-1 in trials is G47Δ, which is considered a very selective and safe oncolytic [25]. 
Among the three mutations introduced to this virus, the defect in the ribonucleotide reductase 
ICP6 gene confers tumour specificity by polarising viral replication towards cells lacking the 
tumour suppressor, p16 [26]. Compared to its predecessors, it clears solid tumours effectively and 
can be used safely as a systemic therapy [27].  
 
Measles virus is another oncolytic candidate. The receptor used by oncolytic measles virus to enter 
cells, CD46, is overexpressed in many tumour cells making the virus naturally predicated to 
replicating within these tissues [28]. Within the last year, seven clinical trials were conducted 
using oncolytic measles virus to treat a range of cancers, including a number of types of leukaemia, 
head and neck tumours and ovarian cancer [29]. As a human pathogen, the vaccine and oncolytic 
measles virus strains were attenuated prior to use by serial passaging in cells from chicken 
embryos [30]. Since their development they have acted protectively; however, there is always a 
minute risk of pathogenic reversion, making the measles virus one of the less safe oncolytic 
options currently being trialled [29].  
Reolysin, or oncolytic reovirus, also naturally displays a high level of tumour selectivity, due to 
the requirement for high Ras signalling in the cells it infects [31]. It is one of the few unmodified 
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viruses in clinical trials for treatment of glioma, solid tumours, melanoma, head and neck tumours 
and many more [14, 25]. However, as anti-reovirus antibodies develop, this treatment wanes in its 
effectivity and tumour regrowth is sometimes observed [32, 33].  
Of the oncolytic viruses, the one most pertinent to this thesis is VACV. JX-594 is a modified 
VACV strain, with high intravenous stability, safety and potency as a cancer treatment [25, 34, 35]. 
As VACV can generally infect a large number of tissues, it can potentially be used against a wide 
array of tumour types [36]. However, its efficacy is highly variable. For example, in a study of 10 
patients with liver tumours and some metastases, 3 patients displayed tumour regression upon 
treatment with JX-594, the rest were stable in their disease state [37]. Current studies suggest 
increasing viral dose could enhance anti-tumour immunity and extend patient survival [38]. 
Another oncolytic VACV, GL-ONC1, has been engineered to carry a luciferase gene for better 
tracking of viral infection when treating solid tumours [39]. This virus boosts the efficacy of 
existing treatments, such as chemo- and radiotherapy, when used in tandem with theses therapies.  
Other examples of oncolytic viruses include Newcastle-disease virus, vesicular stomatitis virus, 
myxoma virus, Coxsackie virus, parvovirus, poliovirus, Seneca Valley virus and various 
retroviruses [14, 20]. However, despite all these available options for testing, currently, no 
oncolytic treatment is without its drawbacks. Further studies into improving and modifying these 
viruses could lead to the development of more refined and increasingly efficient oncolytic 
weapons.  
  
1.2.3 Oncolytic virus modifications 
With the exception of Reolysin, oncolytic viruses in clinical trials today generally contain genetic 
modifications for their betterment. These can enhance any element of treatment but typically focus 
on improving viral specificity, spread, safety, or potency. Oncolytic VACV possesses a number of 
these modifications. A few examples are described below and illustrated in Figure 1.3.  
There are various ways to improve the specificity or selectivity of oncolytic viruses. One example 
of this is the deletion of viral thymidine kinase (TK). TK is a highly conserved protein that is 
essential for obtaining the DNA precursor dTTP and carrying out replication of cells and virus 
alike [40]. By deleting the viral copy of this gene, TK must then be outsourced for efficient viral 
replication to occur, and so the virus will preferentially replicate in cells with an abundance of this 
protein. As TK is found in high abundance in proliferating cells, including actively growing 
tumours, this introduces a bias in viral replication away from healthy cells and towards 
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proliferating cancer tissues. As such, this deletion has been engineered into a number of oncolytic 
vaccinia viruses [14]. Following a similar rationale, another viral protein required for replication, 
vaccinia growth factor (VGF), can also be deleted to obtain a similar outcome [41, 42]. VGF 
generally activates epidermal growth factor (EGF) signalling in cells and its removal leads to a 
reduction in virulence and preference for replicating in cells with abundant EGF pathway 
activation [43]. Excessive EGF signalling is a defining feature of many tumours, including breast, 
prostate and liver carcinomas [44].  
Certain desirable mutations in these viruses are not lab generated. For example, a natural safety 
feature present within oncolytic VACV, JX-594, is a truncation in the B18R protein [45]. B18R is 
a virulence factor which protects against host interferon responses. Due to a premature stop codon 
in the B18R of JX-594, this virus is more susceptible to destruction by a healthy interferon 
response. Note that tumour cells often have deficient immune and antiviral responses, and so this 
not only makes the virus safer to use, but also more selective for tumour cell replication [46].  
A very common modification for increasing the potency of treatment is the introduction of 
granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is an immune 
stimulatory molecule which promotes differentiation, proliferation and function of a number of 
immune cells. Introduction of a GM-CSF transgene often increases the potency of the anti-tumour 
response by provoking a stronger immune attack at the tumour site. CG0070, Imlygic®, oncolytic 
measles virus and JX-594 all possess this insertion for improved effectivity [35, 47-50]. In the 
case of the VACV oncolytic, JX-594, the addition of GM-CSF allowed the virus to be 
administered intravenously and display increased efficacy against metastases as well as primary 
tumours [51]. It also curbed any errant or unwanted viral replication [35, 52].  
Whilst, these various adjustments made to oncolytic viruses address aspects of oncolytic 
specificity and potency, more modifications could help elevate the status of oncolytic 
virotherapies further. As such, the search for new targets for screening is paramount to advancing 
this field of research.  
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Figure 1.3 – Oncolytic VACV modifications to polarise and prime for tumour cell destruction 
Oncolytic vaccinia viruses can be engineered to better replicate in tumour cells (pink cells) and avoid infection 
healthy cells (purple cells). Viral replication within these cells leads to cell lysis (green cells) and recruitment of 
the immune system. Genetic alterations can include a deletion of B18R to make the virus susceptible to 
interferons, inactivation of the viral thymidine kinase (TK) or vaccinia growth factor (VGF) to alter selectivity 
of viral growth and insertion of GM-CSF to further recruit immune cells. 
 
 
1.2.4 Potential sources of novel genes for tailoring oncolytic viruses  
One of the major benefits working with viruses in therapeutics is their capacity to be edited and 
tailored to specific purposes. As described in the previous section, many modifications have 
already been put into practice to enhance the efficacy of oncolytic viruses. However, there may be 
more untapped target reservoirs that have been overlooked thus far, which could continue to 
improve on the safety, specificity and potency of these viruses.  
To begin the search for novel genetic targets, researchers need to consider which aspects of 
infection it may be beneficial to alter, as well as the dependence of both viruses and tumour cells 
on specific host components. For example, the most commonly used sources of target genes are 
those with product essential for viral replication, such as TK in VACV and ICP6 in HSV-1, 
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described earlier [14, 26]. By targeting genes involved in viral replication, these viruses essentially 
become crippled in the absence of host replication resources. As such, each of the selectivity and 
safety of the treatment is improved by enhancing viral replication in continually replicating cells 
with a plethora of resources, such as tumour cells. Cells with tighter resource regulation are less 
suitable, and so infection typically avoids these healthy cells.  
Another possible area of interest could be genes involved in viral spread. By improving 
dissemination, the virus could be utilised more systemically, yet still have a chance of 
encountering rogue tumour cells before being cleared by the immune system. Interestingly, the 
converse of this may also be of interest. Limiting the ability of oncolytic viruses to spread reduces 
the risk of rampant viral replication and systemic viremia, promoting the safety of these treatments. 
For example, VACV homolog of cellular EGF, VGF, is known to enhance viral spread [43]. Due 
to this feature, deletion of this gene has a bi-fold effect, reducing VACV distribution whilst 
causing the virus to become targeted towards cells with abundant EGF pathway signalling. 
Striking a balance between these alterations could make an intravenous administration approach 
attractive. 
According to precedence, it appears that the best targets for genetic modification are systems, 
pathways or proteins utilised by both viruses and tumours, and less so by healthy cells, for 
effective spread and proliferation. One such unexplored process, is epithelial to mesenchymal 
transition (EMT). This process is described further in the following section, but briefly, it is a 
phenomenon where cells detach, migrate and invade into the surrounding tissues to drive the 
spread of disease. Mining genes associated with this cellular transition and understanding how 
viruses and cancer regulate this process could unveil novel targets for alterations of oncolytic 
viruses.  
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1.3 EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) 
1.3.1 Basics of epithelial to mesenchymal transition 
Epithelial to mesenchymal transition (EMT), or epithelio-mesenchymal transformation as it was 
initially coined, was a term first used in the 1980s to describe a process seen during development 
and embryogenesis [53, 54]. It was originally witnessed by Elizabeth Hay who observed 
molecular and structural changes within cells of the primitive streak in chick embryos that proved 
essential for mesoderm formation and embryonic development. As such, it was one of the first 
terms to describe the plastic and malleable nature of cell differentiation. EMT occurs when cells 
depart from an epithelial-like state, escaping from the anchored, structured epithelium to become 
roaming mesenchymal-like cells (Figure 1.4) [55]. These wandering cells are then able to travel to 
distal sites, where they may differentiate or replicate to establish a new proliferation centre and 
better inhabit their new environment.  
A number of features are considered to be characteristic of EMT. These can be broadly separated 
into two classes: structural and biochemical.  
 
 
Figure 1.4 – Characteristics of EMT  
The process of EMT is characterised by cells changing from an epithelial-like phenotype to a more 
mesenchymal cell structure. This phenomenon is generally characterised by a loss of a cell’s adherence to the 
surface and other cells, as well as a departure from apical-basal polarity. The new elongated cell structure can 
facilitate increased motility and invasiveness. Another observable feature is the change in expression of cell 
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surface markers. Certain proteins, such as E-cadherin and ZO-1, are downregulated whilst others, including 
vimentin and N-cadherin, display increased expression.  
 
1.3.2 EMT-associated cell structures 
Dramatic structural changes are associated with cells undergoing EMT, resulting in a process that 
is relatively simple for scientists to observe. The most characteristic of these changes occur in cell 
attachments, polarity, cytoskeleton and overall shape. 
Structured epithelial layers are typically characterised by their fixtures, found both between cells 
and the basement membrane [56]. These epithelial cells are tightly regulated as they are found at 
all interfaces between the body and external world, and so they serve as a first-line of defence 
against infection and foreign matter. As such, their junctions serve to maintain the barrier function 
required from these cells [57]. To undergo EMT, cells need to lose these anchoring points, which. 
involves the destruction of tight junctions, adherens junctions, desmosomes and a concurrent 
degradation of the basement membrane [58]. Loss of these attachments leaves cells free to move 
independently of their adjoining neighbours.  
Once detached, the cytoskeleton of these cells transforms to facilitate motility. Cells lose their 
apical-basal polarity, favouring a front-tail alignment of cell fibres, which is more conducive to 
motility (Figure 1.5). It is thought that cell-to-cell junctions, described above, are involved the 
establishment of apical-basal polarity, and so, as expected, their loss contributes to the breakdown 
of this top-bottom structure [56]. The rest of the conversion process is mediated by rearrangement 
of the cortical actin cytoskeleton (Figure 1.5). Upon EMT, the actin cytoskeleton is repurposed 
into stress fibres which are typical of a mesenchymal cell. This conversion is mediated by Rho-
GTPase proteins [59]. During the restructuring, cells become more elongated via the generation of 
lamellipodia and filopodia. These newly acquired protrusions act as traction to pull cells through 
the webbing of the extracellular matrix in the desired direction, facilitating movement between 
other cells and through the basement membrane. 
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Figure 1.5 – Cytoskeletal changes are evident upon transition from an epithelial to a mesenchymal 
phenotype 
NMuMG cells were induced to go from an epithelial to a mesenchymal state over a 48 hour period. Dramatic 
cell shape changes were evident, alongside rearrangements of the actin cytoskeleton, loss of epithelial marker, 
E-cadherin and nuclei shape changes visualised with DAPI staining over time. Note that the cells at 24 and 48 
hours are much more elongated and separated compared to those at 0 hours. Scale bar = 50 μm in the phase 
image and 10 μm for the fluorescence images. Image adapted from [60]. 
 
1.3.3 Biochemistry of EMT – Expression of epithelial and mesenchymal markers  
Coupled with the major structural upheaval occurring in transitioning cells, EMT is associated 
with a shift in expression of epithelial and mesenchymal biomarkers. Many of these are surface 
proteins involved in maintaining cellular structures, those required for enhancing cell migration or 
transcription factors which drive changes to gene expression. For example, during the 
destabilisation of cell-to-cell junctions, there is cleavage of the adhesive E-cadherin surface 
protein, resulting in its decreased expression over the course of EMT (Figure 1.5) [61]. This 
allows cells to detach from their surroundings more readily. Gene expression of the E-cadherin 
gene, CDH1, is also altered by promoter repression, gene mutation or hypermethylation [62]. 
Abundant tight junction proteins, such as Claudin-1, Occludin and zonula occludens 1 protein 
(ZO-1), are characteristic of tightly fastened epithelial cells [63]. These proteins span the 
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membranes of adjacent cells, tethering them to each other. Repression of these proteins is a typical 
feature associated with the adoption of a mesenchymal phenotype [64].  
During EMT, loss of epithelial-associated markers is accompanied by a concurrent increase in 
mesenchymal associated proteins. For example, a common mesenchymal marker is N-cadherin, 
another calcium-dependent adhesion molecule like E-cadherin. However, N-cadherin is involved 
in driving increased cell invasion and motility, allowing cells to adhere to various surfaces and 
pull themselves along, rather than anchoring to a specific point [65]. Fibronectin is another protein 
associated with mesenchymal cell migration. It is a scaffolding component of the extracellular 
matrix (ECM) which binds integrin proteins in the membranes of cells, acting as a foothold for 
further movement [63]. Matrix metalloproteinases (MMPs) are also commonly linked to EMT and 
cell migration [66]. These are key mediators of basement membrane degradation and regulation of 
the ECM. Without secretion of MMPs, cells are unable to clear space around themselves to depart 
from their original position.  
Whilst many of the markers described above are of a structural nature, another group of proteins 
should not be overlooked. These are the transcription factors which downregulate epithelial 
markers, whilst promoting expression of mesenchymal-associated genes. Two of the most well-
studied of these factors are Snail and Snail2 (also known as Slug) [67, 68]. Other examples 
include Zinc finger E-box-binding homeobox protein 1 (ZEB1), Twist and lymphoid enhancer-
binding factor 1 (LEF-1) [63]. These regulate the expression of all the markers described above, as 
well as many more required for the major structural and biochemical shift associated with 
mesenchymal transition. As a result, these transcription factors are considered master regulators of 
EMT and can be used to characterise EMT in various developmental and pathological contexts.  
 
1.3.4 Various contexts of EMT 
There are numerous scenarios in which EMT plays an important role. The first of these was 
observed 40 years ago during embryogenesis and development [54]. In this context, EMT 
facilitates implantation of the embryo, formation of the placenta, and generation of the mesoderm, 
endoderm and neural crest, all of which are vital for survival [55]. It does so by enabling cells to 
leave their site of origin and be directed to distal locations where they establish new tissues 
through differentiation and proliferation. In fact, during development EMT is considered to be 
indispensable. Prevention of EMT at this stage leads to embryos being unable to undergo 
gastrulation and becoming inviable [69]. This type of EMT, being the first to be observed and 
studied, is known as type I EMT.  
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The second area in which EMT plays a key part is during wound healing. When the structured 
epithelial layer is broken, and a wound is formed, the surrounding cells must have the capacity to 
migrate into the damaged site, attach there and repopulate to begin the healing process. This 
phenomenon is known as re-epithelialisation [70]. Once the site is repopulated, the barrier 
function of the epithelial layer is restored, and can function as normal to protect the underlying 
tissues from harm. Again, inhibition of EMT in this state leads to the retention of an epithelial-like 
phenotype and delayed or defective wound healing [70, 71]. However, the induction of type II 
EMT is not always beneficial. In certain cases, an EMT response can lead to harmful pathologies. 
An example of this overreaction occurs during fibrosis [55]. A fibrotic response occurs when cells 
transition to become fibrotic due to inflammation. This can lead to the development of scar tissue 
[70]. 
Since its first identification as a developmental process, there has been a marked shift in EMT 
research. This is due to a third type of EMT being identified during tumour metastasis. In order to 
access distal sites of the body, cells within a malignant tumour can undergo type III EMT, invade 
the bloodstream and travel to a secondary site for tumour growth. Researchers have found that, in 
this context, prevention of cytoskeletal actin changes is protective and beneficial for tumour 
prognosis [72].  
The three classical types of EMT have been well-characterised within the literature. However, 
more contemporary research suggests a fourth type of EMT may also exist. This novel context is 
associated with pathological, microbial infections. Microbes induce an EMT-like phenotype in 
order to break through the barrier of the epithelium, and access distal sites around the host [73]. 
These features facilitate both entry of pathogens and spread of infection. Given the ever-increasing 
list of EMT-inducing microbes, it is possible that the definition of EMT should be expanded to 
four distinct types.  
 
1.3.5 Microbes and EMT 
Many microbes drive an EMT-like phenotype in the cells they infect in order to promote the rapid 
spread of infection. Infected cells undergoing EMT become migratory and invasive, allowing 
them to engage a greater number of potential target cells than if they remained sedentary. 
Enhanced motility thereby increases the chances of successful infection taking hold. A number of 
different assays are used to assess EMT, including immunoblot analysis, to examine epithelial and 
mesenchymal protein expression, wound healing assays to look for induction of cell migration and 
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invasion assays, for monitoring cell invasiveness. Using these methods various microbes have 
been found to promote the transition to a mesenchymal phenotype. 
In the case of bacterially-driven EMT, Helicobacter pylori is a well-characterised example. H. 
pylori inserts bacterial protein CagA into host stomach epithelial cells via a type IV secretion 
system [74]. CagA then translocates to tight junctions, recruits the tight junction protein, ZO-1, to 
sites of bacterial infection and disrupts cell-to-cell junctions. CagA also binds to E-cadherin and 
reduces E-cadherin-associated epithelial gene expression, leading to the adoption of a 
mesenchymal-like state [75]. Many researchers have noted that H. pylori induces secretion of 
transforming growth factor beta (TGF-β) via another bacterial protein, CagE, and this may also be 
used to drive EMT [76-78] (Figure 1.6A). In fact, infected cells migrate faster than uninfected 
cells, except when CagE is absent, suggesting CagE enhances H. pylori-mediated EMT [78] 
(Figure 1.6B and C). The disruption of the rigid epithelium and loss of barrier function within the 
stomach provides better access for H. pylori to the underlying tissues and novel cells to infect, 
illustrating how EMT is used to boost pathogenesis.  
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Figure 1.6 – H. pylori promotes secretion of TGF-β and cell migration, EMT characteristics, 
following infection  
(A) ELISA indicated the production of EMT-inducing ligand, TGF-β from stomach adenocarcinoma cells 
increased in concert with the dose of H. pylori (Hp MOI) introduced. [76]. (B) Wound closure in cells exposed 
to H. pylori (G27) was also significantly faster than mock cells and those exposed to a ΔCagE mutant H. pylori 
(G27ΔE). This was seen at 24 and 48 hours post-infection (hpi) in human gastric cancer cells [78].  
 
A number of viruses also initiate EMT signalling. These viruses, like bacteria, benefit from 
disrupting the integrity of the epithelial cell barrier, as well as the resulting exposure to naïve cells 
ripe for infection. The progression through EMT and coercion of cells to becoming migratory can 
assist in carrying infection throughout the body. This allows viruses to infiltrate the host organism, 
evade the host antibody neutralisation response and access distal sites unhindered. An example of 
this occurs during ebolavirus infection. Cells infected with ebolavirus display decreased 
expression of epithelial markers, E-cadherin and claudin-1, whilst mesenchymal markers, 
fibronectin, N-cadherin and vimentin increase. These typical hallmarks of EMT are accompanied 
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by cells adopting a mesenchymal phenotype, increasing secretion of TGF-β and promoting 
phosphorylation of EMT associated transcription factors, such as Smad3 [79, 80] (Figure 1.7). It 
was suggested that induction of TGF-β signalling and the resulting EMT phenotype is important 
for spread and virulence of ebolavirus, as it facilitates greater barrier disruption and drives 
symptoms of haemorrhagic fever [79].  
 
Figure 1.7 – Ebolavirus-infection induces an EMT phenotype and expression of EMT-associated 
proteins  
(A) Infection with an ebolavirus containing GFP (EBOV-GFP) induces an EMT phenotype, including the 
elongation of cells, dissociation of cell-to-cell junctions and spindle-like formation at 24 hpi. (B) This is 
accompanied by increase in mesenchymal marker expression, a decrease in epithelial markers and 
phosphorylation of Smad3 (C). Fold change in expression can be seen on the right. TGF-β secretion is also 
increased (data not shown). Adapted from [79].  
 
Another example of this phenomenon occurs during HCV infection. HCV is known to induce 
expression of EMT markers upon infection and cause a mesenchymal-like cell phenotype as seen 
in Figure 1.8A and B [81]. This virus also activates the TGF-β1 promoter and promotes secretion 
of TGF-β, which can then increase invasion of infected LX-2 cells. This invasion phenotype is lost 
in the presence of an siRNA targeting TGF-β1 [82, 83] (Figure 1.8C). These results suggest HCV, 
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like ebolavirus, utilises host TGF-β signalling to induce transformation of cells and increase their 
capacity for spread and invasion.  
 
Figure 1.8 – EMT and cell invasion can be observed in HCV-infected cells in a TGF-β-dependent 
manner 
(A) Primary human hepatocytes become elongated and spindle-shaped after 3 weeks of infection with HCV 
strain 1a. (B) Structural changes in infected cells correlate with changes in epithelial and mesenchymal marker 
expression as detected via immunoblot. This is observed both for HCV genotype 1a and strain 2a [81]. (C) LX-2 
cells treated with conditioned media (CM) from mock and HCV-infected cells display more invasion, as 
visualised in purple (top left and right respectively). This phenotype was retained when cells were transfected 
with an siRNA targeting GFP (bottom left) but lost upon depletion of TGF-β (bottom right), suggesting invasion 
is a TGF-β-mediated phenotype [82].  
 
Other viruses also possess the ability to induce a partial or complete EMT response, including 
hepatitis B virus (HBV) [84, 85], Epstein-Barr virus (EBV) [86] and SARS-CoV [87, 88]. These 
viruses co-opt host EMT signalling pathways in order to enhance their invasion and spread 
capacity. These pathways are described in the following section. 
Mock HCV 1a 
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1.3.6 Pathways capable of regulating EMT 
A number of signalling pathways are known to drive EMT. They are generally initiated by ligand-
binding at the cell surface, which triggers a downstream signalling cascade and results in the 
transcription of EMT-driving genes. The three major EMT signalling pathways are mediated by 
the Wnt, Notch and TGF-β proteins [89]. 
The Wnt signalling pathway induces EMT by Wnt binding to the Frizzled receptor on the cell 
surface and inhibiting GSK3β. The action promotes the stabilisation of β-catenin, which can then 
translocate to the nucleus and instigate transcription of EMT-associated genes [90]. Due to this 
feature, the Wnt pathway is typically studied in the contexts of developmental biology and cancer 
progression [55, 91-93]. This is due to the fact that Wnt signalling is associated with a notable 
increase in cell motility, which is beneficial during gastrulation, but pathological in the context of 
invasive tumour development.  
The Notch signalling pathway on the other hand acts slightly differently. The Notch proteins have 
an intracellular signalling domain and an extracellular domain, which acts as a receptor. Upon 
ligand binding, the intracellular domain is cleaved, enters the nucleus and recruits transcription 
factors for EMT initiation. Despite the alternate mechanism of this pathway, Notch signalling is 
still associated with a similar response to the other EMT pathways, as well as a poorer tumour 
prognosis [94].  
However, the TGF-β-mediated signalling pathway is the most frequently observed instigator of 
EMT during development and cancer metastasis. It has also been observed as a driver of microbe-
induced EMT [95]. Like Wnt signalling, this pathway is mediated by binding of the ligand, in this 
case TGF-β, to the receptor at the cell surface and eventually leads to gene transcription (Figure 
1.9). Once again, these genes are the major influence for the transition to a more mesenchymal-
like phenotype [96]. As the TGF-β pathway proved most relevant to our research, the details of 
this pathway are discussed further.   
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1.4 TGF-Β SIGNALLING 
1.4.1 Beneficial and pathological contexts of TGF-β signalling 
The TGF-β signalling pathway is one of the most ubiquitously distributed signalling networks in 
the human body. This is thought to be due to its seemingly limitless array of functions, including, 
regulation of the cell cycle, cell migration, apoptosis and cell senescence, proliferation, and 
differentiation. In fact, the TGF-β receptor (TGFβR) complex is found in almost all cell types, 
suggesting all cells have the capacity to respond to TGF-β stimulation [97]. Interestingly, 
depending on the context, the TGF-β ligand can sometimes mediate drastically opposing outcomes. 
This is thought to be influenced by the multitude of binding partners available to TGF-β pathway 
components. Due to this feature, TGF-β signalling is often considered a double-edged sword, 
acting beneficially or detrimentally in very similar contexts.  
In the context of development, TGF-β is considered indispensable for embryo formation. In fact, 
when TGFβR signalling is disrupted via the addition of inhibitors, the distinct tissues of the 
mesoderm and endoderm are lost [98]. However, in specific tissues, such as the lung, increased 
TGF-β1 levels are correlated with the development of cell differentiation-associated pathologies 
and chronic diseases [99].  
Once an organism enters adulthood, the TGF-β pathway begins to contribute to metabolism and 
homeostasis. One instance of this is during wound healing, where, upon the occurrence of trauma, 
surrounding cells escape from the nearby epithelium to repopulate the wound site. When this 
system is disrupted, individuals often develop diseases related to malformed vasculature which 
can cause excessive bleeding and gastrointestinal polyp formation [98]. Conversely, excessive 
TGF-β is linked to the development of scar tissue and fibrosis related diseases [100-102].  
One of the most important contexts where TGF-β can be both hero and villain is during cancer 
development [103]. There is mounting evidence suggesting components of the TGF-β signalling 
cascade have the ability to suppress tumour progression. For example, Smad4 was initially 
identified due to its potent anti-tumour abilities and its loss in malignant pancreatic and colon 
tumours [104-107]. The type II TGFβR (TGFβRII) is also often mutated in problematic gastric 
tumours, gliomas and non-small cell lung cancers, suggesting it may also play a role in preventing 
tumour progression [103]. In fact, TGF-β itself is known to dampen cell proliferation, which 
disrupts the expansion of malignant cells and hinders tumour growth [108]. However, upon 
progression to late-stage tumours, TGF-β has a much more pathological role. This is especially 
true in relation to TGF-β-induced EMT. EMT is an absolutely essential process for wound healing 
and organ development, yet it is also the major determinant of metastatic potential in tumour cells 
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[109, 110]. Malignant cancers often display rampant TGF-β pathway activation in order to drive 
this detrimental EMT phenotype [103]. As such, TGF-β can be both a target and a therapeutic, 
depending on the context.  
 
1.4.2 The cascade 
The first step in this pathway is the secretion and activation of latent TGF-β. Once cleaved, active 
TGF-β associates with its receptors at the cell surface. The TGFβR is a two-part receptor which 
becomes phosphorylated and can then act on downstream transcription factors, known as Smad 
proteins. In this case, Smad2 and Smad3 interact with the receptor and become C-terminally 
phosphorylated at the SSXS motif [111]. An inhibitory protein, Smad7 can antagonise this step via 
a number of mechanisms [112-114]. Following activation, Smad2 and Smad3 form homo- or 
heterodimers and then complex with the constitutively active Smad, Smad4. The whole complex 
then translocates to the nucleus, where along with DNA binding partners (DBPs), they can 
modulate gene expression of target genes. These target genes control a variety of functions within 
the cells, including, but not limited to, wound healing, transcription or cytoskeletal rearrangements 
(Figure 1.9) [115-117].  
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Figure 1.9 – The TGF-β signalling pathway 
Signalling is initiated by extracellular TGF-β binding to its heterodimeric receptor at the cell surface. This action 
sets the signalling cascade into motion by pushing the type II TGF-β receptor (TGFβRII) to phosphorylate the 
type I receptor (TGFβRI), which can then in turn act on receptor Smads, Smad2 and Smad3. The phosphorylated 
receptor Smads form hetero- or homodimers, complex with the common Smad, Smad4, and translocate to the 
nucleus. In the nucleus this signalling complex initiates transcription of Smad target genes with the assistance of 
DNA binding partners (DBPs). Transcription can be divided into two classes, Smad4-dependent genes 
(described in purple) and Smad4-indepdent genes (described in orange). In certain conditions, an inhibitory 
Smad, Smad7, is able to impede signalling by inhibiting receptor Smad phosphorylation. 
  
1.4.3 The TGF-β ligand 
The TGF-β ligand superfamily is a large group containing many biologically important proteins 
such as TGF-β, activins, bone morphogenic proteins (BMPs), growth and differentiation factors 
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(GDFs) and the anti-Muellarian hormone (AMH). Over 40 members of this family have been 
identified due to a conserved cysteine-knot domain which is responsible for receptor interactions 
[118]. These ligands regulate a huge number of cellular processes, including cell migration, 
morphology and growth. Due to their array of functions, secretion and activation of these ligands 
is tightly monitored. One such mechanism of regulation is first secreting the ligands in a latent 
form, which must be processed and cleaved in order to interact with the cell surface receptor. In 
the case of TGF-β, the original protein translated from TGFβ mRNA is known as the pre-pro-
TGF-β peptide, and consists of a pre-signal peptide, a pro-region latency-associated peptide (LAP) 
and a mature TGF-β monomer (Figure 1.10) [119]. Upon removal of the signal peptide region, we 
see the formation of pro-TGF-β, which can then dimerise and modified to form the small latent 
complex. This combines with another protein, the latent TGF-β binding protein (LTBP) prior to 
secretion from the cell. Once in the extracellular space, LAP and LTBP are proteolytically cleaved 
from the inactive form of the TGF-β protein [120, 121]. This step is mediated by a number of 
molecules and signals, including MMP proteases, thrombospondin-1, plasmin, integrins and low 
pH, and results in free mature TGF-β able to associate with its receptors at the cell surface [122]. 
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Figure 1.10 – Forms of latent and active TGF-β 
Initially, TGF-β is produced as a pre-pro-peptide, consisting of three parts: the signal peptide (SP), a latency-
associated peptide (LAP) and the pro-form of TGF-β. The signal peptide promotes the export of TGF-β from 
cells. Once removed, the remaining LAP and TGF-β peptides are packaged into a dimer known as the small 
latency complex. Another protein, the latent TGF-β binding protein (LTBP) is then able to associate with the 
LAP via a single disulfide bond. The whole complex is then termed the large latency complex and is secreted 
from cells. In order to be activated, both the LAP and LTBP need to be cleaved in order to leave the active TGF-
β protein able to associate with the TGF-β cell surface receptor complex. Image adapted from [100, 119, 123]. 
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1.4.4 Receptor signalling in the TGF-β superfamily 
Signalling in the TGF-β superfamily is initiated by receptor activation. This step sets off a 
signalling cascade that ends with a flurry of changes to gene transcription. There are various 
members of the TGF-β receptor family (see Table 1.1); however, we can divide them into two 
broad classes, the type II receptors and the type I receptors. Currently, 5 type II and 7 type I 
receptors have been identified [124]. Both types consist of an extracellular ligand-binding domain, 
a transmembrane section and a long intracellular serine-threonine kinase domain. In the basal state 
they typically exist as homodimers at the cell surface; however, for signal induction to occur their 
localisation and orientation needs to change. This process is triggered by ligand binding to two of 
its type II receptor proteins at the cell surface. This then promotes the recruitment of a type I 
receptor homodimer, forming a heteromeric complex consisting of two homodimers of type I and 
type II proteins. Once in close proximity and ligand-bound, the type II receptor phosphorylates the 
type I receptor and leads to its activation. Without this interaction a GS motif inserted in the 
kinase domain of the type I receptor prevents its activity. Association with the type II receptor 
removes the influence of this inhibitory site and stabilises the formation of the receptor 
conglomerate [125, 126]. At this point, the receptor complex is free to interact with transcription 
factors, known as Smad proteins, to perpetuate the TGF-β signal. 
Various combinations of these proteins exist at the cell surface, each of which facilitate binding to 
the 40 plus ligands in the TGF-β family [127]. The most common combinations of type II and type 
I receptors in the TGF-β family are listed within Table 1.1, alongside their corresponding ligands 
and interacting Smad proteins [116, 124, 128]. Note that while some receptor combinations have 
been observed, biological activity for a number of these is less well characterised. For example, 
TGF-β has been observed to bind a number of type I receptors in complex with TGFβRII; 
however, it is only in the case of TGFβRI/TGFβRII complexes that signal transduction is thought 
to occur. It is important to note that these receptors are capable of associating in a ligand 
independent manner; however, their interactions are stabilised in the presence of TGF-β [129-131]. 
Ligand specificity is conferred by ligand interactions with a three-fingered domain in the 
extracellular region of the receptor proteins [118]. Interestingly, it seems that receptors also 
display preferences for Smad protein interactions. A type I receptor which interacts with Smad2 
and Smad3 appears unable to bind Smad1, Smad5 or Smad8 and vice versa. This selectivity is 
conferred by L45 loop motifs in the TGFβRI protein, which transiently bind to L3 motifs in Smad 
proteins and leads to their C-terminal phosphorylation and activation [111, 132-135]. 
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Table 1.1 – Combinations and names of type II and type I TGF-β family receptors  
Type II 
receptors 
Type I 
receptors Ligands 
Biological 
activity Interacting Smads 
TGFβRII 
ActR1 TGF-β - 
Smad1, Smad5, Smad8 
TSR-1 TGF-β - 
TGFβRI TGF-β Yes Smad2, Smad3 
ActRII 
ActRI Activins, BMPs - Smad1, Smad5, Smad8 
ActRIB 
Activins Yes 
Smad2, Smad3 
Nodal, BMPs - 
ActRIC Nodal, Activins BMPs, - 
TGFβRI 
BMPs 
- 
BMPRIA Yes 
Smad1, Smad5, Smad8 BMPRIB Yes 
N/A Yes 
ActRIIB 
ActRI Activins, BMPs Yes Smad1, Smad5, Smad8 
ActRIB 
Activins Yes 
Smad2, Smad3 
Nodal, BMPs - 
ActRIC Nodal, Activins, BMPS - 
TGFβRI 
BMPs 
- 
BMPRIB - Smad1, Smad5, Smad8 
AMHRII 
ActRI 
AMH 
- 
Smad1, Smad5, Smad8 BMPRIA - 
BMPRIB - 
BMPRII 
ActRI  
BMPs 
Yes 
Smad1, Smad5, Smad8 
TSR-1 - 
TGFβRI - Smad2, Smad3 
BMPRIA Yes 
Smad1, Smad5, Smad8 
BMPRIB Yes 
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1.4.5 Adaptors and anchors of receptor-Smad interactions 
Another consideration in receptor-mediated signalling is the presence of adaptor proteins, which 
can facilitate and stabilise the interactions between receptor proteins and Smad proteins. The most 
well documented of these is the Smad anchor for receptor activation (SARA) protein. SARA 
contains both a Smad binding domain and a receptor-interacting C-terminal region [136, 137]. 
Mutations to SARA can lead to mislocalisation of Smad2 and a depleted downstream response to 
TGF-β [138]. In fact, a total deletion of SARA led to an increase in Smad2 destruction via 
increased interaction with components of ubiquitination pathways [139]. SARA may also play a 
role in assisting the inhibitory Smad, Smad7, in dephosphorylating the type I receptor, and so 
plays a complex role in both positively and negatively regulating TGF-β signalling [140].  
 
1.4.6 The Smad protein family 
The transcriptional mediators of the TGF-β superfamily are proteins known as Smads. The human 
genome encodes 8 Smad proteins which can be divided into three classes: receptor-interacting 
Smads (R-Smads), the common Smad (Co-Smad) and inhibitory Smads (I-Smads) [115, 141]. As 
the name suggests, R-Smads require interaction with their preferred receptor in order to be 
activated. Upon ligand binding, these proteins become activated via C-terminal phosphorylation at 
the SSXS motif. This event is thought to be essential for R-Smad function [111, 132, 133]. The 
Co-Smad, on the other hand, is constitutively active and does not interact with ligand receptors at 
the cell surface. I-Smads also bind the receptor complex and by doing so they compete for binding 
with R-Smads and inhibit downstream signalling [112, 142]. They can also target these same 
proteins for destruction by ubiquitination pathways [113]. Members of this family are described in 
Table 1.2. 
In the context of TGF-β signalling, R-Smads, Smad2 and Smad3 carry signal from the receptor to 
the nucleus by forming a complex with the Co-Smad, Smad4. This process can be antagonised by 
I-Smad, Smad7. The remaining members of the Smad family, Smad1, Smad5, Smad6 and Smad8 
(also known as Smad9) are typically associated with another signalling pathway, the BMP ligand-
mediated pathway [116, 143-146]. 
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Table 1.2 – List of human Smad proteins and their functions 
Classes Name Activating 
ligand 
Action 
R- Smad Smad1 BMP Transcription factor activated by BMP type I 
receptor, complexes with Smad4, regulates cell 
proliferation and differentiation  
Smad2 TGF-β Transcription factor activated by TGF-β and 
activin signalling, generally cannot bind DNA 
directly but acts in concert with Smad3 and 
Smad4 
Smad3 TGF-β Transcription factor activated by TGF-β and 
activin signalling, binds DNA, Smad2 and Smad4 
Smad5 BMP Transcription factor activated by BMP type I 
receptor, complexes with Smad4 
Smad8 
(Smad9) 
BMP Transcription factor activated by BMP type I 
receptor, complexes with Smad4, regulates 
proliferation 
Co-Smad Smad4 N/A Complexes with R-Smads, translocates to the 
nucleus, aids in altering gene expression, 
regulates proliferation 
I-Smad Smad6 TGF-β, BMP Broad inhibitory protein, competes with R-Smads 
for receptor binding, also targets them for 
degradation by ubiquitination pathways 
Smad7 TGF-β, BMP Broad inhibitory protein, competes with R-Smads 
for receptor binding, also targets them for 
degradation by ubiquitination pathways  
 
Not only are these three classes based on functional differences, but also structural differences 
(Figure 1.11). R-Smads and the Co-Smad possess two conserved globular domains, Mad 
homology domain 1 and 2 (MH1 and MH2), joined by a variable linker region, whilst I-Smads 
lack the MH1 domain [116]. The basic structure of each of the Smad classes can be seen in Figure 
1.11. Different elements within each of the proteins assist in their varying functions. For example, 
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R-Smads and the Co-Smad possess a nuclear localisation signal in the MH1 domain which 
facilitates access to their targets in the nucleus [147-149]. They also contain a DNA binding 
domain, consisting of a β-hairpin structure, for docking to these same targets [150, 151]. 
Interestingly, in humans, the most common splice variant of Smad2 contains an insert at this site 
which prevents direct DNA binding [150]. Another feature present in Smad4 only is the Smad 
activation domain in the linker region. This 48-amino acid sequence does not affect complex 
formation between Smad4 and other transcription factors but is key to the transcriptional 
activation of these attached components [152]. Finally, all Smad proteins possess an L3 loop in 
their MH2 domains to modulate receptor and Smad-Smad interactions. It is thought the L3 loop is 
responsible for the specificity Smad proteins display towards different type I receptors [134, 153]. 
Not all the features found in Smad proteins assist in activation. For instance, Smad4 contains a 
nuclear export signal in the linker region for shuttling out of the nucleus. This assists in 
controlling constitutive pathway activity [154]. I-Smads can also be exported from the nucleus in 
response to TGF-β stimulation; however, the driving factor for this is less clear due to the lack of 
nuclear export signal. This phenomenon requires an intact MH2 domain, and is potentially through 
interactions with another exported protein, Smurf1 [155, 156]. Another mechanism adopted by R-
Smads and I-Smads to negatively regulate signalling is the incorporation of a PY motif within the 
linker region. These motifs act as binding sites for several ubiquitin ligases and become beacons 
for targeted degradation of these proteins when bound [157, 158]. Smad8 is the exception to this 
rule as it is an R-Smad that does not contain a PY motif.  
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Figure 1.11 – Structure and components of Smad proteins 
The three classes of Smad proteins, R-Smads, the Co-Smad and I-Smads share many features, including two 
distinct regions of homology, the MH1 and MH2 domains. These are connected by a less conserved linker 
region. Various motifs can be found within these proteins to assist with their functions. Members of each class 
are as follows; R-Smads: Smad1, Smad2, Smad3, Smad5, Smad8; Co-Smad: Smad4; I-Smads: Smad6, Smad7 
[116, 141, 149]. 
 
1.4.7 Activation, inhibition and regulation of Smad protein activity 
Smad proteins are expressed in almost all cell types due to the abundant, diverse and important 
roles of TGF-β signalling. Due to this feature, their activity needs to be tightly regulated, and so a 
number of mechanisms have evolved for maintaining control of Smad proteins.  
Typically, R-Smad activation is regulated by phosphorylation mechanisms [159]. These proteins 
are produced in an inactive monomer form, which is then activated by phosphorylation at the C-
terminal [111, 132]. To control their activation, cells have developed mechanisms for the 
dephosphorylation of Smad proteins. For instance, PPM1A is a phosphatase capable of removing 
phosphorylation from the C-terminal of Smad2 and Smad3 proteins and mediates their ejection 
from the nucleus [159]. This allows cells to de-escalate the TGF-β response, to prevent 
constitutive pathway activation following ligand binding. Furthermore, proteins such as Smurf and 
Arkadia target activated R-Smads for degradation by adding ubiquitin tags to these proteins [160, 
161].  
Smad4, on the other hand, due to its constitutive activation, requires a number of regulatory 
controls to prevent errant and unchecked activity. For instance, at the Smad activation domain, a 
mitogen activated protein kinase (MAPK)-responsive phosphorylation site is present which 
enhances co-activator binding and nuclear translocation of Smad4 [162, 163]. However, a Wnt-
mediated kinase, GSK3, uses this initial phosphorylation site to dock to Smad4 and introduce 
three upstream phosphate groups, which function in an inhibitory fashion [162]. Another control 
mechanism is mediated by ubiquitination pathways. In its basal state Smad4 is mono-ubiquitinated, 
to constrain signalling [164]. A number of proteins are capable of adding ubiquitin to Smad4, 
including the SCF E3 ligase-ubiquitin complex which prevents TGF-β-associated cell cycle arrest 
in a Smad4 mediated manner [165]. Other examples include Jab1 and Ras [166-168]. Whilst these 
proteins mediate Smad4 degradation, others act to remove the ubiquitin from Smad4, leading to an 
enhancement of TGF-β signal transduction. One such de-ubiquitinating protein is FAM/USP9x 
[169]. A final regulation mechanism is sumoylation. This is a process where SUMO, or small 
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ubiquitin-related modifier protein, destabilises protein-protein interactions and cellular trafficking 
of proteins to alter their functions [170]. In this case, SUMO interferes with ubiquitination, 
protecting against degradation and promoting nuclear accumulation and DNA binding of Smad4 
[171].  
I-Smads are less well-studied in terms of their activation profiles. However, research has begun to 
suggest they are also regulated by typical phosphorylation and ubiquitination mechanisms. For 
example, phosphorylation of Smad7 at the linker site affects its abilities as a transcription factor 
[172]. However, this does not appear to affect its interactions with the TGFβR complex. 
Furthermore, Smad7 is known to be targeted by ubiquitin ligases for destruction, potentially even 
the Smurf1 and 2 proteins. However, acetylation of the ubiquitin ligase target sites leads to 
protection of this protein and maintenance of its stability [173]. These data suggest that Smad7 
regulation is a balancing act between competing regulatory mechanisms. 
Together, these mechanisms maintain the balance of pro- and anti-TGF-β signals within the cell 
and assist in regulating the various biologically important processes controlled by TGF-β 
signalling.  
 
1.4.8 The interplay between Smad proteins 
The Smad proteins constantly interact to influence each other and cellular transcription in tandem. 
These interactions are regulated by different mechanisms depending on the Smad protein. For 
example, R-Smads, Smad2 and Smad3 are sterically hindered from forming complexes until C-
terminally phosphorylated [174]. Smad4, on the other hand, due to its constitutive activation 
profile, does not require any extra inputs or signals to form oligomers with R-Smad proteins [164, 
174]. The amalgamation of these R-Smad/Smad4 complexes leads to a synergistic interaction, 
boosting activity of each Smad protein within the trimer, as well as enhancing the capacity for 
signal potentiation [125, 174]. Other than phosphorylation events, inherent features of R-Smad 
proteins can also affect the formation of Smad complexes. For instance, Smad2 and Smad3 are 
known to have different binding affinities for Smad4. Smad2 is binds Smad4 more strongly than 
Smad3, regardless of its C-terminal phosphorylation profile. This is thought to be due to a feature 
of its linker region, as a chimeric Smad3 protein containing the linker sequence of Smad2 bound 
Smad4 more effectively [175]. Curiously, the stoichiometry of Smad complexes is also not 
entirely understood as yet. One possible explanation is the preferences of certain transcriptional 
co-factors for different R-Smad/Smad4 trimers, which either bind R-Smad homodimers, or 
Smad2-Smad3 heterodimers, exclusively [176]. These results suggest that C-terminal 
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phosphorylation, linker sequence and co-factor preferences all influence the formation of Smad 
transcriptional complexes.  
 
1.4.9 Nuclear shuttling of Smads 
Once complexed, the next stage of the signalling cycle involves nuclear shuttling of Smad proteins. 
A huge number of genes are modulated via the TGF-β and BMP signalling pathways, affecting 
anything from cellular proliferation and differentiation to growth arrest and apoptosis. However, 
in order to alter gene expression, the transcription factors need to gain access to the nucleus and 
genetic material found within.  
In the case of R-Smad proteins, it is proposed that activation by the receptor leads to 
conformational changes that expose the nuclear localisation signal and allow binding of nuclear 
import proteins, such as importin-β1 [177]. Once bound, the R-Smads can traverse the boundary 
between cytoplasm and nucleus through nuclear pores. For instance, in the absence of TGF-β, 
Smad2 proteins typically localise in the cytoplasm, remaining coupled to the microtubule network 
[178, 179]. Upon ligand stimulation, this cytoplasmic distribution is replaced with a nuclear one. 
Smad3 proteins, on the other hand, have mysteriously been shown to lie predominantly within the 
nucleus in the absence of TGF-β stimulation [175]. However, when tethered to this site and unable 
interact with the activated TGFβR complex, these proteins do not undergo TGFβR-mediated 
conformational changes and their function is severely impeded [175]. Interestingly, another 
nuclear shuttling mechanism is mediated by SARA. It appears SARA binds to monomeric, 
inactive Smad2 and blocks its nuclear translocation; however, once phosphorylated by the TGF-β 
receptor and dissociated from SARA, Smad2 is free to translocate to the nucleus as desired. It 
even appears that purified Smad2, free from SARA but not phosphorylated can still accumulate in 
the nucleus. These results suggest C-terminal phosphorylation is less important for direct nuclear 
transport than the release of Smad2 from SARA [178]. Previous groups have shown that the 
maintenance of R-Smad proteins within the nucleus is also ligand-dependent, but Smad4-
independent [154, 180, 181]. This may be due to the fact that Smad4 constantly shuttles between 
nucleus and cytoplasm in a ligand-independent manner [116]. 
One other mechanism for negative regulation of Smad signalling is the nuclear export of Smad 
proteins. Smad4 possesses a nuclear export signal that allows export proteins, such as XPO1 (also 
known as CRM1), to promote shuttling to the cell cytoplasm [181]. This is absent in Smad2 and 
Smad3 and as such, use of the drug leptomycin B, which inhibits the nuclear export signal, leads 
to accumulation of Smad4 in the nucleus but does not affect Smad2 and Smad3 trafficking [180]. 
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Smad2 and Smad3 are exported by different mechanisms. Firstly, they are dephosphorylated, 
causing them to dissociate from each other and then be marked for export in an XPO1-
independent manner. Again, groups have suggested Smad2 and Smad3 behave slightly differently, 
with Smad2 being chauffeured out of the nucleus by directly contacting nucleoporins, whilst 
Smad3 is chaperoned by karyopherin molecules out of the nucleus [182, 183].  
 
1.4.10 Nuclear helpers or hinderers of Smad transcription factors  
Once within the nucleus, Smad proteins are free to bind to their desired target genes and induce or 
repress gene expression as required. However, Smad proteins have a fairly low affinity for DNA 
binding. In fact, the diversity in genes observed to be targeted by Smad proteins is thought to be 
due to interactions with a number of sequence-specific, high affinity transcription factors, rather 
than conferred by the Smad proteins themselves.  
Smad proteins interact with binding partner intermediaries through their MH2 domains, which 
attach to a Smad interaction motif (SIM) present in these proteins [176]. These DBPs often have 
their own target genes, which are added to the Smad target repertoire upon Smad binding (Figure 
1.12). Examples include the AP-1 complex, forkhead activin signal transducer-1 (FAST-1), Mixer, 
Milk, Runx1, Sp1, Max and TFE3 [184-191]. AP-1 is composed of proteins from the Jun or Fos 
families and is thought to be essential for aspects of TGF-β signalling [184]. It works by 
strengthening the bond between Smad3 and target DNA. However, AP-1 has a complex 
relationship with Smad signalling, seemingly increasing transcription of its own targets whilst 
repressing expression of direct targets of Smad3 [185]. FAST-1, Mixer and Milk, on the other 
hand, promote Smad-mediated transcription. They possess a Smad interacting motif that is highly 
similar to that found in SARA; however, they only bind active Smad2. As such, they promote 
Smad activity by recruiting Smad oligomers to their respective binding sequences [186, 187]. In 
the case of FAST-1, this reaction appears to be synergistic, as alone FAST-1 appears insufficient 
to induce transcription [187, 188]. Runx1 is another transcriptional effector, which recruits Smad 
proteins to specific subnuclear foci to promote transcription of specific target genes, whilst Sp1 
assists in driving TGF-β-mediated EMT [189, 190]. Other than the afore mentioned Smad-DBP 
complexes, some interactions can be more inhibitory in nature. For example, both Max and TFE3 
proteins share a leucine-rich zipper region which binds to the MH1 domain of Smad3 and Smad4, 
as well as associating with target gene promoters. Despite their similar structures, TFE3 proves to 
have an enhancing action and Max, an inhibitory one, as it disrupts Smad3-mediated transcription 
[191]. 
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Whilst numerous DBPs have been identified, other proteins are also able to influence the 
transcriptional activity of Smad proteins. They are known as co-activators or repressors depending 
on the outcome of their binding (Figure 1.12). These proteins do not directly bind DNA but can 
associate with Smad proteins to alter their affinities. Co-factors may also account for the opposing 
reactions observed post-TGF-β treatment, such as growth arrest vs. cell proliferation. One such 
example is the CREB-binding protein (CBP)/p300 histone acetyltransferase complex, which 
promotes DNA binding of R-Smads via acetylation of a lysine within the MH2 domain of these 
proteins [192, 193]. These proteins are capable of interactions with Smad2 and Smad3, but not 
Smad4 [194]. PKA, another co-activator, directly binds to Smad4 and promotes TGF-β-associated 
growth inhibition and EMT [195]. Not all of these co-factors promote the activity of Smad 
proteins. Co-repressors of the TGF-β signalling pathway can include proteins such as, Ski and Sno. 
These bind to both R-Smads and Smad4, via their N-termini, to interfere with target gene 
transcription [196]. Sip1 is also capable of binding activated R-Smad proteins to block their 
activity [197]. 
A third class of proteins, known as adaptor proteins, can assist in Smad-induced transcription. 
These proteins do not directly bind DNA or promote Smad activity in isolation; however, they are 
able to strengthen interactions of Smad proteins to their co-factors and boost their transcriptional 
capacity (Figure 1.12). MSG1, for example, solidifies the bond between CBP/p300 and Smad4 to 
promote Smad4-dependent gene transcription [198]. SMIF, another adaptor protein, works in a 
similar manner and is seen to accumulate in the nucleus upon TGF-β treatment [199]. The same is 
true for steroid receptor co-activator-1 (SRC-1) [200]. Curiously, Ski and Sno can also act as 
adaptor proteins, promoting interactions between Smad proteins and other repressors, such as N-
Cor [201]. 
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Figure 1.12 – Smad binding partners and their respective roles 
The R-Smad proteins, Smad2 and Smad3, as well as Smad4, are known to complex with a wide array of proteins 
within the nucleus in order to modulate gene expression. Some of these assist or inhibit Smad binding to DNA. 
These are known as DBPs. The second group of proteins do not interact with DNA, but directly influence Smad 
protein activity. These co-factors (Co-X) can activate, in the case of co-activators, or inhibit Smad-mediated 
transcription. Finally, adaptor proteins (Ad) assist Smads in binding their various co-factors. These three groups 
are shown in green, blue and pink respectively. Adapted from [116].  
 
1.4.11 Smad transcriptional targets 
Over 500 genes have been identified as targets for Smad transcription factors and their co-factors 
[141]. These genes are characterised by the presence of unique sequences within their promoters 
that have been identified as Smad-binding motifs. For example, Smad3 was originally identified is 
binding a short palindromic motif in target promoters, GTCTAGAC [202-204]. Later evidence 
suggested only half of this, GTCT or its complement, CAGA, was sufficient for Smad binding 
[202]. These sequences were aptly named Smad binding elements (SBEs) or CAGA boxes. 
Interestingly, despite their similar structure, Smad2, unlike Smad3, is unable to directly associate 
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with DNA due to an extra exon present within its β-hairpin DNA binding site [205, 206]. As such, 
Smad2 relies heavily on co-activators and DBPs in order to influence gene transcription.  
A huge number of co-factors, described above, bind to and regulate Smad protein transcriptional 
activity. Curiously, some of these binding proteins display preferences for particular R-Smad 
complexes. For example, Fast-1 prefers to bind to the complex containing two Smad2 proteins and 
a Smad4 protein. This four protein heteromer is known as ARF1 [176]. ARF2 is a similar complex 
where Fast-1 has been replaced with Fast-3. These complexes are particularly important in driving 
expression of genes related to development and gastrulation, and they bind a promoter motif 
known as the activin responsive element (ARE) [207]. In fact, ARE sequences bound to luciferase 
genes are considered direct tests for Smad2 activity. 
Other than CAGA boxes and the ARE motif, another DNA-Smad interaction point is known as the 
Smad binding region (SBR). Genes such as c-JUN contain the SBR and only respond to single 
Smad3 and Smad4 dimers [176]. The PAI-1 target gene also contains sites known as consensus 
tetradecanoylphorbol acetate (TPA)-responsive elements or TREs. These sites are the binding 
elements for AP-1 transcription factors and form the basis of 3TP-lux luciferase constructs for 
testing Smad3 activity [202]. 
After Smad proteins and their various binding partners attach to their respective binding motifs, 
they enhance transcription of the effector genes of this pathway. Once again, despite their similar 
structures, the two R-Smads oversee genes of differing functions. For example, Smad2, typically 
controls genes involved in metabolism, cell motility, structure and adhesion, whilst Smad3 
modulates a variety of transcription factors [175]. A number of common Smad target genes and 
their functions have been listed in Table 1.3. Many of these have been identified by broad 
transcriptomic approaches [208]. These genes are all typically regulated by Smad2, Smad3 or a 
combination of both. In some cases, Smad4 is also required. As such, these genes are labelled 
Smad4-dependent in nature. All of those listed appear to play some role in TGF-β-induced EMT, 
apoptosis or overall pathway regulation. For example, PAI-1 is strongly upregulated by TGF-β 
treatment in order to regulate EMT-associated cell migration [209]. Others, such as Ski and Sno, 
have a more complex relationship with the TGF-β ligand. In the case of Ski, low concentrations of 
TGF-β increase Ski, high levels of TGF-β repress transcription [210].  
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Table 1.3 – Common transcriptional targets of the TGF-β/Smad signalling pathway 
Target  Full name Function Associat-
ed Smad 
c-JUN v-jun sarcoma 
virus 17 
homolog 
Transcription factor, part of AP-1 transcriptional 
complex, can both activate and inhibit Smad3-
mediated transcription [211, 212] 
Smad3 
Snail2 Snail homolog 2 
(also known as 
Slug) 
Transcription factor, master EMT regulator, 
similar function to Snail1; however, not all 
transcriptional targets are shared [213, 214]  
Smad3 
PAI-1 Plasminogen 
activator 
inhibitor-1 
Inhibits breakdown of plasminogen, affects 
function of matrix metalloproteinases (MMPs,) 
maintains extracellular matrix (ECM) [215] 
Smad3-
Smad4  
TGFb Transforming 
growth factor-
beta 
Pleiotropic cytokine, positive feedback regulator, 
modulates an array of cellular functions involved 
in cell growth, migration and survival [216] 
Smad3 
Snail1 Snail homolog 1 Transcription factor, master EMT regulator, 
represses transcription of epithelial genes and 
promotes mesenchymal expression [89, 217] 
Smad3 
GADD45
B 
Growth arrest 
and DNA 
damage-
inducible beta 
Stress response gene, mediator of TGF-β-induced 
apoptosis [218] 
Smad2/ 
Smad3-
Smad4 
Ski Ski oncoprotein Co-repressor, negative feedback regulator, 
competes with CBP for Smad3 binding, 
strengthens bond between DNA and inactive R-
Smad/Smad4 complexes [219, 220] 
Smad2/ 
Smad3 
Sno Ski-like protein Co-repressor, negative feedback regulator, recruits 
nuclear receptor co-repressor-1 to inhibit Smad2-
Smad4-dependent transcription [221] 
Smad2/ 
Smad3 
Smad7 Similar to 
mothers against 
decapentaplegia 
homolog 7 
Inhibitory Smad protein, compete with R-Smads 
for receptor binding [222] 
Smad2/ 
Smad3 
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Smurf1 E3 ubiquitin 
ligase Smurf1 
Inhibitor of Smad signalling, targets TGFβR 
proteins for degradation by ubiquitination 
pathways, recruited by Smad7 [223] 
Smad2/ 
Smad3 –
Smad4 
 
 
1.4.12 Non-Smad mediators of TGF-β signalling 
In the canonical TGF-β signalling pathway, TGF-β binding to its surface receptor initiates a 
cascade, which results in Smad protein activation and downstream transcription. However, the 
TGFβR complex also has the ability to act in a non-canonical manner and feed into other host 
signalling pathways, such as the extracellular signal-related kinase (ERK), c-JUN N-terminal 
kinase (JNK), phosphatidylinositol 3-kinase (P13K) and RhoA-mediated pathways [116, 224, 
225].  
Non-canonical TGF-β signalling can enhance the phenotypes observed following Smad protein 
activation. For instance, TGF-β-mediated ERK signalling can contribute to EMT progression 
[226]. This signal is transduced by TGFβRII being phosphorylated by intermediates of the MAPK 
pathway, such as Shc. This activates the Ras signalling pathway, which promotes ERK 
phosphorylation and activation [224]. ERK can then act directly on Smad proteins to influence 
their activity, or influences co-factors, such as AP-1, to bind Smad proteins and promote target 
gene transcription [224, 227].  
Another member of the MAPK pathway, JNK, is capable of acting in a similar way to ERK to 
promote TGF-β-induced EMT [224, 228, 229]. Again, the TGFβRII protein is responsible for 
activating this system. It does so in this case via interactions with the TAK1 protein and a poly-
ubiquitinated form of TRAF6, which is an immunomodulatory protein. These two proteins 
activate downstream MAPKs and lead to JNK activation. The p38 MAPK, is activated in an 
identical manner and also influences TGF-β signalling [116]. 
The TGF-β receptor-mediated interaction with the P13K protein is more direct. In this case, 
TGFβRII binds a subunit of P13K, which phosphorylates Akt. This enhances transcription of 
genes which drive EMT, apoptosis, and inhibit growth arrest [224]. Both of these proteins also 
display the capacity for direct R-Smad interactions [230]. In this context, P13K is responsible for 
ubiquitin-mediated degradation of Smad proteins.  
RhoA is another mediator of non-canonical TGF-β-induced cell migration [231]. However, the 
relationship between RhoA and cell motility is fairly complex. Given the wide distribution of 
RhoA within the cell, it is both responsible for leading edge cellular extensions which pull cells 
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forward, as well as mediating the attachments at the rear of cells which anchor them [232]. Due to 
this feature, TGF-β is both able to inhibit and promote RhoA signalling through a variety of 
mediators including Par6, PKCζ and Smurf1. The TGFβRII can also directly interact with RhoA 
[224, 232].  
These non-canonical pathways contribute to the outcomes of TGF-β signalling, especially in 
relation to EMT and apoptosis. However, they can also play a role in determining whether the 
outcome of TGF-β binding will be helpful or harmful.  
 
1.4.13 Cross talk mechanisms 
Whilst the TGF-β signalling cascade consists of both canonical and non-canonical pathway 
elements which manipulate the outcomes of signal transduction, they are not the only influences 
on this system. A number of other signalling pathways are independently activated and able to 
feed into the TGF-β signalling cascade. One prominent example of this is the epidermal growth 
factor receptor (EGFR) mediated signalling pathway.  
Activation of the EGFR signalling cascade is mediated by extracellular ligand binding to the 
transmembrane receptor, EGFR [44]. Curiously, this sets off an array of pathways not too 
dissimilar to those activated by non-canonical TGF-β signalling, including activation of the ERK 
proteins, and P13/Akt. EGFR also has the capacity to activate the JAK/STAT and protein kinase C 
(PKC) signalling cascades. These modulate TGF-β signalling at a number of points, causing 
ubiquitination of Smad proteins, interfering with Smad target transcription, or promoting nuclear 
translocation and activity of Smad proteins [101, 162, 163, 230, 233, 234]. As a result, EGFR 
signalling both positively and negatively regulates TGF-β signalling depending on the context.  
Different cross-talk potential stems from interactions with members of other MAPK cascades, as 
well as the other major EMT regulators, the Wnt and Notch signalling pathways [235]. For 
example, downstream Wnt pathway mediator, β-catenin, can form a complex with Smad proteins 
to influence gene transcription. This is also true for the intracellular domain of the Notch receptor, 
the NCID, which binds to Smad3 in order to express particular Notch and TGF-β target genes 
[236].  
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1.5 SURVIVAL IN A HOSTILE ENVIRONMENT – VIRUSES AND CELL SIGNALLING  
1.5.1 Viral manipulation of host signalling  
As intracellular parasites, viruses often have to modulate host cell signalling in order to survive 
and replicate effectively. These manipulated pathways are involved in processes such as apoptosis, 
replication, antiviral responses and cell behaviour.  
For instance, apoptosis is one of the leading defence mechanisms employed by cells to control the 
spread of infection. This programmed cell death event does not lead to lysis and, as such, infection 
is contained to the dying cell and is unable to access further targets for infection [237]. Due to this 
feature, countless viruses have evolved to inhibit the induction of apoptosis, allowing the virus to 
replicate errantly until the cell bursts and viral progeny are expelled towards new cells. One 
example is adenovirus, which contains at least four proteins to inhibit the apoptosis cascade at 
different levels, disrupting p53, Bax, Fas and Bcl-2 [238]. VACV also possesses a range of anti-
apoptotic proteins [239, 240]. Curiously, some viruses prefer for apoptosis to continue, as it limits 
the severity of the following inflammatory response, allowing the virus population to expand 
relatively undetected. Examples of pro-apoptotic viruses include human papillomavirus (HPV) 
and HIV [238].  
Other than apoptosis pathways, another commonly manipulated group of cellular proteins are 
those involved in replication. The majority of viruses, as compact packages of genetic material, do 
not carry all the machinery required for their own replication. As such, they rely on host resources 
in order to multiply efficiently. In fact, some of the most commonly hijacked resources are host 
polymerases which are repurposed as tools for viral replication [241, 242]. It should be noted that 
viruses which replicate entirely in the host cell cytoplasm do not have access to host polymerases 
and so often carry their own. Also, as mammalian cells do not possess RNA-dependent RNA 
polymerases, or reverse transcriptase enzymes, viruses which require these must encode their own 
[243]. 
As expected, another system viruses seek to manipulate is host antiviral response. For example, 
cells use interferons to mediate the antiviral response, and prepare neighbouring uninfected cells 
to combat infection [244]. Viruses possess a number of mechanisms to subvert these pathways 
[245, 246]. For instance, VACV encodes at least ten proteins which interfere with the induction of 
interferon responses by disrupting NF-κB activation, STAT phosphorylation, IFN receptors and 
the actions of adaptor proteins or host detection mechanisms [244]. Given how gene-poor viruses 
tend to be, this large portion of resources devoted to subverting the interferon response, suggests 
how crucial this pathway is in the balance of infection.  
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Finally, it is often beneficial for viruses to alter the structure and behaviour of the cells they infect. 
For instance, VACV entirely restructures the host cytoskeleton in order to traffic around the cell to 
the surface, and to be extruded towards other cells for infection [247-249]. Other viruses, such as 
Dengue virus promote cell motility and invasion in order to magnify the rate of spread around the 
host organism [250, 251]. As such, these viruses target specific host cell signalling pathways 
known to modulate structure and behaviour of cells, to subvert these as vessels for the distribution 
of infection.  
 
1.5.2 Viruses and TGF-β 
A frequently manipulated system during infection is the TGF-β signalling pathway described 
earlier, which occurs ubiquitously in all cell types. In fact, the original discovery of TGF-β in the 
late 1970s was as a secreted factor from virally-transformed sarcoma cells, and was initially 
termed sarcoma growth factor (SGF) [252]. Five years later, Anzano et al. characterised SGF as a 
mixture of two transforming factor proteins, TGF-α and TGF-β [253]. Since the discovery of 
TGF-β, examples of viruses both upregulating and downregulating the TGF-β signalling pathway 
can be seen throughout the literature.  
Various mechanisms are in place to alter TGF-β signalling and can target any stage of the pathway 
(Figure 1.13). For instance, Influenza A virus has a unique strategy to increase the action of TGF-
β on the receptor. The neuraminidase protein of Influenza A activates secreted latent TGF-β by 
cleaving it from the LAP [254, 255]. However, TGF-β can act in an antiviral fashion, so highly 
pathogenic influenza viruses often possess a neuraminidase that cannot cleave the sialic acids 
within the LAP [255].  
Other viruses, such as HCV, manipulate the TGFβR directly. HCV non-structural protein, NS5A, 
uses amino acids 148-237 to bind TGFβRI and inhibit its activity on R-Smad protein 
phosphorylation. This leads to a loss of Smad3-Smad4 complex formation, nuclear-localisation of 
Smad proteins and aberrant formation of Smad-DNA complexes, effectively inhibiting 
downstream TGF-β signalling [256]. Another example occurs in HIV infection, where an HIV 
envelope protein contains a conserved (W/R)XXD motif which displays homology to TGF-β and 
can act on the TGFβR to boost its activity [257]. 
A fairly common approach to modulating TGF-β signalling involves the interaction of a viral 
protein with a member of the Smad transcription family. A clear example of this was published by 
Zhao et al., looking at the N protein of SARS-CoV. They found a direct interaction between the 
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MH2 domain of Smad3 and both the C- and N-terminus of N protein which led to an abrogation of 
Smad3-Smad4 dependent apoptosis [88]. HBV protein X (pX) is another example of a virally 
encoded protein directly interacting with a Smad. In this case, pX interacts with the MH1 domain 
of Smad4 in a ligand-independent manner and facilitates nuclear translocation of this protein [258]. 
However, not all viruses wish to increase Smad activity. Again, HCV acts in an inhibitory way, 
encoding proteins which directly antagonise Smad proteins. For example, HCV core protein and 
non-structural protein 3, NS3, were found to bind Smad3 and diminish its DNA binding ability 
[259].  
Rather than eliciting protein-protein interactions, a number of viruses alter transcription of TGF-β 
or associated transcripts to activate this pathway. A multitude of viral infections are associated 
with an increase TGFβ mRNA expression, including HIV [260], HBV [261], SARS-CoV [262], 
HPV [263, 264], human cytomegalovirus (HCMV) [265, 266], human T-cell lymphotropic virus-1 
(HTLV-1) [267], EBV [268], respiratory syncytial virus (RSV)[269], African swine fever virus 
(ASFV) and rotavirus [270-272]. ASFV is unique in its ability to induce both transcription of 
TGFβ and the TGFβRI gene as early as 2 hours and 1 day post-infection, respectively [273-275]. 
Adenovirus (AdV), on the other hand, is known to inhibit the TGF-β promoter using its E1A gene 
to counteract TGF-β-associated cell cycle growth arrest and promote unchecked viral replication 
[193, 276]. E1A displays homology to Smad co-activator p300 and inhibits Smad activity via 
competitive binding [193, 277]. Transcription of other components of the pathway can also be 
affected. For example, rotavirus inhibits expression of TGFβRII and Smad3 via expression of a 
microRNA, miR-142-5p [272]. 
More and more viruses are being found to exploit this pathway via currently unknown 
mechanisms. Recent evidence has suggested ebolavirus may manipulate this pathway to elicit 
TGF-β secretion from infected cells [79, 80]. Reovirus provides another example of a virus 
altering expression of TGF-β pathway components, TGFβRII and p-Smad3. Certain subviral 
forms of reovirus can also directly increase TGF-β expression [278, 279].  
Within this thesis, we discuss evidence suggesting VACV may also belong to this group; however, 
the mechanism by which it activates the TGF-β signalling pathway is unlike any of the viruses 
described previously. As such, VACV may provide novel insights into the regulation of the TGF-β 
signalling pathway. 
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Figure 1.13 – Viral interactions with the TGF-β signalling pathway 
We can divide viruses into three categories depending on the point at which they manipulate the TGF-β 
signalling pathway. The first group includes those that act on the TGF-β protein or the TGF-β receptor in the 
cytoplasm or extracellular space. These alter TGF-β secretion, activation or TGFβR function. The second 
category of viruses includes those that interact with Smad transcription factors directly to either boost or inhibit 
their activity. Note there have been viruses found to bind each of the three Smad proteins shown, Smad2, Smad3 
and Smad4. The last group of viruses alter TGFβ mRNA production at the promoter level within the cell nucleus. 
Numerous viruses belong to this category. Abbreviations: AdV – Adenovirus, ASFV – African Swine Fever 
virus, EBV – Epstein-Barr virus, HBV- Hepatitis B virus, HCMV – Human cytomegalovirus, HCV – Hepatitis 
C virus, HIV – Human immunodeficiency virus, HPV – Human papilloma virus, HTLV-1 – Human T- 
lymphotropic virus-1, RSV – Respiratory syncytial virus, SARS-CoV – SARS coronavirus. 
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1.6 VACCINIA VIRUS AND THE POXVIRUS FAMILY 
1.6.1 Outline and history of vaccinia virus  
Vaccinia virus (VACV) is a large, double-stranded DNA virus and member of the 
Orthopoxviridae family. These viruses are distinguished from other sizeable viruses by their 
recognisable structures, self-sufficient replication cycles and substantial genomes. They typically 
form asymmetrical, brick-shaped virions, encased in one to three membranes and containing two 
lateral bodies, a dumbbell-shaped core and linear dsDNA genome [280]. Furthermore, a defining 
characteristic of poxvirus replication is that it occurs entirely within the cell cytoplasm in distinct 
foci known as virus factories. This lack of host cell contribution forces the virus to carry all its 
own replication machinery within its capsid and 200kb genome [281-283]. Due to this feature, 
poxvirus genomes rival that of small bacteria [284, 285]. Prominent viruses in this family include 
variola virus (VARV), the causative agent of smallpox, as well as a number of other disease-
causing viruses, such as cowpox (CPXV), horsepox (HSPV) and ectromelia virus (ECTV) [286]. 
Unlike VACV, these other orthopoxviruses can be fairly species-specific, infecting predominantly 
humans, cows, horses and mice. In many cases these viruses are even named after their species of 
origin; however, this is not the case for VACV. Originally thought to be CPXV, it is believed 
VACV was isolated by Edward Jenner in his search for a smallpox vaccine during the late 1700s. 
However, recent evidence suggests VACV is more closely related to the now extinct, HSPV than 
CPXV [287, 288] (Figure 1.14). Today, the exact origins of VACV are still a mystery in the field 
of virology [289].  
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Figure 1.14 – Phylogenetic tree of gene sequences from the Orthopoxvirus genus. 
One hundred and forty-one genes were used to align sequences from 17 orthopoxviruses via the Bayesian 
interference method of phylogenetic prediction. Note that horsepox virus (HSPV), highlighted in red, most 
closely aligns with the various VACV strains (blue) used for this analysis. These are distinct from cowpox virus 
strains (CPXV) shown in green. Adapted from Hendrickson et al., 2010 [290]. 
 
Despite its questionable origins, VACV is considered to be one of the most effective and 
successful vaccine viruses in history. Following its use in the smallpox eradication campaign, the 
WHO declared smallpox to be globally eliminated; the first disease in history to be declared so 
due to human intervention. Since this time, numerous VACV strains have been propagated around 
the world [291, 292]. For instance, one of the oldest documented strains of VACV is the Wyeth 
strain which was distributed widely around the United States and Africa as a smallpox vaccine 
during the 1960s [293, 294]. Today we know this strain as the main proponent of the Dryvax 
vaccine, the only currently available, commercially approved smallpox vaccine. It is also the 
background strain for the JX-594 oncolytic VACV [37]. The Western Reserve strain (VACV-WR); 
the most commonly used VACV today and the one utilised within this thesis is a descendent of the 
Wyeth virus [295]. Other notable VACVs include the virulent European strains, Lister, and 
Copenhagen and the modified vaccinia virus Ankara strain (MVA), which was a lab-generated 
strain considered ideal for use in therapeutics [292, 296, 297]. This last virus contains major 
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genome deletions resulting from serial passages in chicken embryo fibroblasts which left the virus 
demonstrably attenuated; a desirable safety feature for continued public use [298-301]. Together 
these viruses have allowed scientists to amass a wealth of information on VACV and have hinted 
at novel therapeutic roles for this virus.  
 
1.6.2 The replication cycle of VACV 
Like other poxviruses, VACV replicates entirely in the host cell cytoplasm. This is mostly due to 
its large, complex genome which supplies all the information for its own replication. Due to this 
complexity, not all aspects of the VACV replication cycle are fully understood as yet. However, 
the basic steps of viral entry, replication and egress have been outlined.  
Initially, virus particles bind to the cell surface where their outer membranes fuse with the plasma 
membrane to facilitate entry into the cytoplasm [302, 303]. In some cases, it is possible for the 
virus to enter the cell via the endosomal route, where fusion is dependent on low pH within the 
vesicle [304, 305]. Once the virion has entered the cell it undergoes a process of uncoating and 
core disassembly to leave the genetic material exposed [281, 282, 306, 307]. Following this stage, 
transcription of viral genes begins. In the VACV replication cycle, transcription can be divided 
into three temporal classes: early, intermediate and late gene expression. Early gene expression 
initiates transcription of genes involved in DNA replication and those required for intermediate 
and late gene expression, such as nucleotide metabolism enzymes [283]. At this point, DNA 
replication is initiated, before further gene expression ensues. The later stages of transcription 
produce the both the genes involved in DNA processing and packaging, as well as structural 
components of the progeny virions [308, 309]. This site of replication is a perinuclear area known 
as the virus factory [310, 311] (Figure 1.15).  
Following replication, new virion particles are assembled into concurrently forming membrane 
structures derived from the endoplasmic reticulum. These newly packaged virions are known as 
mature virions (MVs) [309, 312, 313]. At this point the majority of MVs lay in wait to be expelled 
during cell lysis whilst a few are detoured to the Golgi apparatus on microtubules [293, 314]. 
Those that head to the Golgi apparatus are further wrapped in a double membrane before shuttling 
to the cell periphery. Again, transport is carried out using microtubule-based transport and these 
triple wrapped viruses are called intracellular enveloped viruses (IEVs) [314-318]. During early 
infection most MVs are polarised towards being wrapped; however, this is reversed at later time 
points [319]. As such, most IEVs are produced during early VACV infection.  
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Finally, IEVs are released via fusion with the cell surface membrane. Those that remain associated 
with the cell surface are known as cell-associated enveloped virus (CEVs). The rest are pushed off 
the surface via actin polymerisation beneath the virion [320, 321]. Once disassociated, they are 
called extracellular enveloped viruses (EEVs) [322]. EEV are important for viral spread and 
dissemination. Researchers determined that VACV strains which produced higher levels of 
extracellular virus were disseminated to more organs within a mouse model experiment. These 
same strains were able to access the brain and displayed increased lethality as a result [294].  
 
Figure 1.15 – VACV replication cycle  
Replication of VACV begins with viral particles entering cells via binding or fusion. Once the virus particle has 
entered the cell it is uncoated before the initiation of early gene expression. At the end of this stage, DNA 
replication of the viral genome begins and leads to intermediate and late gene expression. The newly synthesised 
genomes and proteins are then packaged into membrane crescents in a perinuclear area known as the virus 
factory (highlighted in purple). These newly formed progeny mature before being transported to the Golgi 
apparatus, where they are double-wrapped to form triple wrapped viral particles. These are then transported to 
the cell surface where the membrane fuses with the host lipid bilayer, and are then released via a number of 
mechanisms, including exocytosis or actin tail formation (shown in red). 
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1.6.3 VACV and the relationship with host signalling 
As the VACV replication cycle occurs largely independently of host machinery, it was originally 
assumed that the reliance of VACV on host components was fairly minimal. However, as research 
continues into this virus, it has become evident that many aspects of cell signalling are essential 
for the VACV replication cycle to progress and for infection to spread effectively. One of the most 
well-studied of these scenarios occurs during VACV-induced cell migration [323, 324]. Various 
groups have attributed this phenotype to a viral protein, F11 [323-327]. F11 mediates cell 
migration via interactions with members of the host RhoA signalling pathway [323, 324, 326, 
327]. These essential cellular proteins have a complex relationship with cell migration, as they 
modulate the balance between cell contractility at the rear of cells and the leading edge extension 
[232, 328]. For instance, depletion of RhoA in keratinocytes leads to a loss of cell migration; 
however, RhoA-null macrophages, despite displaying defective lamellipodia formation, migrate 
faster than their unaltered neighbours [329, 330]. F11 functions by binding Rho-GTPases, at a 
motif common to the binding site of RhoA effector protein, ROCK. This step interferes with 
RhoA signalling and promotes VACV-induced cell motility and actin tail formation [324, 326, 
327]. In fact, in virus lacking this protein, such as the attenuated virus strain, MVA, cell migration 
can be restored through the introduction of full-length F11 [331].  
Another point at which VACV relies on the cell it infects is during early infection, where cells 
contract in a microtubule-dependent manner, leading to union of the viral replication centres 
within the cell and formation of a single, perinuclear virus factory. This process has been 
attributed to host mitogen-activated protein kinase (MAPK) signalling and the recruitment of 
microtubule-interacting, JNKs [249, 332]. In fact, knockout of these JNK proteins leads to a 
reduction in the cell contractility phenotype associated with early VACV infection. JNKs may also 
contribute to the microtubule-dependent release of VACV, as their loss also results in defects in 
viral trafficking, EEV release and viral spread [249].  
One of the most commonly manipulated cellular systems during viral infection is the apoptosis 
signalling cascade described earlier. This programmed cell death process is presided over by 
proteases, known as caspase proteins which cleave downstream effector proteins that initiate the 
process of cell death. Examples of common caspases include caspase-3, caspase-8 and caspase-9 
[333, 334]. As a result, VACV possesses numerous mechanisms to interact with caspase proteins 
[335-337]. For example, upon induction of apoptosis with cyclohexamide and TNF-α, cells 
expressing VACV protein, B13, were protected from caspase3-mediated cell death [240]. Other 
vaccinia proteins, such as F1 and N1 can act in a similar capacity [240, 336]. Using these anti-
 Chapter 1: INTRODUCTION 
University of Sydney 51 2018 
apoptotic molecules, VACV is able to evade destruction, continue replicating and lead to the 
dissemination of infection by cell lysis. 
With continuing research, it is clear that an increasing number of host proteins and pathways are 
involved in maintaining the infectivity and spread of VACV. Increasing our understanding of 
which host components are required for infection could not only provide new information on the 
VACV replication cycle, but also aid in the development of potent VACV-based therapeutic 
agents. 
 
1.6.4 Desirable features for clinical applications of vaccinia 
VACV is considered ideal for use in therapeutics due to its unique qualifications, having already 
earned its place as the major component of the smallpox vaccine. Not only does this global model 
of infection make VACV desirable for continued use, but it adds to other favourable 
characteristics that have renewed scientific interest in VACV as a clinical agent.  
Firstly, VACV is a large, complex dsDNA virus that is amenable to substantial genetic changes, 
including the capacity to accept large insertions of exogenous DNA [285]. The 200kb genome of 
VACV can accept substantial genetic insertions; up to 25,000 base pairs in some contexts [284, 
285]. These genetic modifications can introduce fluorescent tags to aid in the visualisation of virus 
transport and cell trafficking [338, 339]. This genome plasticity has also allowed for the 
generation of various deletion mutants to assist in clarifying the roles of viral proteins during 
infection [43, 340-344]. The ease with which these alterations are carried out allows VACV to be 
designed and modified for specific uses.  
As a lab organism and therapeutic agent, VACV is also relatively safe to work with and 
vaccination is available for laboratory workers. Whilst being able to infect a wide variety of cell 
lines in vitro, in immunocompetent individuals, it causes very low to mild, self-limiting infection 
making it a low risk organism for use [345-347]. Additionally, VACV replicates largely in the 
host cell cytoplasm making it safer to use than other viruses that replicate within the nucleus, as 
there is reduced risk of integration-associated defects [348]. Furthermore, VACV carries all its 
own replication machinery and replicates entirely in the host cell cytoplasm. This increases the 
safety of this virus, as there is limited risk of integration-related defects caused by viral insertion 
into the host genome. Taken together, these features mark VACV as an ideal model organism, 
therapeutic agent or vector. 
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1.6.5 Current and potential uses of VACV 
There are a number of fields in which viruses can be used for treating or protecting against disease. 
As described earlier, the majority of these reside in vaccine, vector or oncolytic research. 
Fortuitously, VACV displays potential for use in all of these [36, 52]. For example, VACV is not 
only the major component of the smallpox vaccine, but also shows great promise as a courier for 
viral antigens in other recombinant vaccines. HIV envelope proteins, including gp120, and EBV 
membrane antigens, such as EBNA1 are both able to be delivered by vaccinia virions in this way, 
stimulating lasting anti-HIV and -EBV antibody responses, respectively [349-351]. Especially in 
the case of EBV, the success of the recombinant vaccinia vaccine has seen this treatment passed 
into human trials. This same principle can be used in the development of cancer vaccines, where 
VACV is engineered to carry tumour antigens, boosting anti-tumour immunity and assisting in 
clearing malignancies. In this case, VACV plays the dual role of an oncolytic virus and 
recombinant vaccine. One example of this is PANVAC-VF, a recombinant VACV in phase III 
clinical trials which contains carcinoembryonic antigen and mucin-1; antigens readily found in 
pancreatic cancers [352]. A result of this vaccine is the induction of a potent tumour antigen 
specific T-cell response [353, 354]. Given the amenability of these viruses to substantial genetic 
changes and large cargoes, as well as the constant development of efficient editing tools such as 
CRISPR-Cas9 technologies, VACV is sure to remain a fixture in viral therapeutic research [355].  
 
1.6.6 Ectromelia virus (ECTV) 
As described in Section 1.6.1, VACV is by no means the only member of the Orthopoxviridae 
family. While all viruses within this group share common traits related to their replication cycle 
and structure, they additionally possess demarcating features which influence their infection 
outcomes, host range and usefulness in laboratory contexts.  
One of the most divergent poxviruses and a virus of particular interest within this thesis is ECTV 
[356]. ECTV was discovered in 1930 when introduced into an animal laboratory by an infected 
mouse [357]. Researchers noted that mice which survived the initial infection developed a disease 
that was reminiscent of smallpox in humans, known as mousepox [358]. The symptoms included 
the formation of a characteristic pustular rash, fever and general malaise which often led to death, 
depending on the viral strain and mouse species in use [358]. For instance, ECTV Naval strain 
caused generally mild infection in CD-1 mice; however, was irrevocably lethal in BALB/c 
animals [359]. Due to this feature, scientists considered ECTV infection as a valuable substitute 
for smallpox and prime candidate for an animal model of poxvirus pathogenesis [360, 361]. 
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Genetically, ECTV appears to be an interesting case. As observed in Figure 1.14, ECTV is quite 
distinct from other orthopoxviruses; no other viruses within this family share the same branch, 
suggesting it may possess a number of unique features due to its isolation [356]. Typically, 
poxviruses possess a central conserved genome region, which displays > 90% homology across 
the family [356, 358]. This region is devoted to genes concerned with viral replication and 
assembly. As such, the largest discrepancies between viral genomes can be observed at each end 
where genes for modulating host interactions are situated [358]. Despite this it appears that the 
right end of the ECTV genome is similar to the same region within VACV, indicating an early 
recombination event may have occurred [362]. Due to this feature, ECTV is uniquely placed for 
assisting scientists in studying the functions of VACV genes. Within this thesis we attempt to 
elucidate the mechanism of TGF-β pathway induction by VACV. As ECTV is unable to induce 
the same outcome, differences between the genomes of these viruses could provide clues on the 
responsible genes within VACV.   
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1.7 PROJECT AIMS AND HYPOTHESES 
1.7.1 Aims 
The overall aim of this project was to characterise the role of TGF-β/Smad signalling during 
VACV infection. This was investigated at the transcriptional, translational, activation and 
phenotypic levels. As previous research in the lab has established activation of this pathway 
following VACV infection, this thesis will go on to outline further evidence corroborating this 
data, as well as aiming to answer novel questions about the involvement of specific TGF-β/Smad, 
and related, EGFR pathway components.  
Various cellular and chemical tools were employed to address the major aims of this thesis. 
Initially, we were concerned with investigating the transcriptional response to VACV infection, 
with a specific focus on downstream targets of TGF-β/Smad signalling. At this point, the role of 
the Co-Smad, Smad4, and the mechanism of TGF-β pathway activation were investigated. Finally, 
we attempted to gain information on the pathway activation and cross-talk mechanisms which may 
promote TGF-β signalling during infection. The major questions for each chapter are described 
below: 
 
1. Which components of the TGF-β-mediated signalling are activated upon VACV infection 
and contribute to the infected cell phenotype? 
2. Does Smad4 influence cell-to-cell spread, replication or phenotype of VACV infection? 
3. How does VACV activate the TGF-β signalling cascade and does it employ cross-talk 
pathways, such as the EGFR-mediated cascade, to do so?  
4. Can global transcriptomic analysis provide more information on mechanism of activation 
of this pathway during VACV infection? 
 
We hypothesised that VACV utilises an unknown mechanism, at least partially involving VGF, to 
activate TGF-β and EGFR signalling cascades, in order to promote efficient viral spread and 
replication. Together these studies hope to provide information for the development of novel and 
improvement of existing oncolytic therapies.  
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2.1 MATERIALS  
2.1.1 Reagents and commercial kits 
All reagents, chemicals, consumables and commercial kits used in this research are listed within 
the table below, along with their corresponding supplier and catalogue number (Table 2.1).  
 
Table 2.1 – List of reagents and consumables 
Reagents and Consumables Cat. No., Supplier 
0.25% Trypsin-EDTA 1X 25200-114, Gibco 
100 x 20 mm Standard dishes 353003, Becton Dickinson 
10mL Serological pipets 357551, Becton Dickinson 
12-Well Falcon Clear Flat-Bottom TC-treated Cell culture 
plate with Lid 
FAL353043, In Vitro 
2-[N-morpholino]ethanesulfonic acid (MES) M8250, Sigma-Aldrich 
24-Well Falcon Clear Flat-Bottom TC-treated Cell culture 
plate with Lid 
FAL353047, In Vitro  
25mL Serological pipets 357535, Becton Dickinson 
2-Mercaptoethanol M6250, Sigma-Aldrich 
3-[N-morpholino]propanesulfonic acid (MOPS) M1254, Sigma-Aldrich 
3’, 3”, 5’, 5”-tetrabromophenolsulfonphthalein 
(Bromophenol blue) 
B8026, Sigma-Aldrich 
30% Acrylamide/Bis solution 161-0156, Bio Rad 
4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-
2-yl]benzamide (SB-431542) 
1614, Tocris 
4’,6-Diamidino-2-phenlindole dihydrochloride (DAPI) D9542, Sigma-Aldrich 
60 x 15mm Standard dishes  3510007, Becton Dickinson 
6-Well Falcon Clear Flat-Bottom TC-treated Cell culture 
plate with Lid  
FAL353046, In Vitro 
8-well Cell Culture Slide FAL354118, In Vitro 
Agarose, molecular grade BIO-41026, Bioline 
Alexa Fluor® 488 Phalloidin A12379, Life Technologies 
Alexa Fluor® 568 Phalloidin A12380, Life Technologies 
Amersham™ ECL Prime Western Blotting Detection 
Reagent 
RPN2232, GE Healthcare 
Amersham™ Hyperfilm ECL 28-9068-40, GE Healthcare  
Amersham™ Protran® Supported 0.45 NC 200mmx4m 
roll/PK 
10600018, Ge Healthcare 
Ammonium persulfate (APS) A3678, Sigma-Aldrich 
Blasticidin  Ant-bl-1, InvivoGen 
Boric acid AM0588, Astral Scientific 
Bovine serum albumin (BSA) BP1600-100, Fisher Scientific 
Bromophenol blue B0126, Sigma-Aldrich 
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Carboxymethylcellulose sodium salts, medium viscosity 
(CMC) 
C9481, Sigma-Aldrich 
Chloroform 152-2.5L GL, Ajax Finechem 
Crystal violet 0528, Amresco 
D-Glucose 14431-43-7, Astral Scientific 
Diethylpyrocarbonate (DEPC) D5758, Sigma-Aldrich 
Dimethylsulfoxide (DMSO) D2650, Sigma-Aldrich 
dNTP Set BIO-39026, Bioline 
Dual Luciferase® Reporter Assay System  E1910, Promega 
Dulbecco’s Modified Eagle Medium (DMEM) (1X), 
liquid (High Glucose)  
11965-092, Gibco 
ECL Western Blotting Reagent RPN2106, GE Healthcare 
ECL Western Blotting Substrate 32106, Thermo Fisher Scientific  
Epidermal growth factor (EGF) E9644, Sigma-Aldrich 
Ethanol 214-2.5L, Ajax Finechem 
Ethidium bromide  0492, Amresco 
Ethylenediamenetetraacetic acid (EDTA) disodium salt 
dihydrate 
AM0105, Astral Scientific 
Fast SYBR® Green Master Mix 1-Pack 4385612, Life Technologies  
Foetal bovine serum (FBS) 16000-044, Gibco 
Formaldehyde 252549, Sigma-Aldrich 
Formamide  F7508, Sigma-Aldrich 
Gefitinib SCZSC, Santa Cruz 
Gel loading dye blue (6X) B7021, New England Biolabs 
GelRed™ Nucleic acid gel stain 41003, Biotium 
Glycerol, minimum 99% GC G5150, Sigma-Aldrich 
Glycine  56-40-6, Astral Scientific  
GM6001 (Ilomastat) MMP Inhibitor CC1010, Merck Millipore 
Human transforming growth factor beta (TGF-β) 100-21C, Pepro Tech 
Hybond-C Extra, Amersham™ RPN203E, GE Healthcare 
Hygromycin  Anti-hg-1, Invivogen 
Hyperladder I Bio33026, Bioline 
Immersion oil AV239000, Olympus 
Immersion oil AV9602, Olympus 
Lens paper 400176, Olympus 
Lipofectamine® 2000 Reagent (1 mg/mL) 11668-027, Life Technologies 
Magnesium acetate tetrahydrate M5661, Sigma-Aldrich 
Magnesium chloride 296, APS Chemical 
Methanol 318-2.5L, Ajax Finechem 
MicroAmp Fast Optical 96-well reaction plate with 
barcode, 0.1 mL 
4346906, Life Technologies 
MicroAmp Optical Adhesive Film 4360954, Life Technologies  
Microscope coverslips no. 1 thickness circular, 12 mm CS12RD, Livingstone 
Microscope coverslips no. 1 thickness square, 22x22 mm CS22X22-0-2, Livingstone 
MMP Inhibitor II 444247, Merck Millipore 
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Modified eagle medium (MEM) (2X), liquid 11935-046, Life Technologies  
Mps1-IN-2, ≥ 98% (HPLC) SML1387, Sigma-Aldrich 
Paraformaldehyde (PFA) P6148, Sigma-Aldrich 
Penicillin-Streptomycin-Glutamine (100X) (PSG) 10378-016, Life Technologies 
Phenol Buffer Saturated (pH 6.7/8.0) 0945, Astral Scientific 
Phenol-Chloroform (pH 6.7/8.0)  0883, Astral Scientific 
Phosphate Buffered Saline tablet AME404, Astral Scientific 
Polyoxyethylene sorbitan monolaurate (Tween-20) P2287, Sigma-Aldrich 
Polyvinyl Alcohol 4-88 (Mowiol) 81381, Sigma-Aldrich 
QCM™ Gelatin Invadopodia Assay (Green) ECM670, Merck Millipore 
QIAPrep® Spin Minikit P27106, Qiagen 
QIAQuick® Gel Extraction Kit P28704, Qiagen 
RNeasy® Mini Kit  P74106, Qiagen 
RQ1 RNase-Free DNase M6101, Promega 
Skim Milk Powder LP0031, Oxoid  
Snap Strip II PCR tubes 8-Strip Standard Tube & with 
Individual Attached Flat Caps  
I3245-00, Astral Scientific  
Sodium chloride AMX190, Astral Scientific 
Sodium dihydrogen orthophosphate 471, APS Chemicals 
Sodium Dodecyl Sulfate (SDS) AM0227, Astral Scientific 
Sodium pyruvate 11360070, Life Technologies 
SuperScript® VILO cDNA synthesis kit 11754050, Life Technologies 
Syringe filter 0.22 μm  GSWP04700, Merck Millipore 
Taq DNA polymerase with Thermopol buffer M0267L, New England Biolabs 
Tetracycline Hydrochloride Crystalline T3383, Sigma-Aldrich 
Tetramethylethylenediamene (TEMED)  T9281, Sigma-Aldrich 
Transforming growth factor-β (TGF-β) T7039, Sigma-Aldrich  
Tris-hydroxymethyl-aminomethane (Tris-base) AM0479, Astral Scientific 
Triton X-100 T8787, Sigma-Aldrich 
TRIzol Reagent 15596-026, Life Technologies  
Zeocin Ant-zn-1, InvivoGen 
 
 
2.1.2 Equipment and software list 
All equipment and software utilised for experimental procedures and analyses are named within 
the table below (Table 2.2). 
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Table 2.2 – List of machines, equipment and software  
Equipment and Software Manufacturer 
Adobe Photoshop and Illustrator Softwares 
CS6 (v. 6.1) 
Adobe Systems (USA) 
AnalySIS Life Science Series Starter Software Olympus (Japan) 
Applied Biosystems® 7500 Fast Real-time 
PCR System 
Life Technologies (USA) 
CP1000 Photographic Film Developer AGFA-Gavaert (Belgium) 
Endnote X7.7.1 Thomas Reuters (Spain) 
Eppendorf Centrifuge 5424 Eppendorf (Germany) 
Eppendorf Centrifuge 5702 Eppendorf (Germany) 
Eppendorf Centrifuge 5810R Eppendorf (Germany) 
GelDoc™ XR BioRad (USA) 
Geneious v 5.5.3 Biomatters Limited (New Zealand) 
GraphPad Software v.7.0 GraphPad Software Inc. (USA) 
GS800 Calibrated Densitometer BioRad (USA) 
ImageJ Software v. 1.50c National Institute of Health (USA) 
Mastercycler EP Gradient S Eppendorf (Germany) 
Medium Orbital Shaking Incubator Ratek (Australia) 
Mini-PROTEAN® Tetra Cell (SDS-PAGE 
Electrophoresis cell) 
BioRad (USA) 
Mini-Sub Cell GT (DNA gel electrophoresis 
cell) 
BioRad (USA) 
Nanodrop 1000 Spectrophotometer Thermo Fisher Scientific (AUS) 
Nikon Eclipse Ti-E Microscope, with iXon 
Ultra 888 EMCDD camera 
Nikon (Japan), Andor (UK) 
NIS-Elements Microscope Imaging Software 
AR 4.51.00 
Nikon (Japan) 
Olympus BX51 Microscope, Mercury Burner, 
F-View Monochrome-fluorescence camera 
Olympus (Japan) 
PowerPac HC BioRad (USA) 
Quantity One Software BioRad (USA) 
TD-20/20 Luminometer Promega (USA) 
Water thermostats TW-2.03 Elmi Limited (Latvia)  
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2.1.3 Plasmids 
Two plasmids, pR-luc and pT313, were used to carry out luciferase assays in this thesis. The pR-
luc plasmid was obtained from collaborator, Joel Mackay (University of Sydney, Australia), and is 
a pRL-TK plasmid (Promega) containing a constitutively expressed Renilla luciferase gene under 
the control of a TK promoter. The second plasmid, pT313, was provided by collaborator, Caroline 
Hill (Francis Crick Institute, UK) [215]. It was constructed using a pGL3 plasmid backbone 
(Promega) with a CAGA box sequence, ARE sequence or SBR insert at the XhoI site. In the 
presence of transcription factors which recognise these motifs, such as Smad2 and Smad3, Firefly 
luciferase is transcribed and expressed. This can be detected by a luminometer.  
 
2.1.4 Antibodies 
Various primary and secondary antibodies were used in this work to carry out a number of 
applications. The primary and secondary antibodies used within this thesis are listed within the 
tables below (Tables 2.3 and 2.4). Their applications, including Western blot (WB) and 
immunofluorescence assay (IFA), and their appropriate concentrations for use are also outlined.  
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Table 2.3 – Primary antibodies 
Primary antibodies 
Antibody Species 
Appli-
cation 
Concen
-tration 
Supplier 
Anti-β-actin (A-74) Mouse WB 1:1500 Sigma-Aldrich (AUS) 
Anti-A36 Rabbit WB 1:3000 [363] 
Anti-B5 (19C2) Rat IFA 1:300 M. Way (CRUK) 
Anti-Caspase 3 (H-277) Rabbit WB 1:1000 Santa Cruz (USA) 
Anti-PAI-1 (C-9) Mouse 
WB, 
IFA 
1:1000, 
1:300 
Santa Cruz (USA) 
Anti-Phospho-Smad2 
(Ser245/250/255) (3104) 
Rabbit WB 1:1000 Cell Signalling Technology (USA) 
Anti-Phospho-Smad2 
(Ser465/467)(138D4) 
Rabbit WB 1:1000 Cell Signalling Technology (USA) 
Anti-Smad2 (86F7) Rabbit WB 1:2000 Cell Signalling Technology (USA) 
Anti-Smad4 (B-8) Mouse WB 1:1000 Santa Cruz (USA) 
Anti-Snail1 (H-130) Rabbit 
WB, 
IFA 
1:1000, 
1:300 
Santa Cruz (USA) 
Anti-Snail2 (H140) Rabbit 
WB, 
IFA 
1:1000, 
1:300 
Santa Cruz (USA) 
 
Table 2.4 – Secondary antibodies 
Secondary antibodies 
Antibody 
Spe-
cies 
Applic-
ation 
Concen
-tration 
Supplier 
Anti-mouse IgG – Alexa Fluor® 488  Goat IFA 1:200 Life Technologies (USA) 
Anti-mouse IgG – Alexa Fluor® 568  Goat IFA 1:200 Life Technologies (USA) 
Anti-mouse IgG – HRP Conjugated  Goat WB 1:5000 Santa Cruz (USA) 
Anti-rabbit IgG – Alexa Fluor® 488  Goat IFA 1:200 Life Technologies (USA) 
Anti-rabbit IgG – Alexa Fluor® 568  Goat IFA 1:200 Life Technologies (USA) 
Anti-rabbit IgG – HRP Conjugated Goat WB 
1:3000
0 
Santa Cruz (USA) 
Anti-rat IgG – Alexa Fluor® 488  Goat IFA 1:200 Life Technologies (USA) 
Anti-rat IgG – Alexa Fluor® 568  Goat IFA 1:200 Life Technologies (USA) 
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2.1.5 Microscope filter sets 
Various fluorophores and their associated microscope filters were used for imaging cells on the 
Olympus BX51 and the Nikon Ti-E Eclipse microscopes. Note that Chroma filters were used on 
the Olympus microscope, whilst Semrock filters were fitted on the Nikon Ti-E Eclipse. Those 
used to generate data in this thesis are listed in the following table (Table 2.5). 
 
Table 2.5 – Microscope filter sets 
Filter (Brand) Fluorophore 
Absorbanc
e (nm) 
Emission 
(nm) 
Assigned 
colour 
TxRED (Chroma or 
Semrock) 
Alexa Fluor® 568 578 603 Red 
mCherry 579 604 Red 
FITC (Chroma or Semrock) 
Alexa Fluor® 488 495 519 Green 
GFP 395, 475 509 Green 
DAPI (Chroma or Semrock) DAPI 359 461 Blue 
ECFP (Semrock)  Cerulean  433 475 Cyan 
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2.2 TISSUE CULTURE 
2.2.1 Cell lines and cell culture  
The majority of cell lines used in these experiments were maintained in Dulbecco’s modified 
eagle medium (DMEM, Gibco) supplemented with 10% foetal bovine serum (FBS, Gibco), as 
well as 1X penicillin (100 U), streptomycin (100 μg) and glutamine mix (292 μg/mL) (PSG, 
Gibco). Human colorectal adenocarcinoma (HT-29) cells and human prostate carcinoma (LNCaP) 
cells are the exceptions to this rule and were cultured in McCoy’s 5A Modified (Gibco) or RPMI 
(Gibco) media respectively. The same supplements described above were also introduced to these 
culture media. For the HT-29 cells and human pancreatic epitheloid carcinoma (PANC-1) cells, an 
additional supplement of 1mM sodium pyruvate was also included. All cell lines were incubated at 
37°C and 5% CO2 for the duration of culturing (Table 2.6).  
 
Table 2.6 – Cell lines used in this study 
Cell line Species Media Source 
HaCaT TR Human DMEM L. Levy (INSERM, France) 
HaCaT TRS4 Human DMEM L. Levy (INSERM, France) 
HaCaT CAGA12-
GFP 
Human DMEM A. Gowripalan (University of Sydney, Australia) 
BSC-1 (ATCC, 
CCL-26) 
African 
green 
monkey 
DMEM M. Way (CRUK, UK) 
HeLa (ATCC, 
CCL-2) 
Human DMEM M. Way (CRUK, UK) 
GBM A-172 
(ATCC, CRL-
1620) 
Human DMEM 
R. Christopherson (University of Sydney, 
Australia) 
SK Mel (ATCC, 
HTB-72) 
Human DMEM 
R. Christopherson (University of Sydney, 
Australia) 
HT-29 (ATCC, 
HTB-38) 
Human 
McCoy’s 
5A 
D. Richardson (University of Sydney, Australia) 
PANC-1 (ATCC, 
CRL-1469) 
Human DMEM D. Richardson (University of Sydney, Australia) 
LNCaP Human RPMI S. Assinder (University of Sydney, Australia) 
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2.2.2 Tetracycline-inducible cell lines 
Two tetracycline (Tet)-inducible HaCaT cells lines; HaCaT TR and HaCaT TRS4, were obtained 
from collaborator, Laurence Levy (INSERM, France) [364]. Briefly, these were created by first 
transfecting HaCaT cells with a pcDNA plasmid containing a tetracycline repressor (TR) 
(Invitrogen). The first cell line, HaCaT TR cells, were only subjected to this transfection step and 
were grown in media containing 10 μg/mL blasticidin to maintain the selective pressure. HaCaT 
TRS4 cells, on the other hand, were additionally transfected with a Tet-inducible siRNA, which 
targets nucleotides 85 to 103 of Smad4 (GGTGGAGAGAGTGAAACAT). Knockdown of Smad4 
following this step was validated via immunoblot. This cell line was grown in the same media as 
HaCaT TR cells, with an additional supplement of zeocin (400 μg/mL). Prior to experimentation, 
cells were induced for 48 hours with 2 μg/mL Tet. 
 
2.2.3 Viruses and infection 
All viruses used in this study are listed within the table below (Table 2.7). These include a number 
of vaccinia viruses (VACV), Ectromelia viruses (ECTV) and a herpes virus. A lentivirus used for 
transduction experiments is also described. 
 
Table 2.7 – Viruses used in this study 
Virus Name Virus Strain Source 
VACV-WR VACV WR ATCC VR-1354 
VACV-WR (mCherry) VACV WR 
C. McKenzie/ D. Procter (University of 
Sydney, Australia) 
VACV-WR (LifeAct-
GFP) 
VACV WR C. McKenzie (University of Sydney, Australia) 
VACV-WR (Nuc-Cer) VACV WR B. Marzook (University of Sydney, Australia) 
ΔVGF VACV WR [43] 
ECTV-Mos ECTV Moscow ATCC VR-1374 
ECTV-Mos (LifeAct 
GFP) 
ECTV Moscow 
K. Dilworth, J. Horsington (University of 
Sydney, Australia) 
Herpes simplex virus-1 HSV-1 Strain 17 C. Denes (University of Sydney, Australia) 
CAGA12-GFP 
Lentivirus 
Lenti-
virus 
 S. Turville (Kirby Institute, UNSW, Australia) 
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A number of these viruses contained fluorescent protein inserts. The VACV-WR containing an 
mCherry insert (VACV-WR (mCherry)) was constructed by introducing a recombination cassette 
carrying an mCherry-A36R under the control of a viral early/late promoter (pE/L), into a ΔA36 
virus background and selecting for rescued plaque phenotype and fluorescence. This same method 
was used in the generation of ECTV-Mos (LifeAct-GFP) albeit with a pE/L-LifeAct-GFP-137.5 
construct being used to rescue Δ137.5. The LifeAct-GFP containing VACV-WR (VACV-WR 
(LifeAct-GFP)) has been previously characterised [248]. This virus contains a pE/L-LifeAct-GFP 
transgene. Finally, the VACV-WR (Nuc-Cer) was made using a construct containing a nuclear 
localisation signal fused to a fluorescent cerulean protein and viral B5 gene under the control of 
the pE/L promoter. This was used to rescue the plaque phenotype of a VACV lacking B5 to create 
a recombined VACV-WR (Nuc-Cer) virus. This work was performed by C. McKenzie, J. 
Horsington and B. Marzook (University of Sydney). 
All infections were carried out in media lacking foetal bovine serum. This serum-free media (SFM) 
was applied to cells for 1 hour post-infection, before being replaced with the serum-containing 
equivalent for the remainder of the experiment.  
 
2.2.4 Treatments 
Various cell treatments were used throughout the duration of this research. All reagents used were 
maintained in DMSO and frozen according to the manufacturer’s instructions for extended storage. 
The reagents used in this study include transforming growth factor-beta (TGF-β) (Sigma-Aldrich) 
to a final concentration of 2 μg/mL, as well as a TGF-β receptor inhibitor, SB-431542 (Tocris) 
used at 10 μM. Inhibitors of MMPs, Ilomastat (Millipore) (10 uM) and MMP inhibitor II 
(Calbiochem) (30 μM) were also applied at fixed concentrations. Mps1 Inhibitor 2 (Mps1-IN-2) 
(Sigma-Aldrich) was used at 15 nM. Epidermal growth factor (EGF) (Sigma-Aldrich) (10 ng/mL) 
and an EGF-receptor inhibitor, gefitinib (Santa Cruz) (1 μM), were also utilised in this thesis [365]. 
In most cases, unless otherwise specified, treatments were added to cells in SFM at the same time 
as infection. At 1 hour post-treatment a rescue step, similar to the infection protocol, was 
performed by supplementing cells with serum-containing media. For plaque assays, treatments 
were added to semi-solid overlays at the desired concentration for the duration of the experiment.  
  
 Chapter 2: MATERIALS AND METHODS 
University of Sydney 66 2018 
2.3 RNA EXTRACTION AND ANALYSIS 
2.3.1 Primer sequences 
Sequences for quantitative PCR (qRT-PCR) primers were obtained from various research papers 
for the selected target genes [109, 364, 366-368]. For our purposes, GAPDH was selected as a 
cellular control, whilst D12 and A17 acted as early and late viral control genes respectively. The 
remaining genes selected were all targets of the Smad signalling pathway, known to be transcribed 
following pathway activation [364]. Primer pairs and their functionality were verified via PCR and 
agarose gel electrophoresis (Table 2.8, Appendix 8.5.1).  
 
Table 2.8 – Quantitative PCR (qRT-PCR) primer pair sequences  
Gene Primer pair 
Product 
size 
(bp) 
Annealing 
temp. 
(°C) 
GAPDH 
FW 5’-GGAGTCAACGGATTTGGTCGTA-3’ 
REV 5’-GGCAACAATATCCACTTTACCAGAGT-3’ 
78 56 
c-JUN 
FW 5'-TCCACGGCCAACATGCT-3' 
REV 5'-CCACTGTTAACGTGGTTCATGAC-3' 
71 61 
Snail2 
FW 5’-ATACCACAACCAGAGATCCTCA-3’ 
REV 5’-GACTCACTCGCCCCAAAGATG-3’ 
139 59 
PAI-1 
FW 5'-CCGGAACAGCCTGAAGAAGTG-3' 
REV 5'-GTGTTTCAGCAGGTGGCGC-3' 
300 61 
TGFb 
FW 5’-ACCTGAACCCGTGTTGCTCT-3’ 
REV 5’-CTAAGGCGAAAGCCCTCAAT-3’ 
228 61 
A17 
FW 5′-ATGAGTTATTTAAGATATTACAATATGCTT-3′ 
REV 5 -TCGTCAGTATTTAAACTGTTAAATGTTGGT-3′ 
500 57 
D12 
FW 5′-ACCTCAGCGCACGCAATAAACTGTTCA-3’ 
REV 5′-AGTCATACTAGAATAAAGCAGCGAGT-3′ 
605 56 
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2.3.2 RNA extraction 
Protocol accompanying RNeasy Mini Kit (Qiagen) was followed to extract RNA from appropriate 
cells. Briefly, cells were cultured to confluency in 6-well plates. Coverslips were placed in a well 
from each condition and used to verify infection (as in Section 2.6). Protein samples were also 
collected simultaneously to allow for protein analysis as described in Section. 2.5. For RNA 
extraction, confluent cells were treated or infected for the specified time period, then lysed and 
homogenised via the syringe method. After this point, manufacturer’s protocol was followed to 
obtain total RNA from lysates. A second protocol accompanying the TRIzol reagent (Life 
Technologies) was also utilised for some samples. Again, cells were cultured as before being lysed 
in the appropriate volume of TRIzol reagent. The manufacturer’s protocol was followed for this 
work. Quality of the collected RNA was assessed via Nanodrop 1000 Spectrophotometer analysis 
and formaldehyde agarose (FA) gel electrophoresis. Samples were stored in RNase-free water at -
20°C prior to RNAseq or qRT-PCR.  
 
2.3.3 FA gel electrophoresis 
For verification of RNA quality, FA gel electrophoresis was conducted according to instructions 
provided with the RNeasy Mini Kit (Qiagen). Briefly, buffers and gels were made as follows. 
 
10X FA Gel Buffer, pH 7.0 
200 mM 3-[N-morpholino]propanesulfonic acid (MOPS) 
50 mM Sodium acetate 
10 mM  Ethylenediamenetetraacetic acid (EDTA) 
 
1X FA Gel Running Buffer 
1X  10X FA Gel Buffer 
2% (v/v) 37% Formaldehyde 
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FA Gel 
1.2% (w/v) Agarose 
1X  10X FA Gel Buffer 
1.8% (v/v) 37% Formaldehyde 
253 nM Ethidium bromide 
 
5X RNA loading buffer 
0.16% (v/v) Saturated aqueous bromophenol blue solution 
4 mM  EDTA 
7.2% (v/v) 37% Formaldehyde 
20% (v/v) 100% Glycerol 
30.8% (v/v) Formamide 
4X  10X FA Gel buffer 
 
FA gels were prepared to a final concentration of 1.2% agarose according to instructions from 
Qiagen and then equilibrated in 1X FA Gel Running buffer for 30 minutes. RNA samples were 
also prepared by adding 1 volume of 5X RNA loading buffer to 4 volumes of RNA. These 
samples were heated to 65°C for 3-5 minutes before being chilled on ice to await loading. 
Following gel equilibration, prepped total RNA samples were loaded and run on gels. The results 
were able to be visualised on a GelDoc (BioRad) due to ethidium bromide staining.  
 
2.3.4 DNase treatment and cDNA synthesis 
Before qRT-PCR could be performed, total RNA needed to be DNase treated and then converted 
to cDNA. For DNase treatment, protocol accompanying RQ1 RNase-free DNase (Promega) was 
followed. This ensured the adequate removal of genomic DNA contamination from the total RNA 
samples. Once the DNase treatment was completed, samples were then converted to cDNA using 
the SuperScript VILO cDNA synthesis kit (Thermo Fisher Scientific). Yields were again verified 
by Nanodrop 1000 Spectrophotometer, as well as being used as a template for standard PCR using 
the primers described above.  
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2.3.5 Polymerase chain reaction (PCR) 
For testing the functionality of real-time PCR primers, a standard polymerase chain reaction (PCR) 
was performed. The protocol accompanying Taq polymerase (New England Biolabs) was 
followed to carry out the PCR. Briefly, template, primers, dNTPs, MgCl2 and Taq DNA 
polymerase with Thermopol buffer were mixed according to the manufacturer’s instructions. For 
use as a template, cDNA was synthesised from total RNA as described above. Once mixed, the 
samples were loaded into a Mastercycler EP Gradient machine. The PCR conditions are described 
below (Table 2.9). 
 
Table 2.9 – Conditions used in PCR analysis 
Step Temperature Duration Cycle 
Initial denaturation 94°C 3 minutes - 
Denaturation 94°C 30 seconds 
30 cycles Annealing 55-61°C 30 seconds 
Extension 72°C 30 seconds 
Final extension 72°C 2 minutes - 
 
The different primer pairs used in this experiment are described in Section 2.3.1. Note that the 
annealing temperature for each primer set varied, and so the protocol for each reaction was 
adjusted accordingly. The annealing temperatures are listed in Table 2.8. 
 
2.3.6 Quantitative PCR (qRT-PCR) 
Following DNase treatment and cDNA synthesis, samples were analysed via qRT-PCR. To do this, 
samples were mixed with Fast SYBR® Green Master Mix (Life Technologies) according to the 
manufacturer’s directions. Approximately 10 ng of cDNA was analysed in each case, using the 
primers delineated above. The reaction mixes were then transferred to MicroAmp™ Fast Optical 
96-well reaction plates and sealed with MicroAmp™ optical adhesive film (Life Technologies). 
Plates were loaded into the 7500 Fast Real-time PCR system (Applied Biosystems) and the qRT-
PCR was run under the following conditions (Table 2.10).  
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Table 2.10 – Conditions used in real-time PCR analysis 
Step Temperature Duration Cycle 
AmpliTaq Fast DNA polymerase, UP activation 95°C 20 seconds Hold 
Denature 95°C 3 seconds 
40 cycles 
Anneal/extend 60°C 30 seconds 
Hold 4°C - Hold 
 
2.3.7 RNAseq 
The basic protocol for RNA sequencing is outlined within Figure 2.1. It involves pulling out 
mRNA molecules via poly-A tail selection with oligodT-coated magnetic beads. These mRNAs 
are fragmented, randomly primed and converted to short cDNA sequences by first and second 
strand synthesis steps. The cDNAs can then be used for Illumina library prep where they are 
phosphorylated, the tails are adenylated, and they are made ready for ligation to an array of 
adapter sequences. These sequences are then amplified via PCR. The adapters facilitate 
sequencing and allow the library to be pooled and normalised to a reference genome or 
transcriptome. Upon library generation, mRNAs are identified and counted [369]. 
 
Figure 2.1 – Basic workflow of RNAseq analysis 
The process of RNAseq begins with extracting mRNA molecules via their poly-A tails, which bind to oligodT-
coated magnetic beads. The sequences are then fragmented, randomly primed, converted to cDNA and then ends 
are repaired. The next stage is binding to adaptor sequences and addition to flowcells. The adapters are 
amplified via PCR, then all samples are pooled, and a sequencing library is generated.  
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For RNA sequencing in this thesis, total RNA samples were prepared as above to a concentration 
of 70 ng/μL in a final volume of 60 μL in RNAse-free water. All work was done in triplicate, 
before shipping to the Ramaciotti Centre for Genomics (UNSW, Australia) where various quality 
control assessments were performed. These are described in Appendix 8.5. Illumina sequencing 
was then conducted using the TruSeq Stranded mRNA-seq sample preparation kit and two 
HiSeq2500 75bp paired-ends high output runs. This analysis provided a total of 30 million read 
pairs per sample.  
 
2.3.8 Analysis of mRNA 
Data was obtained in the form of FastQ analysis files. Collaborator, Ulf Schmitz (University of 
Sydney, Australia), assisted in analysis of the RNA sequencing data using a variety of programs. 
Briefly, FastQC (v, 0.11.5) and MultiQC (v. 1.2) tools were used for quality control measures, 
pcaExplorer (v. 2.4.0) for principal components analysis, STAR (v. 2.5.2a) for read alignment, 
featureCounts (v. 1.5.0-p3) for obtaining normalized transcript counts, DESeq2 (v. 1.18.1) for 
differential gene expression analysis and Goseq (v. 1.30.0) for ontology analysis. Further analysis, 
in the form of heat maps, was performed using GraphPad Prism 7 software. In this case, transcript 
counts were normalised to GAPDH levels before being distributed along a standard bell curve 
using Z-score analysis. These Z-scores were then used to generate heat map profiles. EMT gene 
lists were obtained from an online resource, dbEMT (http://dbemt.bioinfo-minzhao.org/) 
developed by the Zhao lab (University of Sunshine Coast, Australia).  
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2.4 TRANSFECTIONS AND TRANSDUCTIONS 
2.4.1 Luciferase assays 
Luciferase assays were conducted according to the literature, using the plasmids described above 
(Section 2.1.3) [215]. Initially, HeLa cells were seeded to 90% confluency in 24-well plates. To 
obtain the highest transfection efficiency and lowest cytotoxicity, transfection conditions were 
optimised. Both the pR-luc and pT313 plasmids were diluted in SFM to a final concentration of 25 
ng/mL and 150 ng/mL, respectively. Lipofectamine™ 2000 was also diluted (1:25) in SFM to 
allow for a volume of 50 μL per well and left to stand for 5 minutes. Plasmid DNA mix was then 
added dropwise to Lipofectamine™ 2000 dilution to give a total volume of 100 μL per well. The 
resulting mixture was added to cells prior to incubation at 37°C for 24-48 hours, allowing for 
effective transfection to occur.  
 
2.4.2 CRISPR-Cas9 genome editing 
To generate a cell line deficient in Smad4 CRISPR-Cas9 genome editing was carried out by an 
Honours student, Weng Sam Chan. Briefly, guide RNAs were designed to target the 5’ end of 
Smad4 to generate an early stop codon and prevent transcription of this gene. These sequences 
were cloned into CRISPR-Cas9 plasmid, PX458, obtained from Addgene and used for genome 
editing of HeLa cells via transfection [370]. A further guide was designed against an off-target 
control gene, EMX1 and used in tandem. Edited cells could be visualised by GFP-expression and 
Smad4 levels were then verified by immunoblot analysis (described in Section 2.5). Further 
descriptions and guide sequences have been described earlier (Weng Sam Chan, Honours thesis, 
2015). 
 
2.4.3 Transducing cells 
HaCaT cells were transduced with a lentivirus vector to create the HaCaT CAGA12-GFP cell line 
used in this work. This CAGA12-GFP expression plasmid was originally obtained from Dr 
Christina Stuelten (NIH, USA) before being propagated in our lab by C. McKenzie [371]. The 
lentivirus was then generated by collaborator, Stuart Turville (Kirby Institute, UNSW, Australia) 
to introduce this Smad-responsive CAGA12-GFP element (see Figure 2.2). For this work, cells 
were grown to 70% confluency in 12-well plates before being transduced with 1:3 serial dilutions 
of lentivirus in 10% FBS/DMEM. After 24 hours, cells were transferred to 6cm dishes containing 
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coverslips. The coverslips were used to monitor transduction efficiency, by monitoring GFP 
expression post-TGF-β-treatment or VACV-WR-infection.  
 
Figure 2.2 – Transduction of HaCaT cells with CAGA12-GFP-containing lentivirus. 
Lentivirus containing a CAGA12-GFP sequence was used to transduce HaCaT cells resulting in insertion of this 
sequence in the cell genome. GFP expression was then correlated to binding of Smad3/Smad4 and DBPs to the 
CAGA12 sequence. This process is induced by TGF-β treatment and/or VACV infection.  
 
  
 Chapter 2: MATERIALS AND METHODS 
University of Sydney 74 2018 
2.5 PROTEIN EXPRESSION  
2.5.1 Protein extraction and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The appropriate cells were seeded to confluency in 6-well plates for protein extraction. Once 
confluent, cells were either treated or infected as specified and then lysed when appropriate. For 
cell lysis, reducing sample buffer containing 62.5 mM Tris-HCl, 0.25 M glycerol, 2% (w/v) SDS, 
0.1% (w/v) bromophenol blue and 12.5% (v/v) 2-mercaptoethanol was added to cells, before 
harvesting after 1-2 minutes.  
Prior to electrophoresis, lysates were rotated between a 95°C heat block for 3 minutes and ice for 
3 minutes. This routine was carried out 3 times to degrade the protein mix. Lysates were then 
loaded in a 10% SDS-PAGE gel composed of a resolving and stacking gel component. Gel 
electrophoresis was performed in SDS running buffer to resolve proteins in a Mini-PROTEAN® 
Tetra cell (Bio-Rad).  
 
Resolving gel 
10% (v/v) Acrylamide/Bis solution [37.5:1] 
0.375 M  Tris-HCl, pH 8.8 
0.1% (w/v)  Sodium dodecyl sulfate (SDS) 
0.1% (w/v)  Ammonium persulfate (APS) 
0.1% (v/v) Tetramethylethylenediamene (TEMED) 
 
Stacking gel 
4% (v/v) Acrylamide/Bis solution [37.5:1] 
0.375 M Tris-HCl, pH 6.8 
0.1% (w/v) SDS 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
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SDS Running buffer 
24.9 mM Tris Base 
192 mM Glycine 
3.46 mM SDS 
 
2.5.2 Transfer and Immunoblot  
Once proteins had been run and separated in an SDS-PAGE gel, they were ready to be transferred 
to a membrane in preparation for immunoblot analysis. The transfer system we used in this work 
is a wet transfer system, which accompanies the Mini-PROTEAN® Tetra Cell, known as the Mini 
Trans-Blot® Cell. Proteins were transferred onto Amersham™ Protran® Supported 0.45 NC 
nitrocellulose membrane according to the manufacturer’s instructions at 4°C for 1 hour at 350 mA 
in transfer buffer.  
 
SDS Transfer Buffer 
24.9 mM  Tris Base 
192 mM Glycine 
 
After the 1 hour transfer, nitrocellulose membranes were blocked in PBST-Milk overnight with 
rocking at 4°C (except Phospho-Smad2 blots, see below). Following blocking, the appropriate 
primary antibodies were applied to membranes in PBST-Milk. The antibodies used for 
immunoblotting include those against, PAI-1, Smad4, β-actin, GFP, B5, A36 or Phospho-Smad2 
(linker). These are described in Tables 2.3 and 2.4. Note that the protocol for the Phospho-Smad2 
primary antibody differed slightly (see below). In the other instances, the membranes were 
exposed to primary antibody for 1 hour at room temperature with rocking or 24 hours at 4°C with 
rocking. They were then washed via agitation 3 times in PBST-Milk for 5 minutes each. 
Corresponding secondary antibodies conjugated to horse radish peroxidase (HRP) were then 
added in PBST-Milk for 30 minutes at room temperature with rocking. Following this step, 
membranes were washed 3-5 times in PBST and once in PBS prior to the addition of ECL 
Reagent. For this work we used Amersham™ ECL Prime Western Blotting Detection Reagent 
(GE Healthcare). Immunoblots were then imaged by applying Amersham™ Hyperfilm ECL for 
the specified exposure time and developing in the CP1000 Photographic Film Developer.  
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PBS 
137 mM Sodium chloride 
2.7 mM Potassium chloride 
10 mM  Phosphate buffer 
 
PBST 
1X  PBS 
0.1% (v/v)  Tween 20 
 
PBST-Milk 
1X  PBST 
4% (w/v) Skim milk powder 
 
Phosphorylated proteins are known to be sensitive to degradation at higher temperatures and 
certain buffer compositions. As such, for immunoblots examining phosphorylated Smad2 (linker), 
all work was conducted at 4°C, unless otherwise specified. The above protocol was followed until 
the overnight blocking stage. For this step, membranes were incubated in 5% (w/v) bovine serum 
albumin (BSA) in TBST. Primary antibody was then diluted in 5% BSA-TBST and applied to 
membranes for 4 hours at room temperature. As above, washes were conducted prior to the 
addition of secondary antibody; however, any buffer containing phosphate buffer (PBS) was 
replaced with the Tris-containing equivalent (TBS). Following the addition of secondary antibody, 
blots were washed and imaged as before. 
 
TBS, pH 7.6 
20 mM Tris-buffer 
150 mM NaCl 
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TBST 
1X   TBS 
0.1% (v/v) Tween 20 
 
TBST-Milk 
1X  TBST 
4% (w/v) Skim milk powder 
 
2.5.3 Stripping immunoblots 
Due to the need for detecting multiple proteins, nitrocellulose membranes were often stripped after 
imaging, to allow for secondary and tertiary probing steps. For this, membranes were stripped in 
stripping buffer, at 60°C for 1 hour with shaking. At this point, membranes were washed in PBST 
or TBST 3 times, and then probing was repeated with the desired primary and secondary 
antibodies as above. 
 
Stripping Buffer 
65 mM Tris-HCl 
2% (w/v) SDS 
0.7% (v/v) 2-mercaptoethanol 
 
2.5.4 Generation of protein interaction networks 
Protein interaction networks were formed using the STRING Network software (v. 10.5) from the 
Elixir Core Data Resource Group. Proteins of interest were searched for using this program, which 
generated a list and visual representation of known and predicted protein interactions. Note that 
predicted interactions were based on database searches and textmining conducted by the program. 
These interactions were each given a confidence score where scores above 0.95 were accepted in 
this thesis.  
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2.6 IMAGING 
2.6.1 Immunofluorescence assay 
For immunofluorescence assays, cells were seeded onto glass coverslips till the desired level of 
confluency was reached. At this point, virus and/or treatment were introduced as appropriate. 
When the designated time-points were reached, coverslips were washed in phosphate buffered 
saline (PBS) and fixed in 3% paraformaldehyde (PFA) in cytoskeletal buffer (CB). Post-fixation, 
cells were stained, mounted and imaged. Staining involved permeabilising cells in 0.1% (w/v) 
Triton-X-100 in CB, followed by a 20 minute blocking step in blocking buffer. After this the 
appropriate primary antibody was added for 1 hour at a 1:300 dilution in blocking buffer. The 
coverslips were then washed in PBS and the corresponding secondary antibody at a 1:200 dilution 
was applied for 45 minutes. At this point another PBS wash was conducted. Finally, the coverslips 
were stained in DAPI diluted in CB (1 μg/mL) for 5 minutes. Coverslips were then mounted on 
glass slides with Mowiol mounting media and allowed to air-dry prior to imaging.  
 
Cytoskeletal Buffer (CB), pH 6.1 
10 mM  2-[N-morpholino]ethanesulfonic acid (MES) buffer 
0.15 M  Sodium chloride  
5 mM  Ethyleneglycoltetraacetic acid (EGTA) 
5 mM   Magnesium chloride 
5 mM  Glucose 
 
Blocking buffer 
1% (v/v) Bovine serum albumin (BSA) 
2% (v/v) Foetal bovine serum (FBS) 
Make up in CB 
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Mowiol Mounting Media, pH 8.5 
10% (w/v)  Polyvinyl alcohol 4-88 
25% (w/v) Glycerol 
 
2.6.2 Fluorescence microscopy 
Two wide-field fluorescent microscopes were used for the majority of this project. The first, an 
Olympus BX51 microscope was used in coordination with the AnalySIS Life Science Series 
Starter Software (Olympus) and the F-view monochrome fluorescence camera (Olympus). The 
second was a Nikon Ti-E Eclipse microscope, with NIS-Elements Microscope Imaging Software 
(AR 4.51.00) (Nikon) and iXon Ultra 888 EMCDD (Andor) camera, alongside a Lumencor 
Spectra X fluorescent light source. The filters used on these cameras are described in Table 2.5. 
Note that Chroma filters were used in the Olympus BX51 system, whilst Semrock standard filters 
were used with the Nikon Ti-E Eclipse microscope. All images obtained were edited and analysed 
using ImageJ (v. 1.50c) and Photoshop CS6 (v. 6.1) software programs. 
 
2.6.3 Live-cell imaging and cell tracking 
All live-cell imaging was carried out on the Nikon Ti-E Eclipse microscope using NIS-Elements 
Microscope Imaging Software (AR 4.51.00). Conditions were optimised for extended cell survival, 
including maintaining a temperature of 37°C, 85% humidity, 5% CO2 and 15% O2. Cells were 
imaged in 10% FBS/DMEM. Tracking of cell displacement was conducted manually using ImageJ 
(v. 1.50c) software. Measurements were taken as distance moved in a straight line from the cell 
starting point. For long experiments (24-72 hours), displacement was measured every 10 frames.  
 
2.6.4 Generation of intensity profiles  
Intensity plots and profiles were generated using images obtained from live-cell imaging. ImageJ 
(v. 1.50c) software was used to analyse data. For intensity plots, nuclei were identified and 
outlined as regions of interest (ROIs). These ROIs were then applied to images obtained with the 
FITC or TxRED filters, and fluorophore intensity was measured within each ROI. Graphs were 
generated showing GFP vs. mCherry intensity at each ROI (Figure 2.3). mCherry expression was 
used as an indication of infection with VACV-WR (mCherry). Alternatively, a line method was 
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adopted. Twenty-four evenly spaced diameters were drawn over a plaque image and the profile for 
each fluorophore over each line was plotted. An intensity profile was generated for each image 
using the average of the 24 histograms (Figure 2.3).  
 
 
Figure 2.3 – Methods for generating intensity profiles 
Two methods were used in this thesis to generate intensity plots or profiles. The nuclear ROI method (left) was 
used on immunofluorescence images to define mCherry and GFP expression levels in single cells. The 24-line 
method (right) was used for analysing plaque images. Lines were drawn over a plaque image, their intensity 
profiles were measured and averaged to give a final result.  
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2.7 PHENOTYPE STUDIES 
2.7.1 Plaque assays and analyses 
For plaque assays, BSC-1 cells or HaCaT cells were generally utilised unless otherwise stated. 
Briefly, cells were seeded in 6-well plates till confluent before being infected with the appropriate 
virus. Infection was carried out at specified MOIs in SFM for 1 hour. Following infection, media 
was removed and an overlay consisting of 1.5% (w/v) carboxymethylcellulose (CMC), 1X 
Modified eagle medium (MEM, Gibco), 1X PSG, 1.25% (v/v) FBS was applied for 36-72 hours, 
in the case of VACV, or 72-120 hours for ECTV. During this time, plates were incubated at 37°C 
in 5% CO2. Following incubation, the supplemented CMC/MEM overlay was removed and wells 
were washed thoroughly in PBS. At this point, cells were either fixed for 10 minutes in 3% PFA in 
CB, or 30 minutes in 1% (w/v) crystal violet and 20% (v/v) methanol, as specified. Once fixed, 
wells were once again washed in PBS and then stained for immunofluorescence analysis (in the 
case of PFA fixation) before imaging.  
In terms of plaque analyses, two general metrics were applied. Firstly, plaque size was measured 
by determining plaque diameters using ImageJ (v. 1.50c) software. In this case, the plaque edge 
was delineated by the presence of overt cytopathic effects or, when using fluorescent viruses, by 
the presence of a fluorescent signal. The second measure, plaque clearance, was assayed by 
outlining plaque edges as before and measuring the areas within these plaques occupied by cells 
using the threshold function on ImageJ (v. 1.50c) software. This area was then subtracted from the 
total plaque area to provide a measure of the negative space within plaques. This number was 
referred to as plaque clearance within this thesis and was represented as a percentage of empty 
space compared to total plaque area. The steps for this analysis are represented as a schematic in 
Figure 2.4. 
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Figure 2.4 – Methodology for plaque clearance measurements 
Plaque clearance was defined in this thesis as the area of space within a viral plaque not occupied by cells. It was 
measured by determining the total plaque area (yellow), as delineated by presence of cytopathic effect or 
fluorescent signal. Once this area had been outlined, fluorescence was used to determine how much of the 
plaque was filled by cells (red). This area was selected utilising the threshold function on ImageJ (v.150c). 
Subtracting this filled area from the total plaque area provided a measurement of the clear space within plaques 
(blue). When represented as a proportion of the total plaque area this was deemed the plaque clearance 
percentage. Note that total plaque area is equivalent to the area occupied by cells plus the negative space. 
 
 
2.7.2 Single-step growth curves  
For analysis of viral growth, single step growth curves were performed using the appropriate cells. 
Briefly, cells were seeded into 12-well plates and grown to confluency, before being infected at an 
MOI of 5. If treatments were required, they were carried out as described above. In the case of the 
Tet-inducible HaCaT cells, cells were treated with tetracycline 48 hours prior to infection and/or 
treatment. At specified times post-infection, cells and supernatant were collected, via scraping and 
aspiration respectively. The cell mixtures were then freeze-thawed three times in liquid nitrogen 
and a 37°C water bath, before viral titre was determined via a standard plaque assay on BSC-1 
cells. 
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2.7.3 EEV Release 
Release of extracellular enveloped virus (EEV) was measured using an EEV release assay. Similar 
to single-step growth curves, cells were grown to confluency in 12-well plates before infection 
with VACV-WR at an MOI of 0.1 for 1 hour. Again, if treatments were required they were carried 
out as above. At 1 hour, virus was removed, cells were washed thoroughly in PBS and fresh media 
was added. At the specified time-points, only supernatant was collected, and the viral titre was 
determined using standard plaque assays. Assays were performed in triplicate.  
 
2.7.4 Wound healing or scratch assays 
The appropriate cells were seeded to confluency on square glass coverslips for scratch assays. 
Once confluent, cells were serum starved in 0.2% FBS/DMEM for 24 hours. At this point, 
wounding and infection were carried out. To ensure consistency, wounds were made by dragging 
a yellow P200 tip down the surface of the glass coverslip, with the tip held at a 45° angle to the 
coverslip face. Typically, five parallel wounds were made per coverslip. After wounding 
coverslips were lightly washed in PBS before being infected with VACV-WR (mCherry) virus at 
an MOI of 5 for 1 hour. Following this step, the SFM was removed and replaced with serum-
containing media. In certain cases, treatments were also applied to cells at this time point, 
including TGF-β or SB-431542 at concentrations described earlier. After 24-48 hours coverslips 
were washed in PBS, fixed in 3% PFA in CB for 10 minutes, and then washed again in PBS. 
Immunofluorescent staining was then carried out as previously described before imaging.  
 
2.7.5 Invadopodia assays 
Instructions accompanying the QCM Gelatin Invadopodia Assay (Green) (Merck Millipore) were 
followed. The general steps are outlined in Figure 2.5. The experiment consisted of three stages; 
priming glass slides with fluorescent gelatin, incubating cells on the gelatin substrate, and then 
fluorescently staining cells for visualisation. For the first stage, the surface of BD Falcon 8-well 
chamber slides was prepared with reagents found within the kit. Firstly, slides were primed with 
1X Poly-L-lysine solution at room temperature for 20 minutes. Following a PBS wash, 1X 
glutaraldehyde in PBS was then added for 15 minutes. Finally, a 1:5 mixture of 1X Fluorescein-
gelatin and 1X Unlabelled gelatin was made up in PBS, heated to 60°C for 5 minutes, then layered 
onto the washed glass slides for 10 minutes. After this stage, slides were kept protected from light. 
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The slides were disinfected in 70% ethanol for 30 minutes then quenched for 30 minutes in cell 
culture media prior to cell seeding.  
For the second stage, 1 x 104 cells were added to each well of the chamber slide. To ensure even 
distribution, slides were kept at room temperature for 15-20 minutes before incubation at 37°C. At 
this point, they were also infected and/or treated as previously described. After 24-48 hours, cells 
were fixed in 3% PFA in CB, and stained as described for immunofluorescence assays. Before 
imaging, chambers were removed, and protective glass coverslips were mounted over cells.  
 
Figure 2.5 –Schematic of the QCM Gelatin invadopodia assay (Green) (Promega)  
Various reagents were layered onto the surface of the 8-well chamber glass slides for the invasion assay. Once 
the slides had been primed, via the addition of poly-L-lysine, glutaraldehyde, fluorescent gelatin, ethanol and 
growth media, cells were able to be layered on top. After 24-48 hours the cells were fixed, and the fluorescent 
gelatin surface was imaged on an Olympus BX51 microscope. Image adapted from Promega.  
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3.1 INTRODUCTION 
3.1.1 VACV drives major changes in infected cells 
Vaccinia is the prototypical member of the Orthopoxviridae family. Since its use in the smallpox 
vaccine, it has garnered a lot of interest as a model for poxvirus infection. One particular focus area 
is its ability to hijack cellular processes, which it uses to drive viral replication and pathogenesis. 
Typically, this manipulation of cells results in observable structural changes which are termed 
cytopathic effects (CPEs).  
There are numerous CPEs associated with different temporal stages of VACV infection. For 
example, shortly after VACV entry, cells round up in a microtubule-dependent manner (Figure 
3.1A). This contractility phenotype is thought to aid in viral transport to the perinuclear region and 
in the conglomeration of viral replication foci, leading to the formation of a single virus factory 
[332, 372]. Once localised to these central regions, the virus elicits a global reduction in host 
protein synthesis, a consequence of the virus sequestering host resources for itself (Figure 3.1B) 
[373-375]. Another result of this cytoskeletal remodelling is a concomitant increase in cell 
migration capacity [323, 376]. This phenotype is evident in wound healing assays and thought to 
enhance viral cell-to-cell spread (Figure 3.1C) [326, 327].  
In contrast to early infection, the late infection phenotype is typified by the formation of web-like, 
stellate cells (Figure 3.1D) [332, 376]. These cells separate from each other and become 
independent vessels of infection. Interestingly, viral gene expression is necessary for this 
transformation to occur, as late cytopathic changes are absent when VACV replication is inhibited 
with cytosine arabinoside (Ara-C) [376, 377] (Figure 3.1D).  
The structural and behavioural changes observed in VACV-infected cells, including cell migration 
elongation, and detachment, are reminiscent of EMT-associated processes. Given that VACV is 
able to modulate host systems, it is possible that VACV repurposes EMT signalling pathways to 
force a mesenchymal transition and promote viral spread.  
 
 
 
 EMT AND TGF-β PATHWAY ACTIVATION 
University of Sydney 87 2018 
Uninfected Uninfected 
VACV-infected VACV 3 hpi 
 
 
 
 
 
 
 
Figure 3.1– Various cytopathic effects are observed during VACV infection 
(A) Rounding of HeLa cells can be observed at 3 hpi with VACV. Scale bar = 10 μm. (Adapted from. [332]). (B) 
Amino acid incorporation and protein synthesis is reduced in cells infected with VACV at an MOI of 10 (●), 50 
(▲) and 100 (■), compared to uninfected cells (○) [373]. (C) Wound healing assays highlight increased migration 
of VACV-infected BSC-1 cells compared to their uninfected counterparts. Images were obtained 24 hours after 
scratches were made. (Adapted from [376]). (D) At 24 hpi VACV Western reserve (WR) strain induces the 
formation of branched, stellate cells compared to the mock uninfected cells. This morphology is dependent on late 
viral gene expression, as it is lost in the presence of Ara-C, an inhibitor of viral replication (Adapted from [376]).  
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3.1.2 VACV, EMT and TGF-β - The legacy 
VACV is known to manipulate a variety of host signalling pathways, including RhoA signalling 
pathways for increased cell migration, MAPK cascades for cytoskeletal reorganisation and 
apoptotic pathways for prolonged cell survival [240, 249, 324, 326, 327, 332]. However, there are 
many VACV-host interactions which are yet to be characterised.  
Given the strong resemblance between VACV-infected cells and those undergoing EMT, we 
wanted to determine whether classical EMT pathways were activated by this virus during infection 
and could be responsible for mediating these cellular transitions. A number of possible pathways 
were investigated; however, the one which proved to be the most interesting in this context was the 
TGF-β signalling pathway (Figure 3.2). Previous work conducted using luciferase assays found that 
transcription factors, Smad2 and Smad3, were active in VACV-infected cells (Figure 3.2A) (C. 
McKenzie, PhD thesis, 2016). This result was sustained over time and conserved following 
infection with multiple VACV strains (Figure 3.2B and C). Whilst the data highlighted a role for 
the TGF-β pathway during VACV infection, other EMT-associated signalling pathways, such as 
those mediated by Wnt and Notch signalling proteins, did not appear to be affected (Figure 3.2D, 
data not shown).  
To build on this preliminary luciferase data, we decided to examine different steps in the TGF-β 
pathway to gauge a sense of how active this pathway is during VACV infection. The stages 
investigated both previously and within this chapter are described below. 
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Figure 3.2 – Luciferase data suggests TGF-β signalling is upregulated during VACV infection  
(A) Luciferase reporters were used to detect activity of TGF-β-associated transcription factors, Smad2 (ARE-Luc) 
and Smad3 (SBR-luc, CAGA12-Luc) in uninfected or VACV-infected (MOI of 5) at 8 hours. All cases displayed 
significant induction of Smad activity upon infection. (B) Smad3 signalling was also induced by VACV-WR to a 
similar extent and over a comparable time-frame as TGF-β treated (2 μg/mL) cells. (C) These results were seen 
across multiple strains of VACV, including VACV-WR, VACV-Lister and Chorioallantois VACV Ankara strain 
(VACV-CVA) at 24 hpi. (D) This activation phenotype was not seen when using a Wnt/β-catenin-associated 
luciferase reporter (TCFr-Luc) over a 24 hour period. Assays were conducted in HeLa cells. Error bars refer to 
SEM. (C. McKenzie, PhD thesis, 2016).  
 
. 
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3.1.3 Stages of the TGF-β pathway for further investigation 
As the TGF-β signalling cascade consists of numerous components that rely on each other for 
sequential activation, there are many points at which a virus can intercede and manipulate this 
pathway (Figure 1.13). We can look at three key stages in this process to determine if and how 
pathway activation is transpiring. The first stage consists of activation of the TGFβR complex and 
C-terminal phosphorylation of Smad proteins. This is succeeded by Smad transcription factor 
activity on their promoter binding elements within the nucleus. Finally, we can examine the 
generation of Smad target genes to provide an indication on the phenotypic outcomes of TGF-β 
signalling during VACV infection. 
 
3.1.4 Stage 1: Phosphorylation of receptor Smad proteins, Smad2 and Smad3  
The foremost step in TGF-β signalling is activation of the TGFβR complex by TGF-β (Figure 1.9). 
As described earlier, ligand binding allows TGFβRI and TGFβRII proteins to conglomerate and 
form a functional heteromer [133, 174, 378]. Ligand binding also promotes endocytosis of the 
receptor complex, balancing pathway regulation by both increasing contact between the TGFβR 
complex and R-Smads, as well as targeting these complexed proteins for ubiquitin-mediated 
destruction [379, 380]. Without TGF-β ligand, the TGFβR components are dispersed and Smad 
protein levels and activity are greatly diminished [381, 382]. In the canonical system, the activated 
receptor complex potentiates intracellular signalling by binding to L3 motifs of Smad2 and Smad3 
proteins, leading to their phosphorylation at the C-terminal SSXS motif [111, 132]. Within the 
canonical signalling pathway, this stage in particular is believed to be crucial for downstream target 
gene transcription to occur [133]. As such, R-Smad C-terminal phosphorylation is considered a 
hallmark of canonical TGF-β signalling. In fact, a number of viral infections, including HCV and 
reovirus infections, are associated with changes in p-Smad2 or p-Smad3 levels [256, 278, 279].  
In our research, immunoblotting techniques revealed that R-Smad proteins were C-terminally 
phosphorylated at the SSXS motif following TGF-β treatment (data not shown). This phenotype 
was also observed in VACV-infected cells for both Smad2 and Smad3 (Figure 3.3). These data 
suggested the TGFβRI protein was effectively acting on R-Smad proteins during VACV infection, 
leading to their activation by C-terminal phosphorylation. Having confirmed this stage, our 
experimental focus shifted to Smad activity within the nucleus and the production of downstream 
Smad target genes. 
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Figure 3.3 – C-terminal phosphorylation of R-Smad proteins is observed following TGF-β treatment 
and VACV infection 
Immunoblot analysis showed increased levels of p-Smad2 and p-Smad3 in VACV-infected (MOI of 5) cells at 8 
hpi. This was contrasted to lysates obtained from uninfected cells. In both cases, overall expression of Smad2 and 
Smad3 was unchanged. A36 and β-actin were used as viral and cellular loading controls respectively (C. R. 
Abbott, unpublished, 2017).  
 
3.1.5 Stage 2: Activity of Smad proteins  
The penultimate step in the TGF-β signalling pathway is binding of Smad transcription factors to 
their gene targets in the nucleus. The transcriptional activity of these proteins is influenced by a 
number of factors. For instance, motifs present in gene promoters, Smad phosphorylation profiles, 
cellular localisation and interactions with other DBPs [141, 150, 176, 202]. From the preliminary 
data presented in Figure 3.2, it is clear that Smad2 and Smad3 both display significant activity on 
ARE, SBR and CAGA12 motifs following VACV infection. However, to provide us with more 
information and increased flexibility, a second system was generated to look at this same process in 
a new light.  
CAGA boxes were the first Smad binding site to be identified in the promoters of various Smad 
target genes [202, 203]. Due to the wealth of information on their functions and binding partners, 
these motifs are now used as markers for the detection of Smad3 target genes and as tools for the 
measurement of Smad3 activity [371, 383]. In this research, we aimed to create a live-cell Smad3 
monitoring system. As a result, a cell line was created using lentiviral transduction to introduce a 
CAGA12-GFP construct. This construct produced GFP upon binding of Smad3 to CAGA12, and so 
allowed the real-time assessment of Smad3 activity at the single-cell level following VACV 
infection.  
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3.1.6 Stage 3: Production of Smad protein transcriptional targets  
Following Smad binding to DNA, we see a concomitant rise in transcription of Smad target genes. 
The production of these genes is an important step to monitor in the TGF-β signalling pathway, as, 
without alterations in gene expression, we would not expect to see changes in cell shape, structure 
or behaviour; the driving forces of EMT [141]. Due to this, various groups have studied the global 
changes in gene expression following TGF-β stimulation [141, 364].  
For ease of assessment in our context, a group of Smad target genes were selected to study with 
varying functions during EMT. For example, c-JUN is a well-studied proto-oncogene that is 
expressed in response to TGF-β stimulation of cells. It has the ability to dimerise with other 
members of the Jun family or Fos family of proteins, forming transcriptional complexes collectively 
known as AP-1 [384]. The AP-1 complex has been found to play an enigmatic role in tumour 
development, affecting transcription of a wide array of pro- and anti-oncogenic transcriptional 
targets [385]. It does so via interactions with Smad3, binding to TRE consensus sequences which 
are known AP-1 binding sites [211]. In fact, c-JUN can influence its own transcription, as well as 
the expression of other EMT-associated genes in this manner [384, 386]. However, it also has the 
ability to inhibit transcription by preventing Smad3 binding to CAGA motifs [212]. This complex 
relationship with oncogenesis, EMT and TGF-β-induced transcription makes c-JUN an ideal target 
for further investigation.  
Snail and Snail2 (also known as Slug) are also transcription factors. These were chosen for study as 
they are commonly associated with Smad signalling and are considered markers of EMT-associated 
signalling [68]. They mediate the expression of a number of EMT-associated genes, such as E-
cadherin, claudins, occludins, N-cadherin, vimentin and fibronectin, by binding to E-box motifs and 
inhibiting epithelial gene expression, whilst concurrently promoting mesenchymal gene expression 
[89, 387]. Interestingly, despite displaying high homology, Snail and Snail2 are thought to work on 
different transcriptional targets [214]. However, both are considered to be key drivers in the 
repression of epithelial-associated genes and expression of mesenchymal markers. 
Finally, plasminogen activator inhibitor-1 or PAI-1 is another highly upregulated gene following 
Smad signalling. It has been implicated in numerous pathologies, including inflammation, 
fibrinolysis, atherosclerosis, Type II diabetes mellitus and aging in general [388-391]. The promoter 
element of PAI-1 contains a number of Smad binding sites. It acts to drive EMT by inhibiting the 
cleavage of plasminogen to plasmin, simultaneously abrogating plasmin induction of matrix 
metalloproteinases (MMPs) [391]. This contributes to cytoskeletal reorganisation of cells and 
increased migration, which are key to the progression of EMT. 
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The chosen genes all have a strong link to TGF-β signalling, have the ability to act as proxies for 
Smad2 and Smad3 activity, in the case of c-JUN, Snail and Snail2, and are known to contribute to 
the transition towards a mesenchymal state. As a result, we hoped they would shed light on VACV-
induced EMT. 
 
3.1.7 Chapter aims 
In this chapter, we aimed to characterise the EMT response observed during VACV infection and 
determine which aspects of the downstream TGF-β signalling cascade are concurrently upregulated. 
This research builds on previous data obtained in our laboratory looking at phosphorylation and 
activation of Smad transcription factors in various VACV contexts. To further investigate the 
downstream elements of this pathway (particularly Stage2 and 3 of the TGF-β confirmation process) 
a number of techniques were utilised. This included the generation of a TGF-β-responsive, GFP-
producing cell line to look at Smad activity on promoters of TGF-β target genes, as well as qRT-
PCR and immunofluorescence analyses for assessment of TGF-β target expression. The goal of this 
work was to gain some clarity on the intricacies of TGF-β signalling during VACV infection. Our 
aims were as follows: 
 
• Does VACV induce an EMT-like phenotype in infected cells? 
• If so, does this encompass all aspects of EMT, including cell elongation, detachment, 
migration and invasion? 
• Is the EMT phenotype induced by VACV observed over multiple cell types? 
• Could the TGF-β signalling pathway be responsible for EMT development in VACV 
infection? 
• Which stages of TGF-β signalling are activated or upregulated in the context of VACV? 
• What is the timing of VACV-induced activation of this pathway? 
• Can we develop a system to monitor activation of TGF-β signalling in a live-cell assay? 
• Do our results align with the previously obtained data in our laboratory? 
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3.2 RESULTS  
3.2.1 An EMT phenotype is observed in VACV-infected cells 
A number of viruses engender an EMT-like cytopathic effect in the cells they infect. These cells are 
characterised by the acquisition of an elongated shape, an increase in motility and invasiveness, as 
well as the dissolution of cell-to-cell junctions and the rearrangement of the actin cytoskeleton [55]. 
We observed a number of these characteristics following VACV-WR infection of African green 
monkey kidney epithelial (BSC-1) and human keratinocyte (HaCaT) cells (Figure 3.4). The 
transition from flat, pancake-like epithelial cells to cells with long elongated, protrusions was 
evident in both cases. Furthermore, the actin cytoskeleton (red) shifted away from a cortical actin 
arrangement, where actin was predominantly located at the cell periphery, to structures where actin 
filaments formed long protrusions and ran parallel to the long axis of the cell. Due to this feature, 
cells became streamlined and spindle-shaped. Infected cells also lost cell-to-cell junctions, 
becoming separated from their neighbours. This was in stark contrast to the tightly-associated, 
epithelial-like cells in the uninfected condition.  
 
Figure 3.4 – VACV induces an EMT-like state in infected cells 
BSC-1 (left) and HaCaT (right) cells display elongated, mesenchymal-like phenotypes at 24 hpi with VACV-WR 
(MOI of 5). The actin cytoskeleton (red) organisation also appears to change upon infection. The viral envelope 
protein, B5 was stained in green and dsDNA in blue. Cells were imaged using the Olympus BX51 microscope. 
Images are representative examples from 3 experiments. Scale bar = 50 μm.  
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3.2.2 Behavioural features of EMT, including cell migration, are seen following VACV 
infection 
In concert with the major restructuring of cells, EMT is also linked to drastic alterations in cell 
behaviour. One such change is the development of nomadic, roaming cells, which have a greater 
capacity for spread than their tethered counterparts. After observing the EMT-like event, which 
occurred during late VACV infection, we wanted to determine whether accompanying behavioural 
changes, such as increased cell migration, could also be detected in this context (Figure 3.5).  
A classic method for studying cell movement is the wound healing assay, which consists of creating 
a wound or scratch in a cell monolayer and monitoring infiltration back into this site over time. 
Earlier studies in the literature used wound healing assays to show that VACV induces motility of 
infected BSC-1 cells [324, 331, 376]. We have previously replicated this experiment in our 
laboratory and obtained a similar result (Figure 3.5) (A. Gowripalan Honours thesis, 2013). Note 
that the VACV-WR used within this experiment contained an mCherry construct under the control 
of a viral promoter, pE/L (VACV-WR (mCherry)), resulting in a diffuse red fluorescent signal upon 
infection (C, McKenzie, PhD thesis, 2016). Use of this virus allowed for easy visualisation of 
infection during imaging. Interestingly, during this analysis it appeared that not only were BSC-1 
cells more motile upon TGF-β treatment and VACV-WR infection, but the migration phenotype 
proved to be partially dependent on TGF-β signalling, as it was abrogated in the presence of a 
TGFβRI inhibitor, SB-431542 (A. Gowripalan, Honours thesis 2013).  
 
 EMT AND TGF-β PATHWAY ACTIVATION 
University of Sydney 96 2018 
 
Figure 3.5 – VACV-infected BSC-1 cells migrate faster than uninfected cells and in a TGF-β-
dependent manner 
(A) Wounded BSC-1 cell monolayers display increased cell infiltration upon treatment with TGF-β (2 μg/mL) and 
infection with VACV-WR (mCherry) (MOI of 5) at 24 hours post-treatment. This phenotype was lost in the 
presence of small molecular TGFβR inhibitor, SB-431542. In this assay, virus was visualised in red and dsDNA in 
blue. Images were taken using the Olympus BX51 microscope. Scale bar = 200 μm. (B) Counts of nuclei within 
the wound site also suggest that VACV-induced cell migration is TGF-β signalling-dependent. n=5. Error bars 
refer to SEM. Adapted from A. Gowripalan, Honours thesis, 2013. 
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To confirm the migration phenotype induced by VACV in other cell types, further wound healing 
assays were conducted on human melanoma (SK Mel), human cervical cancer epithelial (HeLa) and 
HaCaT cells. All of these cell types have all been previously applied to wound healing assays and 
are known to respond to TGF-β treatment [392-395]. They are also capable of undergoing EMT, 
making them suitable for our studies. However, the results obtained with these cell types proved 
more complex than previously thought (Appendix 8.2). As such, live monitoring of wound healing 
assays was thought to be more appropriate in this context (Figure 3.6). Again, as with BSC-1 cells, 
TGF-β treatment appears to increase the rate of HaCaT cell migration, with wounds closing 
approximately 36-40 hours after scratching. This is compared to the 42-48 hours it takes for 
untreated HaCaT cells. However, the results obtained for VACV-infected HaCaT cells make it 
impossible to quantify wound closure. As infection spreads through the cell monolayer, the integrity 
of this layer is obliterated, leading to mass areas of cell clearance and erasure of the original 
boundaries of the wound site. Cells may be moving; however, they do not appear to move in a 
singular direction into the wound site. In fact, over time the wound diameter even appears to be 
increasing. From these results, we cannot conclusively say whether VACV affects migration of 
HaCaT cells as it seems the assay is simply not appropriate in this context. Wound healing assays 
are designed to monitor cell movements along a single axis, and as such, they cannot account for 
more randomised migration patterns. It is possible that different methods would be more suitable 
for monitoring VACV-induction of cell migration.  
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Figure 3.6 – Movie stills of HaCaT wounds reveal that wound healing is diminished upon VACV 
infection 
Live monitoring of HaCaT cells infected with VACV-WR (mCherry) (MOI of 5) revealed they did not invade 
into wound sites as effectively as uninfected or TGF-β treated (2 μg/mL) cells. Virus can be seen in red. Wound 
edges are outlined in the white dashed lines. Images were taken using the Nikon Ti-E Eclipse microscope over a 
24 hour period. Three movie stills from each 12 hour interval are shown. Scale bar = 200 μm. 
 
3.2.3 Live monitoring of VACV-induced cell migration 
Due to limitations in wound healing assays, it was proposed that live tracking of cell movements 
could give a clearer indication of VACV-induced cell motility. This technique accounts for cells 
moving in any direction, rather than those that migrate along a single vector. 
To track the movements of infected cells a number of VACV-WR viruses were employed. The first 
of which, VACV-WR (mCherry), contained an mCherry insert and was used previously (Figures 
3.5 and 3.6). This virus diffusely stained infected cells red. Whilst helpful for identification 
purposes, it did not provide detailed information on the internal workings of infected cells. As such, 
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two other viruses were also utilised, each of which contained a fluorophore bound to a targeting 
protein. For example, VACV-WR (LifeAct-GFP) contained a construct possessing a LifeAct 
protein bound to GFP, which stains the actin cytoskeleton green within infected cells. Another 
construct, consists of a fluorescent cerulean protein attached to a nuclear localisation signal to 
visualise the nuclei of infected cells in cyan. The virus containing this insert was named VACV-WR 
(Nuc-Cer) (Section 2.2.3). A benefit of these viruses is they allow tracking in a live system, whilst 
also providing information on the cells they infect.  
The results in Figure 3.7 illustrate how infected HaCaT cells move and change over time compared 
to uninfected cells. For this assay, cells were tracked in developing plaques, shown in Figure 3.7A. 
As we can see in this analysis, the VACV-WR (Nuc-Cer) plaques appeared to expand slower than 
the other viruses used for this research. The VACV-WR (mCherry)-infected cells seemed to migrate 
the fastest and displayed the most rapid plaque expansion (Figure 3.7A and B). However, overall it 
did appear that migration was faster in infected cells when compared to uninfected cells, regardless 
of the virus used (Figure 3.7C). Examining the dynamics of migration in closer detail, it is clear that 
cells within the centre of plaques appear to move more rapidly than those at the periphery (Figure 
3.7B). This is seen as reduced cell overlap in the three overlaid frames, and the increased incidence 
of distinct single-coloured cells within the plaque centre. In this image, stationary cells appear white. 
Overall, these experiments support the observation that VACV is capable of inducing migration of 
cells. 
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Figure 3.7 – Tracking of single cell movements revealed that VACV-WR infection promotes cell 
motility 
(A) Movie stills generated via fluorescence microscopy revealed that cells infected with VACV-WR (mCherry), 
VACV-WR (LifeAct-GFP) and VACV-WR (Nuc-Cer) form large plaques over time. Images were collected using 
the Nikon Ti-E Eclipse microscope over a 48 hour period. Scale bar = 200 μm. (B) Using a representative plaque, 
three frames collected 6 hours apart were overlaid to study cell movement. The first image shown in red was 
collected at 42 hours, the second in green at 45 hours and the final image in blue at 48 hours. Within the centre of 
the plaques there is clear cell movement over time, shown as cells appearing red, blue, green or a mixture of these. 
White cells are stationary over the three frames. Scale bar = 200 μm. These images were used to track 
displacement over time of infected cells and those in an uninfected monolayer (C). Five cells were monitored in 
each condition. Despite variance in the different viruses used there is a clear increase in distance from the cell 
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starting point upon infection. Uninfected cells are not entirely stationary, but do not move aggressively in any 
particular direction. Data shown is representative of three independent experiments.  
 
3.2.4 VACV infection and the induction of cell invasion 
Increased invasion is another feature commonly associated with cells undergoing the progression 
towards a mesenchymal-like phenotype. In the context of viral infection, an invasive phenotype 
drives rapid and increased spread of virus, allowing infected cells to access a variety of tissues. 
Invasion also facilitates motility via degradation of the extracellular matrix and extension of 
invadopodia. To determine whether this invasion phenotype was observed as a result of VACV-
infection, we conducted invadopodia assays.  
A number of cell lines were used for this analysis. SK Mel and GBM cells were provided by 
collaborator Richard Christopherson (University of Sydney, Australia) to act as negative and 
positive controls, respectively. The first is a non-invasive melanoma cell line, whilst the second was 
generated from a highly invasive glioblastoma tumour [396]. For the test conditions, BSC-1 cells 
and HaCaT cells were both examined, due to the EMT-like phenotype observed earlier (Figure 3.4). 
Whilst, BSC-1 cells proved to be suitable, HaCaT cells were found to be inherently invasive (Figure 
3.8, Appendix 8.2). As a result, no discernible differences could be detected between uninfected, 
TGF-β-treated and VACV-WR-infected HaCaT cells (Appendix 8.2). As such, BSC-1 cells were 
chosen for further analysis. 
In Figure 3.8, there is clear degradation of the gelatin layer observed when wells were seeded with 
the positive control, GBM cells. This phenotype is not present in the SK Mel condition where the 
gelatin layer appears intact and uniform. Uninfected BSC-1 cells strongly resemble SK Mel cells in 
their invasive capacity, however, treatment with TGF-β or infection with VACV-WR pushed 
towards an aggressive invasion phenotype. Attempts were made to quantify this data; however, 
difficulties were encountered in reproducibility and detection of the invaded area (Appendix 8.2). 
Qualitatively, we can see that VACV is capable of promoting BSC-1 cell invasion.  
To determine whether this process was reliant on TGF-β pathway effectors, further assays were 
conducted. Typically, TGF-β-mediated cell invasion is regulated by members of the matrix 
metalloproteinase (MMP) family [397, 398]. There are 23 human MMPs, which cooperatively act 
to regulate invasion of cells into their surroundings, via degradation of various molecules in the 
ECM. As VACV appears to be able to induce invasion of BSC-1 cells into fluorescent gelatin, we 
wanted to determine if it uses MMPs in order to do so. To study this, we used a number of small 
molecule inhibitors to interfere with MMP functions. The first inhibitor, GM6001 (Merck 
 EMT AND TGF-β PATHWAY ACTIVATION 
University of Sydney 102 2018 
Millipore), targets the actions of MMP-1, -2, -3, -8 and -9, whilst MMP inhibitor II (Calbiochem) 
targets MMP-1, -3, -7 and -9. From the results, there is evidence that both inhibitors may affect the 
ability of VACV to induce invasion, suggesting MMPs mediate this invasion phenotype (Figure 
3.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 – VACV-infection increased invasion potential of infected BSC-1 cells 
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(A) Gelatin invadopodia assays (Green) using SK Mel, GBM and BSC-1 cells revealed that TGF-β treatment (2 
μg/mL) and VACV infection (MOI of 5) increased the ability of BSC-1 cells to invade into a fluorescent, 
gelatinous substrate. These levels became comparable to our positive control GBM cell line. The invasion 
phenotype was lost in the presence of GM6001 (10 μM) and MMP inhibitor II (30 μM), suggesting MMPs 
mediate this process. Images were captured at 24 hpi visualised on the Olympus BX51 microscope. Gelatin 
underlay was depicted in green, the actin cytoskeleton in red and cell nuclei in blue. Scale bar = 200 μm.  
 
3.2.5 TGF-β and VACV-WR promote sustained Smad3 activity  
Given the abundance of data suggesting VACV induced an EMT-like response within infected cells, 
we wanted to determine if TGF-β components were responsible for this phenotype. To better 
investigate this, we developed a tool to monitor Smad3 activity in live cells at the single-cell level. 
This was to not only assist in clarifying the dynamics of TGF-β signalling, but address aspects of 
cell autonomy and response timing.  
The HaCaT CAGA12-GFP cell line possesses a construct which facilitates the expression of GFP 
upon binding of Smad3 to the CAGA12 motif within target gene promoters. The making of these 
cells is described in Appendix 8.1 [371]. Due to the seemingly high frequency of successful 
lentiviral transduction, we did not feel the need to generate a clonal cell population, and so mixed 
populations were used for our research. When these cells were used in experimentation, it became 
evident that TGF-β treatment and VACV infection led to the clear induction of a Smad3 response, 
as detected by GFP expression (Figure 3.9). This result not only suggested VACV can activate 
TGF-β signalling but supported previous luciferase data (Figure 3.2). 
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Figure 3.9 – HaCaT CAGA12-GFP cells express GFP in response to TGF-β treatment and VACV-WR 
infection 
At 10 hpi, TGF-β treated (2 μg/ml) and VACV-WR (mCherry)-infected (MOI of 5) infected HaCaT CAGA12-
GFP cells display increased GFP expression compared to uninfected/untreated cells. mCherry expression (red) 
indicates presence of virus. CAGA12-GFP appears in green and dsDNA in blue. Images were taken on the 
Olympus BX51 microscope. Scale bar = 200 μm. n=3. 
 
To gain insight into the dynamics of GFP expression we conducted a number of time course 
experiments. Initially, HaCaT CAGA12-GFP cells were grown to confluency prior to treatment with 
TGF-β or infection with VACV-WR, as before (Figure 3.10). The images indicate that over time 
uninfected cells display low levels of transient GFP expression, perhaps due to TGF-β and Smad3 
responses associated with dividing or crowded cells [399, 400]. However, compared to the 
expression seen over the course of TGF-β treatment we can see this response is limited both in 
number of GFP-positive cells and level of fluorescence. The pattern and timing of GFP expression 
in VACV-WR-infected cells resembles the TGF-β condition, with the expression of mCherry 
observed following infection. Interestingly, at 8 and 10 hpi it appears that GFP and mCherry 
expression display little overlap or co-localisation, as confirmed via intensity plots (Figure 3.10). 
This suggests TGF-β pathway activation is more apparent in cell proximal to infection, rather than 
infected cells themselves. However, at 12 hpi we begin to see this pattern change with the gradual 
appearance of double-positive fluorescent cells. 
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Figure 3.10 – CAGA12-GFP-containing HaCaT cells display strong activation over-time after TGF-β 
treatment and VACV-WR infection  
Immunofluorescence images of lentiviral-transduced HaCaT cells show strong GFP expression following 
treatment with TGF-β (2 μg/mL) or infection with VACV-WR (mCherry) virus (MOI of 5). At the specified time-
points, DAPI (blue), CAGA12- GFP (green) and mCherry (red) were visualised using the Nikon Ti-E Eclipse. 
Scale bar = 200 μm. Intensity profiles generated using ImageJ software confirmed the elevated GFP levels in the 
infected condition. Five hundred cells were chosen at random for analysis.  
 
3.2.6 Smad3 activity is spatially linked to VACV-WR infection 
We continued to examine the locality of the TGF-β response following infection using live-cell 
imaging experiments. In this case, HaCaT CAGA12-GFP cells were infected with low 
concentrations of VACV-WR (mCherry), and plaque development was imaged at 15 minute 
intervals for a 20 hour period (Figure 3.11). As the VACV-WR plaque grew, we saw the increase in 
area of mCherry expression as expected. Concurrently, a ring of GFP-expressing cells developed 
around the plaques. Given the nature of the pE/L promoter driving mCherry expression, we could 
not definitively state whether these cells were uninfected, or undergoing early VACV infection. In 
the images there were also background cells with lower levels of GFP expression, suggesting a low 
level of basal TGF-β pathway activation was present in all cells. This is reminiscent of the 
uninfected cells observed in Figure 3.10. For analysis, 24 diameters were drawn through the centre 
of the plaque and the intensity of each fluorophore was measured along this line (see Figure 2.3). 
The lines were then averaged to generate the intensity profiles shown. Again, we see a consistent 
spike of green fluorescence adjacent to the infected cells, which moves outward at the same rate as 
plaque spread. At later time points, particularly 24h00m and 28h00m, we began to see clearance 
within the centre of plaques. These voids appeared as black holes within the plaque and could be 
seen both in the images themselves, as well as the intensity profiles. This data suggests TGF-β 
pathway activation occurs in infection adjacent cells, prior to VACV infection taking hold. 
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Figure 3.11 – Live plaque analysis in transduced HaCaT cells shows CAGA12 activity following 
VACV-WR (mCherry) infection 
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Elevated GFP levels can be observed in CAGA12-GFP-transduced HaCaT cells following infection with VACV-
WR (mCherry) (MOI of 1) via live-cell imaging. All images were captured using the Nikon Ti-E Eclipse 
microscope. Scale bar = 400 μm. Intensity profiles were generated using the 24-line method.  
 
3.2.7 Target genes of the TGF-β signalling pathway are transcribed following VACV-WR 
infection 
The expression of Smad target genes is a key step in the progression of TGF-β signalling and the 
initiation of EMT, as these are critical for mediating various effector functions. Using qRT-PCR 
analysis we were able to study some of these genes. Figure 3.12 illustrates the transcript levels of 
target genes after TGF-β stimulation, as well as infection with VACV-WR.  
Following treatment with TGF-β, there is increase in steady state levels of Smad target genes, 
indicative of the induction of expression due to Smad2 and Smad3 activity. These genes include, c-
JUN, Snail2 and PAI-1. However, these genes do not seem to display a coordinated pattern of 
expression. Whilst c-JUN and PAI-1 mRNAs increase over time, from the 8 to 12 hour time points, 
Snail2 is expression is more complex. Snail2 is transcribed early following TGF-β treatment, 
decreases at 10 hours and then is increased again at 12 hours. We also observe expression of Smad 
target genes following infection with VACV-WR. Interestingly, VACV induction of Smad target 
genes follows a different pattern to the TGF-β condition. Again c-JUN mRNA expression increases 
over time; however, this is slightly delayed compared to TGF-β treatment with significant levels 
only being detected at 10 hpi. Interestingly, Snail2 is also transcribed at 8 hpi as with the TGF-β 
condition but peters out at 10 and 12 hpi. Levels of PAI-1 follow a similar pattern following TGF-β 
treatment and infection. However, at 12hpi, PAI-1 transcript levels in VACV-WR-infected cells 
exceed those seen in TGF-β-treated cells. Overall, our data is consistent with an induction of 
various Smad target genes following both TGF-β treatment and VACV infection; however, the 
expression profiles of each condition differ slightly.  
The other mRNAs examined in this experiment were the cellular control, GAPDH, to which all 
gene expression levels were normalised to, and viral controls, D12 and A17. As expected, D12 and 
A17 were only seen during VACV infection, and early gene, D12, was transcribed before late gene, 
A17.  
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Figure 3.12 – Smad target genes are expressed following VACV-WR infection of HaCaT cells 
HaCaT cells were lysed using TRIzol reagent at 8, 10 and 12 hours post-TGF-β treatment (2 μg/mL) or post 
VACV-WR infection (MOI of 10). Expression of various mRNAs was investigated via qRT-PCR analysis. Smad 
target genes, c-JUN, Snail2 and PAI-1, and viral control genes, D12 and A17, were normalised to the cellular 
control, GAPDH. n=4. Error bars refer to SEM. 
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3.2.8 Protein expression of Smad targets is increased during infection with VACV-WR 
Our previous results indicate that induction of Smad target genes occurs at the transcriptional level 
following VACV infection. The next step was to evaluate expression of these same targets at the 
level of translation. Two cell lines were used for this analysis. PANC-1 and HT-29 are pancreatic 
carcinoma and colorectal adenocarcinoma cells, respectively. They are both epithelial cell lines 
which have been shown to be capable of undergoing EMT and are known to express Snail and 
Snail2 following TGF-β stimulation [401-403]. Note that HaCaT cells were also assayed but will be 
discussed in depth within future chapters (Section 4.2.3). Upon treatment with TGF-β, PANC-1 
cells in particular (Figure 3.13A, C and E), display slight morphological changes, becoming 
detached from their neighbours and beginning to elongate. This is also observed in VACV-WR-
infected cells. This phenomenon is less obvious in HT-29 cells (Figure 3.13B, D and F). Despite the 
morphological indicators of EMT being less pronounced than in BSC-1 and HaCaT cells (Figure 
3.4), immunofluorescence analysis revealed expression of Smad targets, Snail1, Snail2 and PAI-1, 
in both PANC-1 and HT-29 cells. Expression of these targets can be seen in both the TGF-β-treated 
and VACV-WR conditions. These results indicate VACV-WR is able to induce expression of a 
number of TGF-β pathway-associated targets. 
 EMT AND TGF-β PATHWAY ACTIVATION 
University of Sydney 112 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 – Smad targets are upregulated following TGF-β treatment and VACV infection in 
multiple cell types 
PANCI-1 (A, C, E) and HT-29 (B, D, F) cells show expression of Snail (A, B), Snail2 (C, D) and PAI-1 (E, F) 
following 8 hours of treatment with TGF-β (2 μg/mL) or infection with VACV-WR (MOI of 5). Viral envelope 
protein, B5 was visualised in red, whilst Smad targets and DAPI are in green and blue, respectively. Images were 
taken on Olympus BX51 microscope and are representative of three independent experiments. Scale bar = 50 μm.   
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3.3 DISCUSSION 
3.3.1 VACV induces an EMT-like event in a number of cell types 
A number of prominent viruses, including ebolavirus, HCV, HBV and EBV, are known to elicit 
EMT responses within infected cells [79, 85, 86, 404]. However, as the viral research field 
continues to expand, there is the increasing potential for other viruses to also be identified as EMT 
inducers. In fact, many viruses cause cells to become elongated upon infection; a hallmark of EMT 
[79, 376, 405]. Another subset of viruses manipulate the TGF-β signalling pathway [95]. Bringing 
together phenotypic and transcriptomic data could reveal viruses at the intersect of these two groups 
which are able to induce EMT in a TGF-β-dependent manner and have gone unnoticed as yet. For 
example, SARS-CoV is known to activate Smad3-mediated signalling through the use of its 
nucleocapsid protein. It also promotes the stretching and detachment of cells. Both of these are 
characteristic of TGF-β-induced EMT, begging the question of whether SARS-CoV is a driver of 
EMT [87, 88, 262, 406].  
Within this chapter, we discuss the possibility of VACV being another overlooked virus with the 
capacity to drive EMT. The standard hallmarks of EMT, loss of apical-basal polarity, the 
development of spindle-shaped cells, and increased cell migration and invasion, can all be observed 
during VACV infection (Figures 3.4, 3.7 and 3.8). However, the degree and severity of this EMT 
phenotype appears to vary depending on cell type (Figure 3.13). Previous researchers have 
suggested EMT is a spectrum, more plastic and less binary than once thought [407, 408]. Therefore, 
certain cell types are more prone or resistant to undergoing cellular transitions. It is possible that 
this is the case for the cell lines examined here. For example, HT-29 cells are known to undergo 
EMT as detected by expression of epithelial and mesenchymal markers, but do not become 
elongated, detached or motile as a result of this process [403]. Aligning with these results, we see 
VACV inducing expression of TGF-β-associated drivers of EMT, but none of the typical structural 
hallmarks of EMT within these HT-29 cells (Figure 3.13). BSC-1 cells, on the other hand, undergo 
major structural changes upon VACV infection, whilst HaCaT and PANC-1 cells lie somewhere in 
the middle of this spectrum (Figures 3.4 and 3.13). As EMT appears to be fairly fluid, it is 
promising that our results were obtained in multiple cell types. However, to definitively characterise 
VACV as an EMT-causing virus it would be beneficial to examine the expression of marker 
proteins, such as E-cadherin, vimentin and N-cadherin. This ensures any conclusions drawn are not 
entirely based on cell phenotype observations.  
Another avenue to be considered is the poorly pathogenic, related virus, MVA. As discussed above, 
the formation of stellate cells upon VACV infection displays strong parallels to cellular 
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restructuring observed during EMT [376]. However, this phenotype is absent upon infection with 
MVA, suggesting this virus is incapable of inducing an EMT-like event [298]. Given that the major 
differences between the VACV and MVA genomes lie in six major deletions at the left and right-
hand ends, it is possible that one of these regions is responsible for initiating EMT during VACV 
infection [299, 300]. As such, genomic comparison of the two viruses may provide clues on how 
VACV is able to induce EMT, whilst MVA cannot.  
 
3.3.2 VACV-induced cell migration may be regulated by multiple signalling pathways 
Mesenchymal cells are known for their increased migratory and invasive capacity. A number of 
pathogens are thought to induce EMT in order to enhance the capacity for infected cell spread [78, 
79, 85, 86, 251, 376, 404, 409]. These roving infectious bodies are able to rapidly access more 
targets than stationary cells, and easily evade clearance by the immune system whilst disseminating 
virions to distal tissues. In fact, deletion of a pro-migration factor during Dengue virus infection 
reduced pathogenesis and delayed lethality of infection in mice [410, 411]. We theorised that 
VACV also promotes an EMT-like phenotype to enhance the dynamic rate of viral spread.  
Previous studies of VACV-induced cell migration found that infected BSC-1 cells migrate faster 
into wound sites than their uninfected counterparts [324, 376]. These results were replicated here; 
however, it seemed other cell lines did not behave in the same manner (Figure 3.5) (A. Gowripalan, 
Honours thesis 2013). In our research, SK Mel, HeLa and HaCaT cells, which have been used 
previously for wound healing assays, scattered upon infection with VACV, disrupting the cell 
monolayer so that the original wound sites became masked (Figure 3.6, Appendix 8.2.1) [392, 394, 
395]. Other groups have observed this same randomized cell movement following VACV infection 
of Vero cells, suggesting other factors, such as sheer stress are required to force VACV-infected 
cells to move in a unidirectional manner [412]. In this case, we chose to move forward with live-
cell tracking analyses which were more amenable to our research (Figure 3.7). However, another 
possible technique which could be utilised for future experiments is microfluidics, which is a 
relatively novel tool for studying both cell migration and invasion. It functions by applying 
chemokine gradients to cells and monitoring their movements throughout various chambers, which 
could be beneficial in the context of VACV infection [412, 413]. For instance, to determine if 
VACV induces cell migration through the use of secreted factors, a gradient of VACV-conditioned 
medium could be generated. This could then be used to entice the movement of uninfected cells and 
study the dynamics of VACV-induced cell migration using a technique unlike wound healing 
assays.  
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The induction of cell migration by VACV has been observed previously and viral protein F11 is 
known to play a key role [324]. When F11 levels were depleted by siRNA there was a concomitant 
loss of cell migration detected by wound healing assays [324]. Furthermore, knockout of F11 
impacted processes involved in cell detachment and plaque spread, both of which are important for 
in vitro and in vivo spread [323, 326]. In fact, in the attenuated virus, MVA, which possesses a 
truncated F11 and poor cell migration phenotype, restoration of full-length F11 rescued cell motility 
[324, 331].  
As described earlier, F11 mediates cell movement through interactions with members of the RhoA 
signalling pathway [323-327]. Curiously, RhoA is also known to interact with components of the 
TGF-β signalling pathway and is essential for TGF-β induced EMT in chick embryos [231] (Figure 
3.14). RhoA promotes the nuclear translocation of Smads, phosphorylation of Smads and binding to 
SBE motifs in Smad target promoters [414]. TGF-β can even promote the expression of RhoA at 
early time points post-treatment in order to boost cell motility [414, 415]. However, long term 
exposure to TGF-β decreases levels of RhoA [415]. The data indicates that TGF-β may weigh into 
the balancing act of RhoA expression that is required for cell migration. Due to these characteristics 
it would be interesting to note if F11 and TGF-β work cooperatively or antagonistically to modulate 
RhoA signalling and promote cell migration during VACV infection. Given that inhibition of the 
TGFβRI, with SB-431542, leads to a reduction in cell migration, it is plausible that F11, RhoA and 
TGF-β signalling may be cooperating to coordinate cell motility (Figure 3.5) (A. Gowripalan, 
Honours thesis 2013. One method to investigate this could be the use of a ΔF11 VACV in assays 
for TGF-β signalling, including immunoblots for Smad C-terminal phosphorylation, luciferase 
assays, qRT-PCR and GFP expression in HaCaT CAGA12-GFP cells. Any defects or reductions 
observed would indicate these pathways act in tandem, whilst increases would suggest the opposite.  
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Figure 3.14 – The interaction between TGF-β, RhoA signalling and cell migration 
The interplay between TGF-β and RhoA regulation is fairly complex in relation to promoting or inhibiting cell 
migration. The shift in behaviours is temporal, depending on the length of exposure to TGF-β treatment. Soon 
after treatment, TGF-β promotes RhoA signalling which in turn boosts cell migration. After some time, this 
phenotype is reversed, through the action of a number of mediator proteins. VACV protein F11 also interacts with 
RhoA to promote cell migration. It should be noted that RhoA also exerts an influence on downstream TGF-β 
signalling, boosting the activity of Smad proteins. As such, it is possible that these two pathways work together 
during VACV infection to induce cell motility. Adapted from [89, 224] and [415]. 
 
3.3.3 Induction of cell invasion can promote viral spread in vivo and in vitro 
Whilst cell migration allows cells to move on a two-dimensional plane, invasion permits them to 
infiltrate barriers and travel in a third direction, a critical aspect of in vivo spread and tissue 
infiltration. In fact, cell invasion could be considered an important virulence factor for viruses, as it 
facilitates their entry into the bloodstream where they can be systemically distributed. This same 
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strategy is adopted by tumour tissues following EMT, to access distal sites of the body and establish 
metastases [416]. These invasive tumour types are generally associated with poorer prognoses.  
VACV may also be able to promote its spread via the manipulation of cell invasion. In fact, the 
most pathogenic strains of VACV are known to be neurovirulent in mouse models and so, 
inherently more invasive than less pathogenic strains [294]. To determine whether VACV utilises 
TGF-β signalling and its effectors to modulate this invasion phenotype, we conducted invadopodia 
assays (Figure 3.8).The results confirmed the ability of neurovirulent strain, VACV-WR, to induce 
invasion of BSC-1 cells into a fluorescent gelatin substrate, to a similar degree as our positive 
control, the TGF-β treated cells. This process also appeared to be dependent on effectors commonly 
associated with the TGF-β pathway, MMPs. MMPs are proteins which typically act in concert to 
degrade the extracellular matrix, facilitating migration and invasion by creating a clear path for cell 
intravasation [66]. A variety of the human MMPs can be modulated by the TGF-β signalling 
pathway [417]. For example, TGF-β-dependent MMP-2 and MMP-9 expression is reliant on 
MAPK signalling in cancer cells [418]. In the case of MMP-1 and MMP-7, Smad proteins 
themselves bind to the promoters of these genes and lead to their negative regulation [417]. MMP-2, 
MMP-9, MMP-13 and MMP-14, on the other hand, can influence TGF-β itself by activating the 
TGF-β ligand, as well as TGFβRI and TGFβRII and R-Smads in arterial tissues [417, 419]. The link 
between viruses and MMPs is also well established. For instance, RSV and Dengue viral infections 
are both associated with an increase in MMP-9 [420, 421]. As such, it is possible that VACV takes 
advantage of the complex TGF-β and MMP relationship to increase virulence through enhancing 
cell invasion.  
Throughout these experiments we encountered difficulties in quantification of this invasion 
phenotype. These may have stemmed from the uneven illumination of the field of view observed 
when using the green FITC filter, which made the automated outlining and measuring of invaded 
areas cumbersome (Figure 3.8). In the future, use of more powerful microscopes may allow for 
better assessment of these results. Other groups have also begun using microfluidic technologies to 
investigate the invasive properties of cells, which could prove useful and more reproducible in the 
context of VACV infection [422]. Another issue which was encountered during invasion assays was 
the fact that our primarily used cell type, the HaCaT keratinocyte cell line, proved to be inherently 
invasive (Appendix 8.2). This trend has also been observed by other groups, albeit using different 
invasion assay techniques [423]. Unfortunately, the natural invasion profile of these keratinocytes, 
combined with the difficulties associated with data quantification meant that we could not 
determine whether VACV affected cell invasion in HaCaTs. To the eye, the differences between 
uninfected, TGF-β-treated and VACV-WR-infected HaCaT cells were not discernible. 
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Three characteristics of EMT, structural changes, cell migration and increased invasion, were found 
to occur in cells following VACV infection. A number of these features also appeared to be 
dependent on TGF-β signalling, indicating that the TGF-β signalling pathway may be responsible 
for mediating the induction of EMT during VACV infection. However, further investigation is 
required to attribute this phenotype directly to components of the TGF-β signalling pathway. 
 
3.3.4 Activation of the TGF-β signalling pathway was apparent during VACV infection 
The TGF-β pathway is known to regulate a wide range of cellular processes including proliferation, 
differentiation and migration. Its pleiotropic nature makes it an attractive target for a number of 
viruses that have evolved to manipulate this pathway, a subset of these doing so in order to initiate 
EMT [79, 95, 264]. As described earlier, these viruses affect various points in the TGF-β signalling 
cascade (Figure 1.13). To determine which levels of TGF-β signalling may be activated during 
VACV infection, various assays were conducted. 
Due to the fact that this thesis builds on previous data obtained within our laboratory, it was 
promising to note that the data presented here aligned fairly well with the early work. For example, 
Smad3 activity was originally assayed directly via luciferase assay, and indirectly using 
immunoblot analysis to evaluate C-terminal phosphorylation (Figure 3.3). Now indirectly, we have 
confirmed Smad3 activity through the use of qRT-PCR and immunofluorescence analysis, which 
assayed for expression of Smad3 targets (Figures 3.12 and 3.13) Especially in the qRT-PCR 
analysis, the timing of these gene expression responses; with c-JUN and PAI-1 being expressed 
increasingly and Snail2 appearing more transient, supported the early Smad3 activation results and 
correlated with data seen in the literature [364]. 
However, within our recent research, we also wanted to examine the activity of Smad proteins on a 
cell-to-cell basis. To do so, we generated a live-cell reporter system, the HaCaT CAGA12-GFP cell 
line, which produces GFP upon Smad3 binding and activation. Our results indicated that the 
introduction of VACV led to strong GFP expression from 8 hpi when virus also begins to appear 
(Figures 3.9 and 3.10). TGF-β also induced Smad3 activity at the matching time-point, which 
corroborated previous luciferase time courses (Figure 3.2). However, a curious observation that 
came from observing cells at the single cell resolution, was that cells which were obviously infected 
did not appear to produce high levels of GFP, only those in the near vicinity appeared to do so 
(Figures 3.10 and 3.11). This result proved somewhat perplexing as it suggested activation of the 
TGF-β signalling pathway by VACV was paracrine in nature, rather than autocrine, and purported a 
role for a factor released from or tethered to VACV-infected cells. The confusion was also 
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compounded by data which demonstrated that high infection frequencies resulted in all cells 
displaying increased levels of Smad target expression (Figures 3.9 and 3.13). These results led us to 
examine the possibility of a TGF-β pathway-activating secreted factor, which will be discussed in 
greater detail within the following chapters (Chapter 5).  
Whilst the majority of our research was conducted to study the role of the TGF-β signalling 
pathway, this is not the only pathway involved in the initiation of EMT in cells. From our results, 
another pathway, the Wnt ligand-mediated pathway did not appear to be activated by VACV 
infection. However, recently, another group published results suggesting the VACV A49 protein is 
capable of inducing Wnt/β-catenin signalling [424]. In this paper, an A49 transfection and 
overexpression model was used to assay the activity of this system away from a whole VACV 
model. As a result, the paper does not directly contradict our early luciferase data, yet it does raise 
questions on the role of other EMT pathways during VACV infection (Figure 3.2). Interestingly, a 
number of groups have suggested there is a certain level of cross-talk between the TGF-β and Wnt 
signalling pathways, with certain TGF-β-mediated functions being unable to occur in the absence of 
Wnt signalling [425, 426]. Furthermore, our luciferase assays were designed to investigate the 
activity of β-catenin (Figure 3.2). However, there is increasing evidence for a non-canonical, β-
catenin-independent, Wnt signalling pathway in the induction of an EMT response [427]. This 
system may be used by A49 to promote Wnt signalling during VACV infection. Overall, the results 
indicate that other EMT signalling pathways should not be discounted as yet in the context of 
VACV infection. 
 
3.3.5 Smad target genes may be important mediators of VACV-induced EMT 
Effector proteins are often the key mediators of the phenotypes associated with different signalling 
pathways. In the case of the EMT signalling pathways, these effector proteins mediate many of the 
outcomes associated with mesenchymal transition, including manipulating transcription of epithelial 
and mesenchymal genes, promoting cell migration and rearranging the cell cytoskeleton as desired.  
During this research, a number of Smad target genes were found to be expressed following VACV 
infection, to a higher degree than in uninfected cells (Figure 3.12). These were also seen at the 
protein level suggesting they are not post-transcriptionally lost or degraded after infection (Figure 
3.13). In the case of Snail1, Snail2 and c-JUN, this is highly informative, as it suggests these master 
EMT regulators may be responsible for the appearance of the mesenchymal cell morphology seen 
following VACV infection. PAI-1, on the other hand, is a more direct effector of the cell motility 
response, and so could directly contribute to VACV-induced cell migration [428]. However, the 
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targets chosen for this analysis, whilst all downstream molecules of the TGF-β signalling pathway, 
are not unique to this system. For example, PAI-1 is upregulated by the TGF-β, tumour necrosis 
factor alpha (TNF-α) and epidermal growth factor (EGF) ligands [429-431]. As a result, we cannot 
conclusively state that the TGF-β pathway itself is responsible for mediating the detected 
transcriptional responses in VACV-infected cells. To clarify this, we need to broadly examine the 
transcription of targets exclusive to the TGF-β signalling pathway or evaluate the TGF-β ligand 
itself.  
Studying global transcriptional changes provides researchers with an option to study entire 
signalling cascades, rather than being restricted to trial-and-error qRT-PCR approaches. 
Furthermore, with unbiased, global transcriptomic approaches, novel targets of interest can be 
found (discussed further in Chapter 6). There are numerous transcripts which could be of interest, 
for instance, the H2AFZ gene. H2AFZ encodes the H2A.Z protein, a histone variant protein, which 
has been deemed a so-called master regulator of EMT [432]. In its absence, TGF-β was unable to 
reduce expression of epithelial markers, including E-cadherin [433]. Other commonly studied genes 
regulated by TGF-β, include GADD45B, Ski, Sno, Smad7 and Smurf1 which are all important 
regulators of EMT [202, 364]. This subset of genes is particularly interesting because they are either 
inhibited by or interfere with TGF-β signalling. Together these analyses can provide a clearer 
picture on the activation and effector profile of the TGF-β signalling pathway during infection. 
A final consideration within this chapter is the causality link between TGF-β signalling and EMT-
associated phenotypes. As yet, we have not directly shown an involvement of TGF-β signalling in 
VACV-induced cell elongation, migration or invasion. One method to address this concern is to 
conduct further phenotypic examinations in the presence of the TGFβRI inhibitor, SB-431542. 
Whilst preliminary data, did suggest this chemical did dampen BSC-1 cell migration, it would be 
advantageous to confirm this phenotype in other cell types. Another option is through the 
characterisation of VACV-infected cells which have been depleted of one or more of their Smad 
proteins.  
 
3.3.6 Conclusions  
Within this chapter we attempted to characterise the EMT response observed during VACV 
infection and determine which cellular signalling pathways may be modulating this phenotype. Our 
results depicted an EMT-like event, with cells becoming elongated, separated and detached 
following exposure to VACV. These newly mesenchymal-like cells also became more motile and 
invasive. However, we cannot definitively say that VACV induces classic EMT without further 
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profiling of typical EMT associated markers, such as E-cadherin, vimentin and N-cadherin, which 
are key surface proteins of epithelial and mesenchymal cells. Regardless of this, the structural and 
behavioural changes we observed strongly resembled EMT may be mediated by the TGF-β 
signalling pathway, which we have shown to be activated at a number of levels following VACV 
infection. A combination of techniques, including immunoblot, luciferase assay, fluorescence 
microscopy and qRT-PCR, were used to confirm previous results. Furthermore, the target genes of 
Smad transcription factors are known to modulate cell plasticity, with a number of these considered 
master regulators of EMT. A select few of these were chosen for analysis and found to be 
increasingly expressed, at both the transcript and protein levels, following infection with VACV. 
These may be responsible for coordinating the phenotypes and behaviours of VACV-infected cells. 
As EMT is thought to promote viral spread and distribution, induction of this phenotype during 
VACV infection could contribute strongly to viral pathogenesis and is a promising avenue for 
antiviral and oncolytic virus research. 
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CHAPTER 4: THE ROLE OF SMAD4 
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4.1 INTRODUCTION 
4.1.1 Smad4, the common Smad 
The major overseers of TGF-β signal transduction at the intracellular level are transcription factors 
known as Smad proteins. As described earlier, these proteins carry signal directly from the TGFβR 
complex to the nucleus, where they manipulate gene expression. Three transcription factors appear 
within the canonical TGF-β signalling pathway. Two of these are R-Smads, Smad2 and Smad3, 
whilst the third is known as the Co-Smad, Smad4. Due to the differences in structure and function 
of the Smad proteins they display different patterns of activation, nuclear shuttling, transcriptional 
activity and degradation [116, 141]. In these cases, Smad4 appears to be the most distinct.  
The Smad4 gene is located at chromosomal loci 18q21.1 and generates a product of approximately 
552 amino acids or 67 kDa in length. With its 3 major structural domains, the MH1, MH2 and 
linker regions, Smad4 is able to enhance transcription of a select group of genes, which mediate 
functions such as cell migration, apoptosis and cell cycle regulation (Figure 1.11) [149, 364]. 
Interestingly, expression of these genes is often associated with a potent tumour suppressive activity. 
In fact, originally, Smad4 was discovered due to its relationship to pancreatic carcinomas. More 
than 50% of pancreatic tumours display Smad4 loss-of-function mutations, which are associated 
with poor prognoses and survival rates of less than 5% over 5 years [434-436]. This link between 
Smad4 and pancreatic cancers is so strong that another name for the Smad4 gene is DPC4, which 
stands for deleted in pancreatic carcinoma 4. More recently this defective Smad4 phenotype has 
also been observed in aggressive colorectal and cervical cancers [434-437]. Due to this strong 
connection with cancerous tissues, many researchers have attempted to characterise Smad4 
functions in the hope of identifying novel anticancer strategies. 
 
4.1.2 Previous studies of Smad4 
Due to its unique function in the TGF-β superfamily, Smad4 has been studied extensively in both in 
vitro and in vivo contexts. For instance, a mouse model using a Cre-loxP gene editing approach 
found that removal of Smad4 severely affected the health of adult mice [438]. These mice displayed 
numerous tissue pathologies, including, increased incidence of autoimmune diabetes, lack of proper 
cerebral development and formation of spontaneous head and neck tumours [439-441]. Furthermore, 
when Smad4 is removed at the embryonic stage, lethality of mice ensues by day 7 [442]. In this 
context, embryos were found to be malformed, poorly differentiated and lacked any distinguishable 
signs of mesoderm formation, suggesting that Smad4 was essential for embryonic development and 
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gastrulation. However, outside of this model, loss of Smad4 is not always lethal at the embryonic 
development stage. In fact, humans born with mutations in their Smad4 can develop a malady 
known as juvenile polyposis syndrome [443]. This syndrome is typified by the formation of 
gastrointestinal polyps from a young age, which, if treated or removed, are not severely detrimental 
to quality of life. Another disorder, hereditary haemorrhagic telangiectasia, which is associated with 
the malformation of blood vessels, is also thought to be linked to Smad4 mutations. In both cases, 
these pathologies are characterised by cells migrating, proliferating and/or differentiating in an 
aberrant manner, suggesting Smad4 is a master coordinator of cell behaviour. 
Other known associations between Smad4 and cellular processes have also been characterised. For 
instance, caspase-3 is a central mediator of apoptosis that integrates signals from caspase-8, 
caspase-9 and a milieu of regulatory proteins. This pro-apoptotic protein is activated upon Smad4 
knockdown, suggesting that typically Smad4 is involved in the dampening of apoptotic inputs and 
the maintenance of pro-survival signals [444]. In fact, Smad4-associated gene product, GADD45B, 
is considered a master regulator of TGF-β-induced apoptosis [218]. Other than apoptosis, in some 
contexts, such as breast cancer, Smad4 can promote EMT and metastasis, which in turn enhances 
spread and survival of the tumours [445]. This is starkly contrasted to the typical tumour suppressor 
role of Smad4 and suggests the actions of this protein may be largely context dependent. 
 
4.1.3 The relationship between Smad4 and target gene expression 
Signalling by the TGF-β pathway culminates within the nucleus with the expression of Smad target 
genes. These are expressed following binding of R-Smad/Smad4 heterotrimers to their respective 
promoter elements. Yet, despite its title as the Co-Smad and its presence in the majority of Smad 
transcriptional complexes, Smad4 is surprisingly dispensable for transcription of particular genes 
[364]. As such, we can divide gene expression into two broad classes, Smad4-dependent and 
Smad4-independent. As we can see in Figure 4.1 the two gene groups serve broadly different 
functions and modulate a variety of outcomes associated with TGF-β signalling and EMT 
progression [364]. For instance, Smad4-dependent genes, such as PAI-1, ITGB6 and AKAP12, are 
implicated in cell migration, fibrosis and basement membrane deposition, all hallmarks of EMT and 
associated with poor prognoses in cancer patients [209, 446-448]. Conversely, other Smad4-
dependent genes, such as GADD45B, have potent anti-tumour properties, and indicate that Smad4 
may be involved in balancing pro- and anti-cancer signals [449]. Smad4-independent genes, on the 
other hand, are involved in transcriptional regulation. For example, the transcription factor c-JUN, 
discussed earlier, is a Smad3 target and negatively regulates TGF-β signalling by interfering with 
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binding of Smad3 to its transcriptional targets [450]. Conversely, Snail2 represses transcription of 
epithelial-associated genes, such as E-cadherin, claudin and occludin, and inducing mesenchymal 
genes like vimentin [67, 213, 451]. Other prominent examples of Smad4-independent genes include 
inhibitory genes, such as Sno, oncogenes like Runx1 and ELK3, structural scaffolding protein, 
Claudin1, and cytoskeletal regulators such as Actinin α1 [64, 364, 452, 453] (Figure 4.1). Together 
these genes modulate a variety of outcomes associated with cancer progression, tumour suppression 
and viral infections, suggesting they may act in concert to influence the VACV infection phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Genes with Smad4 dependency modulate different functions to Smad4-independent genes 
Knockdown of Smad4 in HaCaT cells revealed genes with (red) and without (green) Smad4 dependency. The 
functions of each gene subset are described on the right in relation to typical outcomes of TGF-treatment [364]. 
Note that the genes described in this thesis, c-JUN, Snail2 and PAI-1 are listed in their respective categories. 
 
4.1.4 HaCaT TR and TRS4 cells 
As described above, Smad4 plays a pivotal role in EMT development. Within this chapter, we 
wanted to determine if it is also involved in driving VACV-associated EMT. To study the role of 
this protein in infected cells, HaCaT TR and TRS4 cells were obtained from a collaborator, 
Laurence Levy (INSERM, France). These cell lines have been previously described and their 
response to TGF-β stimulation characterised [364]. Briefly, they enable the depletion of Smad4 
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through control of Tetracycline (Tet). HaCaT TR cells are a control cell line, containing a Tet 
repressor (TR) that does not alter gene expression in the presence of Tet. The TRS4 cells contain 
TR, but additionally carry a Tet-inducible siRNA against Smad4. In the absence of Tet treatment, 
the TR is bound to the siRNA construct and prevents its action. However, upon Tet induction, the 
TR detaches, freeing the Smad4 siRNA and promoting the depletion of Smad4. This knockdown 
was found to reduce Smad4 protein levels by approximately 60%, which we aimed to replicate 
within this thesis. Overall, these systems provided us with a way to determine the contribution of 
Smad4 to VACV infection and EMT-like phenotypes.  
 
4.1.5 CRISPR-Cas9 editing tools 
The CRISPR-Cas9 gene editing system is based on a bacterial editing protein Cas9, which can be 
targeted using guide RNAs towards a target sequence and has achieved prominence over the past 
decade [370]. The Cas9 protein cleaves a dsDNA target and causes a double stranded break that can 
lead to loss-of-function mutations. In recent years, this technique has been increasingly employed 
due to its high success rate compared to the established homologous recombination techniques. 
Previous work in our lab used this system to generate a HeLa cell line where Smad4 expression was 
effectively ablated (Weng Sam Chan, Honours thesis, 2015). These cells were used as a second 
model for studying the role of Smad4 in VACV-infected cells. Not only do these cells provide a 
confirmatory mechanism for the HaCaT TRS4 system, they allow us to determine whether we see 
similar results in another cell line.  
 
4.1.6 Chapter aims 
The aim of this chapter was to characterise the importance of the Co-Smad, Smad4 in various 
aspects of VACV infection, particularly those associated with spread of virions, cell migration, viral 
replication and apoptosis induction. Two main methods were chosen for our purposes of 
investigating the role of Smad4. Firstly, the HaCaT TRS4 cell line containing a Tetracycline-
inducible siRNA against Smad4 was used to deplete Smad4 levels in infected cells [364]. These 
cells were used to characterise the infection phenotype in a Smad4-depleted background. Secondly, 
CRISPR-Cas9 was used to knock out Smad4 expression entirely in HeLa cells, to act as a 
confirmatory model (Weng Sam Chan, Honours thesis, 2015). Both systems were used to answer a 
number of questions: 
• Can Smad4 be effectively depleted from the HaCaT TRS4 system in our hands? 
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• Do we see a loss of Smad4-associated target genes and proteins upon Tet-induced Smad4 
knockdown? 
• Does Smad4 play a role in aspects of VACV infection, such as cell migration, viral spread 
and replication rate? 
• Does global transcriptomic analysis reveal interesting or novel targets for study that clarify 
relationship between Smad4 and VACV infection? 
• Can CRISPR-Cas9 editing be utilised to knockout Smad4 from a HeLa cell population? 
• Does complete knockout of Smad4 via CRISPR-Cas9 affect viral infection phenotype, and 
do these results align with those previously obtained from the HaCaT TRS4 model? 
 
Together these aims provide clarity on the involvement of Smad4 in VACV spread, replication and 
pathogenesis and contribute to our understanding of VACV-induced TGF-β signalling.   
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4.2 RESULTS 
4.2.1 Efficient Smad4 knockdown can be observed in HaCaT TRS4 cells 
To determine the role of Smad4 during VACV infection we needed to use an effective tool for 
depletion of Smad4. From collaborators, we obtained HaCaT TR and TRS4 cells to inducibly 
deplete Smad4 expression. Before further analysis of these cell lines, we confirmed efficient Smad4 
knockdown in the HaCaT TRS4 cells using immunoblot and immunofluorescence analysis. The 
immunoblot data shown below illustrates strong knockdown of Smad4 following 48 hours of Tet 
treatment in the TRS4 cells, but not the TR cells (Figure 4.2). As expected, Tet treatment of TR 
cells did not influence Smad4 levels, allowing these cells to serve as an effective negative control 
for the effects of Tet-treatment. In this case, the β-actin loading control suggests a similar amount of 
protein was present in each sample, confirming the observed knockdown is not a technical artefact. 
The results correlate with previously obtained data using these cell lines [364]. 
 
 
 
 
 
 
 
 
Figure 4.2 – Knockdown of Smad4 in tetracycline treated-HaCaT TRS4 cells as shown by immunoblot 
HaCaT TR and TRS4 cells were either left untreated or subjected to tetracycline treatment for 48 hours before 
lysates were obtained. Lysates were then run on a nitrocellulose membrane and probed for the presence of Smad4 
and β-actin.  
 
4.2.2 Smad target gene expression is affected by the presence of Smad4 following VACV 
infection 
Following the validation of Smad4 depletion in HaCaT TRS4 cells, we aimed to determine whether 
Smad4 affected downstream gene expression in the context of VACV infection. As described above, 
gene expression can be divided into two categories, Smad4-dependent and Smad4-independent. 
These classes are well defined following TGF-β treatment; however, we were curious as to whether 
the pattern of Smad4 dependence was maintained when using VACV to activate the TGF-β 
signalling pathway. The results are presented in Figure 4.3. 
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As in Figure 3.12 from the previous chapter, qRT-PCR was used to study the expression of Smad 
target genes, c-JUN, Snail2 and PAI-1. Smad target gene expression was evident following TGF-β 
treatment and VACV infection at 10 hours post-treatment in HaCaT cells. These results aligned 
with our previous observations (Figure 3.12). In TR cells, Tet treatment did not significantly affect 
expression of the selected targets (Figure 4.3A, C and E). 
In TRS4 cells; however, the dependence of certain genes on Smad4 became clearer (Figure 4.3B, D, 
and F). Again, TGF-β-treated and VACV-infected conditions displayed an increased level of target 
gene transcription compared to the uninfected cells. However, once treated with Tet, transcript 
levels of Smad4-dependent target, PAI-1, were reduced. C-JUN and Snail2, the Smad4-independent 
genes, on the other hand, were seemingly unaffected by Tet treatment. This pattern was mirrored by 
VACV-infected cells at 10 hpi. Our results indicated that, as with TGF-β treatment, VACV induced 
a number of genes in a Smad4-dependent and Smad4-independent manner. These genes may be 
responsible for mediating the EMT-like events in VACV-infected cells.  
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Figure 4.3 – qRT-PCR analysis helped to determine how dependent certain genes are on Smad4 
following TGF-β treatment and VACV infection 
Once confluent, HaCaT TR (A, C, E) and TRS4 cells (B, D, F) were subjected to 48 hours of Tet treatment (2 
μg/mL) before being left untreated (A, B), treated with TGF-β (2 μg/mL) (C, D) or infected with VACV-WR to 
an MOI of 10 (E, F) for 10 hours. Total RNA was then extracted and subjected to quantitative analysis by qRT-
PCR assays. Smad4-independent targets, c-JUN and Snail2, appeared unaffected by Tet treatment in both cell 
types. PAI-1, a Smad4-dependent target, was reduced following Smad4 depletion in TRS4 cells, but not in the 
control, TR cells. This was only observed in cases of PAI-1 induction, such as with TGF-β treatment and VACV-
WR infection. Cellular control, GAPDH, and viral loading controls, D12 and A17, were also used for this analysis. 
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Analysis was performed using GraphPad Prism 7.0 software. n=3. Error bars refer to SEM. Student’s unpaired t-
test.  
 
 
4.2.3 Protein expression of Smad4-dependent targets is diminished within induced HaCaT 
TRS4 cells 
To gain further insight into Smad4 target expression we examined protein levels of TGF-β targets. 
This would provide us with more information on post-transcriptional regulation of these genes and 
allow a comparison between the transcriptional profile and protein expression profile. The 
expression of two Smad4-independent targets, Snail and Snail2, as well as a Smad4-dependent 
target, PAI-1, were studied in HaCaT TRS4 cells using immunofluorescence analysis (Figure 4.4). 
The results suggest that in the absence of Tet, TGF-β is able to induce expression of Snail, Snail2 
and PAI-1. This aligns with the data from Figure 3.12 discussed earlier, and with the transcriptional 
data seen in Figure 4.3. Not only does TGF-β alter amount of Smad targets expressed, it also 
appears to change the pattern of expression. For example, TGF-β increases the cytosolic localisation 
of Snail and Snail2 but appears to promote the nuclear accumulation of PAI-1. This same phenotype 
is observed following infection with VACV-WR for 8 hours. Conversely, upon Tet treatment we 
again see another phenotype appearing. Whilst Tet appears to bear no influence on TGF-β induction 
of Snail and Snail2, PAI-1 expression is greatly reduced. This is also the case in Tet-treated, 
VACV-WR-infected cells. As PAI-1 is known to be dependent on Smad4 this result is in 
accordance with qRT-PCR analysis. Interestingly, Snail2 localisation in cells is altered upon Tet 
treatment, suggesting some interplay between Smad4 or Smad4 targets and Snail2 trafficking. 
Under the conditions we used, there were no significant differences observed in cell morphology 
following Tet treatment and VACV infection suggesting multiple components contribute to the 
phenotypic cell changes that occur following virus replication. 
 THE ROLE OF SMAD4 
University of Sydney 132 2018 
 
 
Figure 4.4 – Smad4 knockdown can be observed via immunofluorescence of Smad4-dependent and 
Smad4-independent targets 
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Immunofluorescence assays on HaCaT TRS4 cells infected with VACV-WR (MOI of 5) for 8 hours revealed 
subsequent knockdown of Smad4-dependent targets. Smad4-independent targets, Snail (A), Snail2 (B), as well as 
Smad4-dependent target, PAI-1 (C), were visualised in regular (left) or Smad4-depleted cells (right) in green. 
DAPI (blue) and viral B5 (red) were also visible. Imaging was carried out on the Olympus BX51 microscope. 
Images are representative of three independent experiments. Scale bar = 50 μm.  
 
4.2.4 Efficient spread of VACV is reliant on Smad4 expression in HaCaT cells 
Effective spread of VACV can be assayed using the classical virology technique, the plaque assay. 
Plaque assays restrict diffusion of virions through the media, and as such, viral spread is limited to 
direct cell-to-cell transfer.  
We wanted to determine if Smad4 is required for efficient cell-to-cell spread of VACV. Vaccinia 
plaques, visualised by crystal violet staining (Figure 4.5A), phase microscopy (Figure 4.5B) and 
fluorescence analysis (Figure 4.5C), were visibly smaller upon Smad4 depletion at 2.5 days after 
infection (Figure 4.5D). When quantified, it was found that knockdown of Smad4 decreased plaque 
size by 13% compared to untreated cells. This result was not seen in another DNA virus, HSV-1 
(Figure 4.5A and F). Upon closer inspection of plaques made with VACV-WR (LifeAct-GFP), it 
appeared plaque phenotype was also altered upon tetracycline treatment (Figure 4.5E). Wild-type 
plaques contained large areas of cell clearance at their centre. This could be due to cells migrating 
further to the plaque peripheries, or as a result of apoptosis sloughing off large areas of cells. These 
possibilities are described in future sections (Section 4.2.6 and Appendix 8.3). Either way, this 
phenotype is lost upon Smad4 knockdown. Figure 4.5E indicates this is up to a 5-fold reduction in 
area of plaque clearance. Taken together the results indicate effective spread of VACV is reliant on 
the presence of Smad4.  
 THE ROLE OF SMAD4 
University of Sydney 134 2018 
Figure 4.5 – Smad4 knockdown decreases spread and clearance of VACV plaques, but not herpes 
virus plaques 
(A) VACV-WR and herpes simplex virus (HSV-1) plaques were grown for 2.5 days in confluent HaCaT TRS4 
cells that were either left untreated or treated with Tet (2 μg/mL) for 48 hours prior to infection. For imaging, 
wells were fixed stained in crystal violet and methanol. A slight reduction in plaque size is observed in VACV-
WR infected cells upon Smad4 knockdown. Note that HSV-1 can form large lytic plaques which were excluded 
from this analysis. Scale bar = 10 mm. (B-E) An altered plaque phenotype was also observed upon Smad4 
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knockdown in cells infected with VACV-WR (LifeAct-GFP). Cells were infected as in (A); however, these were 
fixed using the PFA method. Both by camera (B) and fluorescent microscopy (C) phenotypic changes could be 
observed and correlated with a reduction in plaque size (D) and clearance (E). Images were taken on the Nikon Ti-
E Eclipse microscope. Scale bar = 200 μm. (F) HSV-1 plaques did not follow the same trend in plaque size 
reduction. Thirty plaques were measured in each condition. 
 
4.2.5 Smad4 affects viral replication but does not interfere with actin-mediated viral release 
To examine whether the reduction in viral spread seen in Figure 4.5 was due to a defect in the 
replication cycle, we took a closer look at viral growth kinetics. Using single-step growth curves 
and EEV release assays we found that virus titre at 24 hpi is reduced in both cases (Figure 4.6A and 
B). This reduction is slight but significant at the late infection time points. This suggests replication 
is unaffected at early time-points post-infection but encounters difficulties over time, leading to a 
decrease in EEV release. As EEV is the predominant viral form involved in long distance viral 
spread, but of limited importance during plaque assays, the defect in plaque formation observed in 
Figure 4.5 was not attributed to this lower EEV production. 
Another mechanism of viral spread is the production of long actin protrusions beneath cell-
associated virions, which propel virus particles great distances away from the cell to better their 
chances of encountering an uninfected target cell. To test whether Smad4 was important for this 
actin tail formation we conducted immunofluorescence assays. Our results demonstrated that, actin 
tail incidence and length were unaffected by Tet treatment, suggesting there is no overt role for 
Smad4 in the extrusion of cell-associated virions within these cells (Figure 4.6C and D).  
Overall the data collected may indicate a role for Smad4 in viral replication that is only evident and 
significant following multiple rounds of replication. Our interpretation of these data is that virus 
replication at the single cell level is unaffected by knockdown of Smad4; however, spread from 
cell-to-cell at the end of each replication cycle may be hindered. This leads to an ever-increasing 
delay in viral replication and accounts for the drop in viral titres at later time points. 
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Figure 4.6 – Smad4 knockdown alters growth kinetics at late time points post-infection but has no 
effect on actin tail formation 
(A) Previously described results from our lab indicate Smad4 knockdown affects viral titre at time points late after 
infection, such as 24 hpi. HaCaT TRS4 cells were grown to confluency and treated with 2 μg/mL Tet for 48 hours. 
Cells were then infected with VACV-WR (MOI of 1) for 4, 8, 12 and 24 hours. Viral titre in supernatant and cell 
scrapings was then determined by standard plaque assay. (A. Gowripalan, Honours thesis, 2013). (B) EEV release 
was measured at the specified time points post-infection with VACV-WR (MOI of 0.1). Viral titre in supernatant 
indicated Smad4 knockdown decreased EEV release at 24 hpi; however, actin tail formation (C, D) was 
unaffected. Error bars refer to SEM. (C) Actin tails were observed at 8 hpi with VACV-WR (MOI of 5) in HaCaT 
TRS4 cells. Actin was stained in red, viral envelope protein, B5, in green and DAPI in blue. Images shown are 
representative and were taken using the Nikon Ti-E Eclipse microscope. Scale bar = 5 μm. (D) Actin tail length 
was not found to differ between untreated and Tet-treated cells. Thirty actin tails were analysed in each condition. 
 
 
4.2.6 Cell migration is Smad4 dependent following VACV infection 
As described in the previous chapter, VACV is able to induce migration of infected cells. This is 
thought to enhance viral spread. As our results suggest that that plaque size and viral spread are 
dependent on Smad4, we theorised this discrepancy could be due to Smad4 contributing to the 
induction of cell migration. To determine if this was the case, live-cell imaging was used to monitor 
motility of infected cells in control and Smad4-depleted background conditions. For better tracking 
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of cell movements, a virus carrying a cerulean protein fused to a nuclear localisation signal was 
used. This allowed for the visualisation of nuclei and tracking of cell movements. In Figure 4.7 we 
observed that all VACV-WR viruses tested displayed decreased plaque size upon Tet treatment. 
This correlated with a reduction in motility in the same conditions. This was evident both in the 
distance and displacement measurements of cells over time. However, it did appear that our viruses 
displayed different rates of plaque expansion, which is a factor to be considered during analysis.  
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Figure 4.7 – Live-cell microscopy revealed that Smad4 is important for VACV-induced cell migration 
VACV plaques formed in confluent HaCaT cells display large levels of induced cell migration over 2 dpi. This is 
seen when using vaccinia viruses containing mCherry, LifeAct-GFP or Nuc-Cer constructs where infected cells 
appear red, green and blue, respectively. When Smad4 is depleted, plaque size is reduced in both crystal violet (A, 
B) and live-cell fluorescence microscopy (C) conditions. (A) Plaques were fixed at 2.5 dpi. Scale bar = 10 mm. (C) 
Movie stills were collected using the Nikon Ti-E Eclipse from 10 hpi for a period of 48 hours. Scale bar = 200 μm. 
(D) The trends of cell displacement from time of infection confirmed these plaque size reductions were associated 
with a decrease in cell migration upon Tet treatment of infected cells (dashed lines). Five cells were tracked in 
each condition.  
 
4.2.7 Loss of PAI-1 may contribute to phenotype associated with Smad4 knockdown 
Upon Smad4 knockdown, we observed the loss of Smad4-dependent target gene expression [364]. 
Furthermore, it appeared that Smad4 was required for efficient cell-to-cell spread and replication of 
VACV (Figures 4.5, 4.6 and 4.7). As a result, we hypothesised that VACV requires not only Smad4, 
but also the contribution of Smad4-dependent targets for maintaining these features of infection. 
Immunofluorescence assays indicate PAI-1, a characteristic Smad4-dependent target, is strongly 
expressed in VACV-WR (LifeAct-GFP) plaques at 2.5 days post-infection (Figure 4.8). There is 
also a vivid ring of PAI-1 expression immediately adjacent to the plaque forefront, which is evident 
in both the images and intensity profiles. This is reminiscent of CAGA12-GFP expression seen in 
Figures 3.10 and 3.11 and is restricted to cells in close proximity to infection. However, it may be 
possible that these cells are in fact early infected cells, which have not had the chance for the viral 
promoter, pE/L, to drive the expression of detectable levels of LifeAct-GFP expression as yet. In 
Tet-treated cells, PAI-1 expression is greatly reduced within the plaque and the surrounding 
uninfected cells. This result is also reflected in the intensity profiles, suggesting VACV induction of 
PAI-1 expression is Smad4-dependent.  
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Figure 4.8 – Smad4-dependent target expression is also altered in VACV-WR plaques upon Smad4 
knockdown 
Immunofluorescent analysis shows expression of Smad4-dependent target, PAI-1, is higher in infected cells at 2.5 
days post-infection. However, pre-treatment with 2 μg/mL Tet reduces PAI-1 expression dramatically. VACV-
WR (LifeAct-GFP) was used for this experiment, so PAI-1 appears red, virally-infected cells green and DAPI 
blue. Scale bar = 200 μm. Intensity profiles (shown on the right) for GFP and PAI-1 expression also confirm PAI-
1 expression is strongest within and around plaques and lost upon Smad4 knockdown. Images were taken using 
the Olympus BX51 system. Scale bar =200 μm. 
 
4.2.8 CRISPR-Cas9 knockout of Smad4 increases evidence for a Smad4 requirement in 
VACV plaque spread 
To confirm the importance of Smad4 during infection, we employed CRISPR-Cas9 technology to 
generate cells which lack Smad4 (Weng Sam Chan, Honours thesis, 2015). Note that due to 
difficulties in generation of a clonal cell population, a mixed cell population was used for these 
experiments. These cells were generated by student, Weng Sam Chan. Briefly, HeLa cells were 
transfected with empty plasmid (PX458), a non-specific guide (EMXG1) and a guide targeting 
Smad4 (Smad4G3). Once these cells had been transfected, a number of experiments were carried 
out to characterise aspects of this cell line. Firstly, Smad4 knockout was confirmed by immunoblot 
analysis, which revealed loss of Smad4 only in the last condition, when normalised to the β-actin 
loading control (Figure 4.9A). These results suggest a high frequency of cells within the mixed 
population had Smad4 successfully edited out. The same result was not mirrored by the negative 
controls, PX458 and EMXG1. Following immunoblot validation, these cells were infected with 
VACV-WR (LifeAct-GFP). In this experiment, plaques were found to be smaller in the Smad4G3 
condition, with size reducing from an average of 707.6 +/- 15.2 to 595.4 +/- 15.3 μm (Figure 4.9B 
and C). No significant changes to plaque size were observed when EMXG1 cells were used. These 
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results were reminiscent of those obtained with the HaCaT TRS4 cells (Figure 4.5). Furthermore, 
plaque clearance was also found to be reduced; however, the reduction was not as drastic as before 
in HaCaT cells (Figure 4.9D). Overall, our results suggest Smad4 is required by VACV to spread 
effectively in multiple cell types.  
Figure 4.9 – CRISPR-Cas9 can effectively knockout Smad4 and alter VACV spread 
(A) Immunoblot indicates the level of Smad4 expressed by HeLa cells is not altered by the presence of empty 
vector, PX458, or off-target CRISPR guide sequence, EMXG1.A guide targeting Smad4, Smad4G3, effectively 
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removes Smad4. β-actin was utilised as a loading control. Note that cells were generated by student, Weng Sam 
Chan. (B-D) VACV-WR (LifeAct-GFP) plaques were imaged on the Olympus BX51 microscope at 2 days post-
infection. Non-transfected HeLa cells and EMXG1 transfected cells facilitated growth of larger plaques (C) with 
greater areas of plaque clearance (D). Forty plaques were analysed in each condition. Scale bar = 200um. Error 
bars refer to SEM.  
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4.3 DISCUSSION 
4.3.1 Smad4 function can be effectively depleted from two model systems  
Smad4 or the Co-Smad plays a key role during TGF-β signalling as both chaperone to R-Smads and 
a powerful transcriptional influencer. This feature allows Smad4 to manipulate processes involved 
in cell migration, apoptosis and cytoskeletal reorganisation [445]. As such, it is no surprise that 
intracellular pathogens often manipulate Smad4 in order to take over control of these functions [258, 
454]. In the previous thesis chapter, we suggested that TGF-β signalling and Smad proteins are 
influenced by VACV infection, in a manner thought to result in the initiation of an EMT-like 
process. To determine whether the Smad4 had any bearing on this VACV infection we utilised two 
different tools in this chapter.  
Firstly, we employed the HaCaT TR and TRS4 cells, which have been previously verified as a 
model for Tet-inducible Smad4 knockdown [364]. The keratinocyte cells proved to be a valuable 
resource for studying EMT and TGF-β signalling during VACV infection. This is both because they 
have been well characterised in an EMT context and have been previously used in VACV 
experiments within the literature [395, 455]. As in the earlier research, we managed to obtain 
efficient Smad4 knockdown, of approximately 60-70% in the HaCaT TRS4 cells only (Figure 4.2) 
[364]. To corroborate these results, we then went on to confirm the loss of Smad4-dependent target 
gene expression using qRT-PCR analysis and immunofluorescence analysis (Figures 4.3 and 4.4). 
Whilst the data displays a clear reduction in chosen target, PAI-1, more confidence could be 
garnered in our results through the examination of further Smad4-dependent targets, such as 
GADD45B and Smurf1, which mediate apoptosis and TGF-β pathway inhibition respectively [218, 
223]. Furthermore, as PAI-1 is not uniquely controlled by Smad signalling, a more direct 
examination of Smad4 transcript levels could prove more informative [227, 428]. However, in 
combination with the immunoblot and immunofluorescence analysis it did appear that PAI-1 
expression was Smad4-dependent in the context of VACV infection. Another approach for the 
assessment of Smad4 knockdown, could also be the use of robust transcriptomic techniques to 
measure the expression of a variety of Smad4-dependent genes, including GAPDH, AKAP12, 
CKN1A, PAI-1, ITGB6, Smurf1, HEF1 and PAR6 [364] (Figure 4.1). These could not only act in a 
confirmatory way, but also provide more information on the dynamics of Smad4 signalling during 
VACV infection.  
Whilst the HaCaT TRS4 model appeared to be efficient in Smad4 knockdown, we sought to 
determine the infection outcomes in a Smad4-null model. The rapid development of CRISPR-Cas9 
technologies within the last few years allowed us to investigate this scenario. During an Honours 
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project, student Weng Sam Chan, generated an edited HeLa cell line, verifying the loss of Smad4 
by immunoblot. These knockout cells were then used for further analysis during VACV infection. 
Loss of Smad4 expression was confirmed via immunoblot, and phenotypic results were as before 
with the HaCaT cells (Figure 4.9). A benefit of the CRISPR-Cas9 approach is the ability to 
completely remove Smad4 from single cells. This is opposed to the HaCaT TRS4 model where low 
levels of Smad4 signalling are displayed consistently across the population. Due to difficulties 
encountered in FACS sorting we could not generate a clonal population of CRISPR-Cas9 edited 
cells, and so there are those within the population which still contain functional Smad4 proteins. As 
such, responses to various stimuli may be heterogeneous across the different cells in this population. 
To obtain homogeneity, ideally a single gene-edited cell would be selected and used to generate an 
entire cell population lacking Smad4. However, time constraints and technical difficulties did not 
allow this process to be completed within the scope of this research. Given more time, it would be 
interesting generate an entirely Smad4-null population to monitor VACV replication, spread and 
induction of cell migration. This could be compared to the HaCaT TRS4 cell model, to determine if 
our results are universal or cell-type specific.  
So far, our work has focused on an in vitro model of VACV infection in the context of a Smad4-
depleted background. In vivo models, however, provide information on overall virulence and 
pathogenesis of infection, given the multi-tissue and multicellular nature of the host. Previous 
publications have investigated the spread of VACV in mouse and rat models [456-458]. There is 
also a precedent in the literature for the generation of Smad4-knockout mice [438-441]. As such, a 
future experiment could utilise these mice to determine if VACV-mediated lethality is affected by 
Smad4 absence. Smad4 complex formation is known to be inhibited by host antiviral responses, 
suggesting Smad4 typically acts in a proviral fashion [459]. For instance, HCV replication is 
potently inhibited by miR-199a, a cell miRNA known to inhibit TGF-β signalling at the Smad4 
level [460, 461]. Given that VACV plaque size is already reduced in cell monolayers, which lack an 
immune system and potent antiviral mechanisms, it seems likely that VACV infection would be 
attenuated within these whole animal in vivo models.  
Overall, our methods appeared to effectively reveal the contribution of Smad4 during infection, 
allowing a novel insight into how VACV relies on specific cellular components for aspects of 
infection. However, further work using clonal cell populations, tissue culture or whole animal 
models could provide more insight into the reliance of VACV on Smad4 for overall pathogenesis.  
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4.3.2 VACV infection phenotype is affected by Smad4 knockdown 
The plaque assay is one of the oldest but most commonly used assays for studying viral infection in 
an in vitro setting. It is a robust and sensitive tool that facilitates the study of direct cell-to-cell 
spread of virus and can assay defects in viral entry, replication or egress. It also has the capacity to 
model any deleterious effects viruses may have on cells, including the repurposing of migration 
behaviours, apoptosis pathways, cell structure and overall phenotype. Within recent years 
researchers have noted that not only virion spread, but also cell behaviour contributes to viral 
plaque development, emphasising the role of cellular factors in viral dissemination. 
For our purposes, the plaque assay was a valuable first-line tool to determine if Smad4 depletion 
affects aspects of VACV infection. From our results it was evident that loss of Smad4 led to a slight 
but significant reduction in plaque size in both HaCaT TRS4 and gene-edited HeLa cells (Figure 4.5 
and 4.10). This could be caused by a number of defects within the VACV replication cycle. For 
instance, reduced viral replication in VACV lacking F4 leads to the development of small VACV 
plaques [462]. This same phenotype is observed in ΔA36 or ΔF12 VACVs which display 
difficulties in viral egress from cells [247, 463]. To determine either of these were factors in the 
plaque size reduction observed upon Smad4 knockdown we conducted multiple assays.  
Firstly, viral release and replication were examined. From our analysis, it was evident that total 
VACV virion production decreased over time in Tet treated cells (Figure 4.6A). This was attributed 
to the gradual decline in EEV release observed following Smad4 knockdown (Figure 4.6B). 
However, reduced EEV release is unlikely to account for the reduction in plaque size observed in 
Figure 4.5. This is due to the fact that EEV contribute very little to viral spread in plaque assays, as 
the nature of the medium interferes with viral diffusion and expulsion. For instance, the IHD-J 
strain of VACV is known to produce excessive amounts of EEV compared to the parental virus; 
however, the plaque size of this mutated virus is not increased under semi-solid overlay, suggesting 
EEV are fairly dispensable for plaque formation [464]. As a result, Smad4-associated VACV EEV 
release defects were not thought to be responsible for the observed plaque size change.  
One downfall to come from VACV requiring Smad4 for efficient replication is in its use as an 
oncolytic agent. Many tumours actively downregulate levels of Smad4, which is a known tumour 
suppressor, in order to promote their survival. This is especially true in risk-prone, difficult to treat 
cancer subtypes, such as pancreatic, cervical and colon [105, 437, 465]. As a result of its reliance on 
Smad4, VACV may not effectively replicate within these cells, and so may not be a suitable therapy 
within these contexts. However, in Smad4-rich microenvironments, such as liver or breast tumours, 
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VACV is likely to thrive, suggesting it will be an effective oncolytic therapy in these contexts [445, 
466].  
As mentioned above, viral egress contributes to effective plaque development. For instance, in 
mutated virions which cannot associate with kinesin motor proteins, access to the cell surface and 
plaque size is severely reduced; by almost 90% in particular cases [247, 463]. This is compounded 
in contexts where viruses cannot stimulate the production of actin tails which results in the 
accumulation of virions at the cell surface [467]. To determine if Smad4 impacts viral egress and 
could be responsible for plaque size reductions, actin tail formation was imaged in HaCaT TRS4 
cells. In this case length and phenotype of actin tails were found to be consistent across untreated 
and Tet treated conditions, suggesting Smad4 is dispensable for actin tail formation (Figure 4.6C 
and D). These results also indirectly suggest that VACV is trafficking to the cell periphery 
effectively upon Smad4 knockdown, as the number of virions forming actin tails at the cell surface 
is not reduced.  
Together these results suggest other viral factors, or perhaps features of the cells themselves, are 
responsible for the plaque changes observed upon Smad4 depletion. A curious observation which 
supports this theory is the decline in plaque clearance observed in Figure 4.5. Plaque clearance was 
defined in this thesis as the area within viral plaques that is not occupied by cells (Figure 2.4). We 
theorised that these clearings were the result of cell migration towards plaque peripheries or 
apoptosis leading to cell sloughing, both of which would account for observed phenotype of VACV 
plaques (Figure 4.5). These two possibilities are discussed further in the following sections.  
 
4.3.3 Smad4-dependent cell migration during VACV infection 
The relationship between the TGF-β signalling pathway and cell migration is complex. Not only 
does TGF-β induce de-differentiation of epithelial cells, resulting in a loss of cell-to-cell junctions 
and attachment to the basement membrane, but it can also act as a chemokine, causing cells to 
become motile [468]. However, the involvement of Smad proteins in this process appears to be 
entirely context dependent. For instance, in pancreatic tumours, depleting Smad3 increases cell 
migration, whilst knockdown of Smad2 has an opposing inhibitory effect [469]. Smad4 on the other 
hand, can both inhibit and enhance cell migration. One example occurs when Smad4 inhibits cell 
migration by interfering with JNK activity, where suppression of this leads to the adoption of a 
motile cell phenotype [470-472]. In contrast, the Smad4-dependent target, PAI-1, is known to 
promote cell migration [209, 428, 473]. Previous groups have shown that PAI-1 mediates both a 
TGF-β and an EGF-induced “scatter” response in HaCaT cells [428]. Despite this contradictory role 
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for Smad4 and its target genes, we wanted to examine whether cell migration induced by VACV 
infection occurs in a Smad4-dependent manner.  
Cell migration has previously been shown to be important for VACV plaque development. For 
instance, F11-deleted VACVs produce smaller plaques due to decreased cell motility [326]. 
Furthermore, an MVA virus where cell migration was restored by introducing full-length F11 
produced larger plaques than the parental virus [474]. In this thesis, cell migration was assayed by 
live-cell tracking of infected cells within VACV plaques (Figure 4.7). Correlating with previous 
observations in the lab and the literature, VACV-infected HaCaT cells migrated outwards from the 
centre of the plaque. Our results suggested that this migratory phenotype was impeded by Tet 
treatment, in all the VACV-WR viruses tested, and could explain the reduction in plaque clearance 
upon Smad4 knockdown (Figures 4.5 and 4.7). Given that PAI-1 is known to affect cell migration 
and appeared to be a prime suspect in this context. We examined PAI-1 expression within VACV 
plaques (Figure 4.8). However, expression of this protein was not as straightforward as expected. 
Whilst plaques did appear to display higher levels of PAI-1 than the more distal uninfected cells, a 
clear ring of fluorescence was observed in the cells adjacent to the plaque. We theorised that these 
cells were either uninfected and so VACV was priming them for infection by inducing Smad4 
signalling, or that these cells were in fact undergoing early VACV infection, which could not be 
detected as yet by LifeAct-GFP expression. This result could be clarified with the use of antibody 
stains to detect abundant early VACV proteins, or upon closer examination of cytopathic effect 
changes at the cell peripheries which would indicate if these cells are infected prior to PAI-1 
expression.  
Whilst our results for plaque assays were consistent, it would be advantageous to confirm this 
phenotype using a second technique. One simple solution to this would be to make use of the 
CRISPR-Cas9 edited HeLa cells for live-cell migration analysis. As this system contains cells with 
a complete loss of Smad4, it also has the potential to inhibit plaque size formation further in than 
the HaCaT TRS4 cells. Another limitation within these experiments, is that we cannot confirm 
Smad4 knockdown on a cell-to-cell basis. To address this, we could borrow the principle of our 
CAGA12 cell line, and generate HaCaT TRS4 cells which produce a fluorophore when Smad4 is 
activated. Loss of this fluorescence within a cell would indicate that Smad4 knockdown was 
effective, and then behaviours could be directly correlated to levels of Smad4. 
Cell migration is a desirable phenotype post-viral infection [79, 251, 324, 409, 475]. Cells provide 
both protection and transport means for viruses to traverse the hostile host environment. We can see 
this illustrated in Figure 4.10 This figure highlights the benefits of infected cells becoming 
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elongated, invasive and migratory, as they increase the rate and magnitude of plaque spread. These 
nomadic cells, depicted in pink, are able to interact with many more potential target cells, shown in 
blue, than their stationary, uninfected neighbours (purple). Over time a higher proportion of cells 
become infected and as such, migratory, meaning that cell spread increases exponentially. As cells 
move further, the virus repurposes them to act as vectors, carrying infectious progeny to new and 
distant target cells, resulting in an ever-accelerating and widening spread of infection. This is 
evident in the diagram, as cells apparently out of reach (green) can then be accessed within a single 
viral replication cycle. This allows spread of infection to outspan that achieved by virus replication 
dynamics alone.  
 
Figure 4.10 – Spread of VACV can be improved by inducing cell migration in infected cells 
When infecting a monolayer of tightly, organised epithelial-like cells, inducing a migratory mesenchymal-like 
response is beneficial for increasing the rate of spread. As cells become more mesenchymal, they become 
migratory and invade between the conjoined epithelial cells, to travel further and be exposed to more uninfected 
target cells. The difference is clear when comparing infected cells on the first round of replication (left), to the 
much more elongated cells within the second round of replication (right). These cells force the uninfected 
epithelial-like cells (purple) apart in order to travel greater distances and lead to the breakdown of the epithelial 
layer integrity. Due to this migration, we not only see immediately adjacent cells becoming infected (blue), but 
those which were thought to be out of reach (green) being accessed within a single round of replication. 
Furthermore, the number of cells which could potentially become infected increases dramatically over time and 
outspans the reach of cells that could be infected by viral replication dynamics alone.  
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Aside from VACV, other viruses have also been reported to have interactions with Smad4. For 
example, HBV protein X is known to interact with the MH1 domain of the Co-Smad, to promote 
nuclear translocation, stabilise transcription machinery interactions and sustain expression of 
Smad4 target genes, such as PAI-1 [258]. However, no homologous regions were identified 
between the Smad4-binding region of protein X and the proteins of the VACV proteome. In fact, 
the only non-hepatitis B sequence that displayed homology to protein X was that from parasitic 
nematode, Trichinella spiralis, which has also been shown to upregulate TGF-β signalling in nearby 
immune cells [476, 477]. As we have not identified how VACV interacts with Smad4, it is possible 
that, like HBV, VACV encodes a protein which directly binds to Smad4 [258]. One way to answer 
this question is to identify binding partners of Smad4 in the context of VACV infection. A method 
for doing so is the use of protein-tagged Smad4, to conduct pulldown experiments or co-
immunoprecipitation assays. The outputs of these pulldown assays could then be used to identify 
Smad4 binding partners and provide clues on the interaction between VACV and Smad4.  
Other than Smad4, some viruses have been shown to interact directly with Smad4 target, PAI-1. For 
example, Dengue virus, displays significant reliance on PAI-1 for pathogenesis [478, 479]. PAI-1 is 
linked to symptoms associated with Dengue haemorrhagic fever, such as defects in blood 
coagulation [479, 480]. Dengue virus has also been observed to promote cell motility, and so, it is 
possible that it uses PAI-1 to induce this phenotype. From our results we have not directly identified 
PAI-1 is a mediator for cell migration in the context of VACV infection. It would be of interest to 
use small molecule inhibitors or siRNA technologies to impede the functionality of PAI-1 and 
investigate the effect this has on VACV-induced cell migration. Previous groups have successfully 
used both of these methods to inhibit PAI-1-mediated cell migration [481, 482].  
In fact, there may even be potential links between Smad4-mediated signalling and VACV protein, 
F11. For instance, Smad4 loss activates Rho and ROCK signalling in certain gastric cancers, 
suggesting F11 and Smad4 are both capable of suppressing the same proteins and their associated 
signals [483]. Given their common outcomes, it is possible that F11 and Smad4 work together 
during VACV infection to inhibit RhoA and concurrently promote cell motility. Another member of 
the Rho-GTPase family, Rac1, is turned on by TGF-β signalling and promotes Smad2-mediated cell 
migration [469]. VACV is known to interact with Rac1 to boost cytoskeletal plasticity [484]. 
Overall, the data highlights a possible link between Rho family signalling and TGF-β-signalling 
activation in the context of VACV-induced cell migration.  
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4.3.4 Smad4, apoptosis and VACV 
An important mechanism to be considered during viral infections is the induction of apoptosis. This 
is an antiviral process employed by cells to control the spread of infection, by eliminating at risk 
cells prior to their lysis. Due to its inherent antiviral nature, countless viruses have developed tactics 
to manipulate and inhibit the induction of apoptosis in order to prolong their survival. VACV is no 
exception to this rule. It possesses a number of proteins that interfere with components of the 
apoptosis cascade, including B13, F1, N1, B22 and E3 [239, 240, 485]. However, due to the 
potency of VACV infection, cellular antiviral responses and apoptosis cannot always be avoided.  
The results obtained in Smad4-depleted cells, indicated differences in VACV plaque clearance 
phenotype upon Tet treatment (Figure 4.5). That is, large areas within the plaques appeared devoid 
of cells, unless Smad4 was lost. These spaces could be the result of cells migrating towards the 
plaque front, or cell death due to apoptosis or lysis. Due to this clearance phenotype, we wanted to 
determine whether the methods VACV employs to control apoptosis are subverted in Smad4-
containing cells. To examine this, we observed levels of a common cellular mediator of apoptosis, 
caspase-3, to determine if its activation was affected by Smad4 knockdown within infected cells 
(Appendix 8.3). Interestingly, our results suggested Smad4 bore no influence on the activation of 
caspase-3 during VACV infection. These results were rather surprising given the strong link 
between Smad4 and apoptosis induction within the literature. For example, previous groups have 
found that TGF-β-mediated apoptosis occurs as a result of Smad4 translocating to mitochondria and 
activating pro-apoptotic proteins such as cytochrome X oxidase [486]. This apoptotic phenotype 
was lost after transfection with a Smad4-specific siRNA. Furthermore, a Smad4-dependent target, 
GADD45B, is considered a master regulator of TGF-β-mediated apoptosis [218]. This protein 
promotes activity of p38 MAPK, which can then phosphorylate components of the apoptosis 
signalling cascade, such as Bcl-2 family proteins, to instigate programmed cell death [487].  
However, given that we have only assayed apoptosis using one component from the complex 
apoptosis signalling cascade we cannot definitively conclude that Smad4 bears no influence on 
apoptosis during VACV infection. Loading issues in this experiment also suggest more 
investigation may be required (Appendix 8.3). Further experiments could use flow cytometry 
analysis to quantify apoptotic cells or make use of microscopy techniques to examine the presence 
of apoptotic bodies. Despite this, the preliminary results suggest that the observed differences in 
plaque clearance may not be due to unchecked apoptosis. Further analysis of specific TGF-β 
pathway components, such as GADD45B, and apoptosis regulators, such as Bcl-2 family proteins, 
could shed more light on the dynamics of VACV-induced apoptosis in a Smad4-depleted 
background. 
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4.3.5 Future directions and further analyses 
Until now, we have focused on the role of Smad4 during VACV infection. However, Smad2 and 
Smad3 are also key mediators of Smad-induced EMT and TGF-β-associated cell migration. Despite 
their similar structures, Smad2 and Smad3 are known to play distinct, non-overlapping roles in 
TGF-β signalling. For instance, in pancreatic cells, siRNA-mediated knockdown of Smad2 severely 
diminished the ability of cells to undergo TGF-β-induced migration. Knockdown of Smad3 had an 
opposing effect, causing cells to move further than non-transfected cells [469]. This phenotype was 
also observed in breast cancer cells [488]. As such, investigating the role of these R-Smads and 
their target genes in the context of VACV could be very fruitful. Given that Smad4 appears to 
contribute to efficient plaque spread, we would expect the same from knockdown of Smad2 and/or 
Smad3. The phenotype may even be more pronounced in this second case as R-Smads mediate the 
bulk of transcription associated with the TGF-β signalling pathway. In fact, Smad4 requires one of 
these two in order to act as a transactivator, suggesting Smad4-dependent gene expression would 
also be affected in these cases.  
In our analyses thus far, we have also not characterised the cellular localisation of Smad proteins 
during infection. This could be an important factor to consider if the pattern of distribution is 
different to that observed following TGF-β treatment. Typically, in the absence of TGF-β signal, 
Smad proteins either remain cytoplasmically bound, in the case of Smad2, predominantly nuclear 
for Smad3, or constantly shuttling in and out of the nucleus for Smad4 [149] [175]. Upon activation 
of the TGFβR complex, the expected localisation of Smad proteins is almost entirely nuclear. Given 
that Smad proteins are unable to carry out their transcriptional roles in other cellular compartments, 
it would be interesting to examine their location upon VACV infection. If widely distributed, 
perhaps Smad proteins are less important for transcription in the infected cell context than in the 
canonical pathway. One way to examine the role of Smad cellular localisation could be the use of a 
nuclear export inhibitor, such as leptomycin B, which prevents the action of XPO1 on Smad4 and 
promotes nuclear accumulation of this protein [180]. In this context, we would expect to see a 
reversal of the results obtained using the Smad4 knockdown and gene edited tools, as leptomycin B 
theoretically enhances Smad4-dependent transcription by corralling Smad4 to the nucleus. In the 
absence of an overexpression model, this seems an appropriate measure to increase the activity of 
Smad4 within infected cells and could highlight a proviral role for leptomycin B treatment. Another 
interesting point to consider is that VACV infection is known to upregulate a nuclear pore protein 
[489]. Perhaps this is a mechanism by which VACV ensures continued trafficking of Smad proteins 
to the nucleus and maintains transcription of Smad target genes. Inhibition of this pore protein may 
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be deleterious to viral infection and inhibit VACV-induced activation of Smad signalling. This may 
be another factor to consider in the design of future experiments.  
 
4.3.6 Conclusions 
In this chapter, we aimed to evaluate the role of Smad4 during VACV infection. Using two different 
tools, the HaCaT TRS4 cell system and CRISPR-Cas9 gene editing method, we efficiently depleted 
Smad4 in two different human cell lines. These results were confirmed by immunoblot, as well as 
analysis of Smad4-dependent targets at both the transcript and protein level, by qRT-PCR and 
immunofluorescence assay respectively. These Smad4-depleted tools allowed us to monitor the 
contribution of Smad4 to plaque size, clearance, viral release and the replication cycle. From our 
data, Smad4 appears to be involved in efficient cell-to-cell spread of VACV, with plaque size being 
significantly reduced upon Smad4 depletion. This appeared at least partially to be due to abrogated 
induction of cell migration. This phenotype was also observed in HeLa cells where Smad4 had been 
removed via CRISPR-Cas9 editing. The phenotypic changes to VACV plaques seen upon Smad4 
depletion may be mediated by a loss of PAI-1, which is a known Smad4 target that moderates cell 
migration and is lost in induced VACV plaques. However, the role of PAI-1 has yet to be directly 
investigated in the context of VACV and would be a promising avenue for further research. From 
our results we can conclude that VACV is reliant on Smad4 signalling for efficient spread. This 
could be important knowledge for antiviral development, as well as pertinent to the use of VACV as 
an oncolytic agent in Smad4-depleted tumour types.  
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CHAPTER 5: MECHANISM OF 
VACV-INDUCED TGF-β SIGNALLING 
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5.1 INTRODUCTION 
5.1.1 Viral manipulation of the TGF-β signalling pathway 
Viral infections drastically change the microenvironment of cells, modifying cell behaviour, 
influencing intracellular signalling and altering the milieu of cytokines secreted into the 
extracellular space. Combined, these features create a perfect storm for viral propagation. Of 
particular interest is the composition of the cell secretome, as these factors can influence not only 
the adjacent infected cell, but also other uninfected cells in the surrounding space. Their release can 
be a direct result of viral influence, or an inadvertent consequence of the cell stress response. Some 
of the most commonly secreted factors from virally-infected cells are interleukin family proteins, 
including IL-1β, IL-2 and IL10, interferons such as IFN-α, IFN-β, IFN-γ, pro-inflammatory 
cytokine, TNF-α, and immunoregulatory molecules like GM-CSF and TGF-β [79, 490-492]. These 
modulate an array of functions related to the recruitment of immune cells, inflammation, interferon 
response and cell proliferation [493]. As a result, they can be either proviral or antiviral in nature.  
As described earlier, the TGF-β signalling pathway is commonly manipulated by microbes to 
commandeer various aspects of the host cell. This group includes prominent pathogenic viruses 
such as ebolavirus, HCV and Influenza A virus, to name a few [79, 255, 259, 494]. Numerous 
mechanisms are employed by these to wrest control of the host signalling pathway, including 
boosting the secretion of TGF-β, activating the latent form of the ligand, binding and chaperoning 
the functions of Smad proteins or transactivating the TGFb mRNA promoter itself (Figure 1.13). 
All of these promote either transcription of TGF-β or Smad target genes, in both cases effecting 
proviral changes, such as EMT and cell migration, within the hostile host cell microenvironment. In 
previous chapters we described the ability of VACV to induce aspects of TGF-β signalling. 
However, the mechanism by which it is able to do so is still unclear. To understand how VACV is 
able to promote activity of the TGF-β signalling pathway, we wanted to determine if it utilises any 
of the previously described mechanisms.  
 
5.1.2 Secretion and activation of TGF-β ligand 
Again, examining the TGF-β-mediated signalling cascade, we can see the foremost step in signal 
transduction is TGF-β ligand binding to its cell surface receptor, which then instigates downstream 
phosphorylation events essential for Smad activation [115] (Figure 1.9). A number of viruses 
enhance production of TGF-β for this purpose (Figure 1.13). Their strategies influence TGF-β 
production or secretion at the transcriptional, translational or export stages [79, 88, 254, 261, 265, 
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266]. For example, levels of TGFb transcripts, as detected by qRT-PCR analysis, are increased in 
HBV and HCMV-infected cells as a result of interactions with the TGFb promoter transactivator, 
Egr-1 [261, 266]. At the post-transcriptional stage, ELISA and immunoblot can also be used to 
measure levels of TGF-β protein within infected-cell supernatants. This strategy positively 
identified TGF-β in the secretome of ebolavirus and subviral reovirus infections, where it boosted 
viral spread and pathogenesis [79, 279]. The data suggests production of TGF-β is a proviral tool in 
the arsenal of these pathogens. In fact, inhibition of ligand binding to the TGFβR complex, using 
the SB-431542 chemical inhibitor, decreased ebolavirus replication and virulence in an in vivo 
mouse model [79]. The same inhibitor blocked HCV-induced EMT, which is known to be mediated 
by TGF-β, suggesting there is a role for ligand binding in the pathogenesis of these viruses [494, 
495]. In the previous chapters, we have outlined evidence suggesting that VACV is also able to 
activate the TGF-β signalling pathway. Using techniques adopted from the literature, we hoped to 
determine if VACV was able activate this pathway by increasing TGF-β expression and/or activity, 
as these other viruses do.  
 
5.1.3 The importance of the TGFβR complex 
Once TGF-β ligand is secreted and converted to its active form, the TGF-β receptor is the first 
checkpoint which needs to be passed in order for signalling to continue within the cell. It is 
activated by ligand in the extracellular space binding to both the type II and type I receptors, and 
forming an active receptor complex [128]. Interestingly, TGFβRII, but not type I, is capable of 
binding ligand in the absence of the other receptor protein [128]. This suggests type II receptors 
confer affinity for specific ligands, whilst type I receptors are predominantly involved in signal 
transmission to downstream effector proteins (see Table 1.1). As such, we would expect both these 
proteins to be essential in order for TGF-β signalling during VACV infection.  
Whilst numerous viruses manipulate the TGF-β signalling pathway at the ligand level, much fewer 
are implicated in direct TGFβR complex interactions. One such exception is HCV, which despite 
requiring the receptor complex to induce EMT, also uses its NS5A protein to bind TGFβRI and 
interfere with its kinase abilities [256]. This virus in particular appears to choose particular aspects 
of TGF-β signalling to activate or repress, in order to tailor towards desirable infection outcomes.  
Given the rate-limiting nature of TGFβR complex signal transduction, we wanted to determine 
whether VACV also makes use of this receptor complex for activation of the TGF-β signalling 
pathway. To examine this we used two tools, the SB-431542 small molecule inhibitor described 
earlier, and TGFβRII-deficient LNCaP cells, to inhibit the type I and type II TGFβR proteins, 
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respectively. This tells us not only the role of these proteins during VACV infection, but whether 
increased ligand present in the extracellular space is responsible for signal transduction in this 
context.  
 
5.1.4 Phosphorylation of R-Smads  
The next critical step in the signalling cascade is the activation of Smad proteins via 
phosphorylation events. As described in Section 1.4.5, Smad proteins consist of three structural 
domains, the MH1, MH2 and linker regions. Each of these regions contains features which aid in 
regulating Smad translocation, DNA binding capacity or complex formation (Figure 1.11). 
However, control of Smad protein activity is largely determined by interactions with various 
cellular kinases. These phosphorylation sites are illustrated within Figure 5.1. 
 Many phosphorylation sites have been identified throughout the various Smad domains; however, 
some appear to be more critical to Smad functionality than others. For example, the previously 
described SSXS motif at the C-terminal phosphorylation of R-Smad proteins is considered essential 
for R-Smad/Smad4 complex formation, cellular translocation and downstream TGF-β signalling 
(Figure 3.3) [111, 132, 496, 497]. In fact, dephosphorylation of this site leads to nuclear export of 
Smad proteins and dampening of TGF-β signals [498]. Mutations of the SSXS motif to an AAXA 
sequence also results in complete loss of Smad2 signalling, diminished nuclear accumulation and 
defective interactions with a GST-tagged Smad4 protein [132, 133]. This C-terminal 
phosphorylation event is particularly interesting in that the TGFβRI, or ALK5, protein is one of 
only two kinases known to act on this site (Figure 5.1) [111]. The other of which is a protein known 
as monopolar spindle protein 1 (Mps1) or TTK, which is a dual-specificity kinase that typically 
mediates the correct progression of cell division through mitosis, but additionally has capacity to act 
on, and phosphorylate Smad proteins in a nocodazole-dependent manner [499-501]. Nocodazole 
treatment had previously been shown to increase Smad phosphorylation; however, this was the first 
time it was found to be dependent on a specific cellular factor to do so [179]. Curiously, Mps1 
appears to maintain this kinase ability in the absence of TGFβRI, suggesting it may act 
independently. However, at the current point in time Mps1 has not been investigated in great detail 
in the R-Smad phosphorylation context. 
Despite C-terminal SSXS motif phosphorylation being key to R-Smad transcriptional activity, there 
exists numerous other phosphorylation sites within the MH1 and linker regions of these proteins 
that contribute to the overall outcome of Smad signalling (Figure 5.1). Reversible additions at these 
sites can have various effects on the Smad proteins, boosting, stabilising or inhibiting their 
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activation profiles. These are regulated by multiple cellular kinases [159]. Of particular interest 
within the scope of this thesis are the EGFR-mediated kinases, such as MAPKs and protein kinase 
C (PKC), which enhance R-Smad activity and indicate an element of cross-talk between TGF-β and 
EGF signalling. MAPKs, such as ERK1 and ERK2, can have a dual effect on Smad2 and Smad3 
signalling. For instance, when the MH1 domain is phosphorylated at Thr8 by ERK1, Smad2 
transcriptional activity is enhanced [502]. However, MAPKs also act on a number of sites within 
the linker region, Thr220, Ser245, Ser250 and Ser255 in Smad2, Thr179, Ser204, Ser208 and 
Ser213 in Smad3, and Thr277 in Smad4, that were originally considered detrimental to Smad 
signalling when phosphorylated [503]. More recently however, conflicting evidence has been 
presented suggesting MAPK kinase (MEK)- or ERK-mediated linker phosphorylation increases 
nuclear retention and transcriptional activity of Smad proteins, and suggests outcomes of these 
events are context dependent [504-506]. On the other hand, another EGF-mediated kinase, PKC 
does not alter nuclear shuttling of Smad proteins, but interferes with the ability of Smad3 to bind its 
target gene promoters [233]. Smad2 is less affected in this context due to structural differences at 
the Thr47 and Ser110 sites compared to Thr37 and Ser70 in Smad3. Curiously, MAPKs can also 
phosphorylate Smad7 at Ser249, but this bears no influence on its inhibitory actions [172]. Other 
influential kinases seen in Figure 5.1, include the Ca2+/calmodulin-dependent protein kinase II 
(CAMKII) which mediates TGF-β-associated cell proliferation and the Wnt-inhibited, GSK3 kinase 
which interferes with Smad4 functionality [504, 507].  
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Figure 5.1 – Smad protein structure and phosphorylation sites 
Receptor Smads (top) and Smad4 (bottom) protein structures are shown with their respective and highly 
conserved MH1, linker and MH2 domains outlined. Each Smad protein has a nuclear localisation signal and DNA 
binding domain in their MH1 domains. Smad4 also has an additional nuclear export signal region in its linker 
domain. Phosphorylation sites and their respective kinases are outlined in the figure key. Threonine sites are 
denoted with a T and serines with an S. Whilst Smad4 has a single characterised phosphorylation site in its linker 
region, this differs greatly from the receptor Smad proteins that have an abundance of these sites throughout. Note 
for the receptor Smad proteins, the first number at each phosphorylation site corresponds to Smad2, and the 
second to Smad3.  
 
These phosphorylation events should not be considered in isolation, and in fact, often, co-
operatively influence kinase interactions. Previous reports have shown that C-terminal 
phosphorylation may also contribute to TGF-β-induced linker phosphorylation of Smad3 [497]. It 
was observed that TGF-β treatment was required for phosphorylation of Smad3 at the 4 linker sites 
described above, Thr179, Ser204, Ser208 and Ser213. These events were preceded by C-terminal 
SSXS motif phosphorylation. In cells lacking the type I TGF-β receptor, both C-terminal and linker 
phosphorylation was not observed until the TGFβRI was re-introduced, suggesting a component of 
TGF-β dependency in linker phosphorylation [497]. This is particularly curious as the TGFβRI 
protein is not the kinase responsible for linker phosphorylation; however, it may bear some 
influence on the MAPKs which mediate these events following TGF-β treatment [503]. Conversely, 
C-terminal phosphorylation was not required for EGF-mediated linker phosphorylation, suggesting 
TGF-β and EGF differentially regulate the linker region of R-Smads [497].  
Overall, it is clear that a number of checkpoints are passed from signal transduction to cellular 
change during TGF-β signalling. Some of these events are considered critical for downstream 
signalling to occur. One such restrictive process is the C-terminal SSXS phosphorylation of Smad2 
and Smad3 proteins, the bulk of which is controlled by TGFβRI proteins. As a result, our 
experiments aimed to investigate R-Smad C-terminal phosphorylation by TGFβRI, and also Mps1 
in the context of the VACV-infected cells. A variety of chemical inhibitors were employed to do so. 
Furthermore, as these kinases purportedly act in tandem, we characterised the linker 
phosphorylation profiles of R-Smads during VACV infection to gain insight into the activity of 
these proteins after exposure to VACV. These experiments not only consider the TGF-β signalling 
pathway, but also other cross-talk pathways capable of exerting an effect on Smad proteins.  
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5.1.5 The EGFR signalling pathway and cross-talk with TGF-β signalling  
Many pathways are known to cross-talk with the TGF-β signalling pathway including a number 
which are also known to be important for aspects of VACV spread and replication. By examining 
these pathways, we may be able to gain insight into how VACV is manipulating the TGF-β 
signalling pathway, and whether cross-talk plays a critical role. As mentioned earlier, one signalling 
pathway of interest in this thesis chapter is the EGFR-mediated signalling cascade (Figure 5.2). 
Signal is transduced through this pathway by ligands, such as TGF-α, EGF, or its VACV homolog, 
vaccinia growth factor (VGF), binding to the receptor, the EGFR, at the cell membrane. This can 
then feed into four different signalling cascades, the ERK-mediated, P13K/Akt kinase, JAK/STAT 
or PKC-mediated signalling pathways [508, 509] (Figure 5.2).  
EGF and TGF-β display a high level of cross talk. For example, TGF-β and EGF can both increase 
the expression of the EGFR on the cell surface [510, 511]. In the case of MAPKs, such as ERK, 
TGF-β inhibits EGFR-mediated activation these proteins [512]. This opposes a non-EGFR 
mediated mechanism where TGF-β treatment enhances phosphorylation of ERK proteins [503, 513]. 
EGF on the other hand, promotes activation of MAPKs, which then act on TGF-β-associated 
effectors, such as Smad proteins. For example, ERKs phosphorylate Smad4 at Thr277 in the Smad 
activation domain (SAD) (Figure 5.1). This not only boosts nuclear translocation of Smad4 but also 
binding to co-activator proteins [162, 163]. Another kinase downstream of EGFR, P13K can 
enhance linker and C-terminal phosphorylation of R-Smad proteins to increase their activity and 
promote TGF-β signalling [514]. However, PI3K can also prime these same proteins for 
degradation by the ubiquitination pathway [230]. Conversely, the JAK/STAT proteins influence 
TGF-β signalling by inducing the expression of Smad7, which interferes with Smad3 
phosphorylation and inhibits downstream signalling [515]. In fact, TGF-β can negatively regulate 
its own signalling in this manner, by activating JAK, promoting Smad-mediated phosphorylation of 
STAT proteins and enhancing the expression of I-Smads [101]. However, TGF-β-mediated 
phosphorylation of Smad3 is JAK/STAT signalling-dependent [516]. The final EGFR-controlled 
kinase, PKC also appears to inhibit transcriptional activity of Smad proteins, as described above, by 
phosphorylating Smad3 and interfering with its DNA binding capacity [233]. As a result, the EGFR 
and TGF-β-mediated pathways can act both synergistically and competitively depending on the 
cellular context [234].  
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Figure 5.2 – The EGF-mediated signalling pathway and mechanisms of cross-talk with TGF-β 
signalling 
EGF binding to its receptor on the cell surface can instigate a complex array of signalling cascades. The EGF 
receptor feeds into three distinct signalling pathways, the ERK kinase, PI3K/Akt kinase, JAK/STAT kinase and 
PKC kinase-mediated signalling cascades. Activation of these kinases can influence the outcomes of many 
cellular processes such as those involved in proliferation, differentiation and migration. Some of these also affect 
the TGF-β signalling pathway, as they can phosphorylate the linker region of R-Smad and Co-Smad proteins, lead 
to degradation of various Smad proteins or promote expression of I-Smads. In the diagram, inhibitory interactions 
are depicted as red dashed lines, whilst positive interactions are in green. Adapted from [509] and [517].  
 
In terms of therapeutic treatments, the relationship between TGF-β and EGF signalling is important 
to consider. The EGF signalling family has a history of association with cancer development and 
progression [44, 518]. In fact, many monoclonal antibodies and chemical therapeutics, as well as 
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certain oncolytic viruses use EGFR as a marker, target and entry mechanism to better attack rogue, 
metastatic cancer cells [518-520]. Given that TGF-β signalling is also often rampant in problematic 
tumours, and also a possible anti-cancer target, an oncolytic therapy aimed at both EGF and TGF-β 
signalling has the potential for enhanced specificity and potency [521].  
 
5.1.6 Vaccinia virus growth factor 
There are numerous viruses which make use of the EGF signalling pathway for aspects of infection. 
For example, HCV promotes activation of the EGFR in order to facilitate entry via clathrin-
mediated endocytosis [522]. HCMV and HSV-1 also utilise this molecule as a co-receptor to gain 
access to cells [523, 524]. Another instance occurs during RSV infection, where EGF signalling 
promotes inflammation and facilitates unchecked viral replication [525]. However, VACV uses a 
different mechanism to manipulate this pathway.  
Vaccinia growth factor (VGF) is a protein encoded by VACV. It was originally identified due to its 
homology to cellular proteins, EGF and TGF-α [526, 527]. In fact, VGF competes with EGF for 
binding to the EGFR [519, 528]. Since the identification of VGF, a number of groups have 
attempted to characterise its function and examine the infection outcomes in a VGF-null 
background. An interesting observation saw areas of cellular proliferation at the peripheries of 
VACV lesions which proved to be VGF-dependent [529, 530]. Another characteristic of VGF-
deleted (VACV-ΔVGF) VACV was an attenuated phenotype in mice and rabbits, where much 
higher concentrations of VACV-ΔVGF were required to phenocopy parental VACV infection [43]. 
This suggests that VGF is an important virulence mechanism during in vivo infection. Furthermore, 
initiation of ERK signalling by VGF lends towards a narrower host range, especially in related 
poxviruses such as MVA [531]. Curiously, a group in the mid-1980s found that exogenous EGF 
treatment and occupancy of the EGF receptor inhibited VACV infection in a dose-dependent 
manner [532]. This suggests VGF plays some extraneous function that cannot be performed by 
host-derived EGF alone. This information, combined with the fact that EGF is known to co-operate 
with and modulate the TGF-β signalling pathway, suggested VGF may be a tool used by VACV to 
influence elements of the TGF-β/Smad signalling cascade.  
5.1.7 Ectromelia virus, TGF-β and VGF signalling 
ECTV is another member of the Orthopoxvirus genus which proved to be interesting in the context 
of our research (Figure 5.3). Originally discovered as the causative agent of mousepox, today 
numerous strains of ECTV have been characterised including the Moscow (ECTV-Mos), 
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Hampstead, Naval, Cornell and NIH79 strains [358, 533]. The most virulent and well-characterised 
of these, ECTV-Mos, was chosen for use within this thesis ECTV work [361]. Using this virus with 
our established work flow, it was found that ECTV appeared unable to stimulate TGF-β signalling, 
as detected by luciferase assay and immunoblot (Figure 5.3). As this virus displays a reasonable 
homology with VACV it was chosen for further studies on the contexts of TGF-β signalling during 
poxvirus infection. Furthermore, ECTV is known to encode a truncated VGF protein, which is 12 
amino acids shorter than the VACV version [533]. As such, it is possible that this protein does not 
function in the same way as its VACV counterpart and may be unable to activate downstream 
EGFR signalling. Together, these factors provide numerous points for comparison between VACV 
and ECTV and facilitate the mechanistic study of VACV-induced TGF-β signalling. 
 
Figure 5.3 – Luciferase assays and immunoblots indicate a lack of TGF-β pathway activation upon 
ECTV infection  
(A) When compared to VACV-WR infected and TGF-β-treated cells, ECTV infection does not upregulate 
luciferase production, suggesting Smad3 activity is not increased in these cells. Luciferase assays were conducted 
in HeLa cells as in Figure 3.2 for 8 hours in the case of VACV-WR and TGF-β or 16 hours for ECTV. Note that 
different time points were used for ECTV infection as it replicates slower than VACV-WR. Levels of Renilla to 
Firefly luciferase were graphed as before. n=3. Error bars refer to SEM. (C. McKenzie, PhD thesis, 2016). (B) 
Immunoblot analysis revealed a lack of Smad2 C-terminal activation in ECTV infected cells. This differs from 
VACV-WR-infected and TGF-β-treated conditions. L1 was used as a viral control, whilst β-actin served as a 
cellular loading control). 
 
5.1.8 Chapter aims 
From the previous sections of this thesis it was evident that TGF-β/Smad signalling was highly 
upregulated following VACV infection and plays a role in viral cell-to-cell spread. The next 
question to be addressed was how the virus may be manipulating this pathway. To explore this area 
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of research a number of techniques were employed. Firstly, to look at the importance of the TGF-β 
ligand itself, qRT-PCR, small molecule inhibitors and cell lines, such as LNCaP, lacking the type II 
TGF-β receptor were employed. Following this, we used related virus, Ectromelia virus (ECTV) 
and a ΔVGF VACV, to gain further insights into which viral components are required for activation 
of TGF-β signalling. All the aims within this chapter attempt to address the overarching question of 
how VACV is able to induce EMT and TGF-β signalling. 
 
• Does VACV induce transcription, production or secretion of TGF-β from infected cells? 
• Is the TGF-β receptor complex required for VACV stimulation of Smad signalling? 
• Are other proteins acting in concert with the TGFβR or independently to affect activation of 
Smad proteins? 
• Are other pathways influencing activity of TGF-β signalling in VACV-infected cells? 
• If EGF signalling does co-operate with TGF-β signalling in the context of VACV infection, 
can we manipulate this system to remove the influence of EGF? 
• Is VGF required for VACV-induced TGF-β signalling? 
• Do other orthopoxviruses, such as ECTV, stimulate TGF-β pathway activation? 
• If not, what differences between ECTV and VACV could account for this opposing 
phenotype?  
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5.2 RESULTS 
5.2.1 VACV does not appear to increase TGFb mRNA expression 
One of the most common mechanisms for viral activation of the TGF-β signalling pathway is via 
transcription of TGFb mRNA [260-272]. Members of this group include prominent pathogens such 
as HIV, SARS-CoV and HCV. Upon TGFb transcription, mRNA is translated and released as 
mature TGF-β which is able to bind to its cognate receptor and initiate the signalling cascade 
(Figure 1.9). As such, a simple explanation for how VACV is able to promote TGF-β signalling is 
that it utilises a similar method and stimulates the transcription of TGFb. To determine if this was 
the case we examined the abundance of TGFb mRNA utilising qRT-PCR following VACV 
infection (Figure 5.4). TGF-β is known to positively regulate its own expression. As such, it was 
unsurprising to see an increase in TGFb mRNA transcript levels in RNA extracted from HaCaT 
cells at 10 hours post-TGF-β treatment [216, 534]. However, it seemed that VACV infection did not 
promote the same phenotype, suggesting VACV does not transactivate the TGFb promoter. These 
results correlate with those obtained previously in the lab, where treatment of cells with conditioned 
supernatant collected from VACV-infected cells was unable to stimulate a TGF-β response as 
detected by luciferase assay (data not shown, C. McKenzie, PhD thesis, 2016). Taken together, the 
results appear to indicate that stimulation of this pathway by VACV is not occurring through the 
induction of TGFb nor secretion of TGF-β.  
 
Figure 5.4 - TGFb mRNA is not increasingly transcribed during VACV-WR infection  
Quantitative real-time PCR analysis of total RNA collected from uninfected, TGF-β-treated (2 μg/mL) and 
VACV-WR-infected (MOI of 10) cells at 10 hours post-treatment indicated that VACV does not increase levels of 
TGFb mRNA. This contrasts to TGF-β-treatment which positively regulates its own expression. This experiment 
was conducted using HaCaT cells. n=3. Error bars refer to SEM.  
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5.2.2 In the presence of TGFβR inhibitor, SB-431542, VACV still induces transcription of 
Smad target genes 
Once it appeared that TGF-β was not being secreted by VACV-infected cells, we wanted to 
determine if VACV uses the TGFβR complex for signal transduction. SB-431542 is a small 
molecule inhibitor of TGF-β receptor signalling and was used previously within this thesis (Figure 
3.5). It prevents phosphorylation of the type I receptor by the type II receptor tyrosine kinase and 
thus prevents association of R-Smad proteins with the receptor complex. By doing so, the TGF-β 
signalling pathway is blocked at a very early stage in the signalling process and so we would not 
expect to see any downstream signalling or target transcription if VACV makes use of this complex 
for signal transduction. Again, utilising qRT-PCR, we found that cells treated with TGF-β increased 
transcription of certain Smad target genes, but only in the absence of SB-431542 treatment (Figure 
5.5). Similarly, VACV was able to increase transcript levels of these target genes; however, this 
process occurred regardless of the presence of TGFβRI inhibitor. Note that c-JUN levels were not 
found to increase in this context; however, this was attributed to timing. These results suggested 
activity of the TGF-β receptor was not a contributing factor to VACV-induced TGF-β pathway 
signalling.  
Figure 5.5 – SB-431542 treatment does not affect the ability of VACV-WR to induce transcription of 
Smad target genes 
Ten hours of treatment with TGFβR inhibitor, SB-431542, eliminates the ability of HaCaT cells to respond to 
TGF-β-induced gene transcription (2 μg/mL) as detected by qRT-PCR. VACV-WR (MOI of 10) is still able to 
induce Smad target gene expression at 10 hpi, regardless of the presence of SB-431542. DMSO treatment was 
used as a negative control. n=3. Error bars refer to SEM.  
 
5.2.3 LNCaP cells respond to VACV stimulation of Smad target gene expression 
To corroborate the data obtained in Section 5.2.2 using a different approach, we utilised a prostate 
cancer cell line lacking the type II TGF-β receptor protein. LNCaP cells express TGFβRII only in 
the presence of androgen stimuli [535]. In fact, transfection of these cells with the type II receptor 
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has been used in order to study their responsiveness to TGF-β treatment [536]. We acquired these 
cells from collaborator Dr Stephen Assinder (Sydney Medical School, University of Sydney, 
Australia). Smad target gene expression was examined at 10 hours post-TGF-β treatment and no 
induction of target gene expression was observed (Figure 5.6). This suggested that the cells were 
unresponsive to TGF-β stimulation of c-JUN, Snail2 and PAI-1 transcript expression. Conversely, 
VACV-WR infection was able to promote transcription of PAI-1, transcript levels increasing 6-fold 
following infection. Expression of c-JUN was also increased approximately 3-fold compared to 
untreated cells. As expected, early viral control gene, D12 was only observed in the VACV-WR 
infected cell lysates. These results, in combination with those obtained using the SB-431542 
inhibitor, suggest the type I and type II TGFβR proteins are not required for VACV stimulation of 
downstream TGF-β-associated transcript expression. 
 
Figure 5.6 – LNCaP cells do not respond to TGF-β treatment, but can still transcribe Smad target 
genes following VACV-WR infection 
Quantitative real-time PCR analysis revealed that total RNA extracted from LNCaP cells at 10 hours post-
treatment with TGF-β (2 μg/mL) did not display increased levels of Smad target genes, c-JUN, Snail2 and PAI-1. 
A similar phenotype is observed in untreated cells. At the same time post-VACV-infection (MOI of 10) we see 
transcription of some of these target genes. n=3. Error bars refer to SEM.  
 
5.2.4 The Mps1 kinase is not responsible for R-Smad activation during VACV infection 
Having suggested that the TGFβR complex was not required for TGF-β-like signalling during 
VACV infection, we searched for other possible kinases which may be acting on the R-Smad 
proteins, initiating downstream signalling and enhancing transcript expression. As Mps1 is the only 
other kinase known to phosphorylate the C-terminal SSXS motif of R-Smad proteins we wanted to 
determine if there was a role for Mps1 during VACV infection. To study this, immunoblotting 
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techniques were used. In Figure 5.7 it is clear that C-terminal phosphorylation of Smad2 is 
increased upon treatment with TGF-β, despite overall levels of Smad2 remaining unchanged 
compared to untreated cells. This same phenotype was seen in VACV-WR-infected cell lysates. 
Curiously, in all the conditions, treatment with an inhibitor of Mps1, Mps1-IN-2, did not alter the 
phosphorylation phenotype. For this experiment, β-actin and A36 were used as cellular and viral 
loading controls, respectively.  
 
 
Figure 5.7 – Mps1 does not appear to mediate C-terminal phosphorylation of R-Smads following 
VACV infection 
Immunoblot analysis revealed that C-terminal phosphorylation of Smad2 is observed in VACV-WR-infected 
HaCaT cells at 10 hpi. This phenotype is lost in the presence of Mps1 inhibitor, Mps1-IN-2 (15 nM). TGF-β-
induced Smad2 phosphorylation also did not appear to be Mps1-dependent. Overall, Smad2 levels remained fairly 
constant between the conditions. β-actin and A36 were used as cellular and viral loading controls respectively. 
 
5.2.5 The EGF signalling pathway contributes to linker phosphorylation of Smad2 during 
VACV infection 
There are multiple points at which kinases can interact with the various Smad proteins; however, 
researchers generally agree that C-terminal phosphorylation is most important for Smad2 and 
Smad3 activation [111, 132]. Regardless, N-terminus and linker phosphorylation events are often 
overlooked.  
As described earlier the TGF-β signalling pathway and EGFR signalling pathway display a high 
level of cross-talk such ERK kinases phosphorylating R-Smads within their linker region. In Figure 
5.8, we can see a basal level of phosphorylation of Smad2 at the linker site. This is seen as a visible 
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band in the p-Smad2 (Ser245, 250, 255) condition. The intensity of this band is heightened upon 
addition of exogenous EGF, suggesting EGF can boost Smad2 linker region phosphorylation. 
However, this kinase activity was decreased in the presence of EGFR inhibitor, gefitinib, indicating 
linker phosphorylation cannot occur effectively in the absence of an EGFR signal. When we 
investigated VACV-WR-infected HaCaT cells, p-Smad2 levels were again found to be higher than 
in untreated and uninfected cells.  
Once it appeared that VACV was able to induce linker region phosphorylation at the Ser245, 
Ser250 and Ser255 sites, we wanted to gain insight into the mechanism it uses to do so. As VACV 
encodes a homolog of EGF, VGF, this should theoretically be able to elicit the same effects on the 
TGF-β signalling system and R-Smad proteins as EGF itself. To evaluate this, we wanted to 
determine whether VGF could also increase linker phosphorylation of Smad2 (Figure 5.8). VACV 
lacking VGF (VACV-ΔVGF) was unable to phosphorylate the linker site. These results suggest 
VACV uses the EGFR pathway, either manipulating cellular EGF or utilising VGF, to promote 
linker region phosphorylation of Smad2. 
 
Figure 5.8 – Smad2 linker phosphorylation is affected by the presence of EGF, TGF-β and VGF 
Immunoblot analysis of lysates from HaCaT cells in a number of conditions revealed that Smad2 linker 
phosphorylation is reliant on EGF or VGF signalling at 10 hours. This was especially true in cells treated with 
EGF (10 ng/mL). VACV-WR (MOI of 5) also stimulated this phosphorylation step. However, phosphorylation 
was lost upon the use of VACV-ΔVGF at 16 hpi. An EGFR inhibitor, gefitinib (1 μM), partially abrogated this 
phosphorylation response in EGF-treated and VACV-WR infected cells at 1 hour post-treatment. β-actin and A36 
were used as cellular and viral loading controls respectively. 
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5.2.6 VGF is required for efficient viral growth 
As the EGF signalling pathway appears to be required for efficient Smad linker phosphorylation 
during VACV infection, we wanted to determine if removal of VGF from this system would affect 
any phenotypic aspects of viral infection. To carry out these experiments we made use of VACV-
ΔVGF to study viral replication and spread. Growth curves were conducted in HaCaT cells over a 
24 hour period (Figure 5.9). From the results it is clear that VACV-ΔVGF takes almost exactly 
double the time to reach the same viral titre as VACV-WR despite starting at the same viral 
concentration. Interestingly, both viral titres appear to expand at a similar rate, albeit with a slight 
delay in the VACV-ΔVGF condition.  
 
Figure 5.9 – Growth curves demonstrated that VGF is required for rapid VACV expansion 
HaCaT cells grown to confluency and infected at an MOI of 5 with VACV-WR or VACV-ΔVGF indicated a 
delay in viral growth upon the loss of VGF. The assays were conducted by infecting cells, removing non-adsorbed 
virus after 1 hour and then allowing the titres to expand for the specified times. Viral populations were then 
quantified by standard plaque assay and measured using ImageJ software. The dotted line corresponds to the viral 
titre of VACV-WR at 8 hpi. It takes almost 16 hours for the VACV-ΔVGF population to reach the same level. 
n=3. Error bars refer to SEM. 
 
5.2.7 VACV-ΔVGF does not promote transcription of Smad target genes 
The contribution of VGF to TGF-β signalling was made even clearer through the use of qRT-PCR 
analysis. As before Smad target genes were increasingly transcribed in HaCaT cells treated with 
TGF-β or infected with VACV-WR (Figure 5.10). However, upon loss of VGF, c-JUN and PAI-1 
transcript levels returned to that seen in uninfected cells. This was not due to a lack of virus, as the 
viral gene, D12, was found to be at comparable levels in both the VACV-WR and VACV-ΔVGF 
conditions. Note that as VACV-ΔVGF replicates more slowly than VACV-WR, a later time point 
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of 16 hpi was used for RNA extraction in this condition. This was compared to 8 hours post-
treatment for the others in this experiment.  
 
 
Figure 5.10 – qRT-PCR analysis showed that VACV-ΔVGF is incapable of promoting transcription of 
Smad target genes 
HaCaT cells lysed at 8 hours post-treatment with TGF-β (2 μg/mL) or VACV-WR (MOI of 10), or 16 hpi for 
VACV-ΔVGF (MOI of 10) were found to display different levels of Smad target gene expression. Both c-JUN 
and PAI-1 were found to decrease upon loss of VGF from VACV. Samples were normalised to cellular control 
GAPDH, and D12 was used as a viral control. n=3. Error bars refer to SEM. 
 
5.2.8 Deletion of VGF dramatically reduces VACV plaque size 
Given that our earlier results suggested VACV uses aspects of TGF-β signalling, such as Smad4, to 
spread effectively, we wanted to determine whether VGF plays a complementary role in viral 
dissemination. To study this phenotype, we used plaque assays with the HaCaT TR and TRS4 cell 
lines described previously [364]. From Figure 5.11A, B and C we can see that the deletion of VGF 
dramatically reduces plaque size compared to VACV-WR plaques at 3 dpi. This can be quantified 
as a 25% reduction in plaque size and is consistent across immunofluorescence and crystal violet-
stained plaque assay, suggesting VGF is important for VACV spread. These results were seen 
regardless of Tet treatment in the HaCaT TR cells.  
To further ascertain the relationship between Smad4 and VGF in VACV spread we conducted the 
same analyses in HaCaT TRS4 cells. In these cells, unlike in the HaCaT TR cell model, Tet 
treatment diminishes plaque size. VACV-WR plaques are reduced by 16% upon Smad4 knockdown 
compared to untreated cells (Figure 5.11D, E, and F). These data are consisted with those obtained 
in Figure 4.5. As before, plaque clearance also appears to be inhibited. In the VACV-ΔVGF 
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condition, we again we see smaller plaques compared to the VACV-WR-infected cells. However, 
upon Smad4 knockdown this is even further reduced, producing plaques a mere 50% of the size of 
the untreated VACV-WR plaques (Figure 5.11E). Interestingly, the plaque clearance phenotype 
does not seem to be altered by Tet treatment in VACV-ΔVGF plaques (Figure 5.11F). Together the 
data suggests Smad4 contributes to viral spread in both a VACV-WR and VGF-deficient virus 
background; however, it may work via different mechanisms in each case, given the various fold-
reductions in plaque size observed.  
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Figure 5.11 – Comparison of WR-infected and VACV-ΔVGF-infected HaCaT TRS4 cells following 
Tet-induction. 
HaCaT TR (A-C) and TRS4 cells (D-F) were grown to confluency and treated with Tetracycline for 48 hours 
prior to infection. (A, D) Cells were then infected with low titres of either WR or VACV-ΔVGF for 3 days before 
fixing, staining and imaging on the Nikon Ti-E Eclipse microscope. Nuclear material was stained blue with DAPI, 
viral B5 was stained green and the actin cytoskeleton was stained red. Scale bar = 200 μm. (B, E) Plaques were 
also imaged macroscopically after crystal violet staining. Scale bar = 10 mm. (C, F) VACV-WR and VACV-
ΔVGF plaque sizes were found to be significantly different in both untreated TR (C) and TRS4 cells (F). However, 
Smad4 knockdown decreased WR plaque size to the VACV-ΔVGF size in TRS4 cells only. Thirty plaques were 
measured in each condition. Error bars refer to SEM.  
 
5.2.9 VACV plaque formation is affected by the addition of exogenous TGF-β and EGF, in a 
VGF-dependent manner 
Given the link between the TGF-β and EGFR-mediated signalling pathways, we wanted to 
determine whether VACV-ΔVGF, would still be able to respond to TGF-β effectively. To assay this, 
we conducted a number of plaque assays with or without the addition of exogenous EGF and TGF-
β, to examine the relationship between viral spread these host cell signalling pathways. From the 
results in Figure 5.12 we can see that VACV-WR plaques are much larger at 2 dpi than VACV-
ΔVGF plaques, as expected. However, addition of EGF has a detrimental effect on VACV-WR 
plaques. While EGF can exert an antiviral effect on VACV-WR, TGF-β, appears proviral in nature 
regardless of the expression of VGF. In fact, whilst VACV-ΔVGF plaques stimulated with EGF 
were still smaller than wild-type plaques, those in the presence of TGF-β were not significantly 
different to untreated VACV-WR plaques. Whilst VGF promotes viral spread, addition of EGF can 
dampen this effect and act in an antiviral fashion. Interestingly, in the absence of VGF, EGF is not 
able to restore plaque size to parental levels (at least at the concentrations tested), suggesting VGF 
and EGF are not equivalent.  
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Figure 5.12 – VACV-ΔVGF plaque size increases dramatically upon addition of exogenous EGF or 
TGF-β 
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(A) Immunofluorescence images of VACV-WR and VACV-ΔVGF plaques at 2 dpi revealed that treatment with 
EGF (10 ng/mL) and TGF-β (2 μg/mL) for the duration of plaque formation led to an increase in plaque size in the 
case of VACV-ΔVGF. VACV-WR appeared to be less responsive. Viral envelope protein B5 was stained in red, 
the actin cytoskeleton in green and dsDNA in blue. Scale bar = 200 μm. (B) Plaque sizes were measured using 
ImageJ software and found to increase significantly after addition of EGF (10 ng/mL) and TGF-β (2 μg/mL). 
Forty plaques were counted in each condition. Error bars refer to SEM.  
 
5.2.10 Immunofluorescence suggests an inhibitor of EGFR signalling, gefitinib, does not affect 
VACV infection 
As the EGF signalling pathway is known to act in tandem with TGF-β signalling, to promote target 
expression, we wanted to ascertain whether it plays any role in the VACV context. A number of 
tools were chosen to examine the influence of EGF. As described above, a virus lacking the ability 
to activate extraneous EGF signalling was used for some experiments. Due to the fact that VACV-
ΔVGF lacks the viral homolog of EGF, only endogenous EGF is able to activate the EGFR. In the 
experiments described below, we parse the role of endogenous EGFR signalling. To do this we 
obtained an inhibitor of EGFR signalling, gefitinib. The mechanism of action of gefitinib has not 
been entirely elucidated; however, it is thought to compete with ATP for binding to the EGFR and 
thus prevent its kinase activity [537, 538]. Initial experiments were conducted to determine if 
gefitinib has anti-viral potential and evaluate its suitability for further experiments (Figure 5.13). 
The assays also doubled as infection control experiments for immunoblot analysis described later. 
In this condition, exogenous EGF was used as control. These, immunofluorescence assays indicated 
treatment with low concentrations of gefitinib did not appear to adversely affect cell survival in 
uninfected cells. Similarly, EGF treatment did not lead to the adoption of a distinguishing cell 
phenotype. As with our previous data, VACV-WR caused cells to detach from each other alter their 
morphology after 10 hours. Gefitinib treatment did not appear to affect this infected cell phenotype 
or have any influence on the infection frequency of this virus. 
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Figure 5.13 – Infection control highlights low concentrations of gefitinib do not have an antiviral effect 
To check infection efficiency before immunoblot analysis, immunofluorescence was performed. HaCaT cells 
were either left uninfected or infected with VACV-WR (mCherry) (MOI of 5) virus. At 9 hpi cells were subject to 
gefitinib treatment for 1 hour (1 μM) followed by a 5 minute treatment with EGF (10 ng/mL) prior to lysis. EGF 
and Gefitinib did not appear to have a detrimental effect on cells or infection. Images were taking using the Nikon 
Ti-E Eclipse microscope. Scale bar = 50 μm. 
 
5.2.11 Gefitinib-treated plaques are smaller than untreated plaques 
To determine the role of EGFR signalling in VACV cell-to-cell spread, gefitinib was used on both 
VACV-WR and VACV-ΔVGF plaques. Unsurprisingly, when EGFR signalling was inhibited, and 
the contributions of EGF and VGF removed, VACV-WR plaques decreased in size in a dose-
dependent manner (Figure 5.14). At 4 μM concentrations, gefitinib limits VACV-WR plaque size to 
untreated VACV-ΔVGF levels. Interestingly this result was mirrored in analysis of VACV-ΔVGF 
plaques with or without gefitinib, which revealed that exogenous cellular EGF and non-VGF 
associated EGFR signalling also contributed to plaque size. This was observed as a further 
reduction in plaque size upon gefitinib treatment in a VACV-ΔVGF context (Figure 5.14).  
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Figure 5.14 – Treatment with gefitinib reduces VACV-WR plaque size to a size reminiscent of VACV-
ΔVGF plaques 
(A) Plaque assays were used to show that treatment with various concentrations of gefitinib reduced plaque size of 
VACV-WR plaques at 3 dpi in HaCaT cells. A slight reduction was also seen in VACV-ΔVGF-infected plaques; 
however, both conditions plateaued at 7 μM of gefitinib treatment. Plaques were stained with crystal violet for 
better visualisation and imaging. Scale bar = 10 mm. (B) Plaque size was then measured using ImageJ software. 
Thirty plaques were counted in each condition. n=3. Error bars refer to SEM.  
 
5.2.12 ECTV plaque phenotype suggests TGF-β-induced EMT does not occur in this context 
In the previous section, we studied a virus incapable of eliciting a VGF-mediated EGFR response, 
which aided in clarifying the relationship between EGF and TGF-β signalling during VACV 
infection. We next looked at a virus unable to induce TGF-β signalling, in the hope it could shed 
more light on VACV use of these interrelated host signalling pathways.  
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The mousepox virus strain, ECTV-Mos, used within this thesis is a highly virulent ECTV strain 
whose sequence has now been published [361, 533]. From plaque analysis, ECTV-Mos has a 
significantly different plaque phenotype to VACV when grown in HaCaT cells. Unlike VACV-WR 
plaques which spread outward and leave large areas of clearance behind, ECTV-Mos virus plaques 
were found to be greatly reduced in size. Infected cells clump in the centre of plaques and take 
almost double to time to develop to a similar size to VACV plaques (Figure 5.15). Both viruses 
used in this experiment carried a LifeAct-GFP tag (VACV-WR (LifeAct-GFP) and ECTV-Mos 
(LifeAct-GFP)), which facilitated visualisation of the actin cytoskeleton in infected cells. The 
cytoskeleton of uninfected cells was also visualised with Alexa Fluor® 568 Phalloidin stain. VACV-
WR infection caused cells to become elongated and dramatically rearrange their structure compared 
to the tightly compacted, uninfected cells around the peripheries of the images. This cytoskeletal 
restructuring, which is reminiscent of TGF-β-induced EMT, was not seen in the ECTV-Mos 
condition, where cells remained in close contact and fairly rounded in nature. As a result, it did not 
appear that ECTV-Mos was able to induce an EMT-like response within infected cells. This in 
combination with previous luciferase data, suggested against the notion of ECTV-induced TGF-β 
signalling (Figure 5.3). 
 
Figure 5.15 – Lack of Smad target expression could explain why ECTV does not spread as effectively 
as VACV 
VACV-WR (LifeAct-GFP) plaques are much larger than ECTV-Mos (LifeAct-GFP) plaques in HaCaT cells 
infected for 1.5 days (MOI of 0.01). Both viruses express a LifeAct-GFP construct which causes infected cells to 
appear green (VACV-WR (LifeAct-GFP), ECTV-Mos (LifeAct-GFP)). The actin cytoskeleton and DNA are also 
stained in red and blue respectively. Images were captured using the Olympus BX51 microscope system. Scale 
bar = 200 μm.  
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5.2.13 ECTV does not promote activity of Smad3 in both luciferase and immunofluorescence 
assays  
Phenotypically, it did not appear that ECTV was inducing an EMT-like response within infected 
cells. To confirm this, various analyses were performed.  
Previously, within the laboratory we demonstrated that ECTV was unable to induce a luciferase 
response in CAGA12-luc transfected cells (Figure 5.3) (C. McKenzie, PhD thesis, 2016). This was 
starkly contrasted by the response seen in VACV-WR-infected cells. Continuing along the 
workflow, we then employed the HaCaT CAGA12-GFP cell line to monitor Smad3 activity visually 
in VACV and ECTV-infected cells. Due to the fact that ECTV takes longer to replicate than VACV, 
we used later time points post-infection for our analyses (Figure 5.16). As the plaque phenotypes 
suggested, ECTV does not appear able to induce Smad3 activity between 8 and 20 hpi. This is seen 
as a lack of GFP production in these cells. Again, VACV was able to promote GFP expression in a 
strong and sustained manner. From these results, we concluded that Smad3 activity was not 
increased by the introduction of ECTV-Mos virus, even at delayed time-points compared to VACV 
infection. 
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Figure 5.16 – ECTV infection does not activate Smad3 signalling  
Immunofluorescence analysis using HaCaT-CAGA12-GFP expressing cells indicates ECTV-Mos infection (MOI 
of 5) does not increase Smad3 activity to the same extent as VACV-WR infection. This can be observed at all 
time points from 8-20 hpi. In this experiment, virus was stained in red using an antibody against viral protein, B5, 
CAGA12-GFP in green and DAPI in blue. Imaging was conducted using the Nikon Ti-E Eclipse microscope. Scale 
bar = 200 μm. 
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5.2.14 ECTV also does not induce expression of Smad targets  
As evidence indicated that ECTV does not promote activity of Smad3, we decided to further 
investigate downstream signalling processes. As described previously, this was conducted via qRT-
PCR analysis and immunofluorescence imaging of Smad target expression. In Figure 5.17, we can 
see that cells infected with the Moscow strain of ECTV display much lower transcript levels of c-
JUN and PAI-1, than TGF-β-treated and VACV-infected cells. However, this was not attributed to a 
flaw in viral replication as we see significant levels of viral D12 in both the VACV and ECTV-
infected cells, suggesting this is a feature of ECTV infection rather than due to low viral titres. 
Again, immunofluorescence data aligned with the qRT-PCR results, where protein targets Snail, 
Snail2 and PAI-1 could not readily be detected in ECTV-infected cells (Figure 5.17). This is in 
stark contrast to the levels of each of these observed following VACV infection. Take note that for 
these experiments, viral infection was visualised in green, whilst Smad target proteins can be seen 
in red. Taken together, it appears that Smad signalling is not switched on by ECTV virus, unlike the 
evident activation we see following VACV infection. 
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Figure 5.17 – Smad targets are not upregulated by ECTV infection at both the transcript and protein 
levels 
(A) qRT-PCR analysis in HeLa cells revealed that ECTV does not promote transcription of Smad target genes c-
JUN and PAI-1 to the same extent as TGF-β- and VACV-WR. Note that unlike TGF-β-treated and VACV-WR-
infected conditions where RNA was extracted at 10 hours post-treatment, ECTV-Mos-infection was carried out 
for 18 hours prior to lysis. n=3. Error bars refer to SEM. Student’s unpaired t-test. (B) Comparison between 
HaCaT cells infected with VACV-WR (LifeAct-GFP) (MOI of 10) for 10 hours and ECTV-Mos (LifeAct-GFP) 
(MOI of 10) for 18 hours indicate lack of Smad target expression in the latter case. Note both viruses carried a 
LifeAct-GFP construct for visualisation of infected cells. From left to right, Smad targets, Snail, Snail2 and PAI-1 
appeared in red, infected cells in green and DAPI in blue. The Olympus BX51 microscope was used for imaging 
purposes. Scale bar = 50 μm.  
 
5.2.15 Smad4 is not required for ECTV plaque development 
Taking a look at ECTV plaques left to develop for 5 days, their phenotype appears different to those 
observed following VACV infection. Firstly, cells within an ECTV plaque maintain a rounded, 
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boxed epithelial-like shape. They also do not appear to migrate as far and leave areas of clearance 
within plaques. We wanted to determine whether Smad4 plays a role in ECTV plaque spread, in a 
similar way that it appears to do so for VACV plaques. Figure 5.18 illustrates plaque phenotype and 
size appear to be unaffected by Tet treatment and knockdown of Smad4, again confirming a lack of 
dependence on this pathway during ECTV infection.  
 
Figure 5.18 – Level of Smad4 expression does not affect ECTV plaque size 
Immunofluorescence analysis on HaCaT TRS4 cells pre-treated with Tet (2 μg/mL) then infected with ECTV-
Mos (MOI of 0.1) indicates Smad4 knockdown does not affect plaque phenotype (A) or size (B) at 5 days post-
infection. The ECTV-Mos (LifeAct-GFP) virus used stained the actin cytoskeleton in infected cells green, the 
actin cytoskeleton in all cells red and DAPI in blue. Images were captured on the Olympus BX51 microscope. 
Scale bar = 100 μm. Twenty plaques were measured in each condition. Error bars refer to SEM.   
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5.3 DISCUSSION 
5.3.1 VACV does not use the TGF-β ligand to activate signalling 
Many viruses subvert the TGF-β signalling pathway to promote survival and spread of infection. As 
described earlier, TGF-β mediates an EMT response, causing cells to migrate [96]. These 
wandering cells act as both protectors and distributors for their viral cargo, facilitating 
dissemination of infection throughout the body. Various strategies have been employed by these 
pathogens to stimulate the TGF-β signalling pathway. However, by far the most common approach 
is transactivation of the TGFb promoter (Figure 1.13). This is seen in the context of HBV, HCMV, 
HIV, HPV, EBV, SARS-CoV, ASFV, HCV, HTLV-1, RSV and rotavirus infections [260-272]. 
Others, such as ebolavirus and subviral reovirus stimulate release of TGF-β ligand into the 
extracellular space; however, it is not known at which level they influence production of this 
cytokine [79, 279]. As such, they may also enhance transactivation of TGFb. VACV; however, does 
not seem to fit into this category. From both current and previous results, VACV infection did not 
correlate with increased levels of TGFb transcript as detected by qRT-PCR (Figure 5.4), or 
secretion of TGF-β into the supernatant as detected by luciferase assay (C. McKenzie, PhD thesis, 
2016). Given the nature of this second assay, it also suggested that VACV-conditioned supernatant 
possessed no secreted factor capable of significantly stimulating Smad3 activity when applied to 
cells. This is unlike many of the viruses known to influence this pathway. Even those viruses with 
the ability to interact directly with Smad proteins, such as reovirus, HBV and SARS-CoV, typically 
concurrently enhance the production of TGF-β [88, 258, 261, 262, 278, 279]. However, it may be 
advantageous, as in many of these studies, to use an ELISA assay to measure levels of TGF-β 
within the supernatant. This direct and sensitive assay could provide us with clear information on 
not only the presence of TGF-β, but also the proportion of latent and active ligand being secreted.  
In this research, it must not be overlooked that TGF-β ligand is originally produced in a pre- and 
pro-form (Figure 1.10). As such, the circumstances during influenza virus infections should also be 
considered. Influenza is unique in that it is the only virus known to directly activate the TGF-β 
protein by cleavage of the latent peptide to its functional form [254, 255]. It does so through the 
actions of viral neuraminidase envelope protein. It is possible that VACV also promotes the release 
and cleavage of latent TGF-β to its active form. However, this result may be unlikely given the 
apparent lack of involvement of the TGFβR complex in VACV-induced TGF-β signalling. 
In our research, we demonstrated that inhibition of TGFβRI receptor phosphorylation, with SB-
431542, or total loss of TGFβRII protein, as in LNCaP cells, had no impact on VACV-induced 
Smad target gene transcription (Figures 5.5 and 5.6). In both these contexts, cells were unresponsive 
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to TGF-β treatment, yet triggered by VACV introduction, strengthening the notion that VACV does 
not require TGF-β or the TGFβR complex to activate this pathway. Our results also argue against 
the possibility of a viral homolog of TGF-β or functional mimic. If this was the case, we would still 
expect the TGFβR complex to play a role in TGF-β signalling induction during VACV infection. 
These data are particularly interesting as, to our knowledge, no other microbe-induced receptor-
independent TGF-β signalling has been described previously. Furthermore, manipulation of the 
TGFβR complex usually interferes with viral activation of this pathway. For example, treatment of 
HCV-infected cells with TGFβRI inhibitor, SB-431542 prevented the onset of EMT and 
downregulation of epithelial markers associated with TGF-β signalling [495, 539]. Similarly, 
ebolavirus replication and in vivo infection were attenuated in the presence of SB-431542, 
presumably due to loss of TGF-β signalling [79]. In fact, this drug has even been proposed as an 
antiviral treatment in the case of RSV infections [540]. However, VACV proves to be an exception 
to this trend. 
Given that it is clear that VACV infection increases p-Smad2 and p-Smad3 levels and the fact that 
the TGFβR complex typically phosphorylates these proteins, these results are perplexing (Figure 
3.3). One potentially relevant paper found that when TGFβRII was deleted in the epithelium of 
mice, downstream signalling, including activated Smad2 levels, increased [102]. The authors 
suggested that this increase may have been an artefact from the surrounding tissues. If not, this 
could be a similar phenomenon to that observed during VACV infection, where p-Smad2 and p-
Smad3 levels increase in a seemingly receptor-independent manner.  
 
5.3.2 C-terminal phosphorylation of R-Smads proved to be atypical during VACV infection 
A number of viral infections are correlated to changes in levels of phosphorylated R-Smad proteins 
[79, 278, 541]. As described earlier, VACV also belongs to this group (Figure 3.3). However, in 
this context both TGFβR complex proteins seem to be dispensable for this process. Given that 
TGFβRI appears unnecessary, we investigated the other kinase known to use R-Smads as substrates 
for C-terminal phosphorylation, Mps1.  
Mps1 (or TTK) is heavily involved in the regulation of cell division and mitosis, due to its 
associations with the spindle assembly checkpoint and its competitive binding to microtubules [500, 
501, 542]. More recently, Mps1 was described, as a kinase capable of activating Smad2 and Smad3 
proteins, in a TGFβRI-independent manner [499]. This process was able to be induced by 
nocodazole treatment. Previous groups had also illustrated the capacity of nocodazole to stimulate 
C-terminal phosphorylation of R-Smads, presumably due to its microtubule destabilising abilities 
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[179, 499]. In the absence of a TGF-β signal, Smad proteins are sequestered to microtubules, until 
ligand stimulation where they dissociate via the action of connexion protein, Cx43 [543]. This is 
due to competitive binding of Cx43 and Smads to the same region of β-tubulin within microtubules. 
This freeing of Smad proteins allows them to become phosphorylated and activate downstream 
signalling. In fact, Smad2 phosphorylation and nuclear translocation are reduced upon depletion of 
Cx43 [543]. These microtubule interactions could explain how Mps1 and Smad proteins end up in 
close proximity to one another upon microtubule destabilisation, facilitating increased Mps1-
mediated R-Smad phosphorylation.  
During our experiments we did not find evidence to support a role for Mps1 in C-terminal 
phosphorylation of R-Smads during VACV infection (Figure 5.7). However, it is possible that our 
method of Mps1 inhibition, using Mps1-IN-2 (15 nM) at the recommended concentration, was not 
suitable for these experiments. These results would benefit from having a dose-dependent 
component, or if more time was available, making use of siRNA technologies to deplete Mps1 
levels. Despite these results, Mps1 may indeed play a role in VACV replication. Preliminary 
evidence indicated that VACV plaque size was decreased in the presence of Mps1-IN-2 (Appendix 
8.4). In fact, Mps1 has already been linked to poxvirus replication, where siRNA knockdown of 
Mps1 was found to potently diminish myxoma virus replication [544]. This is thought to be related 
to dysregulation of the cell cycle, which may also be the case during VACV infection. Regardless, 
these results highlight the potential of Mps1 inhibition as a possible antiviral tool, and influencer of 
TGF-β signalling. 
One other factor to consider in this research is the re-organisation of the microtubule network 
during VACV infection. If nocodazole-mediated destabilisation of microtubules increases Smad2 
and Smad3 activation profiles, it is possible a similar occurrence happens after VACV treatment. 
Previous groups have shown a mass rearrangement of microtubules does occur following VACV 
infection [545]. This is thought to be via viral F11-mediated inhibition of host RhoA signalling, 
which enhances microtubule stabilisation but in the context of VACV infection is unable to do so 
[325]. As such, Smad proteins are presumably released from the unstable microtubules in this 
context, which could explain how VACV accesses these proteins. However, ECTV also uses F11 
and microtubule-based transport, presumably destabilising the existing network in order to generate 
its own pathways for shuttling and does not enhance phosphorylation of R-Smads or downstream 
pathway activity, making this scenario less likely to be responsible for VACV-induced TGF-β 
signalling [546] (Figure 5.3).  
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From our data, it does not appear that TGFβRI or Mps1 are essential to VACV-induced TGF-β 
signalling. These results are particularly novel in relation to Smad2 and Smad3 activation, which is 
thought to be entirely dependent on these two cellular proteins.  
 
5.3.3 EGF and TGF-β-mediated signalling influence R-Smads and viral spread 
Despite requiring phosphorylation at the SSXS motif for activity, Smad proteins possess a number 
of other kinase-interacting sites which influence their stability and interactions. As these 
phosphorylation events are reversible, distinct patterns of phosphorylation are associated with 
specific Smad activation and inhibition profiles. Furthermore, it is at these sites that other pathways 
exert influence on TGF-β signalling. For instance, Wnt signalling can promote Smad4 activity by 
inhibiting GSK3, preventing the addition of inhibitory phosphate groups at the linker site and 
blocking ubiquitin-mediated degradation [162]. Due to this feature, MH1 domain and linker region 
phosphorylation are critical when studying R-Smad activities. We examined linker phosphorylation 
by immunoblot analysis. This not only addressed Smad protein activation but provided insight on 
cross-talk between TGF-β and the EGFR signalling pathways capable of acting on this region. From 
our results, Smad2 phosphorylation at the Ser245, Ser250 and Ser255 sites was dramatically 
increased upon VACV infection to a similar extent as EGF-treated cell lysates (Figure 5.8). 
Furthermore, it was dependent on EGFR signalling and VGF as inhibition or removal of these 
diminished linker region phosphorylation. Curiously, while we have not examined C-terminal 
phosphorylation in the context of VACV-ΔVGF, it is known that this event typically precedes 
linker phosphorylation. For instance, in cases where the type I TGF-β receptor was lacking, both C-
terminal and linker phosphorylation were absent until the TGFβRI was re-introduced [497]. This 
suggests that investigation of C-terminal phosphorylation during VACV-ΔVGF infection could be 
important in elucidating the mechanism of R-Smad activation during VACV infection.  
Actions on Smad proteins are not the only point where TGF-β and EGFR signalling pathways 
converge. In fact, TGF-β and EGF both share the ability to stimulate production of PAI-1 or 
SERPINE1 (Figure 5.19). As seen in the generated STRING network, a select group of proteins are 
known to directly interact with PAI-1 [547]. For example, as expected in the canonical PAI-1 
pathway members of the plasminogen activation system, such as tissue plasminogen activator 
(PLAT), urokinase-type plasminogen activator (PLAU) and its receptor (PLAUR), as well as 
plasminogen (PLG) itself directly interact with and are inhibited by PAI-1 [548]. Extracellular 
matrix and serum protein vitronectin (VTN) also bind to PAI-1, to mediate clot formation, 
fibrinolysis and cell migration [549]. Finally, serum albumin (ALB) and VEGF can stimulate PAI-1 
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production in the same way as TGF-β and Smad3 [550]. EGF also appears to be a PAI-1 
transactivator, using its PKC pathway in order to promote PAI-1 transcription [430]. Perhaps the 
convergence of these two pathways at the PAI-1 level could explain how VGF is able to promote 
VACV-cell migration. 
 
Figure 5.19 – STRING Network analyses confirm both TGF-β and EGF directly act on PAI-1  
PAI-1 or SERPINE1 is able to interact directly with a variety of proteins. STRING Network analysis generated 
the plot above depicting first-tier interactors with PAI-1, as determined experimentally or though data mining 
[547]. Unsurprisingly, this list includes members of the plasminogen activation system, such as plasminogen 
activator of the tissue (PLAT), urokinase plasminogen activator (PLAU), plasminogen activator receptor (PLAU) 
as well as plasminogen itself (PLG). Furthermore, as PAI-1 is a known target of TGF-β and Smad3, these are 
listed also. Other cellular interactors include vitronectin (VTN), albumin (ALB) and vascular endothelial growth 
factor A (VEGFA). Interestingly, EGF is considered a direct interactor with PAI-1, due to its transactivation of the 
SERPINE1 gene. 
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In the previous chapters, we demonstrated that TGF-β signalling contributed to efficient VACV 
plaque expansion. In this chapter, we examined the contributions of both the TGF-β and EGF/VGF-
mediated signalling pathways to viral spread. Interestingly, it was found that deletion of VGF 
reduced both the rate of viral replication and the size of VACV plaques dramatically, the latter of 
which could only be partially restored through the addition of exogenous EGF (Figure 5.11 and 
5.12). This suggests VGF may be acting in a manner beyond EGF alone, which is supported by 
observation that addition of EGF to VACV-WR plaques decreases plaque size (Figure 5.12). This 
result has been observed previously, with a group in the mid-1980s suggesting that EGF residency 
at the EGFR inhibited VACV infection in a dose-dependent manner [532]. The authors suggested 
this is due to competition for binding between EGF and VGF for EGFR occupancy. A further 
observation was that VACV-ΔVGF plaques were sensitive to TGF-β, displaying a marked increase 
in plaque size approaching that of VACV-WR (Figure 5.12). This implies that a loss of VGF does 
not impair the ability of VACV to respond to exogenous TGF-β and suggests these two signalling 
pathways are working independently to boost viral spread. This is further supported by the 
observation that EGFR inhibitor, gefitinib, severely decreases plaque size, in a dose-dependent 
manner (Figure 5.14). The antiviral nature of this drug has been described previously, with data 
showing that high concentrations of gefitinib render VACV proteins almost undetectable by 
immunoblot, suggesting viral replication is inhibited in this context [511]. However, these results 
could also be explained by increased cytotoxicity upon gefitinib treatment, which should be 
investigated further [365]. Curiously, the pattern of EGFR expression around VACV plaques is 
very reminiscent of the GFP expression illustrated earlier using the HaCaT CAGA12-GFP cells 
(Figure 3.11) [511]. We observed a bright ring of fluorescence adjacent to the plaque front, 
corresponding to Smad3 activity and TGF-β signalling. This same expression pattern was also seen 
when probing for PAI-1 (Figure 4.8). Given that TGF-β is known to influence EGFR 
transactivation, it is possible that increased TGF-β signalling in these plaque-adjacent cells leads to 
EGFR production [551-553]. This in turn heightens sensitivity of cells to VGF, which can then 
enhance linker phosphorylation of R-Smad proteins, promote Smad3 activity and result in 
production of target gene expression, such as PAI-1. This cycle may explain how VACV uses TGF-
β and VGF signalling to create a positive regulation loop and promote an EMT-like response.  
 
5.3.4 Related viruses could reveal how VACV is able to activate the TGF-β pathway 
One possible system to identify genes in VACV responsible for promoting TGF-β signalling is to 
compare the VACV genome to a closely related virus that is unable to perform this task. Previous 
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evidence gathered in our laboratory suggested ECTV, the causative agent of mousepox, may be 
such a candidate. Early luciferase assays displayed no significant differences between strains of 
VACV and the positive control, TGF-β, in their ability to activate Smad3. However, ECTV-infected 
cells and uninfected cells were distinguished from this group by their lack of Smad3 activation 
(Figure 5.3) (C. McKenzie, PhD thesis, 2016). ECTV infection also does not display the EMT-like 
phenotype associated with VACV-infected cells, suggesting this virus does not make use of TGF-β 
signalling to alter cell structure and behaviour (Figure 5.15). This theory was tested by examining 
GFP expression in HaCaT CAGA12-GFP cells and Smad target expression via qRT-PCR and 
immunofluorescence assays, which were unchanged despite the introduction of ECTV (Figures 5.16 
and 5.17). Furthermore, loss of Smad4 did not affect ECTV plaque size (Figure 5.18). Note that all 
experiments accounted for the decreased replication rate of ECTV, yet still no TGF-β pathway 
activation was seen over time.  
ECTV has proven a powerful model for poxvirus infection, causing a symptomatic disease in mice 
that is reminiscent of VARV infection in humans [360]. Comparing members of the Orthopoxvirus 
genus it is clear that ECTV is one of the most divergent genera, being the first to branch off from 
the rest of the family (Figure 1.14). As a result, the genome homology with other orthopoxviruses is 
lower than between VACV, MPXV, VARV and CPXV, for example [290]. Despite this, many 
genes within ECTV display high homology to those found in VACV and CPXV [358]. This is 
especially true for those involved in subverting host antiviral responses and defence mechanisms. 
Whilst there was not enough time within the scope of this thesis to more directly investigate 
genomic differences between ECTV and VACV, our preliminary data has provided some insight 
into the mechanisms of TGF-β induction in the latter virus. For instance, we know Smad proteins 
are phosphorylated at the C-terminal during VACV infection in a TGFβRI and Mps1-independent 
fashion. This narrowed our search to kinases capable of carrying out this action. However, VACV 
and ECTV share their serine/threonine kinases, implicating a cellular kinase in Smad2 and Smad3 
C-terminal phosphorylation during VACV infection [356, 533]. However, a viral kinase should not 
be entirely excluded, as binding partners, truncations, mutations or inhibitors may also be 
contributing to the differences between the VACV and ECTV infection-associated p-Smad2 and 
Smad3 phenotype. 
 
5.3.5 Future directions and significance  
The mechanism by which VACV activates the TGF-β signalling pathway is yet to be elucidated. It 
is apparent that the process is receptor-independent and does not correlate with secretion of the 
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TGF-β ligand. However, if Smad proteins are being C-terminally phosphorylated in a receptor-
independent manner is still unclear. One way to more directly investigate this is to study p-Smad 
levels in infected cells treated with SB-431542, removing the contribution of TGFβRI and 
examining whether VACV is able to maintain SSXS motif phosphorylation. This may also aid in 
the search of our mystery kinase, hinting at a viral or cellular origin. Another possible avenue to 
consider is continued characterisation of the LNCaP cell line. Determining whether Smad proteins 
are phosphorylated in infected LNCaP cells may provide clues on the importance of R-Smad 
activation in the context of VACV infection. Perhaps C-terminal phosphorylation is dispensable in 
this case, and other factors, such as protein localisation or degradation, become more pertinent. It 
would also be beneficial to entirely eliminate Mps1 as a possible suspect for C-terminal 
phosphorylation.  
Once the mystery of C-terminal phosphorylation is dealt with, we can further study the 
interrelationship between VGF and TGF-β in the context of VACV infection. We theorised that the 
TGF-β and EGFR pathways work in tandem to promote expression of target genes and promote the 
onset of EMT. However, the reliance of VACV on cellular EGF, viral VGF or both together could 
be clarified further. Through transcriptomic analysis (discussed in the follow chapters), we may 
investigate targets of the EGF pathway, specifically those regulated by VGF by comparison 
between VACV-WR and VACV-ΔVGF conditions to identify any novel genes of interest. PAI-1 
could also be examined in greater detail given its allegiance to both signalling pathways. Depletion 
using siRNA and gene editing technologies or inhibition with chemical treatments would be 
advantageous to understanding the contribution of PAI-1 to VACV-induced cell migration, and its 
dependence on both TGF-β and EGFR-mediated signalling pathways.  
Another factor to consider is that VGF does not act alone to promote EGFR-related signalling. In 
fact, previous groups have suggested viral protein, O1 may be another VACV protein required for 
full VGF functionality. For example, a VACV strain not used for the majority of our research, CVA, 
was found to require the inputs of both O1 and VGF to activate ERK signalling [554]. It is possible 
that O1 could be of interest in the context of TGF-β and EGF pathway interactions during VACV-
WR too. In fact, ECTV possess a truncated O1 protein [533]. This may be a contributing factor in 
the inability of ECTV to promote Smad activity, given the cross-talk between the two pathways of 
interest. As such, O1 levels and functionality in the various viral contexts should be examined. 
Given that ECTV is unable to activate TGF-β signalling, it proved fairly useful in providing clues 
on how VACV is able to produce the opposite result. However, ECTV and VACV may be too 
different to definitively identify a viral gene responsible for Smad signalling activation. Another 
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possible route for investigation is the use of the MVA VACV strain. MVA was previously shown in 
our lab to be unable to activate this pathway, as determined by luciferase assays (C. McKenzie, PhD 
thesis, 2016). VACV-WR and MVA share a large, central homologous region, but differ at the left 
and right arms due to six major deletions present in MVA [299]. Given their strong similarities, it is 
possible that rescuing genes or the deleted regions of MVA could restore the TGF-β activation and 
EMT phenotype of infected cells, providing insight on the region of VACV-WR required for this 
induction.  
The experiments described within this chapter, as well as the possible future work outlined above 
all aim to answer the question of how VACV is able to activate the TGF-β signalling pathway. This 
mechanism is particularly relevant to the field of oncolytic virus research. As VACV is a known 
and potent oncolytic agent, honing its efficacy, safety and specificity is of the utmost importance in 
bettering its therapeutic potential. One technique currently used to advance oncolytic virus research 
is to identify genes commonly upregulated in cancer tissues that the virus also relies on for an 
aspect of its survival or spread. For example, VACV requires thymidine kinase (TK) for efficient 
replication [14, 40, 528, 555]. Many tumours upregulate cellular TK to aid in perpetuating cell 
replication [556, 557]. As such, a VACV virus with a deleted TK is more selective to replicating in 
cells with inherently high levels of this protein, such as tumour tissues. This same principle can be 
applied to the activation of TGF-β signalling by this virus. As we have shown in this and previous 
chapters, Smad signalling is required for efficient VACV spread and replication. Furthermore, 
countless tumours are typified by their rampant TGF-β signalling [521, 558, 559]. Therefore, 
understanding how VACV is able to activate this pathway gives researchers a target for 
manipulation and develops the selectivity of the virus, making it more amenable to replication 
within TGF-β-rich cell types.  
 
5.3.6 Conclusions 
Within this chapter, we aimed to clarify how VACV is able to induce and maintain activity of the 
TGF-β signalling pathway within infected cells. The original hypothesis, that VACV induces 
transcription or secretion of TGF-β, was not supported using supernatant studies (conducted 
previously) and qRT-PCR analysis. Furthermore, the TGFβR complex did not appear to be 
important for VACV induction of this pathway, as both the use of a TGFβRI inhibitor and cells 
lacking TGFβRII, still displayed downstream Smad pathway activation. Once these scenarios had 
been excluded, we needed to determine how R-Smad proteins become phosphorylated and activated 
in the context of infection. One potential kinase known to act on the same C-terminal site of Smad2 
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and Smad3 is Mps1. It did not appear from our results that Mps1 is responsible for activating these 
proteins in the context of VACV infection. Looking at other phosphorylation sites within R-Smad 
proteins, it became evident that VACV infection stimulated linker phosphorylation of Smad2 in a 
VGF and EGFR-dependent manner. In the absence of VACV, this process relied on the presence of 
TGF-β; however, upon infection, the ligand appeared more dispensable. Viral protein, VGF, also 
appeared to affect viral replication, cell migration and plaque spread, unless supplemented with 
exogenous EGF and TGF-β. We theorised that EGF or VGF and TGF-β signalling pathways cross-
talk during VACV infection to promote plaque spread and EMT. This hypothesis was supported by 
the fact that virus lacking VGF, VACV-ΔVGF did not effectively activate TGF-β signalling. 
Interestingly, EGF alone was not enough to compensate for the loss of VGF, suggesting they play 
slightly differing roles in VACV spread. In tandem with other mechanism studies, we examined the 
ability of related poxvirus, ECTV-Mos, to stimulate TGF-β signalling, and found it incapable of 
doing so. It also did not appear to rely on members of the Smad signalling pathway, such as Smad4, 
for efficient spread. Perhaps further investigation comparing the differences between ECTV and 
VACV could provide clues into how the latter activates the TGF-β signalling pathway.  
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CHAPTER 6: TRANSCRIPTOMIC 
ANALYSIS OF VACV INFECTION 
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6.1 INTRODUCTION 
6.1.1 Transcriptomic approaches for studying viral infection 
Cell structure, behaviour and function are all dynamic features within cells. Their plasticity is 
conferred by constantly adjusting the expression of specific effector proteins. This balancing act 
allows cells to select desirable phenotypes by adopting the corresponding gene expression profile. 
One method used for regulating expression of effectors is transcriptional regulation, where levels of 
mRNAs are adjusted to exert control over various aspects of the cell. As a result, researchers can 
look at the transcription of genes in order to gain insights into the inner workings of the cell. Over 
the last 20 or so years, many techniques have been developed to study mRNA expression. However, 
in recent years with the development of more global approaches, our experimental reach now 
outspans that of early techniques. 
One of the earliest methods developed for assaying transcript expression was qRT-PCR analysis 
[560]. However, this low-throughput method is slowly being replaced by more all-encompassing 
approaches, including microarrays and next generation sequencing techniques, such as RNAseq. 
Various features of these RNA sequencing technologies can be seen in Table 6.1 (Adapted from 
[369, 561]). In almost all features mentioned, RNAseq appears to be the most desirable option.  
The broad applicability of RNAseq technologies, have lended them to being used in analysis of a 
number of disease-states, including viral-host interactions. For instance, groups studying Varicella-
zoster virus (VZV) used RNAseq to demonstrate that classical dermal symptoms associated with 
chickenpox are due to the increased expression of genes which cause skin blistering and 
keratinocyte distortion during VZV infection [562]. Others have used this technique to profile the 
host response to different Ebola virus variants and assist in identifying host genes which drive 
severe haemorrhagic disease symptoms [563]. Numerous groups have also utilised RNAseq to 
study the effects of VACV itself on the host cell transcriptome [564, 565]. For instance, VACV is 
known to inhibit the host interferon response, through the use of interferon binding proteins, such as 
B18R. However, recently the global effect of this protein on host cell transcription was 
characterised using RNAseq technologies in combination with a ΔB18R VACV [566].This method 
allowed the identification of further interferon-associated genes manipulated by VACV. In this 
thesis chapter, we hoped that the use of RNAseq could shed some light on the mechanism of VACV 
manipulation of TGF-β signalling and its dependence on the VGF protein. 
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Table 6.1 – Comparison of RNA analytic and sequence-based technologies 
Characteristics qRT-PCR Microarray RNAseq 
Developed and used  Early 1990s 1990s 2000s 
Principle 
Quantitative 
PCR  
Hybridisation to 
probes 
High-throughput 
sequencing 
Resolution for identification N/A Several-100bp Single base 
Cost  Low Low-High High 
Throughput Low High High 
Coverage 
Limited to 
primers used 
Limited to 
probes used 
Genome wide 
Comparison to genomic sequence No Required In some cases 
Background noise 
Low 
(depending on 
primers) 
High Low 
Dynamic range for quantifying gene 
expression 
> 107-fold 
A few 
hundredfold 
>8,000-fold 
Ability to detect novel transcripts No No Yes 
Ability to distinguish isoforms Yes Limited Yes 
Ability to distinguish allelic 
expression 
Limited Limited Yes 
SNP detection Limited No Yes 
Required RNA input Low High Low 
 
6.1.2 Different conditions to be explored and their potential insights 
Transcriptomic analysis can often reveal novel clues and pathways for investigation to researchers. 
We proposed that conducting analysis of the transcriptome upon different treatments and during 
VACV infection could inform us on possible mechanisms associated with TGF-β and EGFR 
signalling within these contexts. It would also provide us with a more global picture of the changing 
landscapes of host transcription upon infection. For instance, numerous groups have used RNAseq 
to study patterns of TGF-β target gene expression [567, 568]. This research is conducted in the hope 
that the transcriptomic profile will assist in our understanding of the modulation of conflicting 
outcomes associated with TGF-β signalling. 
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The specific role of Smad4 has also been investigated a number of times [208, 364, 569]. Given one 
of the major functions of Smad4 as a transcription factor is modulating mRNA synthesis in concert 
with R-Smad proteins, various groups have studied its contribution to an array of cellular processes. 
These include the induction of apoptosis, cell cycle arrest, altered cell migration and tumour 
suppression [434, 465, 470, 569, 570]. Additionally, the relationship between Smad4 and gene 
transcription was found to be more complex than originally thought. For instance, R-Smad proteins 
have the capacity to act independently of Smad4 to influence transcription, and others have even 
proposed that Smad4, in tandem with unknown factors, can function independently of R-Smad 
proteins to alter gene expression [364, 569]. As such, both Smad4-dependent and Smad4-
independent transcripts can contribute to various cellular phenotypes. Given these considerations, 
we aimed to determine how Smad4 influences the outcomes of VACV infection, in relation to 
cellular transcript expression. As before, the HaCaT TRS4 cell model proved to be a useful tool in 
this scenario [364].  
VGF, on the other hand, is less well-studied in the context of transcriptional influence. EGF, the 
cellular homolog of VGF, is a known influencer of transcription, as it stimulates the EGFR receptor 
which can act on numerous intermediates, many of which are transcription factors [571]. In fact, the 
EGFR itself can also influence transcription of genes upon translocation to the nucleus, a feature 
thought to drive cancer progression [572]. Together, EGF and its surface receptor modulate an array 
of pro-EMT and tumorigenic events, such as cell migration, invasion and proliferation [573, 574]. 
They can also promote viral entry and viral infection [575-577]. However, the direct influence of 
the vaccinia equivalent, VGF, on cellular host transcription is yet to be investigated. As such in this 
research, we aimed to determine if VGF has a similar effect on synthesis of EGF and EGFR-
associated genes, as well as TGF-β and Smad gene targets.  
Due to the availability of reagents and viruses, eight conditions were chosen to be investigated 
within this thesis. These addressed the contributions of TGF-β-treatment, VACV infection, VGF 
and the role of Smad4 in each of these situations (Table 6.2). A number of queries were hoped to be 
answered, including how similar or dissimilar are TGF-β and VACV in terms of Smad target gene 
transcription, how dependent transcripts expression is on Smad4 in different treatment and viral 
contexts and how potent are the transcriptional responses in each condition. We also wanted to 
identify transcripts lacking upon VGF deletion, to provide clues on how VGF may be contributing 
to VACV-induced TGF-β activation.  
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Table 6.2 - RNAseq samples analysed within this thesis chapter 
Uninduced (- Tet) Smad4 knockdown (+ Tet) 
Uninfected Uninfected + Tet 
TGF-β-treated TGF-β-treated + Tet 
VACV-WR-infected VACV-WR-infected + Tet 
VACV-ΔVGF-infected VACV-ΔVGF-infected + Tet 
 
6.1.3 Chapter aims 
In this chapter we aimed to find novel targets for investigation in the transcriptional profiles of 
uninfected, TGF-β-treated, VACV-WR and VACV-ΔVGF-infected HaCaT cells. These were 
analysed by RNAseq in the hope of better understanding how the TGF-β signalling pathway is 
activated by VACV, and to examine in more detail whether there are different transcriptional 
profiles observed following TGF-β treatment and VACV infection.  
The aims and questions addressed in this chapter are as follows: 
• Can transcription of TGF-β/Smad target genes be detected at a global scale following 
VACV infection? 
• Do results obtained from RNAseq align with those obtained previously during qRT-PCR 
analysis? 
• What differences can be observed in Smad target gene expression between TGF-β-treated 
and VACV-WR-infected mRNAs? 
• Are gene targets associated with driving EMT abundant following VACV-WR infection? 
• Is VACV-ΔVGF virus able to induce transcription of the same targets as VACV-WR? 
• Can any possible clues into mechanism of TGF-β signalling activation be gleaned from 
RNAseq analysis? 
  
 TRANSCRIPTOMIC ANALYSIS OF VACV INFECTION 
University of Sydney 200 2018 
6.2 RESULTS 
6.2.1 Experimental design and stringent quality control measures 
A number of factors were considered in the design of our RNAseq experiment. These included 
reproducibility and number of replicates, feasibility in quantity of conditions for examination and 
overall cost of library generation and sequencing. As described within the introduction of this 
chapter, 8 different conditions were chosen to investigate the role of TGF-β, VACV, VGF and 
Smad4. Each RNA isolation and sample collection steps were carried out 3 times, to give us 
biological triplicates and a total of 24 samples for analysis.  
Once RNA was isolated and purified, samples were put through numerous quality control measures 
prior to being approved for sequencing. These were both conducted within our lab, and by the 
sequencing organisation, the Ramaciotti Centre for Genomics (UNSW, Australia) (Figure 6.1, 
Appendix 8.5). Firstly, to determine whether the RNA acquired from RNA extraction was suitable 
for sequencing analysis, we assayed the quality and quantity of the obtained RNA, the efficiency of 
Smad4 knockdown and confirmed the incidence of infection in VACV-WR-infected conditions.  
To evaluate RNA yield and quality, sample absorbance ratios were checked using a Nanodrop 
spectrophotometer instrument. The results for this analysis can be seen in Table 6.3. As desired, the 
yields were above 3 μg and the A260:280 ratios all fell in an acceptable range of 1.97-2.15. The 
RNA quality was also confirmed via FA gel electrophoresis. This is designed to separate RNA into 
three distinct bands corresponding to the 5S, 18S and 28S fractions, whilst any contaminating DNA 
is observed as a smear at the bottom of the gel. From the results, we can see distinct RNA bands, 
with minimal smearing, which serve as an indication of good quality RNA (Figure 6.1). Finally, 
qRT-PCR analysis, in conjunction with primer testing and the generation of melt curve profiles 
indicated that the samples were of a sufficient standard to be used for RNAseq analysis (Figure 6.1) 
(Appendix 8.5.1).  
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Table 6.3 – RNA quality and yield as determined by Nanodrop analysis of HaCaT TRS4 cell RNA 
extractions 
Sample name Yield (ng/μL) A260:280 A260:230 
Uninfected 
- Tet 
A 
B 
C 
357.9 
467.3 
474.1 
2.07 
2.06 
2.05 
1.98 
2.07 
1.94 
+ Tet 
A 
B 
C 
173.9 
143.1 
135.7 
2.02 
2.01 
2.07 
1.62 
1.59 
1.61 
TGF-β-treated 
- Tet 
A 
B 
C 
310.0 
533.3 
555.2 
2.07 
2.08 
2.07 
1.73 
1.85 
1.83 
+ Tet 
A 
B 
C 
128.7 
114.0 
105.2 
2.03 
2.03 
20.4 
1.85 
2.12 
1.91 
VACV-WR-infected 
- Tet 
A 
B 
C 
326.8 
403.9 
428.2 
2.07 
2.07 
2.05 
2.09 
2.01 
2.1 
+ Tet 
A 
B 
C 
100.2 
118.1 
123.1 
2.04 
2.11 
2.03 
1.65 
1.65 
1.64 
ΔVGF-infected 
- Tet 
A 
B 
C 
828.4 
1260.7 
1242.6 
2.06 
2.07 
2.06 
1.87 
1.87 
1.89 
+ Tet 
A 
B 
C 
825.0 
1387.5 
1096.9 
2.08 
2.08 
2.07 
1.82 
1.88 
1.82 
 
To assay the efficacy of Smad4 depletion in each of our conditions, we utilised qRT-PCR and 
immunofluorescence assays to evaluate expression of Smad4-dependent target, PAI-1. It was 
assumed that a reduction in PAI-1 levels could be directly correlated to effective knockdown of 
Smad4. Our results can be seen in Figure 6.1B and C. As with previously, both TGF-β treatment 
and WR-infection boosted the levels of PAI-1, but this appeared to be dependent on a lack of Tet 
induction. Upon Smad4 depletion and Tet treatment we see a loss in expression of this target in all 
conditions. 
The same assays used to test for Smad4 depletion were also used to monitor the success of infection. 
Viral control genes, D12 and A17, as well as viral protein B5 in the immunofluorescence assay were 
used to determine if cells were being infected by VACV-WR and if the proportion of cells 
becoming infected was a sufficient amount. Particularly in the immunofluorescence assay, it is clear 
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the majority, if not all, the cells display some indicators of viral infection, both in phenotype and 
expression of viral proteins (Figure 6.1B and C). Once all the desired requirements had been 
satisfied samples were able to be sent off for mRNA sequencing analysis using HiSeq2500 
technology.  
 
 
Figure 6.1 – Quality control analyses on total RNA extracted from HaCaT TRS4 cells 
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Following confluency, HaCaT TRS4 cells were pre-treated with Tet for 48 hours, the subjected to the specific 
treatments for 10 hours. At this point total RNA was extracted using the QIAGEN RNeasy Mini Kit. All data 
shown is representative. (A) FA gel electrophoresis revealed distinct and clear RNA bands in each sample type at 
the expected sizes. Note that replicates were not shown in this analysis but have been described further in 
Appendix 8.5. (B) Further qRT-PCR analysis confirmed RNA quality, whilst investigating the efficient 
knockdown of Smad4 via PAI-1 transcript expression. Tet treatment also appeared to decrease levels of PAI-1. 
Infection was confirmed through the presence of D12 transcripts. All samples were normalised to cellular control, 
GAPDH. Error bars refer to SEM. (C) These results were mirrored in immunofluorescence analysis of cells fixed 
prior to RNA extraction. Note that similar cell densities were seen in all conditions. Smad4 can be correlated to 
PAI-1 levels (green) and VACV infection, to the presence of B5 in red. Scale bar = 200 μm. n=3. Representative 
images from the three independent experiments are shown.  
 
6.2.2 RNA sequencing of VACV-WR-infected transcriptomes aligned with previously 
obtained results 
One of the first considerations upon receipt of our RNAseq data was the success rate of transcript 
identification and quantification. To gain insight into this, a number of analyses were performed. 
Firstly, the amount of reads correctly mapped to single loci in the human reference genome was 
determined (Appendix 8.5.3). The results suggested coverage for each of the 24 samples was more 
than sufficient for further analysis, with greater than 30M successful reads per sample and only a 
low proportion being unidentifiable.  
The next step was to determine whether transcripts of known concentration could be assayed to 
produce similar outputs to those previously observed. For this, Smad target genes, c-JUN, Snail2 
and PAI-1 were pulled out of the RNAseq data and compared in each condition (Figure 6.2). As 
seen below, it appears that once again we can identify TGF-β and VACV-WR as stimulators of 
Smad target gene expression. VACV-ΔVGF on the other hand does not increase synthesis of these 
select genes. All raw transcript counts were normalised to GAPDH expression. As hoped, these 
RNAseq readings aligned with those obtained from previous qRT-PCR analysis, and so the data 
could be confidently analysed on a more global scale.  
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Figure 6.2 – Transcript counts obtained from RNAseq mirrored those from qRT-PCR analysis 
Examination of the three Smad target genes investigated within this thesis, c-JUN, Snail2 and PAI-1 found that 
transcript counts obtained following RNAseq and normalised to GAPDH aligned with those seen in earlier qRT-
PCR analysis. These results suggested TGF-β treatment and VACV-WR infection led to increased transcript 
levels of all three genes, whilst introduction of VACV-ΔVGF at 16 hpi did not alter gene expression of these 
targets. Error bars refer to SEM.  
 
6.2.3 The transcriptomic profiles of TGF-β-treated, VACV-WR and VACV-ΔVGF-infected 
conditions were unique yet still shared similarities 
One of the most beneficial aspects of next generation sequencing and transcriptomic analysis is the 
generation of specific profiles of gene expression which can be associated with different cellular 
and environmental contexts. These identifying characteristics can be used to compare various 
stimuli to determine how similar their influence on gene transcription may be.  
Of the statistical analyses performed on our data, principal component analysis was used to visually 
represent differences between the various test conditions (Figure 6.3). This statistical test is used to 
compare datasets with many variables, reducing the comparison to two principal components, 
whilst still illustrating a large proportion of the information. Typically, the first of the principal 
components accounts for the variable displaying the largest difference between the datasets. This is 
reflected on the x-axis below as principal component 1 (PC1) which has a 91% variance in this 
context. The next most variable condition, principal component 2 (PC2) is illustrated on the y-axis 
and displays a 5% variance. This data was generated with the assistance of collaborator, Ulf 
Schmitz (University of Sydney, Australia). The analysis revealed strong similarities between the 
transcriptomes of TGF-β-treated and VACV-WR-infected cells. However, this was only the case in 
the absence of Tet treatment, which led to a stronger resemblance between VACV-WR and VACV-
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ΔVGF infections. This suggested there was a high degree of Smad4-dependent overlap between 
transcription in the VACV-WR and TGF-β conditions.  
 
Figure 6.3 – Principal components analysis was used to illustrate similarities and differences of 
different datasets 
Principal components analysis provides a visual overview of the similarities between the different datasets of our 
RNAseq conditions. The two axes refer to the two principal components that best illustrate the entirety of the data. 
Note that variance on the x-axis is much higher than that on the y-axis. This information was generated with the 
assistance of collaborator, Ulf Schmitz (University of Sydney, Australia), using pcaExplorer software.  
 
Furthermore, if we examine differentially expressed transcripts between various samples, we can 
see that TGF-β and VACV-WR conditions display the most commonalities (Figure 6.4). In this case, 
red dots refer to transcripts which significantly differ in expression between the two conditions. 
From the data, it is evident that the comparison in Figure 6.4D displays the least of these red areas. 
Curiously, loss of VGF appears to significantly affect the transcriptome, with the images in Figure 
6.4B and C appearing quite distinct. 
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Figure 6.4 – Differential gene expression revealed similarities between TGF-β-treated and VACV-WR-
infected cell transcriptomes 
The DESeq2 program was used to generate plots comparing gene expression between different conditions. The 
comparisons included TGF-β-treated vs. untreated cells (A), as well as VACV-WR (B) and VACV-ΔVGF-
infected (C) also to untreated cells. Curiously, the largest differences were seen between uninfected and VACV-
ΔVGF-infected cells. (D) The final comparison highlighted strong similarities between TGF-β and VACV-WR 
datasets in terms of differentially expressed genes. Data was generated in collaboration with Ulf Schmitz 
(University of Sydney, Australia).  
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6.2.4 The TGF-β and VACV-WR conditions display large areas of overlap in their 
transcriptomes 
As seen above in the principal component analysis and differential gene expression graphs, two 
conditions, the TGF-β-treated and VACV-WR-infected, generally align better than the others 
(Figures 6.3 and 6.4). Not only does this correlate with results obtained in previous chapters, it 
suggests that VACV-WR influences global cell transcription in a manner reminiscent of the TGF-β 
ligand itself.  
To characterise this response further, we examined an array of known Smad target genes. This 
provided more detailed information on where TGF-β and VACV-WR align and also where they 
differed. Twenty-five well-studied Smad target genes were chosen and examined in the 4 Tet 
negative conditions (Figure 6.5). As seen via heat map analysis, many of the selected target genes 
are upregulated, as shown in red, in both TGF-β-treated and VACV-WR-infected cells. This 
includes the transcripts for the previously investigated c-JUN, Snail2 and PAI-1, as well as 
oncogenic transcription factors, JUNB, ELK3, SOX4 and RUNX1, EMT contributor, NEDD9, 
inhibitory proteins, SKI, SKIL, SMURF1 and SMAD7, and apoptosis-regulator, GADD45B [218, 
222, 450, 452, 578-583]. Certain genes, such as CITED2 which produces a protein that sequesters 
p300/CBP and oncogene PBX1, are downregulated by both TGF-β and VACV-WR stimulation 
[584]. Interestingly, some genes are differentially regulated in the two conditions, such as 
transcription suppressor, HES1 which is upregulated by VACV infection, but down regulated by 
TGF-β treatment. Others with differential regulation include COL4A1, GATA3, DNA binding 
inhibitors, ID2 and ID3, and the cadherin-7 precursor, PCDH7. Many of these are known to be 
downregulated by TGF-β treatment [364]. Again, TGFb mRNA synthesis appears to be induced by 
TGF-β, but not by VACV-WR infection. Comparing the other two conditions, we do observe some 
similarities; however, there are also fairly striking differences between the uninfected and VACV-
ΔVGF infected datasets. This is particularly evident in the inhibitory genes, SKI, SKIL, SMURF1 
and SMAD7, as well as GATA3, ID2 and the G-protein regulator, RGS3. A description of each of 
the examined genes lies in Table 6.4. Many of these appear to be involved in driving EMT and gene 
transcription.  
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Figure 6.5 – Smad target gene heat map shows VACV-WR and TGF-β display strong similarities in 
gene expression profile 
GraphPad Prism 7 was used to generate a heat map displaying the distribution of expression of 24 common Smad 
target genes. Expression was standardised using a Z-score analysis. The results highlight the similarities between 
the TGF-β and VACV-WR conditions. These transcription abilities seem to be lost in VACV lacking VGF. The 
VACV-ΔVGF condition, whilst displaying some resemblance to the uninfected condition is quite distinct in its 
transcription profile. Again, TGFb mRNA synthesis does not appear to be greatly increased via the addition of 
VACV-WR.  
 
 
Table 6.4 – Names and functions of common Smad target genes 
Name Gene  Description Ref. 
c-JUN JUN JUN proto-oncogene, AP-1 transcription factor component [450] 
Snail2 SNAI2 EMT-driving transcription factor (also known as Slug) [585] 
PAI-1 PAI1 Plasminogen activator-inhibitor-1, modulator of cell migration [586] 
JunB JUNB Oncogene, AP-1 transcription factor component [450] 
ELK3 ELK3 Oncogene, ETS transcription factor [578] 
NEDD9 NEDD9 Enhancer of filamentation, EMT driver  [581] 
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TMEPAI PMEPA1 Transmembrane protein, sequesters Smad proteins, negative 
regulator of TGF-β signalling 
[580] 
SOX4 SOX4 EMT-driving transcription factor  [579] 
Runx1 RUNX1 EMT-driving transcription factor [453, 
582] 
Sno SKIL Negative regulator of TGF-β signalling [452] 
Smurf1 SMURF1 Ubiquitin ligase, targets Smad proteins and TGFβR proteins 
for degradation 
[583] 
Smad7 SMAD7 Inhibitory Smad, block phosphorylation of R-Smads, recruit 
ubiquitin ligases 
[222] 
Ski SKI Negative regulator of TGF-β signalling  [452] 
GADD45B GADD45B Growth arrest and DNA damage-inducible protein, mediator 
of apoptosis 
[218] 
TGF-β TGFb Transforming growth factor-beta, mediates EMT, regulates 
apoptosis and cell cycle progression 
[216, 
534] 
Collagen IV COL4A1 Main structural component of the basement membrane, 
regulates TGF-β production, role in EMT 
[587, 
588] 
HES1 HES1 Hairy and enhancer of split-1 transcription suppressor, 
correlated with EMT 
[589] 
GATA3 GATA3 Trans-acting T-cell specific transcription factor, binds Smad3 
to promote transcription 
[590] 
ID-2 ID2 Inhibitor of differentiation-2, disrupts DNA binding, protects 
against EMT 
[591] 
ID-3 ID3 Inhibitor of differentiation-3, disrupts DNA binding [592] 
Protocadher
in-7 
PCDH7 Inhibitor of cell migration and invasion  [364, 
593] 
Cite2 CITED2 CPB/p30-interacting transactivator-2, competitively binds 
CBP/p300 
[584] 
RGS3 RGS3 Regulator of G-protein signalling-3, inhibits Smad3-mediated 
transcription 
[594] 
PBX1 PBX1 Pre-B-cell leukaemia transcription factor-1, proto-oncogene, 
involved in cell survival 
[364, 
595] 
 
Earlier within this thesis, we attempted to characterise the EMT response in VACV-infected cells. 
One possible avenue for investigation was the expression of EMT-associated genes. With the 
acquisition of our RNAseq data, this assessment was now possible. To evaluate this, common genes 
associated with EMT were found within the literature and using an online EMT resource [63, 596]. 
As TGF-β is known to alter expression of these genes, it served as a positive control for EMT in 
comparison to the other datasets (Figure 6.6). However, analysis of EMT proved difficult. Certain 
 TRANSCRIPTOMIC ANALYSIS OF VACV INFECTION 
University of Sydney 210 2018 
epithelial genes, such as CLDN1 and those for the cytokeratins were downregulated upon TGF-β 
treatment, as expected. These results were also observed during VACV-WR infection. However, 
others, including the prototypical epithelial marker, CDH1 were not decreased in these contexts. 
Numerous mesenchymal genes were also increasingly expressed in these contexts, suggesting a 
transition towards this phenotype may have been occurring. VIM and LAM5; however, proved to be 
more inconsistent. Furthermore, from CDH2 down in the heat map, the VACV-WR dataset strongly 
resembled that seen in untreated cells. As such, the data did not lend itself to confidently labelling 
these events as EMT.  
Interestingly, VACV-ΔVGF influenced gene transcription in a fairly unique way, with almost all 
transcript levels being relatively low. A few exceptions to this trend occurred in CLDN1, KRT5, 
KRT6A, as well as VIM. Certain factors commonly linked to EMT, such as vitronectin, ZEB1 and 
ZEB2 were not detected in any dataset, or were listed in the previous figure, in the case of Snail2 
and RUNX1, so were excluded from this heat map analysis (Table 6.5).  
 
Figure 6.6 – Certain EMT related genes are upregulated by VACV infection 
Heat maps were generated using GraphPad Prism7 to examine the gene expression of twenty epithelial and 
mesenchymal markers following TGF-β treatment, VACV-WR and VACV-ΔVGF infections. Whilst similarities 
exist between the TGF-β and VACV-WR conditions, analysis revealed slight differences between these results. 
The VACV-ΔVGF condition appeared unlike any of the other conditions in terms of EMT-associated gene 
expression. Whilst many mesenchymal genes increased upon TGF-β treatment and VACV-WR infection, certain 
epithelial genes also demonstrated this pattern. It is difficult to determine if EMT is occurring in these contexts.  
Table 6.5 – Typical genes associated with the transition from an epithelial to mesenchymal cell 
phenotype  
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Name Gene Description EMT 
expression 
Ref 
Claudin-1 CLDN1 Tight junction-associated protein Down [597] 
Cytokeratin 
5 
KRT5 Basement membrane component, abundant in 
intermediate filaments and mitochondria, also 
known as keratin 5 
Down [63] 
Cytokeratin 
6 
KRT6A Basement membrane component, abundant in 
intermediate filaments and mitochondria, also 
known as keratin 6 
Down [63] 
Scribble SCRIB Membrane protein, involved in junctions Down [598] 
Occludin OCLN Tight junction-associated protein Down [64] 
ZO-1 TJP1 Tight junction-associated protein Down [63, 
64] 
E-cadherin CDH1 Cell-to-cell adhesion molecule Down [63, 
110] 
Laminin 1 LAMB1 ECM and basement membrane protein  Down [63] 
Vimentin VIM Intermediate filament protein Up [63] 
Laminin 5 LAMA5 ECM and basement membrane protein Up [63] 
β-catenin CTNNB1 Transcriptional regulator, influences cell 
adhesion 
Up [63] 
H2A.X H2AFX Histone variant, master EMT regulator Up [599] 
H2A.Z H2AFZ Histone variant, EMT driver Up [432, 
433] 
N-cadherin CDH2 Transmembrane protein, regulates cell-to-cell 
adhesion 
Up [63] 
Fibronectin FN1 ECM protein Up [63] 
AXL AXL Receptor tyrosine kinase Up [600] 
Integrin α3 ITGA3 Integrin involved in cell migration Up [63] 
α-catenin CTNNA1 Adherens junction-associated protein, binds 
filamentous actin 
Up [596] 
γ-catenin JUP Desmosome-associated protein, transcriptional 
regulator, also known as plakoglobin 
Up [596] 
VEGF VEGFA Stimulates formation of blood vessels Up [601, 
602] 
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6.2.5 VACV utilises VGF for numerous aspects of gene transcription 
Given that EGF is a known influencer of host gene transcription, we wanted to determine if VGF 
was able to fulfil this same role [44, 509, 517]. It was apparent from previous analyses that loss of 
VGF interfered with the ability of VACV to induce Smad target gene expression, as well as genes 
related to EMT (Figures 6.5 and 6.6). Furthermore, direct comparison of differentially expressed 
genes between VACV-WR and VACV-ΔVGF demonstrated that these two contexts have grossly 
distinct transcript expression profiles (Figure 6.7).  
 
Figure 6.7 – DESeq2 comparison of VACV-WR and VACV-ΔVGF 
DESeq2 was used to generate profiles of differential gene expression between VACV-WR and VACV-ΔVGF-
infected cells. The results indicate that the loss of VGF severely affects the profile of gene expression, with large 
amounts of differentially expressed genes shown in red. Similarly expressed genes are displayed in grey. Data was 
generated in collaboration with Ulf Schmitz (University of Sydney, Australia).  
 
For a more all-encompassing view on gene expression upon the loss of VGF, the Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathway analysis tool was utilised. This program 
identifies pathways and systems that are significantly varied between two comparative conditions. 
These enriched pathways each possess a list of commonly associated genes, which regulate a 
variety of functions within cells. Within the schematic below, the pathways that were significantly 
upregulated upon VACV infection are listed (Figure 6.8). Note that no significantly enriched 
pathways were observed in TGF-β-treated cells when compared to untreated cells. Following 
infection with VACV-WR or VACV-ΔVGF, many systems involved in immune disorders, as well 
as metabolism, infectious diseases, cell signalling and immune responses were found to be 
significantly increased (Figure 6.8). For example, the pathway with the most upregulated 
components in both conditions was the systemic lupus erythematosus system. This network 
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encompasses components from cytokine-receptor interaction pathways, JAK/STAT signalling, cell 
adhesion molecules (CAMs), complement and coagulation cascades as well as those involved in 
antigen processing and presentation. Interestingly, cell adhesion molecules were observed at higher 
levels in cells infected with VACV-ΔVGF virus compared to the VACV-WR virus, which is 
consistent with the stationary cell phenotype observed in the first condition. A curious pathway in 
this analysis is the neuroactive-ligand receptor interaction group, which possesses a number of 
peptide, drug and hormone receptors, as well as various membrane channels. This was significant 
only in the VACV-WR condition. A number of non-viral infectious disease responses were also 
detected via this analysis, with some such as Leishmaniasis and Amoebiasis being associated with a 
TGF-β response.  
 
Figure 6.8 - KEGG Pathway analysis revealed cellular pathways with enriched components following 
VACV infection 
The KEGG database was used to generate a list of pathways containing large amounts of differentially expressed 
genes between the input samples. In this case, VACV-WR and VACV-ΔVGF-infected cells displayed various 
differences in immune and disease related pathways. This data was acquired by collaborator, Ulf Schmitz 
(University of Sydney, Australia) and collated and visualised by myself using GraphPad Prism7 software.  
 
To gain more insight into the specific genes altered by loss of VGF, as well as study genes known 
to be modulated by its cellular homolog, EGF, heat map analysis was once again performed (Figure 
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6.9). It is clear from the twenty genes studied that VACV influences expression of genes associated 
with the EGFR pathway and that loss of VGF impedes transcription of these host genes. This is 
especially true for those involved in apoptosis, such as BCL2L1 and MCL1, as well as cell cycle 
progression regulators, such as CCND1, MYC, and PTGS2, to name a few. Particular genes proved 
to be exceptions to this rule for example KIF14 was not increased by VACV infection, FOS proved 
to be higher following VACV-ΔVGF infection and XRCC1 expression appeared unaffected by the 
loss of VGF from VACV. Each of these are outlined in Table 6.6.  
 
Figure 6.9 – Expression of EGF-mediated genes following VACV infection 
Heat maps generated using GraphPad Prism 7 software indicated that VACV-ΔVGF virus was unable to promote 
expression of twenty host genes typically transactivated by EGF. These transcripts are observed following 
VACV-WR infection, TGF-β-treatment and are even present in uninfected cells. Normalized transcript counts 
were again applied to a standard distribution curve through Z-score analysis. 
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Table 6.6 – List of common EGFR pathway gene targets 
Name Gene Description Ref 
KIF14 KIF14 Kinesin-like protein 14, involved in cellular transport, 
implicated in numerous tumours  
[603] 
Bcl-X BCL2L1 B-cell lymphoma extra-large protein, apoptosis regulator, pro-
survival protein 
[604] 
PKM PKM2 Pyruvate kinase M2, involved in glycolysis, regulates EGFR-
mediated transcription 
[605] 
Cyclin D1 CCND1 Cyclin-dependent kinase 1, implicated in tumour cell 
proliferation, chaperones cells through phases of the cell cycle 
[606] 
c-Myc MYC Proto-oncogene, transcription factor involved in driving cell 
proliferation 
[607] 
Mcl MCL1 Induced myeloid leukaemia cell differentiation protein, 
apoptosis regulator, pro-survival protein 
[608] 
Cox-2 PTGS2 Cyclooxygenase-2, major driver of EGF-induced cell 
proliferation 
[609] 
DNA-PK PRKDC DNA-dependent protein kinase, DNA repair protein [610] 
ASPM ASPM Abnormal spindle-like microcephaly associated protein, 
spindle protein, regulates proliferation and brain size 
[611] 
CENPF CENPF Centromere protein F, involved in mitosis progression, 
oncogene 
[612] 
Aurora A AURKA Aurora A kinase, involved in cell division and proliferation, 
located in centrosomes 
[613] 
HIF1α HIF1A Hypoxia-inducible factor 1α, transcription factor, contributes 
to EMT 
[614] 
Cks1 CKS1B Cyclin-dependent kinase regulatory subunit 1, involved in cell 
proliferation, positively regulates ERK and JAK/STAT 
signalling  
[615] 
C-Fos FOS Proto-oncogene, component of the AP-1 transcription factor 
complex 
[607, 
616] 
Exonucleas
e-1 
EXO1 Exonuclease 1, DNA damage repair protein, upregulated in 
breast cancer, modulated by Ras, Myc and EGFR 
[617] 
DTL DTL Denticleless protein homolog, involved in regulation of the 
cell cycle, adaptor for E3 ubiquitin ligases 
[618] 
B-Myb MYBL2 Transcription factor associated with cell cycle progression [619] 
Nek2 NEK2 Serine-threonine kinase, regulates centrosome structure during 
cell division  
[620] 
BCRP ABCG2 ATP-binding cassette transporter protein, also known as 
breast cancer resistance protein, membrane transport protein, 
upregulated in drug resistant cancers 
[621] 
XRCC1 XRCC1 DNA repair protein, regulated by MAPK signalling [622] 
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6.2.6 A partial loss of Smad4 alters host gene expression 
Once the contribution of VGF to gene expression had been clarified, we aimed to uncover the 
influence of Smad4 in our various contexts. As Smad4 was previously seen to enhance viral-
induced cell migration, it was thought that identifying specific genes under its control could provide 
clues on how VACV is able to induce cell migration. This research may also provide information 
on the general EMT phenotype observed during infection.  
The HaCaT TRS4 cell line, described in earlier chapters, once again provide useful to monitor the 
effects of Smad4 knockdown. Prior to RNAseq, depletion of Smad4 was checked in these cells 
using qRT-PCR analysis to assay PAI-1 levels in the RNAseq samples (Figure 6.1B). In this case, 
levels of PAI-1 knockdown were correlated to abundance of Smad4. To further corroborate this, we 
examined the transcript counts of Smad4 directly using the obtained sequencing data. However, in 
this circumstance, the results proved more inconsistent. In Figure 6.10, we can see Smad4 is 
generally reduced in the datasets obtained from Tet-treated cells, as expected. This led to a 
corresponding change in global gene expression as seen in differential gene expression plots (Figure 
6.11). Upon closer examination of the VACV-ΔVGF condition it was apparent that no significant 
changes in Smad4 transcript levels could be detected upon Tet treatment (Figure 6.10). This aligned 
with the results seen in Figure 6.11D, where VACV-ΔVGF samples proved indistinguishable before 
and after Tet treatment. Furthermore, these results reflect the levels of PAI-1 seen in Figure 6.1B 
and indicate that levels of PAI-1 transcript may not be a suitable control for Smad4 knockdown in 
this context. Overall, these results suggest there was insufficient Smad4 knockdown within these 
samples. Due to time constraints, fresh VACV-ΔVGF samples were not able to be generated within 
the scope of this thesis.  
 
Figure 6.10 – Smad4 reduction occurred in certain conditions following Tet treatment 
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Smad4 transcript counts obtained with RNAseq analysis were normalised to GAPDH levels and plotted with 
GraphPad Prism 7 software. Smad4 depletion proved to be inconsistent within the conditions tested, with VACV-
ΔVGF-infected cells displaying no significant differences in Smad4 levels upon Tet treatment at 16hpi. Error bars 
refer to SEM.  
 
 
Figure 6.11 – Loss of Smad4 altered gene expression in most conditions 
Differential gene expression analysis was performed using DESeq2 to determine if loss of Smad4 upon Tet 
treatment changed the transcriptome after exposure to various stimuli. In untreated (A), TGF-β-treated (B) and 
VACV-WR-infected (C) datasets, Smad4 depletion affected expression of certain transcripts, the most so in 
infected cells. VACV-ΔVGF (D) however, due to inefficient Smad4 knockdown had no differentially expressed 
genes being detected. Data was generated in collaboration with Ulf Schmitz (University of Sydney, Australia).  
 
 
From the results in Figure 6.11A, B, and C it is evident that efficient reduction of Smad4 
corresponds with changes in the gene expression profile. As a result, heat maps were once again 
generated to determine if Smad4 influenced gene expression post-VACV-WR infection. Note that 
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VACV-ΔVGF was excluded from this analysis due to the concern with Smad4 knockdown efficacy 
(Figures 6.10 and 6.11). When this was narrowed down to genes known to be modulated by Smad4 
there was a fairly clear trend observed (Figure 6.12). For example, genes such as PAI-1, ITGB6, 
NEDD9, ATF3, GADD45B, AKT3, DLX2 and KFL10 all appear to be downregulated upon Tet 
treatment of cells, particularly when compared to the non-Tet treated, TGF-β-treated or VACV-WR 
infected conditions. The reverse is true for genes known to be downregulated by Smad4, such as 
PARD6B, PBX1, TGM1 and BHLE40. Others which appear to have a less clear expression profile 
include CLDN8, PCDH-7 and CLU which appear to remain unchanged, decrease or increase in 
expression depending on the combination of stimuli applied to cells. A number of Smad4-
independent genes were also chosen for this analysis, including c-JUN, CDKN1A, IFIT2 and RGS2. 
All the genes examined have previously been characterised as either Smad4-dependent or 
independent and are described in Table 6.7 [364].  
 
 
Figure 6.12 – Smad4 knockdown alters gene expression 
Heat maps generated using GraphPad Prism 7 software demonstrated a distinct change in gene expression of 16 
Smad4-associated and 4 Smad4-independent genes upon Tet treatment of HaCaT TRS4 cells. This was especially 
true in TGF-β-treated and VACV-WR-infected cells. Normalized transcript counts were distributed using a Z-
score analysis test. Certain Smad4-independent genes, including the previously studied c-JUN were included for 
comparison. Those in bold were also seen in Figure 6.5 and outlined in Table 6.4, as such, they were excluded 
from Table 6.7. 
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Table 6.7 – Common Smad4-dependent and independent genes  
Name Gene Description Relation to 
Smad4 
Ref 
Akt3 AKT3 RAC-γ serine/threonine protein kinase, regulates 
proliferation and survival, member of EGFR 
pathway, negatively regulates TGF-β signalling 
Dependent 
and up 
[623] 
 
ATF-3 ATF3 Cyclic AMP-dependent transcription factor, 
enhances TGF-β signalling  
Dependent 
and up 
[624] 
Integrin β6 ITGB6 Integrin subunit beta 6, fibronectin and cytoactin 
receptor, can bind TGF-β1 
Dependent 
and up 
[625] 
Dlx2 DLX2 Distal-less homeobox 2, promotes EMT by 
activating Snail 
Dependent 
and up 
[626] 
TIEG KFL10 TGF-β-inducible early growth response protein 
1, promotes TGF-β-induced transcription and 
Smad2 phosphorylation 
Dependent 
and up 
[627] 
Claudin-8 CLDN8 Claudin 8,tight junction protein Dependent 
and down 
[364] 
Clusterin CLU Clusterin, driver of EMT, chaperone protein 
leads to increased expression of mesenchymal 
markers 
Dependent 
and up 
[628] 
TIMP3 TIMP3 Metalloproteinase inhibitor 3, ECM component 
mediated by Sp1 transcription factor 
Dependent 
and down 
[629] 
PAR6B PARD6B Par-6 partitioning defective homolog beta, 
involved in formation of tight junctions 
Dependent 
and down 
[630] 
Transgluta
minase-1 
TGM1 Transglutaminase 1, driver of EMT, involved in 
cell proliferation and differentiation  
Dependent 
and up 
[631] 
BHLHB2 BHLHE40 Basic helix-loop-helix family member 2, also 
known as BHLHE40, transcriptional regulator  
Dependent 
and up 
[364] 
CDKN1A CDKN1A Cyclin-dependent kinase inhibitor IA, also 
known as p21, contributes to cell cycle inhibition 
and TGF-β-mediated growth arrest 
Independe
nt 
[632] 
Ifit2 IFIT2 Interferon-induced protein with tetratricopeptide 
repeats 2 
Independe
nt 
[364] 
RGS2 RGS2 Regulator of G-protein signalling 2, negative 
regulator of signalling, implicated in fibrosis 
Independe
nt 
[633] 
 
Using differential gene expression plots and heat map analysis there appeared to be a distinct 
difference in the transcription profiles of VACV-WR-infected cells with and without Smad4 
depletion. As a result, we wanted to assess, on a broader scale, the signalling pathways which are 
enriched in each of these conditions, to provide insight into the role of Smad4 during VACV-WR 
infection. Once again, KEGG Pathway analysis was employed to compare VACV-WR +/- Tet 
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(Figure 6.13). Numerous pathways involved in metabolism, various diseases and immune pathways 
were detected using this analysis. Curiously, the most significantly enriched pathway upon Smad4 
knockdown was the CAMs pathway, similar to the VACV-ΔVGF in Figure 6.8. Cellular defence 
mechanisms, such as antigen processing and phagosome formation, were also upregulated 
following a reduction in Smad4 levels.  
 
Figure 6.13 – KEGG Pathway analysis of VACV-WR-infected cell transcriptomes 
The KEGG database was used to generate a list of pathways differing in VACV-WR-infected cells upon Tet 
treatment. Many pathways relating to metabolism, immune diseases, and cell signalling and transport pathways 
were pulled out from this analysis. This data was acquired by collaborator, Ulf Schmitz (University of Sydney, 
Australia) and collated and visualised by myself using GraphPad Prism7 software. 
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6.3 DISCUSSION 
6.3.1 The relationship between VACV, TGF-β and EMT 
Global transcriptomic analyses provide researchers with a great deal of freedom and flexibility in 
assessing influencers of gene expression. With the obtained data, they can gain insight into existing 
hypotheses, as well as develop novel theories based on the incoming information. In this thesis 
chapter, we used one of these high-throughput transcript assessment tools, RNAseq to evaluate the 
influence of TGF-β, VACV, VGF and Smad4 on host gene transcription.  
Following quality control assessments, the results obtained from RNASeq experimentation were 
found to align nicely with those previously obtained via qRT-PCR analysis. In this case, c-JUN, 
Snail2 and PAI-1 transcripts were found to be increased following TGF-β-treatment and VACV-
WR infection (Figures 3.12, 6.2 and 6.3). As our analyses continued, it became apparent that TGF-β 
and VACV-WR elicited largely similar gene expression responses, appearing the most similar of 
the conditions tested in this chapter (Figures 6.3, 6.4D and 6.5). Yet there were differences which 
distinguished these conditions. For example, TGF-β is known to increase its own expression, via 
transactivation of the TGFb promoter, yet VACV appears less able to replicate this result [216]. 
Contrastingly, when compared to VACV-ΔVGF virus, parental WR does appear to increase TGF-β 
transcripts slightly. Whether this level of TGFb transcript is sufficient to induce TGF-β pathway 
activation in VACV-WR infected cells is yet to be clarified; however, earlier evidence suggesting 
TGFβR proteins are unimportant for VACV-induced TGF-β pathway activation suggests against 
this theory (Figures 5.5 and 5.6).  
The relationship between TGF-β and EMT progression is well-established in the literature [89, 95, 
96]. Due to the phenotype of VACV-infected cells, becoming elongated, detached and motile, as 
well as the transcriptomic parallels between TGF-β signalling and VACV-WR infection observed 
within this chapter, we wanted to determine if a classic EMT response could also be detected in 
VACV-infected cells (Figures 3.4, 3.7, 6.5 and 6.6). A number of markers are considered essential 
determinants of mesenchymal-associated cellular transitions [63]. In particular, we have the 
cadherin switch from E-type to N-type, loss of tight junction proteins, such as ZO-1 and increased 
expression of EMT-driving transcription factors, including Snail1 and Snail2. Curiously, we could 
only completely satisfy the last of these criteria, and partially address the first, even within the 
positive control, TGF-β-treated cells (Figure 6.6). Given that EMT is considered a spectrum, it is 
possible that a partial EMT was occurring in these cells, where many mesenchymal genes, including 
VIM and CDH2, were upregulated, but others, such as CDH1 and TJP1 were not depleted. Another 
consideration is the timing, which may not have been suitable for the detection of decreased 
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epithelial gene expression [634]. From these assays it is not easy to clarify whether VACV is able to 
stimulate EMT; however, the similarities to the TGF-β treatment control, suggest further study into 
this phenomenon would be valid.  
 
6.3.2 RNAseq analysis revealed a potential role for VGF in VACV-induced gene transcription 
EGF is a known modulator of host-gene transcription, using its surface receptor to activate 
countless downstream kinases, which each in turn control their own transcription factors [508, 509]. 
Given the homologous nature of EGF and vaccinia-sourced VGF, it was assumed these proteins 
would play similar roles in the host cell. VGF is also implicated in maintaining VACV-induced cell 
proliferation, replication rates and plaque phenotype (Figures 5.9, 5.11 and 5.12) [43, 530]. 
However, to our knowledge, no groups have characterised the global transcriptional response 
mediated by VGF in VACV-infected cells. Thus, this became a major aim of this thesis chapter.  
When comparing the expressed gene profiles of VACV-WR and VACV-ΔVGF-infected cells, the 
differences are quite striking, with very little overlap being observed, suggesting VGF is a major 
contributor to transcription following VACV infection (Figure 6.7). These results are also reflected 
in heat map analyses, where countless genes shown to be upregulated by VACV-WR infection, are 
decreased in the presence of VACV-ΔVGF (Figures 6.5, 6.6 and 6.9). In fact, of 20 chosen targets 
from the EGFR pathway, all but 2 were more highly expressed in VACV-ΔVGF-infected cells 
compared to VACV-WR. These two corresponded to a kinesin motor protein, KIF14, and 
transcription factor c-Fos, the second of which is known to accumulate in a VGF-independent 
manner [635]. VACV-ΔVGF virus not only appeared to be deficient in induction of EGFR 
pathway-associated genes, but also those related to TGF-β signalling and EMT progression (Figures 
6.5, 6.6 and 6.9). This result may not be too surprising, given that there are evident cross-talk 
mechanisms between the TGF-β and EGF signalling pathways [101, 162, 163, 230, 233, 234]. For 
instance, Cox-2 is a protein involved in driving cell proliferation via the consumption of 
arachidonic acid and is a downstream target of both the above signalling pathways (Figure 6.9 and 
Table 6.6) [609, 636]. However, upon EGFR inhibition, TGF-β and Smad3 are no longer able to 
stimulate expression of this protein [636]. We received a similar result in Figure 6.9, where VACV-
ΔVGF is no longer able to promote expression of Cox-2 compared to the parental VACV-WR virus. 
Furthermore, KEGG Pathway analysis suggests VACV-ΔVGF possesses increased components for 
the metabolism of arachidonic acid (Figure 6.8). These results propose a role for VGF in the 
production of Cox-2, where its loss leads to a reduction of Cox-2 and a compensatory induction of 
the arachidonic acid metabolic pathway.  
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From the results within this chapter, it is clear that VGF influences downstream target production of 
both the EGF and TGF pathways. It may do so in the first case by competing for binding to the 
EGFR, residing within and activating this protein, and initiating the downstream signalling cascade 
which ultimately leads to EGF-associated gene transcription [519, 528]. This theory is supported by 
the fact that VGF is known to stimulate cell proliferation, a known outcome of EGFR signalling 
[530]. In terms of modulating TGF-β pathway signalling, we know that VGF is capable of 
mediating the linker phosphorylation of Smad2, which is one mechanism it may be using to 
enhance target gene expression (Figure 5.8). Yet, the scale to which VGF deletion cripples the 
ability of VACV to induce TGF-β-associated target genes implies other mechanisms are at play 
(Figure 6.5). For instance, VGF is known to promote the sustained activation of ERK1/2, which has 
the capacity to increase Smad protein activity [162, 163, 554]. Another TGF-β-activating, EGF 
pathway member, Akt, can be ruled out in this context as previous groups have shown activation of 
Akt is unrelated to presence of VGF during VACV infection [337, 514]. However, there are many 
points at which the EGFR pathway intersects with TGF-β signalling, which have yet to be 
investigated in the context of VGF. Each of these should be considered in the search for how VGF 
mediates TGF-β-associated gene transcription.  
 
6.3.3 Smad4 influences gene transcription during VACV infection 
The Co-Smad, Smad4, is distinct from R-Smads in its transcriptional capacities due to its 
constitutive activation, constant nuclear shuttling and ability to form oligomers with other Smad 
proteins. Furthermore, we now possess evidence for the involvement of Smad4 in VACV spread 
throughout a cell monolayer, virus-induced cell migration and production of extracellular virions. 
These results highlight the need for a broad assessment of the genetic influence of Smad4 during 
VACV infection.  
Once again, the HaCaT TRS4 model proved useful for assaying the role of Smad4 in various 
contexts. As described earlier, this system functions by depleting Smad4 in a Tet-inducible manner. 
However, when used during the course of our transcriptomic analyses, concerns developed about 
the efficacy of Smad4 knockdown following Tet treatment. This became especially evident in 
Figure 6.11D, where little to no differences were observed in VACV-ΔVGF-infected cells before 
and after Tet treatment. This result was supported by a direct analysis of Smad4 levels, which 
proved unchanged between the VACV-ΔVGF conditions (Figure 6.10). As a result, the dual 
contributions of VGF and Smad4 were not assayed further within this thesis. With further time and 
resources, the clarification of Smad4 levels by qRT-PCR or repetition of VACV-ΔVGF sample 
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collection would be ideal. Despite inconsistencies with VACV-ΔVGF samples, not all the data from 
these experiments was discarded. As sufficient Smad4 knockdown was detected within the other 
conditions tested, these were able to be analysed further (Figures 6.10, 6.11 and 6.12). 
A major concern of this thesis chapter was the genetic background behind the Smad4-depleted 
phenotype of VACV-WR-infected cells observed in earlier chapters. In this circumstance, KEGG 
pathway analysis proved particularly enlightening (Figure 6.13). The most enriched molecules 
found in VACV-WR-infected cells upon Smad4 knockdown were the CAMs. These proteins are the 
major components of cell binding structures, such as tight junctions, adherens junctions and ECM 
contacts, which keep cells nestled in particular locations [637]. The group encompasses a range of 
cell-surface proteins, including cadherins, integrins, immunoglobulin-like proteins, selectins and 
proteoglycans [638]. Interactions between viruses and CAMs have previously been reported. For 
example, certain viruses, such as HSV-1, utilise Nectin-1, an immunoglobulin-like adhesion 
protein, as an entry receptor to gain access to cells for infection [639]. Others, such as EBV, 
dampen immune signalling by specifically inhibiting expression of CAMs, such as ICAM-1 and 
LFA-3 [640]. VACV potentially regulates expression of these proteins for a similar purpose. 
Interestingly, in our results not only were CAMs detected in VACV-WR + Tet conditions, but also 
following VACV-ΔVGF infection (Figure 6.8). Given that virus spread is reduced in both of these 
conditions, it is possible that the increased membrane adhesion leads to restricted cell migration and 
suboptimal VACV dissemination. In this case, it would appear that Smad4 and VGF contribute to 
viral spread and VACV-induced cell migration by downregulation of CAM proteins. However, 
given the diverse structures and functions of CAM proteins, a closer examination of specific 
molecules would be required to clarify this hypothesis.  
Another possible role for Smad4 during VACV is during immune evasion. Both antigen processing 
and presentation cascades, and phagosome-associated pathways were specifically enriched within 
VACV-infected cells following Smad4 depletion (Figures 6.8 and 6.13). Antigen processing is a 
clear mechanism to alert immune cells to the presence of infection [641]. Many viruses attempt to 
inhibit these pathways in order to evade detection [641]. VACV itself is known to decrease antigen-
loaded MHC class II, in order to remain incognito [642]. Within this thesis, VACV-WR with 
Smad4 deleted appears less able to manipulate this antigen presentation pathway and may be more 
exposed to destruction by the immune system. Furthermore, phagosomes are typically used by cells 
as a defence mechanism to degrade apoptotic cells and infectious microbes. However, the 
relationship between VACV and phagosomes appears complex. VACV is known to promote 
phagosome maturation and acidification, utilising a low pH-dependent mechanism to escape these 
vesicles and enter cells [304, 305]. It may even disguise itself as an apoptotic cell to enhance this 
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engulfment process [643]. However, remaining within these vesicles, as a result of inhibited 
acidification, leads to a dramatic reduction in productive infection [304]. Given that phagosome 
pathways are increased in upon Smad4 depletion, it is possible that VACV-WR virions in this 
environment are less able to escape from phagosomes, resulting in the upregulation of phagosome 
components and increased viral destruction. This could explain the slight replication defects of 
VACV-WR observed earlier in Tet-treated HaCaT TRS4 cells (Figure 4.6).  
Overall, Smad4 appears to contribute to many aspects of VACV-WR-induced gene transcription. 
With the abundance of data available, further investigation could focus on Smad4-dependent genes 
required for cell migration and immune evasion. Understanding how these are regulated would not 
only improve our understanding of VACV-host interactions, but also assist in the development of 
oncolytic VACVs which are able to effectively target Smad4-reduced tumours, such as pancreatic 
and colon carcinomas [434, 435]. 
 
6.3.4 Future directions 
The data provided by RNAseq analyses allow the study of an insurmountable number of cellular 
signalling pathways. However, for the sake of feasibility, particular areas of interest should be 
prioritised. In the context of this thesis, we wanted to ascertain what parallels exist between the 
TGF-β-associated and VACV-infected cell transcriptomes, to determine if the virus utilises this 
signalling pathway in a broader sense than previously observed by qRT-PCR analysis. Given that 
the results in this chapter suggested at strong similarities between these conditions and the initiation 
of a partial EMT response, it may be advantageous to examine markers of EMT more directly. For 
example, CDH1 or E-cadherin, the quintessential epithelial gene, could be investigated in HaCaT 
cells over time to determine whether its expression decreases following stimulation with VACV-
WR [63]. This would provide a more definitive answer on the induction of EMT during VACV 
infection.  
Another facet of this research which has thus far been overlooked is the contribution of VGF to 
viral gene expression. Given the clear influence of this viral protein on VACV induction of host 
signalling, it is reasonable to assume that viral gene expression may be concomitantly altered. Using 
the same dataset, we can analyse VACV genes expressed during parental WR and ΔVGF infection, 
to gain insights on how VACV is able to activate TGF-β signalling, interact with Smad4, promote 
viral spread and other phenotypic differences associated with a loss of VGF signalling. This is 
possible due to the fact that VACV is known to polyadenylate the tails of its mRNA sequences [644, 
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645]. This means that the standard techniques for pooling and studying mRNAs, by accruing all 
sequences with a poly-A tail, can be applied to viral transcripts, as well as host transcripts. 
Addressing each of these features would not only provide great insight into the manipulation of host 
cell signalling pathways by VACV, but also increase our general understanding of regulation of the 
TGF-β and EGFR signalling cascades within pathological settings.  
 
6.3.5 Conclusions 
Within this chapter, we aimed to characterise the transcriptome of HaCaT TRS4 cells following 
stimulation with TGF-β, VACV-WR and a VACV lacking VGF. Prior to analysis, various control 
measures were applied to the two dozen samples in order to check their quality and suitability for 
next generation sequencing. Both our local assays, using Nanodrop spectrophotometer analysis, FA 
gel electrophoresis, qRT-PCR and IFA techniques, as well as those performed by the Ramaciotti 
Centre for Genomics, using Agilent Bioanalyzer technologies, suggested that samples were of 
sufficient standard for RNAseq analysis. At this point, the HiSeq 2500 machine was utilised to 
generate an annotated mRNA library and a plethora of transcriptomic data for further analysis. 
When these results were correlated back to original qRT-PCR analysis, expression of c-JUN, Snail2 
and PAI-1 was once again observed following TGF-β treatment and VACV-WR infection. 
Furthermore, it appeared that the symmetry between TGF-β-treated and VACV-WR-infected cells 
continued on a larger scale, with principal component analysis and different gene expression 
analyses indicating at similarities between these datasets. Taking a closer look at Smad target gene 
expression, it appeared that from 25 genes selected, VACV-WR and TGF-β stimuli aligned closely, 
whilst untreated and VACV-ΔVGF-infected samples were more dissimilar. A number of these 
genes are known to drive an EMT response, and as such, epithelial and mesenchymal markers were 
investigated. However, the classical EMT response, with changes in expression of markers such as 
E-cadherin and vimentin, was not detected in any conditions, suggesting investigation may be 
required. Furthermore, it appears that VACV utilises VGF for many aspects of gene transcription, 
as its loss severely alters the profile of expressed genes. This is especially true when examining 
genes typically transactivated by the EGFR signalling pathway, which are greatly reduced in 
VACV-ΔVGF-infected cells. Furthermore, VACV also appeared to rely on Smad4 for manipulating 
gene transcription. However, inconsistencies in Smad4 knockdown efficacy halted further analyses. 
Clarification of this stage would enable a more detailed examination of Smad4 in the context of 
VACV-WR and VACV-ΔVGF infection to be carried out. With this work we intend to identify 
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novel mechanisms involved in VACV induction of the TGF-β and EGFR signalling pathways, to 
gain a greater understanding of EMT, viral spread and pathogenesis in this context.  
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7.1 VACV RELIES ON ASPECTS OF TGF-Β SIGNALLING FOR EFFICIENT SPREAD 
7.1.1 Numerous elements of TGF-β signalling are activated by VACV infection 
The canonical TGF-β pathway begins with TGF-β ligand binding its cell surface receptor, 
activating these proteins and driving the phosphorylation of downstream transcriptional mediators; 
the Smad proteins. These transcription factors function by complexing, translocating to the nucleus 
and heavy-handedly influencing gene transcription to deliver an outcome typically associated with 
TGF-β treatment. One such outcome is the progression of cells from an epithelial to a 
mesenchymal-like state. This EMT phenomenon promotes increased cell detachment, migration and 
invasion.  
Within this thesis, we observed an EMT-like process occurring during VACV infection (Section 
3.2.1-3.2.4). Infected cells separated from their neighbours, elongated and adopted a spindle-like 
shape and became migratory and invasive. This process was reminiscent of that observed during 
embryonic development, tumour pathogenesis and other EMT-associated viral infections. Further 
investigation, indicated a role for TGF-β signalling in these processes. Various stages of the TGF-β 
signalling cascade were investigated within our analyses (Figure 7.1). At a number of checkpoints, 
it was clear that VACV potently activated this pathway, with the results demonstrating an increase 
in Smad2 and Smad3 phosphorylation, R-Smad activity on promoter elements within the nucleus 
and synthesis of various Smad targets during infection (Sections 3.1.2, 3.1.4 and 3.2.5-3.2.8). 
Curiously, this activation did not appear to be the result of TGF-β production or secretion, or 
TGFβR signalling, as shown with qRT-PCR or SB-431542 treatments and LNCaP cells respectively. 
(Sections 5.2.1-5.2.3). Furthermore, the Mps1 kinase, also known to activate R-Smad proteins, did 
not seem to be involved in R-Smad activation within the VACV context (Section 5.2.4).  
Whilst the mechanism of C-terminal phosphorylation of R-Smads is yet to be determined, there are 
also other stages in the pathway to be investigated. For example, localisation of Smad proteins 
during infection, including their import and export from the nucleus, is important to understanding 
how the activity of Smad proteins is regulated during infection. The activity of I-Smad proteins is 
another factor to note, as well as interactions with various Smad binding partners and the formation 
of Smad complexes. Together with the previous results, these factors could provide insights into 
how VACV is able to unconventionally activate this host signalling pathway.  
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Figure 7.1– Summary of the TGF-β signalling pathway found to be activated during VACV infection 
Activity could be detected at a number of levels in the TGF-β signalling pathway following infection with VACV. 
These steps listed sequentially are C-terminal phosphorylation of R-Smad proteins, Smad promoter activity within 
the nucleus examined via luciferase assay and analysis of HaCaT CAGA12-GFP cells, and the expression of Smad 
target genes as detected by qRT-PCR and IFA (green lines). The stages yet to be investigated are the importance 
of the I-Smads, the formation of Smad complexes, the import and export of Smad proteins from the nucleus and 
the presence of co-factors, DBPs and adaptor proteins in the context of VACV infection. Also, the actions of the 
inhibitory Smads have been ignored thus far. (purple dashed lines). Finally, certain experiments highlighted that 
the TGFβR complex and the TGF-β ligand were potentially not required for VACV activation of this pathway 
(red lines).  
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7.1.2 Utilisation of TGF-β signalling enhances VACV-induced cell migration and spread 
The ability of a virus to spread effectively is key to successful infection. Given the hostile 
atmosphere of the cell microenvironment, it is unsurprising that viruses have evolved to circumvent 
and manipulate aspects of host cell signalling in order to serve their agendas. VACV is no exception 
to this rule. Its spread is thought to be reliant both on direct virion spread, but also elements of cell 
behaviour, such as migratory capacity [324, 326, 327]. Motile cells have a greater capacity for 
dissemination of virus around the host organism, adopting a similar strategy to roving tumour cells 
looking to establish metastases. Previous groups have suggested VACV utilises F11 to influence 
RhoA signalling within cells and promote a migratory cell phenotype [326, 327]. We suggest TGF-
β may also contribute to this phenomenon, perhaps even in tandem with RhoA signalling (Figure 
3.14). 
TGF-β, as described above, is known to stimulate EMT, a consequence of which is cell motility. 
VACV demonstrated a capacity for both TGF-β pathway activation and induction of cell migration 
(Sections 3.2.2, 3.2.3 and 3.2.5-3.2.8). When TGFβ signalling was inhibited, VACV-induced cell 
migration was concurrently depleted (Section 4.2.6). These results suggest stimulation of cell 
migration by VACV is at least partially dependent on TGF-β signalling. Furthermore, plaque 
clearance phenotypes were attributed to cell migration, rather than apoptosis, supporting the 
suggestion that cell migration is important for plaque spread (Sections 4.2.6 and 4.2.7, Appendix 
8.3). Given that VACV lacking VGF displayed less capacity for spread, it was interesting that it 
also appeared less able to stimulate production of Smad target genes (Sections 5.2.6- 5.2.9, 6.2.5). 
The same was true for related virus ECTV, which did not appear to rely on Smad4 for efficient 
spread (Sections 5.2.12-5.2.15). 
 
  
 CONCLUSIONS 
University of Sydney 232 2018 
7.2 STUDYING SMAD PROTEINS AND TARGET GENES COULD REVEAL NOVEL TARGETS  
7.2.1 The specific roles of Smad proteins 
The Smad proteins are the transcriptional regulators of the TGF-β signalling pathway. Without 
these we would not expect to see transcription of effector genes, or progression towards any of the 
phenotypes associated with TGF-β treatment. From our early results, it was clear that TGF-β 
signalling was activated at a number of levels following VACV infection. Not only was this 
pathway found to be activated, but it appeared that Smad proteins were responsible for driving the 
EMT-like response observed during VACV infection. In this case, Smad4 was chosen for further 
analysis due to its status as the Co-Smad, its ability to divide gene transcription into two distinct 
classes, the Smad4-dependent and Smad4-independent genes, as well as the availability of pre-
existing measures for Smad4 depletion. 
For this research, the acquisition of the HaCaT TRS4 cell model proved extremely valuable. 
Initially, Smad4 knockdown was confirmed directly using immunoblot, as well as indirectly, 
utilising qRT-PCR and IFA to examine Smad4-dependent targets (Sections 4.2.1-4.2.3). Using this 
resource, it was found that Smad4 played a role in various aspects of VACV infection. For instance, 
viral cell-to-cell spread, measured via plaque assays, was reduced upon Smad4 depletion (Section 
4.2.4). The cell scattering to plaque edges, measured as areas of clearance within plaques, was 
correspondingly disrupted. These features were not seen following infection with HSV-1, another 
DNA virus. Furthermore, EEV release appeared to be affected in this condition, but not actin tail 
formation or initiation of apoptosis, suggesting Smad4 selectively affects VACV spread and 
replication (Sections 4.2.4-4.2.7). Some of these features were confirmed in a mixed population of 
CRISPR-Cas9 gene-edited HeLa cells (Section 4.2.8). These results may be partially due to loss of 
PAI-1 expression, which is known to affect cell migration (Section 4.2.7). Given this phenotype, 
understanding the role of PAI-1 during VACV infection, especially its role in cell migration and 
viral replication, could prove fruitful.  
As Smad2 and Smad3 also heavily influence gene transcription, a closer understanding of their 
contribution to VACV infection would be interesting. This is supported by their strong C-terminal 
phosphorylation and the production of both Smad2 and Smad3-mediated target genes upon 
infection (Sections 3.1.4, 3.2.7 and 3.2.8). This research may provide clarity on the mechanism of 
VACV-induced TGF-β signalling. 
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7.2.2 A wealth of transcriptional data was provided by RNAseq 
As described above, Smad proteins mediate transcription of a huge array of genes following TGF-β 
treatment. They also take into account extra signals provided by various binding partners, summing 
up these inputs to provide a distinct signal output. To gain a broader picture of Smad target gene 
expression following VACV infection, we adopted broader transcriptomic techniques to build on 
our qRT-PCR data (Section 3.2.7). After various quality control measures, RNAseq was chosen for 
this work due to its power, accuracy and cost-efficiency.  
The RNAseq experiment provided us with a plethora of information to be sorted through and 
evaluated. Our main priorities were Smad target gene transcription, EGF-associated transcription, as 
well as genes associated with EMT progression. The obtained data indicated a strong link between 
Smad target gene transcription and VACV-WR infection, with some genes displaying Smad4 
dependence (Sections 6.2.6). It also confirmed earlier qRT-PCR analysis, with c-JUN, Snail2 and 
PAI-1 expression resembling earlier results (Section 3.2.7). Furthermore, many EMT-related genes 
were up and downregulated according to the typical patters observed during EMT. However, others 
did not appear to align to the common trends, making it difficult to state whether EMT was 
occurring during VACV-WR infection.  
Many genes also appeared to be reliant on VGF for their expression, as loss of VGF severely 
attenuated VACV-induced transcription of Smad targets and EMT-associated genes (Section 6.2.5). 
Given that the VGF homolog, EGF is known to influence Smad target gene transcription and EMT, 
this result was not entirely unsurprising. However, at no point did we directly examine VGF levels, 
and as such, this data may require further confirmation through the use of qRT-PCR assays.  
Overall our results indicate a role for Smad4 and VGF in global gene transcription during VACV 
infection. Due to time constraints, the data could not be analysed in enough detail to provide us with 
any possible mechanisms of VACV-induced TGF-β signalling. However, with further analysis, this 
research may provide a wealth of information on TGF-β and EGFR signalling during VACV 
infection. 
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7.3 CROSS-TALK BETWEEN SIGNALLING PATHWAYS INFLUENCES VACV INFECTION 
7.3.1 The TGF-β signalling cascade and VGF cooperate to enhance signalling activation and 
VACV spread 
Three major pathways are known to directly modulate EMT, the TGF-β-mediated, Wnt-mediated 
and Notch controlled signalling cascades. However, it would be naïve to think any of these 
pathways function in isolation. Given the number of steps from ligand binding to signal output, it is 
unsurprising that systems have developed an array of means to influence the signal transduction 
circuit. In the case of TGF-β signalling, one such pathway capable of cross-talk is the EGFR 
pathway [646]. 
VACV is known to stimulate EGFR signalling through the use of its EGF homolog, VGF which 
promotes viral spread and pathogenesis [43, 530]. Within this thesis, we have shown that a virus 
lacking VGF also appears incapable of promoting downstream TGF-β signalling as measured 
through target gene transcription (Sections 5.2.7 and 6.2.5). Given that we have shown TGF-β 
signalling contributes to VACV spread, it is possible that the concomitant reduction in TGF-β 
pathway activation could be partially responsible for decreased viral spread and replication upon 
VACV-ΔVGF infection (Sections 4.2.4 and 5.2.6-5.2.8). Furthermore, addition of exogenous EGF 
and TGF-β to these ΔVGF plaques increases their size to VACV-WR levels (Section 5.2.9). It could 
be that EGF and VGF work cooperatively to enhance VACV plaque spread, as further removal of 
EGFR signalling using an inhibitor Gefitinib, decreases VACV-ΔVGF plaque size even further 
(Section 5.2.11). Given that ECTV is also incapable of modulating TGF-β signalling, it may be 
interesting to note if this virus possesses a functional VGF homolog, or if it is correspondingly 
unable to induce EGFR signalling.  
Four possible mechanisms to explain these TGF-β and VGF interactions are summarised in Figure 
7.2. In all of these, VACV relies on VGF to stimulate linker phosphorylation of Smad2 (Section 
5.2.5). In the first case, this linker phosphorylation signal is sufficient for R-Smad activation and 
downstream signalling. This scenario may be unlikely, given that C-terminal phosphorylation is 
thought to be the major determinant of R-Smad activity [111, 132, 496, 497]. Furthermore, linker 
phosphorylation is thought to be reliant on phosphorylation at the C-terminal site [497]. The second 
option is that R-Smad phosphorylation at multiple sites, including the SSXS motif is mediated by 
VGF. This could be ruled out by examining C-terminal phosphorylation during VACV-ΔVGF 
infection. Thirdly, C-terminal phosphorylation could once again be regulated by the TGFβRI 
protein. However, this scenario appears quite unlikely given the evidence suggesting a lack of 
TGFβR complex involvement during VACV-induced TGF-β signalling (Sections 5.2.1, 5.2.2 and 
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5.2.3). A final option is that an unknown cellular or viral protein is acting as the C-terminal 
phosphorylation kinase and enhancing activation of R-Smad proteins in the VACV context.  
From the data it is clear that the reliance of VACV on TGF-β signalling is at least partially 
influenced by the presence of viral VGF. Together these pathways contribute to the efficient R-
Smad activation, target gene transcription and the viral cell-to-cell spread required for plaque 
formation.  
 
 
Figure 7.2 - Cooperation between the TGF-β and EGFR signalling pathways in the context of VACV 
infection involves VGF  
The TGF-β and EGFR signalling pathways display high levels of cross-talk at many stages of both pathways. In 
the context of VACV infection, the relationship between these pathways may drive stronger TGF-β signalling 
through the phosphorylation profiles of R-Smad proteins, the driving transcription factors of this pathway. In this 
case 4 possible scenarios, listed in order of increasing likelihood, are described in which VGF modulates R-Smad 
activation. In all the proposed models, VGF is thought to mediate linker phosphorylation. This in combination 
with various C-terminal phosphorylation options leads to R-Smad activation. Firstly, linker phosphorylation alone 
may be sufficient. In the second case, VGF enhances SSXS phosphorylation. Thirdly, the TGFβRI protein is 
contributing to R-Smad activation, or finally a mystery kinase is acting on the SSXS site. These options form the 
basis for future investigations.   
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7.4 SIGNIFICANCE AND FUTURE DIRECTIONS 
7.4.1 Significance and potential applications 
VACV is considered the prototypical poxvirus. Despite being uncertain of its natural host organism, 
VACV has provided scientists with a wealth of information on the poxvirus replication cycle, 
including demystifying processes of entry, egress, temporal gene transcription and capsid formation. 
However, given its relatively complex nature, there is still much we do not know about this virus.  
One possible use for this work is in the development of antivirals. Numerous viruses, including now 
VACV, appear to rely on aspects of TGF-β signalling for efficient replication, spread and 
pathogenesis [79, 80, 88, 254-258, 260-275, 278, 279]. Furthermore, various chemical inhibitors on 
the market as anti-cancer therapeutics interfere with this same signalling pathway [521]. This 
includes SB-431542 which is currently in phase II trials for treatment of glioma, glioblastoma, 
hepatocellular carcinoma and pancreatic cancer. As such, there is the potential for repurposing these 
drugs to antiviral treatments against these pathogens. This same principle can be applied to reliance 
on the EGFR pathway. For example, gefitinib, the EGFR inhibitor described earlier, is already 
being considered as treatment for poxvirus infection [511]. This treatment removes the influence of 
the VGF virulence factor and limits the severity of poxvirus disease. 
Interestingly, VACV appeared to be distinguished by its ability to induce TGF-β signalling, with 
related poxvirus, ECTV being unable to do so. However, VACV is known for its ability to grow in 
a broad range of host organisms and tissues. It is possible that upon infection of its natural mouse 
host, ECTV may also possess this ability in order to enhance pathogenesis. If so, perhaps other 
more pathogenic poxviruses do the same. As such, VACV would serve as a good model of 
pathogenesis for these, whilst being easier to work with in an in vitro setting.  
Another possible application for this research is in the development of oncolytic virus research. 
This is described in more detail within the following section.  
 
7.4.2 VACV and the search for the ideal oncolytic agent 
In the field of oncolytic research, scientists are constantly on the search for techniques to increase 
the safety, potency and specificity of these treatments. Many strategies have been previously 
employed to do this. For example, removal of certain virulence factors, such as B18R in VACV, 
makes these viruses more susceptible to host IFN responses, sparing healthy cells from infection. 
This strategy is particularly effective as tumour cells often display defective IFN production [46] 
Insertions of adjuvants, such as GM-CSF, also enhance the potency of the anti-tumoral immune 
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response. In this setting, the virus acts like a tumour vaccine. The cancer-targeting ability of these 
viruses can also be honed through comparisons between tumour biology and viral replication cycles. 
For instance, TK deletions increase specificity of VACV towards cancer cells with expansive TK 
stocks. This is due to the strict reliance on TK for viral replication. Together these examples 
encompass the major strategies associated with oncolytic virus improvement. 
Within this thesis, we have demonstrated a role for TGF-β signalling in promoting VACV 
replication and spread. Fortuitously, countless tumour types are also associated with rampant TGF-
β signalling [103, 558, 647-649]. Using a similar principle to the TK deletion described above, if 
we interfere with VACV induction of TGF-β signalling, it is more likely to rely on cellular sources 
for these pathway components. This methodology could further polarise oncolytic VACV to 
replicating within TGF-β-rich tumour cells and disrupt healthy cell replication whether the TGF-β 
signalling pathway is more regulated. A virus lacking both this ability and carrying a VGF deletion 
would like to be even more biased to tumour cell replication, favouring cells with both TGF-β and 
EGF signalling dysregulated (Figure 7.3). Again, this is a common feature to multiple tumour types, 
with EGF even being considered a biomarker for cancer detection [44, 517, 518]. Unfortunately, 
from this research we have not been able to identify the mechanism employed by VACV to activate 
this pathway, and as such, have no target for manipulation. Therefore, identifying the responsible 
components of VACV would be of the utmost importance to apply this research to oncolytic virus 
development.  
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Figure 7.3 – Targeting of oncolytic VACV  
The parental VACV strain has the ability to replicate in both healthy cells and tumour cells. Due to inherent 
features of the virus and the cells it is slightly more proficient at replicating within the tumour cells. However, a 
modified VACV which has lost the ability to activate TGF-β and EGFR signalling is more likely to survive and 
replicate in cells with aberrant overactivation of these pathways, which is the case for many tumour types. As such, 
identifying how VACV induces TGF-β signalling becomes a high priority, in the hope that this knowledge could 
be used in combination with a ΔVGF deletion to increase the tumour selectivity of oncolytic virus.  
 
 
7.4.3 Future directions 
From our research, we have shown a relationship between TGF-β signalling and aspects of VACV 
infection. The TGF-β signalling pathway is seen to be activated at the level of R-Smad transcription 
factors, Smad4, promoters of Smad target genes and finally expression of these same targets. 
However, the role of the TGF-β ligand and receptor complex is as yet uncertain. It appears that they 
may be less important during VACV infection than in the canonical TGF-β signalling cascade. Due 
to the curious nature of VACV-induced activation of TGF-β signalling, future work should 
prioritise identifying the mechanism at play in this system. This could be done through the use of 
MVA, to map which genomic regions of VACV may be important for TGF-β pathway activation.  
With hope, this research could aid in the development of novel antivirals and honed oncolytic 
agents, adding to the field of viral therapeutics and improving the reputation of viruses in general.   
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CHAPTER 8: APPENDICES 
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8.1 APPENDIX 1 - GENERATION OF HACAT CAGA12-GFP CELLS 
8.1.1 Generation of HaCaT CAGA12-GFP cells 
The TGF-β signalling pathway is a known initiator of EMT and previous observations in our lab 
have noted a potential role for TGF-β signalling during VACV infection. To further investigate the 
influence of TGF-β pathway components and provide us with a tool to monitor their activity in a 
live setting, we generated the HaCaT CAGA12-GFP cell line. These cells produce GFP upon 
binding of the Smad3/Smad4 complex to the CAGA12 motif within promoters of Smad targets. As 
such, we can correlate GFP expression with activity of the Smad3 protein (see Figures 3.9, 3.10 and 
3.11). To make these cells, various dilutions of a CAGA12-GFP-containing lentivirus were made up 
in media and applied to HaCaT cells. Cells were then treated with the positive control, TGF-β, or 
infected with VACV-WR to induce a response before imaging. Figure 8.1 demonstrates the results 
for three concentrations at which lentivirus was added (1/3, 1/9 and 1/27). Efficient transduction is 
observed at the 1/3, but not the 1/9 or 1/27 concentrations. The 1/9 concentration displayed some 
potential in its TGF-β response; however, no consistent results could be obtained in VACV-WR 
infected cells in this condition. The results show GFP is expressed following TGF-β treatment and 
VACV-WR infection, suggesting Smad3 is active in these cases. Note that, regardless of lentivirus 
concentration, HaCaT CAGA12-GFP cells at 70% confluency do not produce GFP in the absence of 
TGF-β and VACV-WR. Data from the other concentrations tested, 1/81, 1/243 and 1/729 were not 
shown due to lack of observable phenotype. The results for these resembled the 1/27 condition. 
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Figure 8.1 – Efficient transduction of CAGA12-GFP-containing lentivirus can be visualised in HaCaT 
cells 
HaCaT cells were treated with a lentivirus containing a CAGA12-GFP construct generated by a collaborator, 
Stuart Turville (Kirby Institute, UNSW, Australia). Serial dilutions (1/3, 1/9 and 1/27) were made in 
10%FBS/DMEM media to test transduction efficiencies. For imaging, cells were grown on coverslips and treated 
with TGF-β (2 μg/mL) or infected with VACV-WR for 10 hours. Imaging was conducted on the Olympus BX51 
microscope. Scale bar = 200 μm.  
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8.2 APPENDIX 2 – MIGRATION AND INVASION ASSAY OPTIMISATION 
8.2.1 Various cell types and phenotypes observed in wound healing assays 
Several cell types were used to conduct wound healing assays in the context of VACV infection. 
However, other than the classical BSC-1 cell model (Figure 3.5), the others tested, including SK 
Mel, HeLa and HaCaT cells did not appear appropriate due to the complete dissolution of the 
confluent cell monolayer upon infection. These results did not suggest that VACV was incapable of 
inducing cell migration in these cells, rather that cells moved in a random fashion meaning wound 
closure was not a measure of migration in these cell types.  
In Figure 8.2, we see wounds in SK Mel (Figure 8.2A) and HeLa (Figure 8.2B) cells at 24 hours 
post-scratching. For both the cell types it appears that TGF-β treatment increases the rate of wound 
healing. In SK Mel cells, wound diameter is reduced to 341.9 μm upon addition of TGF-β 
compared to the 398.7 μm seen in untreated cells. Similarly, HeLa cells treated with TGF-β had 
wounds reduced from 496.5 μm to 322.5 μm wide. The results for VACV-infected cells proved less 
clear. In this condition, cells do not appear to migrate into the wound site but move randomly in all 
directions to create cell clumps and aggregated cells. In this condition the average wound diameter 
is approximately 615 μm for SK Mel cells and 583 μm in HeLa cells, 1.8-fold larger than in TGF-β-
treated cells in both cases, suggesting VACV infection is detrimental to wound healing. Given that 
these results align with those obtained using HaCaT cells, it appears that scratch assays may not 
always be suitable for measuring cell migration. In our context, single-cell tracking experiments 
were deemed more appropriate.  
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Figure 8.2 – Wound healing assays in SK Mel and HeLa cells were not conclusive in showing VACV-
induced cell migration 
Following serum starvation of confluent SK Mel (A) and HeLa (B) cell monolayers, wound healing assays were 
conducted. Cells were either left untreated, treated with TGF-β (2 μg/mL) or infected with VACV-WR (MOI of 5) 
at the time of scratching, and left for 24 hours. At this point cells were fixed, stained and imaged using the 
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Olympus BX51 microscopes. Viral protein, B5, was stained in green, actin in red and nuclei in blue. Scale bar = 
200 μm. 
 
8.2.2 Quantifying invasive potential from invadopodia assays 
Invadopodia assays were used to determine if VACV-WR infection could raise the invasive 
potential of infected cells. These assays consist of applying an even fluorescent gelatin layer to a 
pre-prepared substrate. Cells are then overlaid on this layer, to degrade the gelatin if they are so 
capable. Whilst the various conditions in Figures 3.8 and 8.3 display clear differences in cell 
invasiveness, we encountered major difficulties in quantifying this process. Quantification was 
carried out by measuring the area within the field of view covered by cells, using the Alexa Fluor ® 
568 Phalloidin stain, and then correlating these to areas of gelatin loss. However, the images 
produced could not clearly distinguish the background from the invaded area. This was attributed to 
uneven illumination of the gelatin backdrop, which interfered with the ImageJ software’s ability to 
identify areas of gelatin degradation. It is possible that using more powerful microscopes, such as 
the Nikon Ti-E Eclipse, could provide more uniformity and facilitate clearer demarcation between 
areas of invasion and the background. Repeating these experiments could provide more information 
on the invasion potential of VACV-infected cells.  
 
8.2.3 HaCaT cells are not suitable for invasion assays due to being inherently invasive 
Another difficulty encountered during invadopodia assays came from the use of HaCaT cells. Our 
most well-characterised cell line in this context was found to not be suitable for this analysis. This is 
due to the fact that HaCaT cells appear to be invasive without external stimulation from our positive 
control, TGF-β, or our test condition, VACV-WR. As seen in Figure 8.3, degradation of fluorescent 
gelatin, which can be correlated to invasion potential, is observed in all HaCaT cell conditions. This 
is to a similar degree, or if not more than our positive control cell line, the GBM line. Due to this 
feature, HaCaT cells were not used for further invasion assays.  
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Figure 8.3 – Inherent invasion potential of HaCaT cells led to technical difficulties during invadopodia 
assays  
HaCaT cells appeared to be inherently invasive regardless of treatment as assayed by a gelatin invadopodia assay 
(Green) (Merck Millipore). This was evident at 24 hours in untreated GBM and HaCaT cells (MOI of 5) cells. SK 
Mel cells were used as a negative control. For imaging, cells were fixed, stained and visualised using the Olympus 
BX51 microscope. Gelatin underlay was visualised in green, the actin cytoskeleton in red and cell nuclei in blue. 
Scale bar = 200 μm. 
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8.3 APPENDIX 3 – SMAD4 AND APOPTOSIS 
8.3.1 Smad4 knockdown does not seem to alter the apoptosis phenotype observed upon VACV 
infection 
In Chapter 4 we discuss the role of Smad4 during VACV infection. One aspect we desired to 
characterise was the apoptosis response to infection following Smad4 depletion. However, due to 
time constraints this phenotype could only be examined preliminarily. However, immunoblot 
analysis appeared to reveal no significant difference between untreated and Tet-treated TRS4 cells 
in caspase-3 activation (Figure 8.4). As caspase-3 is a key mediator of apoptosis, promoting 
membrane blebbing and DNA fragmentation, these results suggest apoptosis is not dependent on 
Smad4 in the context of VACV infection [334, 650]. Unfortunately, due to the quality of the results, 
we would like to characterise this phenotype further. 
 
Figure 8.4 - Caspase-3 levels, as detected by immunoblot, were constant between Smad4-depleted and 
untreated HaCaT TRS4 cells 
 HaCaT TRS4 cells were treated with Tet (2 μg/mL) for 48 hours prior to infection with VACV-WR (MOI of 10) 
for 10 hours. At this point cells were lysed and lysates were probed for inert and activated caspase-3. Immunoblot 
revealed that VACV-WR infection increased levels of active caspase-2, regardless of Tet treatment. This was 
compared to uninfected cells where pro-caspase-3 predominated. A36 and β-actin were used as viral and cellular 
controls respectively. 
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8.4 APPENDIX 4 – MPS1 AND VACV INFECTION 
8.4.1 Mps1 may influence VACV spread as indicated by plaque assays 
To further ascertain the role of Mps1 in VACV infection we conducted a number of plaque assays. 
From the data, it appeared that VACV spread was impaired in the presence of two Mps1 inhibitors, 
Mps1-IN-2 and reversine, in a dose-dependent manner. Interestingly at high concentrations of 
Mps1-IN-2 we see a total antiviral effect (50nM, data not shown), where no plaques could be 
detected at all. It was interesting to note that the inhibitors used had different antiviral efficacies, 
with reversine requiring much higher concentrations to begin to reduce plaque size. These results 
suggest Mps1 may contribute to viral spread through a cell monolayer; however, inconsistencies 
between the inhibitors used suggest further investigation is required.  
 
Figure 8.5 – Inhibition of Mps1 inconsistently affected VACV-WR plaque size in a dose-dependent 
manner 
Confluent HaCaT cells were infected with VACV-WR (MOI of 0.1) for 2 days under a semi-solid overlay. During 
this, certain wells were also subjected to treatment with Mps1-IN-2 or reversine at the specified concentrations. 
As a control, DMSO was also added to one well. At 2dpi, the crystal violet staining method was used before 
plaques were analysed using ImageJ software. Thirty plaques were measured for this analysis. Error bars refer to 
SEM. N = Student’s unpaired t-test.  
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8.5 APPENDIX 5 - RNA QUALITY CONTROL 
8.5.1 Primer testing 
In order to verify the functionality of real-time PCR primers, a standard PCR was performed on 
cDNA synthesised from total RNA collected from WR-infected HaCaT cells. The expected sizes 
for each product are listed in Section 2.3.1. Note that the annealing temperature used for each 
primer pair is also described within this section. When run on an agarose gel, we see predominantly 
single bands of the expected sizes for each primer pair used (Figure 8.6). In the PAI1 condition 
there are a few non-specific bands; however, the predominant product which corresponds to the 
brightest band, was of the expected size so the primer pair continued to be used. It was assumed the 
annealing temperature used for this experiment was slightly too low, which could account for the 
extra bands which were observed. Furthermore, we obtained neat standard curves and melt curve 
plots for this primer pair so they were assumed to be working as desired (Figures 8.6 and 8.7). 
These primer pairs were then used to conduct real-time PCR analysis. 
 
Figure 8.6 – Verification of real-time PCR primer pairs via PCR on WR-infected HaCaT cDNA 
Total RNA was obtained from WR-infected HaCaT cells and converted to cDNA for use as a PCR template. 
Primer pairs recognising a cellular control (GAPDH), Smad target genes (c-JUN, Snail2, PAI1), TGFb and viral 
controls (A17, D12) were used on this template to confirm efficacy of amplification. As seen in the 
electrophoresis gel, all primer pairs produced single bands of the desired sizes.  
 APPENDICES 
University of Sydney 249 2018 
 
Once primers appeared to be able to produce products of the expected size we then tested their 
functionality in real-time PCR assays. To do this we generated primer standard curves. This allowed 
us to measure the efficiency of amplification for each primer pair, which is ideally able to produce 
two copies of a template per cycle. From this we should see an exponential increase in template 
copy number that corresponds to a standard curve with a slope approximately equal to -3.3 when 
graphed against 10-fold dilutions of template cDNA. This correlates to an efficiency (E) of 
approximately 100%, where E = 10(-1/slope)-1. In Figure 8.7 we can see that all the primer pairs 
used generated standard curves that lie within an acceptable range of slope=-3.3. These slopes 
suggest that primer pairs are amplifying the template cDNA effectively.  
 
Figure 8.7 – Primer pair standard curves were generated for those used in real-time PCR analysis 
Various tenfold dilutions of cDNA from TGF-β-treated (to test cellular primers) or VACV-infected conditions (to 
test viral primers) were made up in order to produce standard curves for the desired primer pairs. The primer pairs 
used in this analysis were for cellular genes, GAPDH, c-JUN, Snail2, PAI1, and TGFb, as well as viral genes, A17 
and D12. These were used to conduct real-time PCR analysis before graphing the CT against the cDNA 
concentration used. As the desired slope for a standard curve is approximately -3.3, we see most pairs tested 
falling within an acceptable range of this. 
 
 
Another primer checkpoint is melt-curve or disassociation analysis. This examines the presence of 
primer-dimers and determines the reaction specificity. Melt curves are generated by monitoring the 
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fluorescence released by SYBR green at different temperatures. If specific, the melt curve should 
appear with a single clear peak. Any variations in this pattern could indicate the existence of 
artefacts, or a lack of specificity for the target sequence. In combination with our electrophoresis 
results, the melt curves generated for our primer pairs suggest all reactions are specific and primers 
are functioning as expected. The lack of extra peaks suggests primer-dimers have also been avoided 
(Figure 8.8).  
 
Figure 8.8 - Melt curves analysis suggested primer pairs function as desired during qRT-PCR analysis 
Applied Biosystems 7500 Fast Real-time PCR software was used to generate melt curve analyses for the primer 
pairs described above. The single peaks and strong overlap between the lines are indicators of primer functionality. 
Note that in conditions where we would not expect to see gene expression, such as viral genes in cDNA from 
uninfected cells or TGF-β treated cells, the melt curves differ from the typical pattern. This is also true for certain 
TGF-β target genes in the uninfected condition.  
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8.5.2 Quality control measures applied prior to RNAseq – Ramaciotti Centre for Genomics 
Other than the control measures described previously, samples being sent for RNAseq were put 
through further quality control checkpoints. These include Nanodrop analysis to assay RNA yield, 
immunofluorescence of cells to check infection rates, FA gel electrophoresis to look for 
contamination and real-time PCR assays to verify the quality of the RNA. The results for these 
experiments are described in Section 6.2.2. At this point RNA samples were sent off to Ramaciotti 
Centre for Genomics, UNSW, Sydney Australia where each was assigned a unique identification 
number or LIMS ID. Upon receipt of the samples, further quality control measures were employed 
by the organisation to check the condition of the samples upon arrival. As with our analysis, a 
Nanodrop spectrophotometer was used to check yield and quality of RNA (Table 8.1). Once all 
samples had passed this stage, Agilent Bioanalyzer technology was used for further analysis and to 
generate an RNA integrity number (RIN). As the name suggests, the RIN is an indication of the 
integrity and quality of the RNA being analysed. The ideal RIN is a value of 10. All samples rated 
very highly using this system, suggesting they were of sufficient quality for further assays (Figure 
8.9). This system also separates RNA by electrophoresis, giving 2 distinct bands at 23 and 18S 
respectively. Note that the 5S band is too diffuse to be clearly visualised in this case. However, in 
the graphical depictions of the gel results 3 distinct bands can be detected for each sample (Figure 
8.9B). Again, the intensity of the 5S band is much smaller in comparison. Overall the results 
suggest that the RNA is of high quality, yield and purity, and suitable for analysis via RNA 
sequencing methods.  
Table 8.1 – Quality control data from Nanodrop/Xpose analysis provided by Ramaciotti Centre for 
Genomics upon receipt of RNA samples  
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Sample Name LIMS ID Volume 
( L) 
Total RNA 
( ) 
Concentration 
( / L) 
260/280  260/230  Comments 
UN – Tet A GOW3906 A1 55 4284 84 1.99 1.08  
UN – Tet B GOW3906 A2 55 3962.7 77.7 1.98 1.07  
UN – Tet C GOW3906 A3 55 4115.7 80.7 2 1.03  
UN + Tet A GOW3906 A4 55 1284 84 2.08 1.62  
UN + Tet B GOW3906 A5 55 3738.3 73.3 2.07 1.59  
UN + Tet C GOW3906 A6 55 4498.2 88.2 2.05 1.61  
TGF-β – Tet A GOW3906 A7 55 4222.8 82.8 1.98 1.3  
TGF-β – Tet B GOW3906 A8 55 4115.7 80.7 1.93 1.45  
TGF-β – Tet C GOW3906 A9 55 3886.2 76.2 1.98 1.39  
TGF-β + Tet A GOW3906 A10 55 4151.4 81.4 2.01 1.15  
TGF-β + Tet B GOW3906 A11 55 3967.8 77.8 2.02 1.15  
TGF-β + Tet C GOW3906 A12 55 4375.8 85.8 2.02 1.19  
WR – Tet A GOW3906 A13 55 4600.2 90.2 1.97 1.09  
WR – Tet B GOW3906 A14 55 4411.5 86.5 1.98 1.08  
WR – Tet C GOW3906 A15 55 4355.4 85.4 2 1.1  
WR + Tet A GOW3906 A16 55 3921.9 76.9 2.05 1.65  
WR + Tet B GOW3906 A17 55 3748.5 73.5 2 1.65  
WR + Tet C GOW3906 A18 55 3799.5 74.5 2.02 1.64  
ΔVGF – Tet A GOW3906 A19 55 4059.6 79.6 1.77 1.87  
ΔVGF – Tet B GOW3906 A20 55 4008.6 78.6 1.77 1.85  
ΔVGF – Tet C GOW3906 A21 55 3896.4 76.4 1.81 1.81  
ΔVGF + Tet A GOW3906 A22 55 4477.8 87.8 1.75 1.82  
ΔVGF + Tet B GOW3906 A23 55 4447.2 87.2 1.73 1.87  
ΔVGF + Tet C GOW3906 A24 55 4360.5 85.5 1.8 1.8  
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Figure 8.9 – Electrophoresis summary generated by Ramaciotti Centre for Genomics using the Agilent 
Bioanalyzer 2100 and 2100 Expert software 
 (A) Using Agilent Bioanalyzer technology, electrophoresis of samples was conducted, and each was delineated 
by an LIMS ID outlined in Table 8.1. Clear, distinct bands can be distinguished at the 18S and 28S sites in all 
samples. (B) Results obtained from Bioanalyzer 2100 Expert software (version 2.6) also highlight two clear peaks 
for each sample. These correspond to the 18S and 28S bands respectively. The small peak at 25nt refers to the 
control band (green) in the gels. An RNA Integrity Number (RIN) was also generated, and all samples scored very 
highly using this system suggesting RNA is of high quality.  
 
8.5.3 RNAseq read quality 
A final measure for the quality of data obtained from RNAseq analysis comes from measuring the 
success of read mapping. This is a measure of how many reads can be aligned to known sequences. 
In this case, we desired coverage of approximately 30M reads per sample. As seen in Figure 8.10, 
all our samples came close to or exceed this amount in uniquely mapped reads. A certain proportion 
of the transcripts also translated to reads with too many loci or those which could not be mapped for 
various reasons. These reads were dismissed from our analysis. However, as these only accounted 
for a small proportion of the total number, all samples were considered to have sufficient coverage 
for in-depth transcript analysis.  
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Figure 8.10 – Success in read mapping of RNA samples 
As desired all 24 samples from the 8 separate conditions displayed a number of uniquely mapped reads (blue) 
above 30M, suggesting read coverage was good in all cases. Furthermore, with the exception of Uninfected – Tet 
C (UN-C), the samples which displayed the highest proportions of unmapped reads were the VACV-WR (WR-8h 
A-C and WR-Tet A-C) and VACV-ΔVGF (ΔVGF-16h A-C and ΔVGF-Tet A-C)., as we would expect when 
comparing to the human reference transcriptome. Graph was generated by collaborator, Ulf Schmitz.   
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